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Abstract	
This	 study	 provided	 epidemiological	 and	 molecular	 information	 regarding	 multi-resistant	
ESBL-producing	 bacteria	 over	 two	 years,	 assessed	 the	 effects	 of	 antimicrobial	 agents	 on	
intestinal	 microbiota	 resistance	 and	 identified	 potential	 environmental	 sources	 of	 ESBL	
contamination.	
The	most	prevalent	bacterial	species	to	express	ESBL	resistance	was	Escherichia	coli	[85%	in	
2010	 and	 84%	 in	 2012].	 	 Other	 species	 included	 members	 of	 Enterobacter,	 Klebsiella,	
Citrobacter	and	Proteus.	 	 An	 increase	 in	 resistance	 to	nine	 antibiotics	 [amoxicillin	 1%,	 co-
amoxiclav	14%,	meropenem1%,	cefotaxime	9%,	ertapenem	2%,	ceftazidime	7%,	tigecycline	
5%,	 cefuroxime	 8%	 and	 gentamicin	 6%]	 was	 observed,	 indicating	 that	 multi-resistant	
infections	had	increased	over	the	sampling	period.	
Multiplex	PCR	revealed	that	the	CTX-M	determinant	was	most	prevalent	[38%	in	2010	and	
27%	in	2012],	followed	by	TEM	then	SHV.		Double	resistance	determinants	were	identified	
in	 68%	 of	 the	 total	 isolates.	 	 A	 statistical	 relationship	 was	 determined	 between	 joint	
expression	of	TEM	and	SHV	and	patient	age	[p=0.0174],	suggesting	that	resistance	 initially	
presents	 within	 the	 elderly	 population.	 	 	 ERIC-PCR	 analysis	 was	 used	 to	 identify	 clonal	
relationships	 between	 the	 isolates.	 Ten	 potential	 clonal	 groups	 were	 identified;	 however	
phylogenetic	 analysis	 revealed	 that	 antibiotic	 selection	 and	 conjugation	 was	 taking	 place	
simultaneously,	with	a	turnover	of	isolates	observed	between	the	two	year	cohorts.	
Results	obtained	from	the	simulated	colon	model	suggested	that	the	receipt	of	antibiotics	
may	contribute	to	the	overall	 resistance	of	 the	gut	microbiota.	 	 Increases	 in	co-amoxiclav,	
amoxicillin	 and	 trimethoprim	 resistance	 was	 observed	 after	 dosing,	 while	 gentamicin	
remained	stable.		
One	 hundred	 and	 thirteen	 non	 clinical	 samples	 [animal	 faeces	 and	 food	 products]	 were	
analysed	to	determine	ESBL	presence.		ESBL	producing	isolates	were	recovered	from	32%	of	
the	animal	 faecal	and	60%	of	 food	product	 isolates,	AmpC	was	also	present	 in	15%	of	the	
faecal	 and	 12%	 of	 the	 food	 product	 isolates.	 	 Sequence	 analysis	 of	 the	 SHV	 and	 CTX	
determinants	 revealed	 relationships	 between	 determinants	 associated	 with	 both	 animal	
and	human	infections.	
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Chapter	1 	
	
1	 Introduction	
1.1	Beta-Lactams	and	Beta-Lactamases	
Since	 the	 discovery	 of	 the	 first	 beta-lactam,	 Penicillin,	 in	 the	 1920s,	 research	 into	 the	
discovery	 of	 other	 similar	 antibiotics	 has	 aimed	 to	 improve	 the	 potency,	 antimicrobial	
activity,	breadth	of	spectrum	and	stability	of	these	agents	(1).	In	the	21st	century	the	beta-
lactam	 class	 of	 antibiotics	 now	 include	 penicillins,	 cephalosporins,	 cephamycins,	
carbapenems	 and	 monobactams,	 making	 this	 one	 of	 the	 largest	 prescribed	 class	 of	
antibiotics.	
The	mode	of	action	of	beta-lactams	is	to	prevent	the	synthesis	of	the	bacterial	cell	wall,	by	
interfering	 with	 the	 formation	 of	 peptide	 bonds	 between	 the	 molecules	 that	 form	
peptidoglycan.	 	 Peptidoglycan	 is	 essential	 for	 bacterial	 cell	 wall	 structural	 integrity	 and	
rigidity.		During	the	synthesis	of	peptidoglycan	the	final	transpeptidation	stage	is	facilitated	
by	DD	transpeptidases,	named	penicillin	binding	proteins	[PBP].		Beta-lactam	antibiotics	are	
an	 analogue	 of	 the	 D-alanyl-D-alanine	 terminal	 residues	 on	 the	 adjacent	 peptidoglycan	
layer,	 enabling	 them,	 due	 to	 their	 structural	 similarity,	 to	 irreversibly	 bind	 to	 the	 Ser403	
residue	of	the	active	penicillin	binding	protein	site	(2).		Once	bound	the	beta-lactam	enzyme	
inhibits	 the	 penicillin	 binding	 proteins	 and	 prevents	 the	 final	 transpeptidation	 or	 cross	
linking	stage,	causing	disruption	of	the	cell	wall.	
Within	the	1950s	evidence	of	bacterial	resistance	to	penicillin	began	to	emerge	(3).		By	the	
1970s	 penicillin	 resistant	 Staphylococcus	 aureus,	 a	 leading	 cause	 of	 skin	 infections,	
Streptococcus	 pneumoniae,	 a	 cause	 of	 community	 acquired	 pneumonia,	 and	 Neisseria	
gonorrohoeae,	 a	 sexually	 transmitted	 disease,	 became	 common	 infections.	 	 Resistance	
within	 these	 organisms	 was	 also	 seen	 to	 spread	 worldwide.	 	 In	 current	 years,	 antibiotic	
resistance	has	become	an	increasing	problem,	with	patients	suffering	infections	as	a	result	
of	bacteria	resistant	to	multiple	antibiotic	classes.	
A	 number	 of	 different	 mechanisms	 have	 been	 utilised	 by	 bacteria	 in	 order	 to	 render	
antimicrobial	agents	ineffective.		Three	basic	mechanisms	have	been	regularly	documented	
including:	 target	 molecule	 modification,	 degradation	 of	 the	 antibiotic	 and	 altered	
membrane	permeability	and	excretion	by	efflux	pumps,	Figure	1.1	(4).			
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Figure	1-1,	Different	mechanisms	employed	by	bacteria	to	resist	antibiotics,	[a]	illustrates	
genetic	acquired	resistance	for	example	chromosomal	mutations	and	horizontal	gene	
transfer,	[b]	bacterial	efflux	pumps,	reducing	the	intracellular	concentration	of	the	
antibiotic,	[c]	the	alteration	of	target	sites	of	the	antibiotic,	rendering	the	agent	inactive	and	
[d]	enzymes	for	example	beta-lactamases	that	break	down	the	structure	of	the	antimicrobial	
agent	(5).	
	
	
	
	
	
(a)	
(b)	
(c)	
(d)	
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These	resistance	determinants	may	be	 located	chromosomally	or	extrachromosomally	and	
can	 be	 mobilised	 by	 conjugation,	 transduction	 or	 transformation.	 	 Transfer	 of	 resistance	
determinants	 by	 conjugation	 is	 perhaps	 the	most	 common	mechanism	 used	 by	 bacteria,	
allowing	horizontal	transfer	to	a	wide	range	of	species	(6).	
The	 most	 common	 resistance	 mechanism	 expressed	 against	 beta-lactam	 antibiotics	 are	
beta-lactamases	 (7).	 	 Beta-lactamase	 enzymes	 have	 been	 expressed	 by	 a	 variety	 of	
organisms	 for	many	 years,	 and	 are	 a	 classic	 example	 of	 antibiotic	 destruction	 by	 enzyme	
action.	 	 Inactivation	 of	 beta-lactams	 is	 catalysed	 by	 the	 enzymatic	 cleavage	 of	 the	 beta-
lactam	ring,	Figure	1.2	(8).			
Increased	use	of	penicillin	within	the	clinical	setting	was	associated	with	the	emergence	of	
resistance,	 particularly	 within	 Staphylococcus	 aureus,	 resulting	 from	 a	 plasmid	 encoded	
penicillinase.	 	Many	Gram	negative	 bacteria	 have	 also	 been	 found	 to	 produce	 a	 naturally	
occurring,	 chromosomally	 mediated	 beta-lactamase.	 	 This	 enzyme	 exhibits	 sequence	
homology	with	penicillin	binding	proteins,	and	its	development	has	been	linked	to	selective	
pressure	exerted	on	environmental	organisms	(9).	
Over	 a	 period	 of	 fifteen	 to	 twenty	 years	 many	 attempts	 were	 made	 to	 combat	 beta-
lactamase	 resistances,	 and	 in	 1975	 clavulanic	 acid,	 a	 beta-lactamase	 inhibitor,	 was	
discovered.	 	 When	 combined	 with	 an	 antibiotic,	 such	 as	 amoxicillin,	 this	 conjugate	 will	
irreversibly	bind	and	inhibit	the	enzyme	(10).		In	addition	to	this	approach,	new	beta-lactam	
antibiotics	 were	 designed	 to	 treat	 infections	 caused	 by	 beta-lactamase	 producing	
organisms,	 examples	 include	 ampicillin	 and	 second	 generation	 cephalosporins.		
Nevertheless,	 novel	 variants	 of	 beta-lactamases	 exhibiting	 resistance	 to	 these	 therapies	
occurred,	presumably	as	a	result	of	over	prescribing.		In	the	early	1980s	the	introduction	of	
third	generation	cephalosporins,	for	example	cefotaxime,	ceftriaxone	and	ceftazidime,	into	
clinical	practice	was	seen	as	a	milestone	in	the	battle	against	beta-lactamase	resistance.		For	
a	few	years	these	antimicrobial	agents	were	not	only	effective	against	the	majority	of	beta-
lactamases	 but	 they	 were	 also	 a	 safer	 treatment	 option	 compared	 to	 other	 therapies	
available	at	the	time,	for	example	aminoglycosides	[gentamicin],	polymyxins	[polymyxin	B]	
and	chloramphenicol	(11).		Selective	pressure	over	many	years	using	first,	second	and	third	
generation	beta-lactams	has	resulted	in	a	wide	diversity	of	beta-lactamase	enzymes.			
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Figure	1-2,	Structure	of	beta-lactams,	all	classes	have	a	beta-lactam	ring,	highlighted	in	grey,	
within	their	structure	making	this	an	excellent	target	for	beta-lactamase	enzymes	(12).		
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1.2	Beta-Lactamase	Enzymes	
The	 first	 bacterial	 beta-lactamase	 enzyme	 described	 in	 E.	 coli	 was	 the	 AmpC	 enzyme,	
discovered	in	1940	with	its	structural	gene	identified	in	1965	(13).	 	The	structure	of	AmpC	
was	reported	in	1981	and	it	was	found	to	differ	from	other	beta-lactamase	enzymes	(14).			
In	1965	the	first	plasmid	mediated	beta-lactamase,	TEM-1,	was	described	within	a	strain	of	
E.	coli	(15).		The	TEM-1	enzyme	was	so	called	due	to	its	identification	from	a	blood	culture	of	
a	patient	named	Temoniera	 in	Greece	 (16).	 	Within	a	 few	years,	due	to	 its	plasmid	origin,	
the	TEM-1	beta-lactamase	enzyme	had	spread	to	other	species	of	bacteria	and	throughout	
the	world.	 	TEM-1	resistance	can	currently	be	 identified	 in	a	 range	of	organisms	 including	
many	 different	 members	 of	 the	 Enterobacteriaceae	 family,	 Haemophilus	 influenzae,	
Neisseria	gonorrhoeae	and	Pseudomonas	aeruginosa.		The	first	derivative	of	TEM-1,	TEM-2,	
has	one	single	amino	acid	substitution	identified	by	a	shift	in	the	isoelectric	point	from	5.4	
to	 5.6	 (17).	 	 This	 substitution	 did	 not	 change	 the	 substrate	 profile	 and	 this	 enzyme	 still	
exhibited	beta-lactamase	activity.			
In	1972,	another	beta-lactamase,	SHV-1	[sulphydryl	variable]	was	described	by	Pitton	(18).		
SHV	was	so	named	due	to	its	biochemical	properties,	possessing	a	sulphydryl	variable	active	
site.	 	 SHV-1	 is	 associated	 with	 chromosomally-mediated	 resistance	 in	 the	 majority	 of	
Klebsiella	pneumoniae	isolates	but	is	usually	plasmid	mediated	in	E.coli	(19).			
	
1.3	Extended	Spectrum	Beta-Lactamase	Enzymes	
In	 1985	 the	 first	 report	 of	 a	 plasmid	 encoded	 beta-lactamase	 capable	 of	 hydrolysing	
extended	 spectrum	 antibiotics	 was	 discovered	 within	 Klebsiella	 pneumoniae	 in	 Germany	
(20),	 this	 was	 named	 an	 extended	 spectrum	 beta-lactamase	 [ESBL].	 	 Genetic	 analysis	
revealed	 that	 the	 gene	 encoding	 this	 determinant	 had	 a	 single	 nucleotide	 difference	
compared	to	the	SHV-1	sequence,	and	was	subsequently	named	SHV-2.		After	this	discovery	
many	other	beta-lactamases,	closely	related	to	TEM-1	and	TEM-2	with	the	ability	to	confer	
resistance	 to	 extended	 spectrum	 cephalosporins,	 have	 been	 reported	 in	 Klebsiella	
pneumoniae,	E.	coli	and	Citrobacter	freundii	within	Europe	(21).		
In	 1989	 another	 family	 of	 ESBL	 was	 recognised	 in	 E.	 coli,	 and	 reported	 in	 Germany	 and	
Argentina;	 this	was	 then	 closely	 followed	by	 reports	 in	 France	 and	 Italy.	 	 This	 family	was	
named	CTX-M	due	to	its	ability	to	confer	resistance	predominantly	to	cefotaxime	compared	
to	ceftazidime	(22),	(23).		In	1992	an	ESBL	resembling	the	same	characteristics	as	CTX-M	was	
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isolated	from	the	E.	coli	strain	MEN,	this	determinant	was	sequenced	and	called	MEN-1	(24).		
A	few	years	later	an	MEN-1	related	[83%	sequence	homology]	cefotaxime	resistant	enzyme	
was	isolated	from	an	E.	coli	strain	in	Japan,	this	was	called	TOHO-1	(25).		Further	sequence	
analysis	 comparing	 determinants	 of	 CTX-M-1,	MEN-1	 and	 TOHO-1	 revealed	 that	 CTX-M-1	
was	identical	to	MEN-1	and	that	this	enzyme	was	a	variant	of	TOHO-1	that	is	often	referred	
to	as	CTX-M-2.		CTX-M	enzymes	have	subsequently	been	detected	in	many	different	species	
of	Enterobacteriaceae	with	at	least	65	variants	recorded	(26).	
A	 group	of	oxacillinases	 conferring	 resistance	 to	oxazolylpenicillins	 [oxacillin	or	 cloxacillin]	
with	 a	 similar	 phenotype	 to	 ESBLs	 was	 reported	 in	 Turkey	 in	 1991,	 and	 later	 in	 France.	
Sequence	 analysis	 revealed	 that	 these	 determinants	 were	 mutations	 of	 the	 extended	
spectrum	OXA-type	beta-lactamases	(27).		Since	their	discovery,	these	mutations	known	as	
OXA-type	 ESBLs	 have	 now	 been	 found	 worldwide,	 initially	 conferring	 resistance	 within	
Pseudomonas	 aeruginosa.	 	 Since	 these	 reports	 OXA-1,	 the	 most	 common	 OXA-type,	 has	
been	detected	in	1-10%	of	E.	coli	isolates	(28).	
Since	the	discovery	of	the	main	groups	of	ESBLs	[TEM,	SHV,	CTX-M	and	OXA],	a	number	of	
newer	ESBL	families	have	also	been	isolated.	 	These	varieties	do	not	originate	from	simple	
point	mutations	of	known	beta-lactamases	 [TEM-1	and	2	and	SHV-1]	and	are	classified	by	
their	 geographical	 diversity.	 	 An	 example	 includes	 the	Pseudomonas	 Extended	 Resistance	
[PER]	beta-lactamase,	which	was	first	discovered	within	strains	of	Pseudomonas	aeruginosa	
in	 Turkey	 (29)	 and	was	 later	 associated	with	 resistance	 in	 isolates	of	Salmonella	 enterica,	
Acinetobacter	 baumanii	 and	 Proteus	 mirabilis	 (30).	 	 PER	 type	 enzymes	 have	 a	 25-27%	
homology	similarity	to	the	TEM	and	SHV	enzymes,	have	the	ability	to	hydrolyse	penicillins	
and	cephalosporins	and	are	inactivated	by	the	presence	of	clavulanic	acid	(31).	
Vietnamese	 extended-spectrum	 beta–lactamase	 (VEB)	 type	 ESBLs	 were	 first	 discovered	
within	an	isolate	of	E.	coli	(32)	and	have	been	since	associated	with	resistance	in	Klebsiella	
pneumoniae,	 Enterobacter	 cloacae	 and	 Pseudomonas	 aeruginosa	 (33).	 	 These	 enzymes	
illustrate	 a	 38%	 homology	 similarity	 to	 the	 PER	 type	 ESBLs	 and	 illustrate	 high	 levels	 of	
resistance	to	cefotaxime,	ceftazidime	and	aztreonam	(32).					
Other	uncommon	ESBL	families	have	also	been	reported;	these	include	CME-1,	TLA-1,	SFO-1	
and	GES-1.		These	enzymes	are	most	commonly	associated	with	resistance	in	Pseudomonas	
aeruginosa	 however	 SFO	 has	 also	 been	 reported	 as	 conferring	 resistance	 within	
Enterobacteriaceae	(34).		
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The	 reported	 increase	 of	 ESBL	 producing	 organisms	 is	 of	 considerable	 clinical	 concern,	 as	
they	 demonstrate	 sensitivity	 to	 a	 reduced	 number	 of	 treatment	 options,	 making	 patient	
management	 challenging.	 	 In	 order	 to	 reduce	 inappropriate	 prescribing	 of	 antimicrobial	
agents,	 prompt	 identification	 and	 classification	 of	 the	 resistance	 mechanism	 being	
expressed	 is	 important.	 	 This	 will	 allow	 infection	 control	 actions	 at	 the	 patient	 level	 and	
forward	planning	of	antibiotic	policies	potentially	enhancing	antibiotic	stewardship.		
	
1.4	Classification	of	Extended	Spectrum	Beta-Lactamases	
There	 are	 currently	 two	 schemes	 for	 the	 classification	 of	 ESBL	 enzymes;	 the	 Ambler	
molecular	classification	scheme	(35)		and	the	Bush-Jacoby-Medieros	functional	classification	
system	(36).	 	As	the	names	suggest	each	scheme	is	based	on	very	different	properties	and	
they	are	used	in	combination	when	classifying	ESBL	producing	enzymes.	
The	 Ambler	 system	 divides	 the	 ESBLs	 into	 four	 major	 classes	 labelled	 from	 A-D.	 	 	 This	
classification	is	based	on	the	enzymes’	protein	homology	or	amino	acid	similarity	and	not	on	
phenotypic	characteristics.	 	This	 is	a	 stable	classification	system	as	 it	 reflects	 fundamental	
molecular	relationships	which	cannot	be	distorted	by	mutations.		Classes	A,	C	and	D	include	
all	 serine	 beta-lactamases,	 those	 that	 hydrolyse	 substrates	 through	 an	 active	 serine	 site.		
Class	 B	 includes	metallo	 beta-lactamases	which,	 in	 comparison,	 utilise	 at	 least	 one	 active	
zinc	site	to	confer	resistance	(35).		In	2005,	Hall	and	Barlow	identified	discrepancies	within	
the	Ambler	system,	noting	that	all	metallo	beta-lactamases,	although	being	grouped	within	
the	 same	 classification,	 did	not	 align	when	 considering	 the	DNA	or	protein	 sequences.	 	 It	
was	suggested	that,	since	differences	had	been	identified,	class	B	should	be	subdivided	into	
three	 groups	 B1,	 B2	 and	 B3.	 	 This	 correspondence	 concluded	 that	 modification	 to	 this	
system	would	facilitate	the	discovery	of	any	new	beta-lactamase	groups	(37).			
The	Bush-Jacoby-Medieros	system	divides	beta-lactamases	 into	four	major	classes	 labelled	
1-4,	 by	 functional	 similarities	 with	 further	 sub-divisions	 made	 according	 to	 the	 different	
substrate	 and	 inhibitor	 profiles.	 	 This	 is	 often	 considered	 to	 be	 of	more	 relevance	 to	 the	
diagnostic	setting	as	it	considers	clinically	relevant	beta-lactam	substrate	and	inhibitors	(36).				
The	 first	 functional	 group	 described	 by	 the	 Bush-Jacoby-Medieros	 system	 includes	 the	
chromosomal	and	plasmid	encoded	AmpC	beta-lactamases;	these	are	also	classified	within	
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group	C	of	the	Ambler	system.		This	group	also	includes	beta-lactamases	capable	of	cleaving	
all	beta-lactams	except	carbapenems	(12,	38).	
The	 second	 functional	 group	 described	 by	 the	 Bush-Jacoby-Medieros	 system,	 containing	
eight	subgroups,	incudes	the	most	diverse	group	of	enzymes;	these	are	also	classified	within	
groups	A	and	D	of	 the	Ambler	 system.	 	These	enzymes	have	a	great	efficiency	of	 transfer	
due	to	their	plasmid	origin;	 the	most	commonly	associated	enzymes	within	this	group	are	
TEM-1,	TEM-2	and	SHV-1.	 	All	of	 these	beta-lactamases	have	the	ability	 to	hydrolyse	both	
penicillins	 and	 cephalosporins.	 	 Subgroup	 2be,	 include	 ESBLs	 resulting	 from	mutations	 of	
TEM-1	and	SHV-1,	and	contains	enzymes	 that	have	 the	ability	 to	hydrolyse	penicillins	and	
first,	second,	third	and	fourth	generation	cephalosporins	(12).		Within	this	group	also	lie	the	
CTX-M	enzymes	due	to	their	ability	to	confer	resistance	to	cefotaxime.			
The	 third	 functional	group	contains	a	 less	diverse	 range	of	enzymes	but	 they	are	of	equal	
clinical	 importance.	 	 These	 include	 the	 serine	 beta-lactamases	 and	 also	 some	 of	 the	
carbapenemases;	 enzymes	 exhibiting	 resistance	 to	 carbapenems,	 for	 example	 imipenem,	
meropenem	 or	 ertapenem.	 	 Finally,	 the	 fourth	 functional	 group	 contains	 all	 other	 beta-
lactamases	that	have	not	been	mentioned	above.		It	should	also	be	noted	that	none	of	the	
Ambler	classes	fall	within	the	fourth	functional	group	(36).			
During	 2008,	 Giske	 et	 al.	 proposed	 redefining	 the	 classification	 of	 ESBLs	 with	 a	 view	 to	
simplifying	ESBL	terminology	to	meet	the	needs	of	clinical	and	infection	control	uses.		It	was	
thought	 that	 the	 Bush-Jacoby-Medieros	 and	 Ambler	 systems	 were	 aimed	 primarily	 for	
research	 purposes	 and	 that	 their	 complexity	 made	 them	 less	 accessible	 to	 healthcare	
professionals.	 	 The	 proposed	 system	 included	 both	 beta-lactamase	 classes	 and	 their	
operational	 definitions.	 	 Conclusions	 drawn	 from	 the	 reclassification	 exercise	 questioned	
whether	the	simplified	classification	system	may	prevent	the	detection	of	subtle	differences	
between	enzymes	within	various	groups,	however	this	was	not	intended	to	replace	current	
classification	systems	but	merely	complement	them	(39).		
By	 late	 2009	 information	 regarding	 beta-lactamase	 structure	 had	 increased	 considerably	
with	over	890	unique	protein	sequences	 identified.	 	With	this	additional	 information	Bush	
and	Jacoby	updated	and	expanded	the	original	classification	system.	 	As	with	the	previous	
system,	 enzymes	 were	 classified	 or	 aligned	 based	 on	 the	 inactivation	 of	 beta-lactamase	
inhibitors	 for	example	clavulanic	acid	or	 tazobactam	and	 the	ability	 to	hydrolyse	different	
beta-lactam	classes	(40).
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Group	1	now	contained	a	new	subgroup,	1e,	which	included	variants	of	group	1	with	greater	
activity	against	ceftazidime	as	a	 result	of	amino	acid	 insertions,	substitutions	or	deletions.		
These	enzymes	have	been	 termed	extended	spectrum	AmpC	beta-lactamases	and	 include	
CMY-10,	19	and	37.	 	Also	included	in	this	group	is	a	recently	described	AmpC	variant	from	
Pseudomonas	aeruginosa	with	increased	activity	against	imipenem	(41).			
Group	2	incorporated	the	addition	of	four	new	subgroups,	2ber,	2ce,	2de	and	2df.		Subgroup	
2ber	includes	the	TEM	enzymes	that	express	extended	spectrum	resistance	but	also	confer	
resistance	 to	 clavulanic	 acid	 inhibition.	 	 These	 enzymes	 have	 also	 been	 termed	 complex	
mutant	TEM	(CMT)	and	include	TEM-50	(40).			
Group	2c	which	previously	included	penicillinases	with	the	ability	to	hydrolyse	carbenicillin	
or	ticarcillin	now	contained	a	new	subgroup,	2ce.			Subgroup	2ce	contains	RTG-4,	a	recently	
discovered	 extended	 spectrum	 carbenicillinase	 with	 the	 ability	 to	 hydrolyse	 not	 only	
carbenicillin	but	also	cefepime	and	cefpirome	(42).			
Within	the	next	new	subgroup,	2de,	lie	the	enzymes	with	the	ability	to	hydrolyse	cloxacillin	
or	oxacillin	but	also	have	extended	spectrum	activity	against	oxyimino-beta-lactams	but	not	
carbapenems.	 	The	majority	of	enzymes	characterised	within	this	subgroup	are	derivatives	
of	OXA-10	with	 between	 1	 and	 9	 amino	 acid	 substitutions.	 	 Examples	 of	 such	 derivatives	
include	OXA-11	and	15.	 	 In	contrast	to	subgroup	2de,	group	2df	 includes	all	OXA	enzymes	
with	the	ability	to	hydrolyse	carbapenems,	these	enzymes	are	most	frequently	expressed	in	
Acinetobacter	baumannii	however	plasmid	mediated	resistance	within	OXA-23	and	OXA-48	
has	been	identified	within	Enterobacteriaceae	(43).			
A	 summary	 of	 the	 1995	 Bush-Jacoby-Medieros	 classification	 system,	 the	 updated	 [2009]	
Bush-Jacoby	system	and	the	molecular	Ambler	system	is	illustrated	within	Table	1.1.			Table	
1.2	illustrates	the	proposed	structure	of	the	simplified	classification	system	for	ESBLs.	
	
1.5	ESBL	Types	
As	previously	described	there	are	many	different	types	of	ESBLs,	a	large	proportion	of	which	
have	 evolved	 through	 point	 mutations	 of	 the	 beta-lactamase	 enzymes	 TEM	 or	 SHV	 (9).		
Other	ESBL	classes,	such	as,	CTX,	are	structurally	very	similar	to	TEM	and	SHV,	however,	the	
OXA	class	exhibits	very	different	characteristics.				
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Table	1-1,	The	1995	Bush-Jacoby-Medieros	classification	system,	the	updated	[2009]	Bush-Jacoby	system	and	
molecular	Ambler	 system	for	 the	classification	of	ESBL	enzymes.	 	These	classification	systems	align	different	
enzymes	 based	 on	 the	 inactivation	 of	 beta-lactamase	 inhibitors	 and	 the	 ability	 to	 hydrolyse	 different	 beta-
lactam	 antibiotic	 classes.	 	 These	 systems	 were	 thought	 to	 favour	 research	 making	 them	 less	 accessible	 to	
healthcare	professionals	(40).	
	
CA,	Clavulanic	Acid	 EDTA,	Ethylenediaminetetraacetic	acid	 PER,	VEB	and	PSE,	ESBL	classes	 															IMP	and	VIM,	carbapenemase	
TZP,	Tazobactam	 ACT,	CMY	and	FOX,	ESBL	classes	 	 CARB,	RTG	and	CepA,	ESBL	classes													CcrA	and	IND,	carbapenemase	
NI,	Not	Included	 MIR,	GC1,	and	PC1,	ESBL	classes			 KPC,	IMI	and	SME,	carbapenemase								CphA	and	Sfh-1,	carbapenemase	
	
Bush-Jacoby 
Group 2009 
Bush-Jacoby 
Medeiros 
Group 1995 
Ambler 
Class 
Distinctive 
Substrate(s) 
Inhibited by 
 
CA/TZP  EDTA 
Defining 
Characteristics 
Representative 
Enzyme(s) 
1 1 C Cephalosporins  No           No  Greater hydrolysis of 
cephalosporins than 
benzylpenicillin; 
hydrolyses cephamycins 
E.coli AmpC, P99, 
ACT-1, CMY-2, 
FOX-1, MIR-1 
1e NI C Cephalosporins  No           No Increased hydrolysis of 
ceftazidime and often other 
oxyimino-β-lactams 
GC1, CMY-37 
2a 2a A Penicillins Yes           No Greater hydrolysis of 
benzylpenicillin than 
cephalosporins 
PC1 
2b 2b A Penicillins, early 
cephalosporins 
Yes           No Similar hydrolysis of 
benzylpenicillin and 
cephalosporins 
TEM-1, TEM-2, 
SHV-1 
2be 2be A Extended 
spectrum 
cephalosporins, 
monobactams 
Yes           No Increased hydrolysis of 
oxyimino-β-lactams 
(ceftoaxime, ceftazidime, 
ceftriaxone, cefepime, 
aztreonam)  
TEM-3, SHV-2, 
CTX-M-15, PER-
1, VEB-1 
2br 2br A Penicillins No           No Resistance to clavulanic 
acid, sulbactam and 
tazobactam 
TEM-30, SHV-10 
2ber NI A Extended 
spectrum 
cephalosporins, 
monobactams 
No           No Increased hydrolysis of 
oxyimino-β-lactams 
combined with resistance 
to clavulanic acid, 
sulbactam and tazobactam 
TEM-50 
2c 2c A Carbenicillin Yes           No Increased hydrolysis of 
carbenicillin 
PSE-1, CARB-3 
2ce NI A Carbenicillin, 
cefepime 
Yes           No Increased hydrolysis of 
carbenicillin, cefepime and 
cefpirome 
RTG-4 
2d 2d D Cloxacillin Variable   No            Increased hydrolysis of 
cloxacillin or oxacillin 
OXA-1, OXA-10 
2de NI D Extended 
spectrum 
cephalosporins 
Variable   No            Hydrolyses cloxacillin or 
oxacillin and oxyimino-β-
lactams 
OXA-11, OXA-
15 
2df NI D Carbapenems Variable   No            Hydrolyses cloxacillin or 
oxacillin and carbapenems 
OXA-23, OXA-
48 
2e 2e A Extended 
spectrum 
cephalosporins 
Yes           No Hydrolyses cephalosporins.  
Inhibited by clavulanic 
acid but not aztreonam 
CepA 
2f 2f A Carbapenems Variable   No            Increased hydrolysis of 
carbapenems, oxyimino-β-
lactams, cephamycins 
KPC-2, IMI-1, 
SME-1 
3a 3 B Carbapenems No            Yes Broad-spectrum hydrolysis 
including carbapenems but 
not monobactams 
IMP-1, VIM-1, 
CcrA, IND-1 
3b 3 B Carbapenems No            Yes Preferential hydrolysis of 
carbapenems 
CphA, Sfh-1 
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Table	1-2,	the	proposed	structure	outlined	by	Giske	et	al.	to	redefine	the	classification	of	
ESBLs	(39).			
	
PER,	VEB	and	BES,	ESBL	classes	 	 DHA,	LAT	and	BIL,	ESBL	classes	 																 IMP	and	VIM,	carbapenemases	
ACT,	CMY	and	FOX,	ESBL	classes	 	 ACC,	CMT	and	SFO,	ESBL	classes														 SIM,	AIM	and	NMC,	carbapenemases	
MIR,	MOX,	and	DHA,	ESBL	classes		 BEL,	TLA	and	IBC,	ESBL	classes	 	 KPC,	IMI	and	SME,	carbapenemases					
GES	(1,	3,	7	and	9),	ESBL	classes							 SPM	and	GIM,	carbapenemases	 	 GES	(2,	4,	5,	6	and	8),	carbapenemases	
ESBLA,	Classical	class	A	ESBL	 	 ESBLM,	Miscellaneous	ESBL	 	 ESBLCARBA,	Carbapenemases	
ESBLM-C,	Plasmid	mediated	AmpC	class	C	 ESBLM-D,	OXA	ESBLs	class	D	 	 ESBLCARBA-A,	Class	A	carbapenemases	
ESBLCARBA-B,	Class	B	carbapenemases	 ESBLCARBA-D,	Class	D	carbapenemases	
	
	
Acquired	β-lactamases	with	hydrolytic	activity	against	extended	spectrum	cephalosporins		and/or	
carbapenems	
Β-Lactamase	
classes	
ESBLA	 ESBLM	 ESBLCARBA	
High	prevalence	ESBLA	
CTX-M	
TEM-ESBLs	
SHV-ESBLs	
VEB	
PER	
ESBLM-C	(Plasmid-mediated	
AmpC)	
CMY										LAT	
FOX											BIL	
MIR											ACT	
MOX									ACC	
DHA	
ESBLCARBA-A	
KPC	
GES-2,	-4,	-5,	-6,	-8	
NMC	
SME	
IMI-1,	-2	
Low	prevalence	ESBLA	
GES-1,	-3,	-7,	-9	
SFO-1	
BES-1	
BEL-1	
TLA	
IBC	
CMTa	
ESBL	M-D	(OXA-ESBL)	
OXA-10-group	
OXA-13-group	
OXA-2-group	
OXA-18	
OXA-45	
ESBLCARBA-B	(MBL)	
IMP	
VIM	
SPM-1	
GIM-1	
SIM-1	
AIM-1	
ESBLCARBA-D	(OXA-
Carbapenemases)	
OXA	–	23	group	
OXA	–	24	group	
OXA	–	48b	
OXA	–	58	group	
Operational	
definition	
Non-susceptibility	to	
extended-spectrum	
cephalosporins	
AND	
Clavulanate	synergy	
Non-susceptibility	to	extended-
spectrum	cephalosporins	
AND	
Phenotypic	detection	(ESBLM-C)	
OR	
Genotypic	detection	(ESBLM-D)	
	
Non-susceptibility	to	extended-
spectrum	cephalosporins	and	
at	least	one	carbapenem	
AND	
ESBL	CARBA	detected	with	
phenotypic		and/or	genotypic	
methods	
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1.5.1	 Inhibitor	Resistant	Beta-Lactamases	
Discovered	 within	 the	 1990s,	 inhibitor	 resistant	 beta-lactamases	 are	 a	 class	 of	 beta-
lactamase	enzymes	that	exhibit	resistance	in	the	presence	of	clavulanic	acid.		Although	this	
type	of	resistance	is	not	classified	as	an	ESBL,	they	are	often	discussed	as	ESBLs	as	they	are	
derivatives	 of	 the	 TEM	 or	 SHV	 enzymes.	 	 These	were	 initially	 given	 the	 title	 of	 inhibitor-
resistant	TEM	[IRT]	due	to	the	first	discoveries	being	variants	of	TEM-1	or	TEM-2.		There	are	
now	inhibitor	resistant	beta-lactamases	expressed	within	TEM,	SHV	and	CTX	type	enzymes,	
these	 include	 TEM	1,	 30-40,	 44,	 45,	 51	 and	 58	 (44),	 causing	 resistance	mainly	 associated	
with	 	E.	 coli,	Klebsiella	pneumoniae,	Klebsiella	oxytoca	 and	Citrobacter	 freundii.	 	Although	
inhibitor	 resistance	 beta-lactamases	 demonstrate	 resistance	 to	 clavulanic	 acid,	 rendering	
co-amoxiclav	 therapy	 ineffective,	 they	 remain	 susceptible	 to	 tazobactam	 allowing	
piperacillin-tazobactam	combinations	to	be	considered	as	a	treatment	option.					
Point	mutations	within	 the	gene	encoding	 the	TEM	enzyme	causing	 the	 inhibitor-resistant	
phenotype	 commonly	 result	 in	 polypeptide	 changes,	 resulting	 in	 a	methionine	 residue	 at	
position	69,	an	arginine	at	positions	244	or	275	and	an	asparagine	at	position	276	(19).		In	
comparison,	point	mutations	within	 the	 inhibitor	 resistant	phenotype	differ	 to	 that	of	 the	
ESBL	phenotypes,	however	-	TEM-50	exhibits	substitutions	common	to	both,	indicating	the	
possibility	 of	 a	 new	 class	 of	 beta-lactamase	 sharing	 both	 ESBL	 and	 inhibitor-resistance	
characteristics	(45).	
	
1.5.2	 TEM	
The	 TEM-1	 enzyme	 has	 been	 reported	 to	 be	 responsible	 for	 up	 to	 90%	 of	 ampicillin	
resistance	within	E.	 coli	and	penicillin	 resistance	 in	H.	 influenzae	and	N.	gonorrhoeae	 (28,	
46).		When	compared	to	the	extended	spectrum	TEM	type	there	are	a	number	of	amino	acid	
substitutions	 occurring	 within	 a	 limited	 number	 of	 positions	 [Figure	 1.3a],	 resulting	 in	
phenotypic	alterations,	such	as,	the	ability	to	hydrolyse	non-specific	beta-lactam	antibiotics	
or	an	altered	isoelectric	point.	 	The	most	frequent	substitutions	can	be	observed	at	amino	
acid	 position	 104	 where	 a	 lysine	 is	 substituted	 for	 a	 glutamate	 residue;	 at	 position	 164	
where	a	histidine	or	serine	is	substituted	for	an	arginine;	at	position	238	where	a	serine	is	
substituted	 for	a	glycine	and	at	position	240	where	a	 lysine	 is	 substituted	 for	a	glutamate	
(19).	 	 In	 addition	 to	 the	 above	 substitutions,	 one	 TEM-like	 enzyme,	 TEM-AQ,	 has	 a	
characteristic	 deletion	 of	 a	 single	 amino	 acid	 within	 its	 sequence,	 which	 has	 not	 been	
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reported	 in	 any	 other	 TEM	 enzymes	 (47).	 	 Since	 the	 description	 of	 the	 original	 TEM-1	
enzyme,	there	has	been	a	great	increase	in	the	number	of	ESBL	species	with	more	than	180	
TEM	 variants	 currently	 described.	 	 Although	 TEM	 type	 enzymes	 are	 most	 commonly	
expressed	within	 E.	 coli	 and	 Klebsiella	 pneumoniae	 they	 have	 now	 been	 detected	 within	
other	 species	 of	 Enterobacteriaceae	 with	 increasing	 frequency,	 including	 Enterobacter	
aerogenes,	Proteus	mirabilis,	Morganella	morganii	and	Salmonella	spp.	
	
1.5.3	 SHV	
Although	 less	 common	 than	 the	 TEM	 type	 beta-lactamases,	 SHV-1	 has	 been	 found	 to	 be	
responsible	 for	up	 to	20%	of	 the	plasmid	mediated	ampicillin	 resistance	 in	K.pneumoniae.		
SHV	 type	 enzymes	 have	 also	 been	 reported	 within	 other	 strains	 of	 bacteria	 including	 K.	
pneumoniae,	Citrobacter	diversus,	E.	coli	and	P.	aeruginosa,	and	they	are	expressed	 in	the	
most	commonly	found	conjugative	replicons	capable	of	host	chromosome	integration	(19).		
In	 comparison	 to	 the	 TEM	 type	 enzymes,	 SHV	 amino	 acid	 substitutions	 are	 confined	 to	
fewer	positions	[Figure	1.3b],	and	the	majority	of	SHV	derivatives	hold	the	ESBL	phenotype	
with	one	exception,	SHV-10,	which	is	an	SHV-5	derivative,	and	has	been	observed	to	express	
an	inhibitor	phenotype,	with	one	additional	amino	acid	substitution	–	a	serine	instead	of	a	
glycine	at	position	130	(48).			
Previous	 studies	 have	 indicated	 that	 TEM	 and	 SHV	 type	 enzymes	 have	 frequent	
substitutions	of	a	glycine	residue	at	position	238	and	a	lysine	replacing	glutamate	at	position	
240.	 	 These	 substitutions	 suggest,	 for	 the	 efficient	 hydrolysis	 of	 ceftazidime,	 it	 is	 highly	
important	 to	have	a	serine	at	position	238	and	 for	effective	hydrolysis	of	cefotaxime,	 it	 is	
critical	to	have	a	lysine	at	position	240	(49,	50).			
	
1.5.4	 CTX-M	
The	 CTX-M	 determinant,	 a	 more	 recently	 described	 family	 of	 plasmid	 mediated	 ESBLs,	
preferentially	hydrolyse	cefotaxime	and	share	a	40%	homology	similarity	with	the	TEM	and	
SHV	 type	 enzymes	 (46).	 	 In	 addition,	 the	 CTX	 determinant	 also	 has	 greater	 homology	
similarity	 [95-100%]	 to	 the	chromosomally	mediated	AmpC	enzyme	of	Kluyvera	ascorbata	
[Klu-1	 and	 Klu-2],	 suggesting	 that	 the	 first	 CTX-M	 enzymes	 originated	 from	 within	 this	
species.			
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[a]	
	
[b]	
	
Figure	1-3	[a]:	The	amino	acid	substitutions	in	TEM	ESBL	derivatives.		The	amino	acid	sequences	listed	within	
the	grey	bar	are	those	found	in	the	TEM-1	structural	gene.		All	substitutions	are	listed	above	or	below	with	the	
ESBL	variant	associated,	[b]	The	amino	acid	substitutions	in	SHV	ESBL	derivatives.		The	amino	acids	listed	
within	the	grey	bar	are	those	found	in	the	SHV-1	structural	gene.		All	substitutions	are	listed	above	or	below	
with	the	ESBL	variant	associated	(19).		
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CTX-M	 therefore	 represents	 an	 example	 of	 a	 plasmid	 encoded	 determinant	 that	 is	 often	
found	 at	 chromosomal	 locations	 (51).	 	 This	 class	 of	 ESBL	 includes	 the	 enzymes	 CTX-M-1	
through	to	CTX-M-10	as	well	as	Toho-1	and	Toho-2	(19,	52).		
The	phylogenetic	relationship	exhibited	by	this	family	of	beta-lactamases	indicates	that	they	
can	be	divided	in	five	major	types:	CTX-M-1	type,	including	CTX-M-1	and	CTX-M-3;	CTX-M-2	
type,	including	CTX-M-2,	CTX-M-4	to	CTX-M-7	and	Toho-1;	CTX-M-8	type	including	CTX-M-8	
and	 CTX-M-40;	 CTX-M-9	 type	 including	 CTX-M-9	 and	 CTX-M-15	 and	 the	 CTX-M-25	 type	
including	CTX-M-25	and	CTX-M-39.	All	of	the	CTX-M	enzymes	have	a	serine	at	position	237,	
which	plays	an	important	role	in	the	activity	of	this	class	of	beta-lactamases	(46).		Molecular	
modelling	studies	of	these	enzymes	suggest	that	the	arginine	at	position	276	is	equivalent	to	
the	arginine	at	position	244	found	in	TEM	or	SHV	types	which	plays	an	important	role	in	the	
hydrolysis	of	oxymino-cephalosporins	(52).	
CTX-M-type	enzymes	have	an	increased	ability	to	hydrolyse	first	generation	cephalosporins	
[cephalothin	 or	 chephaloridine].	 	 They	 also	 have	 the	 ability	 to	 hydrolyse	 third	 generation	
cefotaxime	and,	 to	a	 less	extent	ceftazidime,	although	the	hydrolysis	of	ceftazidime	 is	not	
great	enough	for	it	to	be	classified	as	clinically	resistant	(46).		CTX-M	beta-lactamases	have	
mainly	 been	 isolated	 from	Salmonella	 enterica	 serovar	 Typhimurium	and	E.	 coli,	 however	
they	 have	 recently	 been	 detected	 in	 other	 species	 of	 Enterobacteriaceae,	 including	 P.	
mirabilis,	C.	freundii	and	E.	cloacae	(19).	
CTX-M-15,	 first	 reported	 in	 India,	 has	 now	 become	 the	 most	 widely	 distributed	 CTX-M	
enzyme	(53).		Although	many	CTX	determinants	exist,	CTX-M-15	is	considered	of	importance	
due	to	its	ability	to	cause	infection	in	animals	and	humans,	and	have	the	ability	to	survive	in	
the	 environment	 (54).	 	 The	 rapid	 spread	 of	 this	 determinant	 type	 is	 associated	 with	 its	
plasmid	 nature,	 with	many	 different	 size	 plasmids	 associated	 with	 CTX-M	 resistance.	 	 Of	
concern	is	the	ability	of	plasmids	to	carry	multiple	resistance	determinants,	with	CTX-M-15	
often	 being	 accompanied	 by	 TEM-1	 or	 the	 aac(6’)-lb-cr	 gene	 conferring	 resistance	 to	
aminoglycosides	and	some	fluoroquinolones	(55).		
	
1.5.5	 OXA	
Another	family	of	ESBL	enzymes,	demonstrating	high	hydrolytic	activity	against	oxacillin	and	
cloxacillin	 and	 conferring	 resistance	 to	 ampicillin,	 are	 the	 OXA	 type	 enzymes.	 	 These	
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enzymes	 are	 poorly	 inhibited	 by	 clavulanic	 acid	 and	 EDTA,	 and	 illustrate	 intermediate	
resistance	 to	oxymino-cephalosporins	when	 cloned	 into	E.	 coli	 (56).	 	Within	 this	 family	of	
ESBLs	 there	 is	 low	 sequence	 homology	 similarity	 between	 its	 different	members.	 	 This	 is	
thought	 to	 be	 due	 to	 the	 original	 creation	 of	 OXA-type	 classes	 which	 was	 based	 on	
phenotypic	differences	rather	than	genetic	ones.	
Several	OXA	types	are	derivatives	of	OXA-10,	including	OXA-11,	OXA-14,	OXA-16	and	OXA-17	
(57).	 	 These,	 in	 comparison	 to	 other	 OXA	 derivatives,	 differ	 in	 one	 or	 two	 amino	 acid	
substitutions,	including	an	asparagine	residue	for	a	serine	at	position	73	or	an	aspartate	for	
a	glycine	at	position	157.		The	glycine	substitution	at	position	157	is	of	particular	interest	as	
it	seems	to	have	a	strong	correlation	to	high	level	ceftazidime	resistance	(58).	
OXA	 17	 differs	 slightly	 compared	 to	 other	 OXA	 beta-lactamases	 in	 that	 it	 possesses	 the	
ability	to	confer	resistance	to	both	cefotaxime	and	ceftriaxone	as	well	as	marginal	resistance	
against	 ceftazidime.	 	 The	 OXA	 18	 determinant	 also	 differs	 from	 other	 types	 as	 it	 is	 not	
inhibited	by	clavulanic	acid	(59).	 	OXA-48,	first	described	 in	2001,	demonstrates	resistance	
to	 all	 beta-lactam	 antibiotics	 including	 carbapenems	 (43).	 	 This	 type	 of	 resistance	
determinant	 is	of	particular	concern	as	carbapenemase	activity	reduces	treatment	options	
significantly.		
Several	OXA	type	beta-lactamases	do	not	possess	an	ESBL	phenotype,	such	as	OXA-20,	OXA-
22,	 OXA-24-27	 and	 OXA-30.	 	 These	 OXA	 enzymes	 mainly	 confer	 resistance	 within	 P.	
aeruginosa,	 in	 comparison	 to	 other	 types,	 that	 are	 also	 associated	 with	 resistance	 in	
members	of	the		Enterobacteriaceae	family	(19).	
	
1.5.6	 AmpC	
The	AmpC	determinant,	has	the	ability	to	hydrolyse	cephalosporins	and	cephamycins,	and	it	
can	 exhibit	 low	 rates	 of	monobactam,	 cefepime	and	 carbapenem	hydrolysations	 (60,	 61).		
As	previously	described,	it	was	suggested	that	AmpC	may	be	the	archetypal	structural	gene	
for	 the	beta-lactamase	enzyme	(62,	63).	 	 In	comparison	to	TEM	and	the	penicillinase-type	
beta-lactamase,	AmpC	differed	in	sequence	structure	but	it	is	similar	at	its	active	site,	with	
all	of	them	having	a	serine	residue	at	position	80	(63).		Detection	of	this	class	of	enzyme	is	
difficult	as,	unlike	other	beta-lactamases,	they	are	susceptible	to	clavulanic	acid	 inhibition,	
producing	 elevated	numbers	 of	 false	 susceptible	 results	when	disc	 diffusion	 identification	
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methods,	 including	clavulanic	acid,	are	used,	which	causes	 this	beta-lactamase	class	 to	be	
underestimated	(46,	64).			
The	 AmpC	 gene	 has	 been	 detected	 on	 the	 chromosome	 of	 many	 species	 of	
Enterobacteriaceae,	suggesting	chromosomal	transfer.	 	However	AmpC	enzymes	have	also	
been	 detected	 on	 transmissible	 plasmids	 in	 bacteria	 lacking,	 or	 poorly	 expressing,	 the	
chromosomal	blaampc	 gene;	 examples	 include	E.	 coli,	 K.	 pneumoniae	and	P.	mirabilis	 (13).		
The	key	catalytic	 residues	enabling	AmpC	activity	 include	 lysine	at	position	67,	 tyrosine	at	
position	 150,	 lysine	 at	 position	 315	 and	 alanine	 at	 position	 318.	 	 Substitutions	 at	 any	 of	
these	sites	will	dramatically	lower	enzyme	activity	(65).	
The	main	AmpC	determinant	types	include	the	plasmid	mediated	CMY-1	enzyme,	identified	
in	1989	in	South	Korea,	so	named	due	to	its	cephamycinase	activity	(66).		CMY-2	a	derivative	
of	CMY-1,	resulting	in	an	isoelectric	shift	to	9.0,	is	thought	to	have	been	translocated	onto	a	
plasmid	of	Citrobacter	freundii	which	then	spread	to	Klebsiella	pneumoniae	(67).			By	2009,		
43	allele	differences	had	been	detected	in	the	CMY	enzyme	(13).		Since	their	discovery	CMY	
resistance	determinants	have	been	found	within	a	range	of	organisms,	including	E.	coli	and	
their	associated	clinical	conditions	 (68).	 	Reports	of	CMY	resistance	 in	retail	chicken	meat,	
poultry	 farms	 and	 healthy	 domestic	 animals	 have	 raised	 concerns	 of	 animal	 to	 human	
transfer	and	potential	sources	of	intestinal	colonisation	(69).	
DHA	 another	 AmpC	 resistance	 type,	 so	 named	 after	 identification	 from	 a	 patients	 stool	
sample	 in	Dhahran	hospital,	 Saudi	Arabia,	has	now	been	 reported	 in	a	 range	of	 countries	
including	 the	United	States	of	America	 (70)	 and	 Japan,	where	 this	 resistance	determinant	
has	also	been	associated	with	carbapenem	resistance	(71).		Although	reported	in	a	range	of	
countries	DHA	is	reported	to	a	far	lesser	extent	in	comparison	to	CMY.	
				
1.5.7	 Other	Extended	Spectrum	Beta-Lactamases	
Currently	 seven	 types	 of	 PER	 ESBL	 determinants	 have	 been	 identified,	with	 the	 first	 case	
reported	 in	 1991	 from	 a	 patient	 in	 Turkey.	 	 PER-1	 has	 been	 associated	 with	 infections	
caused	by	Salmonella	spp,	Acinetobacter	spp	and	Proteus	vulgaris	and	it	has	been	shown	to	
be	 associated	 with	 the	 transmission	 of	 a	 large	 plasmid	 [154kb	 in	 size],	 or	 	 to	 be	
chromosomally	 located,	 depending	 on	 the	 different	 bacterial	 strains.	 	 The	 PER-1	 enzyme	
exhibits	 high	 levels	 of	 resistance	 to	 ceftazidime	 and	 aztreonam	 but	 is	 susceptible	 to	
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carbapenems	 (72).	 	 The	 PER-2	 enzyme,	 reported	 primarily	 from	 Argentina,	 has	 87%	
homology	 similarity	 to	 PER-1,	 including	 33	 amino	 acid	mutations	within	 the	mature	beta-
lactamase	 (73).	 	 The	 following	 five	 PER	 types	 are	 less	 common:	 PER-3,	 which	 was	 first	
discovered	 in	 France	 in	 an	 isolate	 of	 Aeromonas;	 PER-4,	 isolated	 in	 cultures	 of	 Proteus	
vulgaris;	 PER-5	 and	 PER-7	 determinants	 that	 have	 been	 associated	 with	 resistance	 in	
Acinetobacter	baumannii	and	PER-6,	reported	in	an	environmental	strain	of	Aeromonas	spp.	
The	 VEB-1	 determinant,	 so	 named	 after	 a	 4	 month	 old	 Vietnamese	 child	 suffering	 from	
respiratory	problems,	had	54%	homology	similarity	with	the	PER-1	and	PER-2	type	enzymes.		
Genetic	analysis	of	 the	VEB-1	enzyme	revealed	that	this	enzyme	 is	encoded	within	a	gene	
cassette.	 	Gene	cassettes	are	mobile	units,	which	comprise	a	gene[s]	and	a	recombination	
site	 that	 are	 part	 of	 an	 integrin	 or	 a	 plasmid.	 	 Carrying	 antibiotic	 resistant	 genes	 in	 this	
manner	 allows	 the	 easy	 transfer	 of	 genetic	 information	 and	 resistance	 patterns	 to	 other	
bacterial	 species.	 	 Exploration	 of	 the	 gene	 cassette	 identified	 not	 only	 the	 antibiotic	
resistance	 associated	with	 beta-lactamase	production,	 	 but	 also	 a	 second	 resistance	 gene	
associated	with	aminoglycosides	(32).		
	
1.6	Epidemiology	of	ESBL	Producing	Organisms	
Enterobacteriaceae	 have	 been	 recognised	 as	 a	 major	 cause	 of	 both	 nosocomial	 and	
community	acquired	infections	for	many	years.	 	Until	recently	beta-lactams	have	been	the	
main	therapeutic	agents	of	choice	for	the	treatment	of	such	infections,	however	resistance	
to	 these	 antimicrobials	 have	 been	 reported	worldwide	with	 increasing	 frequency,	making	
treatment	options	more	challenging	(46).	
The	spread	of	ESBL	producing	organisms	began	after	beta-lactam	antibiotics	were	routinely	
used	 clinically	 within	 Western	 Europe.	 	 Shortly	 after	 this	 period	 they	 were	 reported	 in	
different	 continents,	 particularly	 Asia	 and	 the	 US	 (19).	 	 The	 recent	 increase	 and	
dissemination	 of	 ESBL	 production	 is	 thought	 to	 be	 a	 result	 of	 over	 prescribing	 and	
inappropriate	use	of	antibiotics	in	human	and	animal	infections,	and	as	growth	enhancers	in	
farming	 practices,	 hospital	 cross-infection,	 contamination	 into	 the	 food	 chain,	 human	
migration	and	the	potential	failure	of	clinical	laboratories	to	detect	or	recognise	resistance	
mechanisms.	 	 In	 recent	 years,	 the	 number	 of	 ESBL	 infections	 has	 risen	 significantly,	
especially	 within	 E.	 coli,	 in	 contrast	 to	 the	 1990s	 where	 ESBL	 determinant	 presence	 was	
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observed	primarily	in	K.	pneumoniae	(27).		The	Health	Protection	Agency	[HPA]	surveillance	
data	collected	between	1994	and	2004	illustrated	that	cases	of	bacteraemia	caused	by	ESBL	
producing	E.	coli	more	than	doubled	from	8,640	to	17,416	cases	(74).	
Although	reports	of	ESBL	 infections	have	 increased,	ESBL	expression	rates	within	different	
countries	does	 vary.	 	 Reinert	et	al.	 [2007],	completed	a	 study	between	 January	2004	and	
August	2006	to	determine	the	Tigecycline	susceptibility	of	isolates	associated	with	hospital	
infections	from	266	centres	in	Asia,	North	America,	Latin	America	and	Europe.		The	greatest	
detection	 of	 ESBL	 resistance	 was	 in	 Klebsiella	 pneumoniae	 [44%],	 and	 E.	 coli	 [14%]	 for	
centres	in	Latin	America.		Asian	centres	also	showed	a	high	incidence	of	ESBL	detection	with	
22%	of	them	in	Klebsiella	pneumoniae	and	12%	in	E.	coli.		A	slightly	lower	incidence	rate	was	
observed	 in	European	hospitals	with	13%	of	determinants	 found	 in	Klebsiella	pneumoniae	
isolates	 and	 8%	 in	 E.	 coli.	 	 Overall,	 Indian	 centres	 had	 the	 greatest	 prevalence	 of	 ESBL	
infections	in	Enterobacteriaceae	[72%],	followed	by	those	from	Mexico	[71%],	Greece	[43%]	
and	Poland	[38%].	 	This	study	reported	no	ESBL	producing	Klebsiella	pneumoniae	or	E.	coli	
from	 centres	 in	 Austria,	 Czech	 Republic,	 Denmark,	 Finland,	 Ireland,	 Switzerland	 and	 The	
Netherlands	(75).		Interestingly	after	this	study	was	completed	in	2006,	a	report	published	in	
2011	by	Huemer	et	al.	showed	that	ESBL	prevalence	in	Austria	had	started	to	increase,	with	
incidents	of	E.	coli	 isolates	causing	urinary	tract	 infections	in	outpatients	at	 levels	of	8%	in	
Innsbruck	and	5%	in	Bolzano	(76).		A	similar	picture	could	also	be	seen	in	Denmark.		Hansen	
et	al.	 (77)	 investigated	ESBL	prevalence	 rates	 found	 in	 infections	between	September	and	
October	 2007.	 	 Their	 analysis	 of	 14,674	 isolates	 revealed	 352	 positive	 ESBL	 bacteria,	
resulting	 in	 a	 prevalence	 level	 of	 2%.	 	When	 compared	 to	 data	 obtained	 in	 2003,	 these	
results	highlighted	a	significant	increase	in	the	prevalence	of	ESBL	infections.		Reduction	in	
susceptibility	 to	 gentamicin	 and	 ciprofloxacin	 was	 also	 noted,	 reducing	 the	 treatment	
options	for	serious	infections	further	(77).		Within	the	United	Kingdom	[UK]	the	prevalence	
of	ESBL	 infections	mirrored	that	 found	 in	Europe.	 	Horner	et	al.	 (78)	 reported	an	8%	ESBL	
detection	 rate	 when	 studying	 770	 E.	 coli	 bacteraemia	 isolates	 within	 the	 Yorkshire	 and	
Humber	 region.	 	 Results	 of	 this	 study	 also	 highlighted	 an	 increase	 in	 ESBL	 expression	
between	2010	[5%	ESBL	detection]	and	2012	[13%	ESBL	detection].	Although	this	region	of	
the	 UK	 demonstrated	 a	 slightly	 higher	 ESBL	 prevalence,	 susceptibility	 data	 revealed	 low	
levels	of	 resistance	 [14%	and	7%]	 to	ciprofloxacin	and	gentamicin	 (78).	 	Horner	et	al.	 (79)	
also	 demonstrated	 that	 there	 was	 a	 6%	 ESBL	 detection	 rate,	 when	 investigating	 6614	
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Enterobacteriaceae	 isolates,	 collected	 from	urine	 samples,	within	 the	 Leeds	 and	Bradford	
area.		A	higher	incidence	of	ESBL	expression	was	detected	in	Klebsiella	spp	[15%]	compared	
to	 E.coli	 [5%]	 and	 P.mirabilis	 [2%].	 	 Increased	 levels	 of	 ciprofloxacin	 resistance	 were	
observed	within	this	study	[53%]	however	gentamicin	resistance	remained	low	(79).	
One	disturbing	aspect	of	ESBL	epidemiology	is	the	increasing	detection	of	these	organisms	
in	 the	 outpatient	 and	 community	 populations.	 	 During	 2009	 and	 2010	 Burke	 et	 al.	 (80)	
investigated	the	distribution	of	specific	ESBL	clones	to	determine	the	relationship	between	
community	 healthcare	 ESBL	 infections	 and	 those	 seen	 within	 Beaumont	 hospital,	 Dublin	
Ireland.		They	identified	that	these	isolates	were	clonal	and	sporadic,	with	a	pandemic	clone	
that	was	dominant	 in	community	and	hospital	patients.	 	Molecular	typing	of	strains,	using	
pulse	 field	 gel	 electrophoresis	 [PFGE],	 antimicrobial	 susceptibility	 test	 data,	 clinical	
information	 and	patient	 demographics	were	 combined	 in	 an	 analysis	 that	 indicated	 there	
was	continuous	recycling	of	the	pandemic	clone	between	healthcare	facilities	(80).	
The	 European	 Network	 of	 National	 Surveillance	 Systems	 of	 Antimicrobial	 Resistance	
produces	 a	 yearly	 report	 to	 highlight	 and	 compare	 the	 levels	 of	 invasive	 infections	 as	 a	
result	of	 resistant	bacteria	within	European	countries,	available	at	http://ecdc.europa.eu/.	
Figure	1.4	highlights	the	 level	of	third	generation	cephalosporin	resistance	 in	[a]	2001	and	
[b]	 2012.	 	 Results	 should	 be	 determined	with	 caution	 as	 any	 epidemiological	 information	
can	 be	 biased	 by	 reporting,	 monitoring,	 sampling	 differences	 and	 different	 laboratory	
detection	methods	(81).					
The	increased	incidents	of	ESBL	infections	in	hospitals	and	the	community,	and	the	spread	
of	expressed	resistances	in	different	bacterial	species	suggest	that	there	is	a	change	in	the	
dissemination	of	ESBL	resistance.		Until	the	1990s,	most	ESBL	expression	was	predominately	
TEM	or	SHV,	however	these	have	currently	been	overtaken	by	CTX-M	(27,	46,	82).		The	
increase	in	prevalence	of	CTX-M	expression	supports	the	theory	that	the	increase	in	ESBL	
numbers	could	have	originated	in	the	community,	and	have	been	imported	into	the	hospital	
setting.	
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Figure	 1-4,	 Data	 collected	 by	 the	 European	 Network	 of	 National	 Surveillance	 Systems	 of	
Antimicrobial	Resistance	collected	in	[a]	2001	and	[b]	2012.		Results	highlight	and	compare	the	levels	
of	invasive	infections	as	a	result	of	Gram	negative	resistant	bacteria	within	European	countries	(81).	
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There	are	several	lines	of	evidence	that	support	this	theory:	[1]	the	transfer	of	CTX-M-2	and	
CTX-M-9	has	been	demonstrated	between	poultry	and	humans	(46);	[2]	the	origin	of	CTX-M	
resistance	 determinants	 is	 chromosomally	 derived	 and	 present	 in	 many	 environmental	
bacteria	 such	 as	 Kluyvera	 spp.	 (83);	 and	 [3]	 these	 determinants	 have	 been	mobilised,	 as	
suggested	by	the	widespread	occurrence	of	them	in	organisms	such	as	Shigella	spp,	Vibrio	
cholerae	 and	 non-typhoid	 Salmonella,	 as	 compared	 with	 SHV	 and	 TEM	 determinants.		
Furthermore,	 the	 increased	 incidence	of	 ESBL	 infections	 has	 coincided	with	 a	 decrease	 in	
the	 prevalence	 of	 methicillin-resistant	 S.aureus	 [MRSA],	 suggesting	 that	 different	
mechanisms	account	 for	ESBL	 spread	and	 that	 control	methods	 for	MRSA	cannot	prevent	
outbreaks	 of	 ESBL	 organisms	 (84).	 	 Understanding	 the	 different	 species	 involved	 in	 the	
expression	of	CTX-M	type	ESBL	resistance	may	have	important	 implications	for	the	control	
and	spread	of	such	infections	(58,	59).		The	most	widespread	CTX-M	enzymes	are	CTX-M-14,	
CTX-M-3	and	CTX-M-2.	 	These	have	been	 isolated	from	both	humans,	sewage	and	healthy	
animals,	which	could	be	considered	reservoirs,	and	have	been	implicated	in	small	country-
wide	and	international	outbreaks	(56,	85).		These	types	of	infection	have	been	observed	in	
the	 nosocomial	 and	 community	 setting,	 in	 multiple	 geographical	 locations	 and	 are	
consistent	 with	 the	 emergence	 from	 a	 widespread	 reservoir	 due	 to	 independent	 genetic	
events	including	the	mobilisation	of	the	blaCTX-M	genes	from	environmental	bacteria	(52).												
Research	has	attempted	to	assess	if	faecal	carriage,	due	to	intestinal	colonisation	with	ESBL	
producing	organisms,	increases	the	risk	of	ESBL	infections,	particularly	those	of	the	urinary	
tract.	 	 Different	 levels	 of	 intestinal	 colonisation	 have	 been	 observed	 depending	 on	 the	
location	of	the	patient.		Warren	et	al.	[2008]	investigated	475	faecal	samples	and	reported	a	
2%	 colonisation	 rate	 within	 patients	 residing	 in	 the	 community	 compared	 to	 5%	 for	
hospitalised	patients.	 	Further	observations	revealed	that	the	ratio	of	faecal	carriage	being	
converted	 to	 infection	 was	 statistically	 greater	 in	 isolates	 with	 gentamicin	 susceptibility	
compared	 to	 resistant	 strains.	 	When	considering	 length	of	 intestinal	 colonisation,	25%	of	
the	participants	within	this	study	remained	colonised	for	more	than	one	year	(86).	
	
1.7	Potential	Sources	of	Intestinal	Colonisation	
There	 are	 many	 theories	 as	 to	 the	 source	 of	 intestinal	 colonisation	 of	 ESBL	 producing	
organisms	including:	contaminated	food;	bacterial	transfer	from	infected	animals;	travel	and	
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potential	selective	pressures	from	receiving	antimicrobial	chemotherapy.		Colonisation	rates	
range	depending	on	the	geographical	location,	travel	history,	length	of	stay,	and	diet	of	the	
individuals	 studied.	 	 Kuenzli	et	 al.	 [2014]	 reported	 colonisation	 rates	 of	 69%	within	 Swiss	
travellers	returning	from	India,	Sri	Lanka,	Nepal	and	Bhutan.		Highest	rates	were	reported	in	
those	returning	from	India	compared	to	those	returning	from	Sri	Lanka	(87).		Lubbert	et	al.	
[2015]	 performed	 a	 similar	 study	 to	 evaluate	 ESBL	 colonisation	 rates	 of	 international	
travellers,	 traveling	 to	 Asia,	 Africa	 and	 South	 America,	 returning	 to	 Germany.	 	 Results	
demonstrated	 that	 39%	 of	 the	 travellers	 returned	 colonised	 with	 an	 ESBL	 producing	
organism.		Risk	factors	for	colonisation	included	the	occurrence	of	gastroenteritis,	however	
strict	hand	hygiene	and	the	consumption	of	bottled	water	were	not	 linked	with	significant	
protection.	 	 Colonisation	persistence	was	measured	6	months	 after	 travel	with	 9%	of	 the	
travellers	 suffering	persistent	colonisation	 (88).	 	These	studies	however	are	challenging	 to	
control,	 unless	 participants	 are	 screened	 prior	 to	 travel,	 the	 evidence	 that	 resistance	
determinants	are	contracted	through	foreign	travel	becomes	less	convincing.		Nevertheless	
travel	to	selected	geographical	locations	should	be	not	ruled	out	as	a	risk	factor.		
A	 number	 of	 studies	 have	 estimated	 ESBL	 colonisation	 rates	 within	 the	 nosocomial	
environment.	 	 Levy	 et	 al.	 [2010]	 investigated	 K.	 pneumoniae	 producing	 ESBL	 within	 the	
gastrointestinal	tract	of	children	admitted	to	the	paediatric	intensive	care	unit	in	a	hospital	
in	 Brazil.	 	 Of	 the	 children	 tested	 14%	 of	 the	 total	 were	 positive	 for	 ESBL	 colonisation,	
although	7%	of	these	were	colonised	prior	to	admission	to	hospital,	the	source	of	which	was	
unknown	(89).		Vervoort	et	al.	[2014]	determined	the	numbers	of	fluoroquinolone	resistant	
ESBL	 producing	 Enterobacteriaceae	 in	 patients	 diagnosed	 with	 antibiotic	 associated	
diarrhoea.		This	study	revealed	that	37%	of	the	patients	examined	were	colonised	with	ESBL	
producing	 Enterobacteriaceae.	 	 Interestingly	 patients	 diagnosed	 with	 Clostridium	 difficile	
infection	 exhibited	 higher	 colonisation	 rates	 [62%],	 including	 those	 resistant	 to	
fluoroquinolones,	compared	to	the	non-Clostridium	difficile	infected	patients.		Vervoot	et	al.	
concluded	 that	 stringent	 infection	 control	measures	 are	 important	within	 the	 nosocomial	
environment,	 particularly	 considering	patients	with	Clostridium	difficile	 infections	because	
they	 have	 a	 greater	 potential	 for	 ESBL	 colonisation,	 increasing	 the	 risk	 of	 transmission	 to	
other	susceptible	patients	(90).	
Other	 studies	have	highlighted	 that	 the	handling	of	animals	and	 the	consumption	of	 food	
sources	 harbouring	 ESBL	 producing	 organisms	 could	 be	 a	 potential	 route	 of	 colonisation.		
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The	World	Health	Organisation	[WHO]	reported	that	the	immense	use	of	antibiotics	in	non-
human	 infections,	 for	 animal	 prophylaxis	 and	 as	 growth	 enhancers	 is	 of	 great	 concern.	
Increasing	the	risk	of	passage	of	resistance	determinants	from	animal	origin	to	humans	(91).			
Rasheed	et	 al.	 [2014]	 identified	 food	 sources	 and	 environmental	 samples	 that	 harbour	E.	
coli	with	 resistance	 to	one	or	more	antibiotic	drugs	used	within	medicine	and	agriculture.		
ESBL	organisms	were	 isolated	 from	vegetable	 salads,	 raw	chicken,	 raw	egg	and	other	 raw	
meat,	raising	concerns	that	the	transfer	of	resistance	from	pathogens	associated	with	food	
products	 is	common.	 	This	study	concluded	that	good	hygiene	practices	are	essential	both	
within	industrial	and	domestic	food	preparation	areas	(92).		Chicken	has	been	reported	as	a	
potential	source	of	contamination	a	number	of	times:	Casella	et	al.	[2014]	identified	CTX-M	
type	 resistance	genes	within	 chicken	meat	 in	Brazil	 (93);	 Zarfel	et	al.	 [2014]	 isolated	ESBL	
producing	organisms	within	chicken	meat	 in	Austria	 (94)	and	Abreu	et	al.	 [2014]	recorded	
the	 level	of	ESBL	within	 the	 intestinal	 tract	of	 live	chicken	and	 identified	 the	potential	 for	
chicken	to	be	a	reservoir	for	human	colonisation	(95).		Evidence	that	human	intestines	were	
colonised	 by	 ESBL	 producing	 bacteria	 from	 chicken	meat	was	 provided	 by	 Leverstein-van	
Hall	 et	 al.	 [2011],	who	 identified	 six	 chicken-specific	 ESBL	 enzymes	 in	 35%	 of	 the	 human	
infections	studied	 (96).	 	ESBL	producing	bacteria	have	emerged	as	an	 important	source	of	
human	 infection	 that	 can	 acquire	 multiple	 drug	 resistances	 and	 colonise	 the	 human	
intestine,	 increasing	 the	 potential	 to	 infect	 other	 areas	 of	 the	 body.	 	 The	 colonisation	 of	
these	 organisms	 in	 the	 gut	 could	 present	 a	 possibly	 greater	 challenge	 compared	 to	 that	
posed	by	MRSA,	 a	 skin	organism/commensal,	 as	 the	use	of	 surgical	 skin	 formulations	 can	
sufficiently	 reduce	 or	 remove	 colonisation	 on	 the	 skin,	 organisms	 located	 within	 the	 gut	
microflora,	however,	are	more	challenging	to	control	(97).		
	
1.8	Detection	of	ESBL	Producing	Bacteria	
With	 the	 increased	 prevalence	 of	 ESBL	 determinants,	 the	 need	 for	 sensitive	 laboratory	
methods	to	detect	and	identify	their	presence	was	required.		Timely	and	accurate	diagnosis	
of	 ESBL	 production	 is	 of	 great	 importance,	 with	 laboratory	 results	 influencing	 clinical	
decision-making,	 therapy	 choice	 and	 the	 implementation	 of	 infection	 control	 measures.				
Laboratory	 detection	 of	 ESBL	 producing	 organisms	 can	 be	 divided	 into	 two	 groups,	
phenotypic	 and	 genotypic	 methods.	 	 Phenotypic	 approaches	 utilise	 non-molecular	
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techniques	 and	 detect	 the	 enzymes’	 ability	 to	 hydrolyse	 different	 antimicrobial	 agents.		
These	 types	of	 tests	usually	 consist	of	disk	diffusion	methods	and	 they	are	primarily	used	
clinically.	 	Genotypic	methods	utilise	molecular	 techniques	 to	detect	 the	gene	 responsible	
for	ESBL	production	or	to	produce	a	karyotype	for	a	particular	strain.		Molecular	techniques	
include	polymerase	chain	reaction	[PCR],	using	enzyme	specific	primers,	and	Pulse	Field	Gel	
Electrophoresis	[PFGE]	(61).			
In	conjunction	with	the	National	Health	Service	[NHS],	Public	Health	England	[PHE],	formally	
known	 as	 the	 Health	 Protection	 Agency	 [HPA],	 has	 produced	 a	 standard	method	 for	 the	
detection	 and	 reporting	 of	 ESBL	producing	organisms.	 	 This	method	 is	 also	 in	 accordance	
within	 the	 Clinical	 and	 Laboratory	 Standards	 Institute	 [CLSI]	 and	 the	 British	 Society	 of	
Antimicrobial	 Chemotherapy	 [BSAC]	 guidelines.	 	 The	 method	 recommends	 a	 two-step	
approach	if	an	ESBL	producing	organism	is	suspected	(98).		
• Recognition	 of	 ESBL	 producing	 bacteria,	 this	 is	 determined	 by	 investigating	
species	 of	 Enterobacteriaceae	 isolated	 from	 both	 hospital	 and	 community	
patients.	 	 Isolates	 from	 patients	 within	 a	 hospital	 setting	 should	 be	 primarily	
screened	 using	 ceftazidime	 and	 cefotaxime	 or	 cefpodoxime	 as	 a	 resistance	
indicator.	 	 In	 comparison	 isolates	 from	 community	 patients	 should	 only	 be	
screened	 using	 cefpodoxime	 as	 an	 indicator	 along	with	 the	 standard	 antibiotic	
panel.	
• PHE	 standards	 then	 recommend	 that	 any	 suspected	 ESBL	 producing	 organism	
should	 be	 investigated	 further	 using	 phenotypic	 identification	 methods.			
Phenotypic	detection	methods	include	a	range	of	both	manual	investigations	and	
automated	analysis.	
Double	 disc	 diffusion	 is	 an	 example	 of	 a	 manual	 phenotypic	 method	 for	 detecting	 ESBL	
production.	 	 This	 is	 an	easy,	 cost	effective,	method	 for	diagnostic	 laboratories	however	 it	
does	not	detect	AmpC	resistance	(99).	 	AmpC	and	ESBL	detection	 is	another	example	of	a	
manual	 method;	 this	 uses	 disc	 diffusion	 to	 identify	 ESBL	 and	 AmpC	 resistance	
simultaneously.		Ingram	et	al.	[2011]	aimed	to	evaluate	the	sensitivity	and	specificity	of	the	
methods	available	for	the	detection	of	AmpC	production	(100).	 	Screening	methods	based	
on	 cephamycin,	 ceftazidime	and	 cefepime	 susceptibility	 along	with	 confirmatory	methods	
including	 biologically	 based	 assays,	 inhibitor	 based	 assays,	 AmpC	 Etests	 and	 a	 rapid	
chromogenic	 assay	 were	 compared	 to	 an	 AmpC	 multiplex	 PCR	 and	 a	 three	 dimensional	
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enzyme	 extraction	 assay.	 	 Results	 demonstrated	 that	 the	 screening	 methods	 had	 a	
sensitivity	 range	 from	 47-99%	 and	 a	 specificity	 range	 from	 45-95%.	 	 The	 confirmatory	
methods	 illustrated	 varied	 results;	 however	 only	 the	 disc	 diffusion	method	 incorporating	
TRIS-EDTA	and	the	ESBL	and	AmpC	detection	disc	diffusion	technique	listed	above	gave	both	
sensitivities	and	specificities	above	90%	(100).		
A	number	of	chromogenic	culture	media	with	the	ability	to	differentiate	between	non	ESBL	
and	ESBL	producing	organisms	are	now	available.	 	 These	 types	of	media	contain	different	
chromogen	 mixes	 and	 bacteria	 are	 identified	 by	 their	 ability	 to	 utilise	 the	 different	
chromogens	 and	 produce	 coloured	 colonies.	 	 Antibiotics,	 for	 example	 cefotaxime	 and	
ceftazidime,	are	often	included	to	 inhibit	the	growth	of	sensitive	organisms.	 	 	Huang	et	al.	
[2010]	aimed	to	evaluate	ChromID	ESBL	agar,	a	leading	brand	manufactured	by	Biomerieux,	
compared	 to	 the	 new	 Brillance	 ESBL	 agar,	 Oxoid.	 	 Both	 of	 the	 chromogenic	 agars	
demonstrated	sensitivity	levels	of	94.9%,	and	specificities	of	95.5%	and	95.7%	respectively.		
There	was	a	negative	predictive	value	of	99.3%	suggesting	that	Brilliance	media	is	as	good	as	
ChromID	and	will	provide	an	excellent	screening	tool	for	diagnostic	laboratories	(101).		
Phenotypic	methods	 are	 essential	 in	 the	 diagnostic	 environment	 due	 to	 ease	 of	 use	 and	
financial	 cost,	 however	 these	 methods	 only	 provide	 information	 regarding	 positive	 or	
negative	ESBL	production	and	little	regarding	the	gene	being	produced	and	which	subtype	is	
present.	 	 This	 information	 can	 however	 be	 obtained	 using	 genotypic	 techniques.	 	 An	
example	 of	 a	 genotypic	method	 for	 the	 detection	 of	 ESBL	 resistance	 genes	 is	 PCR.	 	 This	
method	 utilises	 primer	 sequences	 designed	 to	 adhere	 to	 the	 genetic	 sequence	 of	 choice	
allowing	 amplification	 of	 a	 gene	 to	 detectable	 levels.	 	 PCR	 is	 relatively	 expensive	 when	
compared	to	some	of	the	phenotypic	methods;	however	it	has	a	much	higher	sensitivity	and	
specificity.		Krishnamurthy	et	al.	[2013]	evaluated	both	phenotypic	and	genotypic	methods	
for	the	detection	of	ESBL	resistance.		Phenotypic	methods	demonstrated	a	lack	of	consistent	
sensitivity	 compared	 to	 the	 genotypic	 PCR	 which	 maintained	 both	 100%	 sensitivity	 and	
specificity.	The	conclusions	were	that	using	a	boiling	technique	for	DNA	extraction	followed	
by	centrifugation	provides	ease	of	use	and	reduces	the	cost	considerably	(102).	
The	 identification	 of	 clonality,	 between	 isolates	 carrying	 resistance	 determinants,	 using	
molecular	 methods	 is	 important	 to	 identify	 resistance	 spread	 within	 a	 study	 population.		
Enterobacterial	 Repetitive	 Intergenic	 Consensus	 [ERIC]	 PCR	 is	 an	 example	 of	 a	 technique	
that	 utilises	 primers	 designed	 to	 amplify	 regions	 of	 noncoding	 DNA	 [intergenic	 regions]	
27	
	
within	Gram	negative	enteric	organisms.		Analysis	will	result	in	multiple	band	patterns	that	
generate	unambiguous	DNA	bacterial	fingerprints,	allowing	for	phylogenetic	determination	
(103).		
Isoelectric	focusing	[IEF]	is	another	example	of	a	genotypic	method	to	detect	ESBL	activity.		
This	 method	 detects	 an	 enzyme	 or	 protein’s	 isoelectric	 point	 by	 introducing	 it	 to	 a	 pH	
gradient	 acrylamide	 gel	matrix.	 	 Upon	 addition	 of	 an	 electric	 current,	 negatively	 charged	
molecules	will	migrate	towards	the	positive	charge	and	positive	molecules	to	the	negative	
charge,	 until	 a	 point	 is	 reached	 where	 the	 pH	 of	 the	 molecule’s	 isoelectric	 point	 is	
accomplished.	 	 Sharma	et	al.	 [2010]	 aimed	 to	evaluate	ESBL	detection	using	 IEF	and	PCR.		
PCR	 detected	 84%	 of	 the	 50	 ESBL	 producing	 bacteria	 compared	 to	 64%	 using	 IEF,	
conclusions	 were	 drawn	 that	 although	 IEF	 was	 considered	 the	method	 of	 choice	 for	 the	
confirmation	 of	 ESBL	 production,	 it	 is	 labour	 extensive,	 expensive	 and	 requires	 specialist	
expertise	to	perform	(104).	
	
1.9	Treatment	Choices	
Treating	 infections	 caused	 by	 ESBL	 producing	 bacteria	 has	 proved	 to	 be	 a	 challenge	 for	
clinicians.	 	 Commonly	 used	 antibiotic	 classes,	 such	 as	 penicillins,	 third	 generation	
cephalosporins	 and	 monobactams,	 are	 often	 rendered	 ineffective	 for	 these	 types	 of	
infections.	 	 With	 ESBL	 production	 affecting	 both	 the	 nosocomial	 and	 community	 setting	
treatment	options	must	be	available	in	a	form	that	suits	both	sets	of	patient	demography.		
Here	 antimicrobial	 susceptibility	 information	 is	 important	 for	 diagnosis	 and	 in	 making	
treatment	decisions	that	target	ESBL	organisms.		A	study	by	Auer	et	al.	[2010]	illustrates	this	
point.	 	 In	an	evaluation	of	 the	oral	 therapy	given	 to	community	patients	 suffering	urinary	
tract	 infections	caused	by	ESBL	producing	E.	 coli,	 the	 resistance	 rates	 to	ciprofloxacin	and	
trimethoprim-sulfmethoxazole	 were	 above	 70%	 while	 those	 for	 gentamicin	 were	 around	
21%.	 	 With	 resistance	 levels	 as	 high	 as	 these,	 the	 authors	 recommended	 that	 these	
antimicrobials	should	not	be	used	for	the	treatment	of	ESBL	infections	but	rather	ones	for	
which	the	bacteria	exhibit	sensitivity.		In	this	study	these	included	fosfomycin,	for	which	the	
bacteria	 exhibited	 97%	 susceptibility,	 nitrofurantoin,	 94%	 susceptibility	 and	 ertapenem,	
100%	susceptibility	(105).		With	new	therapeutic	agents	being	discovered	at	a	slowing	pace,	
it	 may	 be	 necessary	 to	 employ	 previously	 used	 antimicrobial	 agents	 to	 combat	 ESBL	
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infections.		Pivmecillinam	is	an	example	of	an	oral	antibiotic	that	has	been	used	extensively	
within	 Nordic	 countries,	 but	 it	 is	 only	 prescribed	 in	 limited	 amounts	 in	 the	 UK	 and	
elsewhere.	 	 Evidence	 suggests	 that	 pivmecillinam	 has	 activity	 against	 ESBL	 producing	
organisms	and	potential	synergistic	activity	with	beta-lactamase	inhibitors	(106).		Aeur	et	al.	
[2010]	 also	 considered	 pivmecillinam	 as	 a	 treatment	 with	 varying	 results.	 	 Disc	 diffusion	
analysis	of	ESBL	producing	isolates	revealed	a	77%	susceptibility	and	an	85%	rate	when	the	
Etest	 method	 [antibiotic	 gradient	 to	 determine	 the	 MIC]	 was	 used	 (105).	 	 Although	 not	
considered	as	 a	 routine	 treatment	of	 choice	within	 this	 country,	 the	use	of	pivmecillinam	
has	 demonstrated	 better	 susceptibility	 results	 compared	 to	 ciprofloxacin	 and	 gentamicin,	
and	it	could	potentially	be	used	for	the	treatment	of	uncomplicated	urinary	tract	infections	
[lower	urinary	tract	infections	and	cystitis].			
Complicated	 urinary	 tract	 infections	 [upper	 urinary	 tract	 infections	 and	 pyelonephritis]	
caused	 by	 ESBL	 producing	 organisms,	 progressing	 to	 urosepsis,	 are	 also	 problematic	 for	
clinicians.	 	 Local	 prescribing	 guidelines	 are	 often	 inadequate	 and	 a	 delay	 in	 giving	 the	
appropriate	 treatment	 has	 been	 linked	 to	 increased	 mortality	 rates.	 	 Oral	 prescription	
options	 for	 the	 treatment	 of	 complicated	 urinary	 tract	 infections	 are	 limited.	 	Most	 ESBL	
producing	organisms	remain	susceptible	to	nitrofurantoin	however	this	 is	only	licensed	for	
lower	 uncomplicated	 urinary	 tract	 infections.	 	 A	 potential	 agent	 for	 the	 treatment	 of	
systemic	 infections	 is	 fosfomycin,	 although	 this	 is	 usually	 prescribed	 for	 uncomplicated	
infections,	 however,	 if	 pyelonephritis	 or	 severe	 urinary	 sepsis	 is	 suspected	 fosfomycin	
disodium	may	 be	 considered,	 as	 other	 formulations	 should	 not	 be	 used	 because	 of	 their	
limited	systemic	absorption	(107).			
Treatment	failures	have	also	been	reported	when	pivmecillinam	has	been	used	as	a	single	
agent,	 although	 an	 improvement	 was	 noted	 when	 it	 had	 been	 combined	with	 clavulanic	
acid,	 but	 this	 combination	 is	 unlicensed	 at	 present.	 	 Intravenous	 [IV]	 agents,	 such	 as	
gentamicin	and	ertapenem,	are	available	for	the	treatment	of	complicated	infections	if	the	
patient	is	hospitalised.		Currently	carbapenems,	for	example	meropenem	and	imipenem,	are	
the	treatment	of	choice	for	patients	suffering	from	ESBL	related	urosepsis	and	severe	sepsis	
(108).	 	 Concerns	 are	 however	 growing	 regarding	 acquired	 resistance	 to	 carbapenems,	
although	rare	carbapenemase	activity	has	been	reported	in	the	UK.		Klebsiella	pneumoniae	
carbapenemase	 [KPC]	 producing	 organisms	 have	 been	 isolated	 in	 the	 Royal	 Berkshire	
Hospital,	 South	 East	 England.	 	 Two	 cases	 of	 multi-resistant	 organisms	 demonstrating	
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carbapenemase	activity	were	described,	 the	first	associated	with	travel	 to	Curacao,	where	
the	patient	had	been	hospitalised	due	to	ill	health.		The	second	patient	presented	five	days	
after	the	discharge	of	the	first;	clinical	history	revealed	that	both	patients	had	attended	the	
hospital	 at	 the	 same	 time,	 residing	 in	 the	 same	 hospital	 bay.	 	 Phenotypic	 and	 genotypic	
analysis	 revealed	 the	 potential	 nosocomial	 spread	 of	 carbapenemase	 resistance	 (109).		
Increased	 reports	 of	 carbapenemase	 activity	 have	 also	 been	 noted	 in	 areas	 for	 example	
London,	an	outbreak	between	2008	and	2010	described	20	K.	pneumoniae	isolates	carrying	
the	OXA-48	determinant	in	13	patients	[12	renal	cases	and	1	oncology]	(110).		In	light	of	this	
outbreak	a	study	was	 initiated	to	determine	relationships	between	antibiotic	consumption	
and	 the	potential	 to	 forecast	 future	outbreaks.	 	 The	 study	 concluded	 that	monitoring	 the	
consumption	 of	 antimicrobial	 agents,	 in	 this	 case	 meropenem,	 was	 a	 potential	 tool	 for	
predicting	 the	 emergence	 and	 outbreaks	 of	 resistance	 and	 allowed	 the	 evaluation	 of	
antimicrobial	 stewardship	 programmes	 (111).	 	 Since	 the	 early	 reports	 of	 carbapenemase	
activity,	 PHE	 epidemiology	 data	 has	 revealed	 a	 significant	 increase	 in	 the	 numbers	 of	
organisms	 demonstrating	 resistance	 to	 carbapenems.	 	 OXA-48	 resistance	 has	 increased	
from	one	confirmed	case	in	2007	to	179	confirmed	cases	in	2013.		A	similar	picture	has	also	
been	observed	with	KPC	resistance	with	one	confirmed	case	 in	2003	rising	to	630	cases	 in	
2013	 (112).	 	 International	 travel,	 particularly	 to	 the	 Indian	 subcontinent,	 has	 also	 been	
associated	with	carbapenem	resistance,	this	is	due	to	a	recently	described	carbapenemase-
producing	organism	named	the	New	Delhi	metallo-beta-lactamase	[NDM]	(113).			
Picozzi	et	al.	[2009]	followed	49	patients	suffering	from	complicated	urinary	tract	infections	
that	required	hospital	admission.		Seven	of	these	patients	tested	positive	for	ESBL	producing	
E.	coli	 in	their	blood	and	urine	cultures.		The	study	discussed	the	importance	of	identifying	
risk	 factors	 when	 considering	 antimicrobial	 treatment	 options.	 	 These	 factors	 included	
recent	hospitalisation,	recent	surgery,	residence	within	a	long	term	care	facility	and	recent	
treatment	with	antimicrobial	agents.		It	also	concluded	that	the	management	and	treatment	
of	ESBL	infections	is	urgent	in	clinical	practice,	with	increasing	incidence	of	resistance	and	a	
reducing	 number	 of	 treatment	 options,	 multiple	 resistant	 bacteria	 are	 of	 great	 concern	
(114).	
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	 1.10	 	 Antibiotic	Use	and	the	Effects	on	the	Intestinal	Microbiota	
The	human	intestinal	tract	is	thought	to	harbour	around	1000	different	species	of	bacteria	
which	 reside	 in	a	complex	community,	and	contribute	 to	both	human	health	and	disease.			
Within	 this	 community	 it	 is	 also	 estimated	 that	 there	 are	 100-fold	 more	 genes	 present	
compared	 to	 the	 human	 genome,	 highlighting	 the	 potential	 for	 genetic	 exchange	 of	
determinants	within	a	diverse	bacterial	population.	The	impact	of	the	intestinal	microbiota	
on	 human	 health	 includes	 immune	 function,	 host	 metabolism,	 general	 physiology	 and	
nutrition	(115).		Evidence	now	suggests	that	the	microbiota	of	humans	evolves	with	us	and	
subtle	changes	to	diet,	the	location	in	which	we	live	and	the	consumption	of	antibiotics	may	
all	play	a	role	in	disrupting	the	communal	balance	of	the	intestinal	tract	(116).		Changes	to	
the	bacterial	composition	of	the	human	gut	can	have	pathological	consequences	 including	
malnutrition,	 obesity,	 diabetes,	 inflammatory	 bowel	 disease,	 intestinal	 infection	 and	
antibiotic	associated	diarrhoea,	potentially	leading	to	ulcerative	colitis	(115).	
Although	essential	in	the	treatment	of	infectious	diseases,	antibiotics	have	been	associated	
with	rapid	and	sometimes	persistent	changes	to	the	intestinal	microbiota.		The	use	of	broad	
spectrum	 agents,	 prior	 to	 the	 receipt	 of	 laboratory	 results,	 has	 been	 associated	 with	 a	
reduction	in	the	microbiota	bacterial	diversity.	 	 In	addition	the	presence	of	an	antibiotic	in	
the	 gastrointestinal	 tract	 allows	 for	 selection	 of	 resistant	 organisms	while	 those	 that	 are	
sensitive	to	the	agent	will	be	reduced	in	numbers	or	be	removed	completely	(117).	
One	of	the	earliest	reports	of	the	effects	of	antibiotics	on	the	intestinal	microbiota	was	the	
loss	 of	 colonisation	 resistance,	 or	 the	 loss	 of	 competitive	 exclusion.	 	 This	 effect	 saw	 a	
reduction	 in	 the	 number	 and	 diversity	 of	 organisms	 comprising	 the	 microbiota,	 which	
allowed	opportunistic	pathogenic	organisms	such	as	Salmonella	spp	to	colonise	the	area	and	
cause	disease.			
Antibiotic	selection	and	the	loss	of	colonisation	resistance	also	increase	the	risk	of	antibiotic	
associated	diarrhoea,	with	the	organism	Clostridium	difficile	being	particularly	problematic.		
The	 use	 of	 broad	 spectrum	 antibiotics,	 particularly	 third	 generation	 cephalosporins	 and	
clindamycin,	 allow	 resistant	 organisms,	 including	 Clostridium	 difficile,	 to	 populate	 and	
colonise	 the	 intestinal	 tract	 and	 potentially	 cause	 disease	 (118).	 	 Treatment	 for	 patients	
suffering	a	Clostridium	difficile	 infection	 initiate	by	 ceasing	any	antibiotic	 treatment,	 in	an	
attempt	 to	 repopulate	 the	 intestinal	microbiota.	 	 In	 those	patients	with	 severe	 infections,	
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faecal	 transplants	 have	 proven	 beneficial,	 initiating	 the	 repopulation	 of	 the	 intestinal	
microbiota	to	allow	colonisation	resistance	and	competitive	exclusion	(119).															
Selection	of	resistant	organisms	in	the	presence	of	an	antibiotic	has	the	potential	to	increase	
the	resistance	of	the	intestinal	microbiota.		The	mechanism	in	which	resistance	is	obtained	
is	 still	 in	 debate	 however	 include	 mutational	 changes	 within	 the	 bacterial	 genome	 and	
genetic	 exchange	 of	 resistance	 determinants	 through	 conjugation,	 transduction	 or	
transformation	 (117).	 	 Research	 has	 suggested	 that	 gene	 transfer	 is	 common	 in	 the	
intestinal	tract	and	it	is	estimated	that	human	associated	bacteria	are	25	times	more	likely	
to	 demonstrate	 the	 genetic	 exchange	 of	 determinants	 compared	 to	 environmental	
organisms	(117).	
												
1.11	 Clinical	Relevance	and	Impact	of	ESBL	Infections	
The	detection	and	 spread	of	ESBL	 infections	has	added	 to	 the	already	 increasing	 financial	
burden	of	healthcare	providers.		Increased	duration	of	hospital	stays,	prolonged	treatment	
options	and	additional	nursing	requirements	all	contribute	to	the	increased	costs	of	patient	
care.		The	European	branch	of	the	World	Health	Organisation	[WHO]	has	stated	that	within	
the	29	countries	of	 the	region,	25,000	 individuals	die	each	year	due	to	antibiotic	 resistant	
infections,	most	of	which	are	 contracted	within	 a	hospital	 or	healthcare	 setting	 (120).	 	 In	
addition	to	the	increased	cost	to	the	NHS,	the	spread	of	ESBL	producing	bacteria	within	the	
hospital	 and	 community	 setting	 has	 been	 one	 of	 the	 most	 significant	 epidemiological	
changes	 during	 recent	 years,	 increasing	 challenges	 for	 clinicians	 due	 to	 limited	 treatment	
options.	 	 Inadequate	empirical	 therapy	during	 initial	presentation	of	serious	 infections	has	
been	associated	with	 increased	mortality	 (38).	 	Reduction	 in	treatment	options	has	forced	
carbapenems,	particularly	meropenem,	to	be	the	treatment	of	choice,	however,	resistance	
as	 a	 result	 of	 overuse	 of	 this	 agent	 is	 also	 a	 concern	 (121).	 	 ESBL	 producing	
Enterobacteriaceae	 have	 the	 ability	 to	 cause	 a	 wide	 spectrum	 of	 disease,	 ranging	 from	
asymptomatic	 colonisation	 to	 serious	 infections	 including	 urinary	 tract	 infections,	
pneumonia,	bacteraemia	and	peritonitis.		
Many	studies	have	been	carried	out	that	assess	the	clinical	impact	of	ESBL	infections.		Earlier	
studies	 indicate	 that	 ESBL	 infections	were	 associated	with	 prolonged	 stay	 in	 hospital	 and	
careful	antibiotic	selection	(122),	however	more	recent	studies	have	evaluated	the	impact	of	
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ESBL	infections	outside	of	the	hospital	environment.		Yang	et	al.	[2010]	aimed	to	assess	the	
impact	and	outcome	of	community	onset	bacteraemic	urinary	tract	infections	both	with	and	
without	ESBL	production	 in	Taiwan.	 	Urinary	 tract	 infections	were	chosen,	as	 they	are	 the	
most	common	infections	requiring	antimicrobial	therapy	within	adults.		The	study	included	
58	patients,	and	12	infections	were	caused	by	ESBL	producing	organisms.		Results	indicated	
that	the	ESBL	group	demonstrated	a	higher	incidence	of	inappropriate	antibiotic	prescribing	
and	higher	intensive	care	unit	[ICU]	admission	rates	compared	to	non	ESBL	infections	(123).		
Mitchell	 et	 al.	 [2006]	 aimed	 to	 evaluate	 the	 clinical	 and	 economical	 impact	 of	 ESBL	
bacteraemia.	 	 In	this	evaluation	99	cases	resulting	from	ESBL	infections	were	compared	to	
99	control	patients.		Results	revealed	that	patients	with	ESBL	infections	had	a	higher	rate	of	
central	 venous	 and	 urinary	 catheters	 compared	 to	 the	 control	 group	 [45%	 and	 81%	
respectively	compared	to	20%	and	60%].		Higher	rates	of	surgery,	instrumentation,	dialysis	
and	 mechanical	 ventilation	 were	 also	 associated	 with	 ESBL	 infections	 compared	 to	 the	
control	group	[31%,	55%,	13%	and	30%	respectively	compared	to	11%,	26%,	4%	and	11%].		
A	 higher	 incidence	 of	 admission	 to	 ICU	 was	 also	 seen	 within	 the	 patients	 with	 ESBL	
infections,	 22%,	 compared	 to	 8%	 of	 the	 control	 group.	 	 A	 greater	 delay	 in	 receiving	 the	
appropriate	antimicrobial	therapy	was	also	seen	in	65	ESBL	patients	compared	to	seven	of	
the	control	patients.	 	The	study	concluded	 that	 future	efforts	 should	be	 targeted	 towards	
improving	 the	 detection	 and	 identification	 of	 ESBLs,	 improving	 treatment	 options	 and	
expanding	pharmacological	research	to	increase	therapeutic	choices	(124).	
	
1.12	 Study	Aims	
The	aims	of	this	study	were	to:	
• Generate	 phenotypic	 and	 genotypic	 epidemiological	 information	 from	 ESBL	
producing	bacteria	isolated	and	identified	in	four	hospitals	in	the	Hampshire	area.	
• Study	 the	 effects	 of	 bacterial	 growth	 and	 antibiotic	 resistance	 of	 ESBL	 producing	
organisms	resident	in	the	intestinal	microbiota,	prior	to	and	after	the	treatment	of	a	
complicated	urinary	tract	infection.			
• Identify	 potential	 sources	 of	 intestinal	 colonisation	 in	 Hampshire,	 by	 screening	
healthy	 animal	 faeces	 and	 commercial	 meat	 products	 for	 the	 presence	 of	 ESBL	
producing	organisms.	
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Individual	 hospitals	 within	 Hampshire	 gather	 epidemiological	 data	 regarding	 the	 patients	
located	in	that	catchment	area.		The	Hampshire	area	as	a	whole	lacks	epidemiological	data	
regarding	ESBL	producing	organisms	compared	to	other	areas	of	the	UK.	 	Local	Hampshire	
NHS	 trusts	 indicate	 that	 ESBL	 infections	 are	 increasing	 in	 numbers	 posing	 treatment	
challenges.	
To	 gain	 this	 information,	 ESBL	 producing	 isolates	were	 collected	 from	patients,	 attending	
hospitals	or	associated	GP	surgeries	in	four	Hampshire	areas	in	2010	and	2012,	these	were	
then	characterised	molecularly	and	microbiologically.	 	 This	 information,	 together	with	 the	
patient	 demographic	 data	 was	 used	 to:	 monitor	 increasing/decreasing	 levels	 of	 ESBL	
mediated	 resistance;	 identify	 increases/decreases	 in	 antibiotic	 resistance	 within	 the	
different	hospital	 locations	and	in	the	Hampshire	area;	determine	patient	ESBL	risk	factors	
in	 Hampshire	 and	 identify	 any	 clonality	 amongst	 the	 isolates	 and	 spread	 of	 resistance	
determinants.	 	 This	 information	 was	 then	 compared	 to	 antimicrobial	 drug	 prescribing	 in	
order	to	determine	if	increased	prescribing	of	certain	antimicrobial	agents	contribute	to	an	
increase	in	bacterial	resistance.	
The	 colonisation	 of	 ESBL	 producing	 organisms	 as	 part	 of	 the	 intestinal	 microbiota	 is	 a	
potential	patient	risk	factor	for	future	infections	due	to	these	organisms.		Antibiotic	therapy	
has	been	linked	to	increased	resistance	within	the	gut	microbiota	and	this	area	of	the	study	
aimed	to	 identify	the	effects	of	antimicrobial	 treatment	on	ESBL	 intestinal	colonisation.	 	A	
model	 gut	 system	was	 employed	 to	monitor	 the	 removal	 or	 inhibition	 of	 ESBL	 producing	
bacteria	 during	 the	 administration	 of	 antimicrobial	 therapy.	 	 The	 minimum	 inhibitory	
concentration	 of	 each	 organism	 was	 determined	 before	 and	 after	 dosing	 to	 assess	 the	
influence	of	the	particular	agent	on	the	 increase	or	decrease	 in	sensitivity	or	resistance	of	
the	ESBL	producing	organism.	
Entry	of	ESBL	producing	organisms	 into	 the	human	microflora	can	be	mediated	 through	a	
number	of	potential	 sources.	 	 In	 this	 section	of	 the	 thesis,	 food	 types	and	healthy	animal	
faeces	were	assayed	 for	 the	presence	of	 ESBL	producing	organisms.	 	Antibiotic	 resistance	
profiles	 of	 the	 isolates	 and	 ESBL	 determinant	 types	 were	 identified	 and	 sequenced.		
Comparison	 of	 the	 ESBL	 isolates	 from	 hospitals	 and	 the	 environment	 could	 potentially	
highlight	sources	of	intestinal	colonisation	and	human	ESBL	infection.	
The	combined	information	regarding	community	and	hospital-related	infections	associated	
with	ESBL	resistance,	the	identification	of	environmental	ESBL	producing	organisms	and	any	
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increased	 or	 decreased	 resistance	 demonstrated	within	 the	 ESBL	 bacterial	 gut	model	will	
extend	existing	evidence	about	the	epidemiology	of	these	organisms.	 	More	importantly	 it	
will	 aid	 the	 review	 of	 guidelines	 for	 the	 prevention	 and	 management	 of	 patients	 with	
infections	caused	by	antimicrobial	resistant	organisms	in	Hampshire.		
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Chapter	2 	
2	 Materials	and	Methods	
2.1	Microbiological	Techniques	
	 2.1.1	 Collection	of	Bacterial	Isolates	
Two	hundred	and	fifty	bacterial	isolates,	previously	identified	as	ESBL	producing	organisms	
were	 collected	 from	 four	 hospitals	 within	 the	 Hampshire	 region	 [Southampton	 General	
Hospital,	 Winchester	 and	 Eastleigh	 Healthcare	 Trust,	 Basingstoke	 and	 North	 Hampshire	
Foundation	 Trust	 and	 Queen	 Alexandra	 Hospital,	 Portsmouth].	 	 Isolates	 were	 inoculated	
onto	 nutrient	 agar	 slopes	 and	 incubated	 at	 370C,	 under	 aerobic	 conditions	for	 24	 hours.		
Samples	 were	 packaged	 and	 transported	 in	 accordance	 with	 The	 Carriage	 of	 Dangerous	
Goods	 [Classification,	 Packaging	 and	 Labelling]	 and	 Use	 of	 Transportable	 Pressure	
Receptacles	Regulations	1996.			
	
	 2.1.2	 Growth	of	Bacterial	Strains	
To	ensure	purity	of	the	clinical	isolates	prior	to	analysis,	each	bacterial	isolate	was	streaked	
to	purity	onto	a	MacConkey	agar	plate	[Oxoid]	using	a	sterile	wire	 loop.	 	Agar	plates	were	
incubated	 at	 370C,	 under	 aerobic	 conditions	 for	 24	 hours,	 after	 incubation	 plates	 were	
observed	for	pure	culture,	any	mixed	cultures	were	identified	and	each	organism	separated	
to	ensure	purity.	
	
	 2.1.3	 Identification	of	Bacterial	Strains	
Bacterial	 isolates	 that	 were	 not	 identified	 using	 E.	 coli	 specific	 PCR	 [section	 2.2.3],	 were	
identified	to	species	level	using	the	API20e	identification	system	[Biomerieux].		This	system	
is	 used	 for	 the	 identification	 of	 Enterobacteriaceae	 and	 utilises	 20	 microtubule	 tests	
containing	 dehydrated	 substrates	 to	 investigate	 the	 bacterial	 ability	 to:	 ferment	
carbohydrates	 including	 glucose,	mannitol,	 inositol,	 sucrose	 and	 arabinose;	 decarboxylate	
amino	acids,	for	example	arginine,	lysine	and	ornithine;	produce	hydrogen	sulphide,	urease,	
tryptophan	 deaminase	 and	 indole;	 utilise	 citrate	 and	 hydrolyse	 gelatin.	 	 This	 is	 a	 robust	
identification	 system	 that	 is	 utilised	 in	many	 diagnostic	 laboratories,	 with	 a	 sensitivity	 of	
92.8%.			
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Standard	dilutions	of	each	bacterium	were	prepared	by	emulsifying	a	single	bacterial	colony	
into	 5	ml	 of	 sterile	 distilled	 water,	 and	 comparing	 its	 optical	 density	 to	 a	 0.5	McFarland	
control	 [Biomerieux].	 	Each	 inoculum	was	evenly	distributed	within	the	cupules	of	 the	API	
strip;	ensuring	that	wells	[ADC,	LDC,	ODC,	H2S	and	URE]	were	sealed	with	mineral	oil	due	to	
the	 requirement	 for	 anaerobic	 conditions	 and	wells	 [VP	 and	GEL]	were	 filled	 completely.		
Strips	were	incubated	at	370C,	under	aerobic	conditions	for	24	hours.		After	incubation	and	
addition	of	 reagents	 to	the	TDA	[TDA	reagent],	 IND	[James	reagent]	and	VP	[VP1	and	VP2	
reagents]	 cupules,	 the	 colour	 reactions	were	 recorded	 to	obtain	a	 seven	digit	 code,	using	
the	APIWEB	data	base	[Biomerieux],	available	at	https://apiweb.biomerieux.com,	the	code	
could	then	be	converted	to	a	bacterial	 identification.	 	A	percentage	and	T	value	were	also	
estimated	by	the	software	to	determine	the	accuracy	of	the	identification;	any	identification	
less	than	95%	was	discarded	and	repeated.		
	
2.1.4	 Antimicrobial	Susceptibility	and	ESBL	Production													
Investigations	
Antimicrobial	 susceptibility	 investigations	 were	 carried	 out	 in	 accordance	 with	 the	 BSAC	
guidelines.	 	 Standard	 dilutions	 of	 each	 bacterium	 were	 prepared	 by	 emulsifying	 a	 single	
bacterial	colony	into	5	ml	of	sterile	distilled	water,	and	comparing	its	optical	density	to	a	0.5	
McFarland	 control	 [Biomerieux],	 in	 order	 to	 achieve	 semi	 confluent	 growth	 (125).	 	 If	 a	
lighter	growth	was	obtained	zone	diameters	may	appear	falsely	larger	due	to	the	decreased	
number	of	bacteria	compared	to	antibiotic/antibiotic	inhibitor	concentrations.		In	contrast	if	
a	more	dense	growth,	increased	number	of	bacteria,	was	obtained	the	zone	diameter	may	
appear	 falsely	 smaller.	 	Each	 inoculum	was	evenly	 spread	over	 three	diagnostic	 sensitivity	
test	 [DST]	 agar	 plates	 using	 sterile	 cotton	 swabs.	 	 After	 inoculation,	 antibiotic	 discs	 of	
Gentamicin	10	µg/ml,	Cefotaxime	30	µg/ml,	Amoxicillin	10	µg/ml,	Co-amoxiclav	30	µg/ml,	
Cefuroxime	 30	 µg/ml,	 Piperacillin-Tazobactam	 75/10	 µg/ml,	 Ciprofloxacin	 1	 µg/ml,	
Meropenem	 10	 µg/ml,	 Ertapenem	 10	 µg/ml,	 Ceftazidime	 10	 µg/ml,	 Amikacin	 30	 µg/ml,	
Cefepime	30	µg/ml	and	Tigecycline	15	µg/ml	were	evenly	spaced	on	two	of	the	DST	plates.				
A	 control	 strain	of	E.	 coli,	National	Collection	of	 Type	Cultures	 [NCTC]	10418	was	used	 to	
ensure	all	discs	and	media	were	producing	quality	results,	as	advised	by	the	BSAC	guidelines.						
ESBL	 and	AmpC	 identification	 discs	 [MAST]	were	 evenly	 spaced	 onto	 the	 third	DST	 plate.		
This	method	was	chosen	as	it	is	used	routinely	by	a	large	number	of	clinical	laboratories	and	
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previous	 research	 has	 highlighted	 this	 method	 as	 an	 economical,	 accurate	 and	 straight	
forward	 test	 for	 the	 identification	 of	 AmpC	 and	 ESBL	 producing	 organisms	 (126).	 	 This	
investigation	 utilises	 four	 discs	 labelled	 A	 to	 D	 and	 zone	 of	 bacterial	 inhibition	 size	
comparison.		To	ensure	the	quality	of	results,	controls	in	the	form	of	known	ESBL	and	AmpC	
producing	 organisms	 were	 analysed	 prior	 to	 patient	 isolates.	 	 Once	 all	 discs	 had	 been	
applied	to	the	inoculated	agar,	plates	were	incubated	at	370C,	under	aerobic	conditions	for	
24	hours.			
After	 incubation,	 susceptibility	 test	 results	 were	 interpreted	 by	 measuring	 the	 zone	 of	
inhibition	diameters,	in	millimetres,	these	were	then	interpreted	in	relation	to	the	identified	
organism	using	 the	BSAC	guidelines.	 	Organisms	were	 classified	as	 sensitive,	 intermediate	
resistant	[demonstrating	low	level	resistance]	or	resistant	to	each	of	the	agents.			
ESBL	and	AmpC	production	was	determined	by	measuring	the	zone	of	inhibition	diameters	
of	each	of	the	four	discs.		ESBL,	AmpC,	dual	resistance	[ESBL	and	AmpC],	those	organisms	
requiring	further	work	to	identify	the	resistance	mechanism	expressed	and	negative	results	
were	determined	using	the	MAST	ESBL	calculator	spreadsheet	version	10.2,	available	from,	
http://www.mastgrp.com/Users_Details.asp.	
	
2.1.5	 Sample	Collection	for	Faecal	Analysis	using	A	Simulated	Colon	
Model	
After	 NHS	 ethical	 approval	 was	 granted	 [Appendix	 1],	 faecal	 samples	 received	 in	 the	
diagnostic	 laboratory	 [Royal	 Hampshire	 County	 Hospital,	Winchester]	 for	 routine	 analysis	
were	 investigated	 for	ESBL	colonisation.	 	Samples	were	analysed	using	 routine	 techniques	
and	 additionally	 cultured	onto	half	 of	 a	 chromogenic	 agar	 plate	 [Brilliance	media,	Oxoid],	
specific	 for	 the	 growth	 of	 ESBL	 producing	 organisms.	 	 Those	 samples	 that	 demonstrated	
negative	results	 for	all	pathogenic	organisms	 [Campylobacter	spp,	E.	coli	0157,	Salmonella	
spp,	 Shigella	 and	 Clostridium	 difficile]	 with	 positive	 results	 for	 ESBL	 colonisation	 were	
separated,	allowing	a	small	amount	of	the	sample	to	be	included	within	this	study.		Samples	
were	 packaged	 and	 transported	 in	 accordance	 with	 The	 Carriage	 of	 Dangerous	 Goods	
[Classification,	 Packaging	 and	 Labelling]	 and	 Use	 of	 Transportable	 Pressure	 Receptacles	
Regulations	1996	and	stored	within	the	minus	80	freezer	in	a	limited	access	laboratory	prior	
to	analysis.	
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2.1.6	 Constitution	of	Gut	Mimicking	Media	
Gut	mimicking	media	was	prepared	to	reflect	the	composition	of	ileostomy	effluent	to	allow	
the	continuous	growth	of	bacteria,	representative	of	the	human	colon;	all	constituents	were	
diluted	with	distilled	water	and	autoclaved	prior	to	analysis.		Gut	mimicking	media	consisted	
of	60	mM	NaCl,	40	mM	NaHCO3,	10	mM	KCl,	10	g/L	tryptone,	5	g/L	porcine	bile	extract,	5	x	
10-5	g/L	Haemin,	1.2	g/L	starch,	5	g/L	glucose	and	6	g/L	maltose	(127).			
	
2.1.7	 E.Test	Methodology	for	the	Measurement	of	Minimum	
Inhibitory	Concentrations	of	Bacteria	Analysed	in	the	Colon	
Model		
In	 order	 to	 determine	 the	 minimum	 inhibitory	 concentrations	 [MIC]	 of	 the	 different	
organisms	 analysed	 in	 the	 simulated	 colon,	 Epsilometer	 test	 [E	 Test]	 methodology	
[Biomerieux]	 was	 used.	 	 This	 methodology	 allows	 quantitative	 analysis	 to	 determine	 the	
minimum	 concentration	 of	 an	 agent	 required	 to	 inhibit	 bacterial	 growth.	 	 Each	 strip	 is	
coated	 with	 a	 concentration	 gradient	 of	 the	 required	 agent,	 once	 applied	 to	 the	
recommended	agar;	the	antimicrobial	agent	is	instantaneously	released	and	remains	stable	
for	18	 to	24	hours.	 	After	 incubation	 the	MIC	of	each	agent	was	determined	at	 the	point	
where	the	edge	of	the	bacterial	inhibition	ellipse	intercepts	with	the	side	of	the	E	Test	strip.		
Strips	 containing	 co-amoxiclav	 and	 amoxicillin	 at	 concentration	 gradients	 ranging	 from	
0.016	 to	 256	 µg/ml,	 gentamicin	 with	 a	 gradient	 ranging	 from	 0.06	 to	 1024	 µg/ml	 and	
trimethoprim	ranging	from	0.002	to	32	µg/ml	were	used	within	this	area	of	the	study.	
A	0.5	McFarland	dilution	was	achieved,	using	the	same	culture	before	and	after	analysis,	a	
single	 bacterial	 colony	 was	 suspended	 in	 5	 ml	 of	 sterile	 distilled	 water,	 and	 the	 optical	
density	 compared	 to	 the	 0.5	McFarland	 control	 [Biomerieux].	 	 The	 bacterial	 dilution	was	
then	 spread	 evenly	 over	 the	 whole	 of	 a	 DST	 agar	 plate	 and	 the	 appropriate	 E	 Test	 strip	
applied.	 	 Samples	were	 incubated	at	370C	 for	18	 to	24	hours	 in	aerobic	 conditions.	 	After	
incubation	the	MIC	of	each	agent	was	recorded.	
	
	
2.1.8	 Collection	and	Microbiological	Analysis	of	Animal	Faeces	
Animal	 faecal	 samples	 were	 collected	 to	 detect	 ESBL	 intestinal	 colonisation.	 	 All	 animals	
were	healthy	 and	had	not	 received	 any	medication	 for	 one	month	 at	 the	 time	of	 sample	
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collection.	 	 Samples	 were	 placed	 into	 sterile	 universal	 containers	 and	 transported	 to	 the	
university	using	UN3373	receptacles	[transport	of	biological	substances].	
One	gram	of	animal	faeces	was	emulsified	into	Brain	Heart	Infusion	broth	[Fisher]	to	allow	
enrichment	of	small	numbers	of	bacteria.	 	Brain	heart	infusion	broth	was	chosen,	as	it	 is	a	
highly	 nutritious	 media	 for	 the	 growth	 of	 fastidious	 organisms.	 	 In	 addition	 to	 the	
enrichment	properties,	 it	was	also	used	as	a	 sample	diluent,	as	 false	positive	 results	have	
been	reported	when	inoculating	faecal	samples	directly	onto	ESBL	brilliance	media	[Oxoid].		
Samples	were	incubated	for	18	to	24	hours	at	370C	in	aerobic	conditions,	after	which	each	
sample	was	inoculated	onto	quarter	of	an	ESBL	Brilliance	media	plate	[Oxoid]	and	incubated	
for	a	further	18	to	24	hours.	 	Bacteria	suspected	to	be	producing	ESBL	or	AmpC	resistance	
were	 analysed	 using	 the	 MAST	 ESBL	 and	 AmpC	 method	 [see	 section	 2.1.4].	 	 Those	 that	
demonstrated	 positive	 ESBL	 or	 AmpC	 production	 were	 identified	 using	 the	 chromogenic	
agar,	or	by	the	API	20e	identification	system	[Biomerieux],	[see	section	2.1.3],	antimicrobial	
sensitivity	patterns	were	determined	using	disc	diffusion	methodology	[see	section	2.1.4].				
	
2.1.9	 Collection	and	Microbiological	Analysis	of	Fresh	Meat	Samples	
Fresh	 meat	 samples	 were	 collected	 from	 two	 leading	 food	 retailers	 to	 assess	 if	 ESBL	
producing	 organisms	 could	 be	 isolated	 from	 uncooked	meat	 samples.	 	 All	 samples	 were	
purchased	 pre-packed	 and	 originated	 from	 a	 range	 of	 countries	 including	 the	 United	
Kingdom,	Ireland,	Holland,	Denmark	and	New	Zealand;	samples	were	refrigerated	at	2-50C	
prior	to	Microbiological	analysis.	
Fifteen	grams	of	the	different	meat	types	were	weighed	and	transferred	to	a	stomacher	bag	
[four	samples	were	collected	from	each	food	type	to	ensure	reproducibility].		Nine	millilitres	
of	brain	heart	infusion	broth	was	added	to	the	bag	and	the	mixture	was	homogenised	using	
a	 stomacher.	 	 Food	 preparation	 comparisons	 demonstrated	 that	 the	 use	 of	 stomachers	
provided	a	higher	yield	of	viable	micro-organisms	compared	to	the	use	of	blenders	and	 	a	
pestle	 and	 mortar	 (128).	 	 Stomacher	 methodology	 utilises	 paddles	 to	 break	 down	 and	
essentially	 blend	 the	 food	 product	 without	 destroying	 the	 bacteria	 present	 within	 the	
sample.	
The	 homogenised	mixture	 was	 then	 transferred	 back	 into	 the	 brain	 heart	 infusion	 broth	
bottle	and	incubated	at	370C,	in	aerobic	conditions,	for	18	to	24	hours.		After	incubation	the	
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homogenised	 mixture	 was	 analysed	 in	 the	 same	 manner	 as	 described	 in	 the	 analysis	 of	
animal	faecal	samples	[section	2.1.8].			
	
2.2	Molecular	Biology	Techniques	and	Gel	Electrophoresis	
2.2.1	 DNA	Extraction	–	Heat	Method	
Total	 bacteria	 DNA	was	 extracted	 from	 cells	 using	 a	 heat	method.	 	 One	 or	 two	 bacterial	
colonies	were	 suspended	 in	 50	 µl	 of	 sterile	 distilled	water	 in	microcentrifuge	 tubes.	 	 The	
suspensions	 were	 heated	 at	 950C	 for	 3	 minutes	 and	 finally	 centrifuged	 for	 5	 minutes	 at	
13,000	g	at	 room	temperature.	 	Supernatant	 from	each	spun	sample	was	transferred	to	a	
separate	labelled	sterile	micro	centrifuge	tube	and	analysed	immediately	(102).			
	
2.2.2	 Genomic	DNA	Purification	
Genomic	DNA	purification	was	 used	 to	 obtain	DNA	of	 a	 sufficient	 purity	 and	quantity	 for	
Enterobacterial	Repetitive	Intergenic	Consensus	[ERIC]	PCR	and	for	sequence	analysis.		The	
Macherey-Nagel	Nucleospin	Tissue	kit	was	used	to	purify	genomic	DNA	from	the	bacterial	
cells	 according	 to	 the	 manufacturer’s	 instructions.	 	 DNA	 quantification	 was	 determined	
using	a	nanodrop	and	a	working	concentration	of	20	ng/µl	of	DNA	was	achieved	using	sterile	
molecular	grade	water.	
	
2.2.3	 PCR	Detection	of	the	Beta-galactosidase	Gene	for	the	
Identification	of	E.	coli	Strains	
PCR	amplification	of	total	DNA	[obtained	using	the	heat	method]	was	used	to	identify	all	E.	
coli	isolates,	25	µl	reactions	were	achieved	by	mixing	10	µmol/µl	[1	µl]	of	each	forward	and	
reverse	 primer	 [Table	 2.1],	 12.5	 µl	 of	 2	 x	 GoTaq	 Green	master	 mix	 [Promega],	 5.5	 µl	 of	
molecular	 grade	 distilled	 water	 and	 5	 µl	 of	 total	 bacterial	 DNA.	 	 Negative	 controls	 were	
analysed	with	each	set	of	amplifications;	forward	and	reverse	primers	and	master	mix	were	
added	as	previously	described,	the	final	volume	of	25	µl	was	achieved	using	molecular	grade	
distilled	 water.	 	 Gene	 expression	 was	 visualised	 using	 gel	 electrophoresis	 within	 a	 1%	
agarose	 gel.	 	 The	 template	 DNA	 was	 amplified	 on	 the	 Stratagene	 Robocycler,	 using	 the	
following	program:	
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Denature:	 950C	for	3	minutes	
Denature:	 950C	for	45	Seconds		
Anneal:	 600C	for	45	Seconds	 			x	35	cycles	
Extend:	 720C	for	60	Seconds	
Extend:	 720C	for	10	minutes	
	
Table	2-1,	PCR	primers	used	for	the	E.coli	PCR	analysis	(129).	
Primer	Name	 Sequence	5’	to	3’	 Tm	 Amplicon	Size	(bp)	
E.coli-1	(F)	 CTTGCCTGGTTTCCGGCACCAGAA	 60	 762	
E.coli-2	(R)	 AACCACCGCACGATAGAGATTCGGG	 60	 762	
	
2.2.4	 Multiplex	PCR	Amplification	for	the	Detection	of	TEM,	CTX	and	
SHV	Determinants	
Multiplex	PCR	amplification	 for	 the	detection	of	 the	TEM,	CTX	and	SHV	determinants	was	
optimised	 and	 performed	 on	 all	 DNA	 samples	 [obtained	 using	 the	 heat	 method],	 25	 µl	
reactions	were	 achieved	by	mixing	 10	µmol/µl	 [1	 µl]	 of	 each	 forward	 and	 reverse	 primer	
[Table	2.2],	12.5	µl	of	2	x	GoTaq	Green	master	mix	[Promega]	and	6.5	µl	of	total	bacterial	
DNA.		Negative	controls	were	analysed	with	each	set	of	amplifications;	forward	and	reverse	
primers	and	master	mix	were	added	as	described	previously,	 the	 final	volume	[25	µl]	was	
achieved	using	molecular	 grade	distilled	water.	 	Gene	expression	was	 visualised	using	 gel	
electrophoresis,	 within	 a	 1%	 agarose	 gel.	 	 The	 template	 DNA	 was	 amplified	 on	 the	
Stratagene	Robocycler	using	the	following	program:	
	
Denature:	 950C	for	5	minutes	
Denature:	 950C	for	30	seconds	
Anneal:	 540C	for	30	seconds									x	30	cycles	 	
Extend:	 720C	for	120	seconds		
Extend:	 750C	for	10	minutes		
	
The	 optimal	 annealing	 temperature	 for	 the	multiplex	 PCR	was	 determined	 using	 positive	
samples	for	TEM	and	CTX	expression	and	a	temperature	gradient	PCR	ranging	from	500C	to	
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600C.		After	visualisation	of	the	results	obtained,	540C	was	deemed	the	optimum	annealing	
temperature	for	this	experiment.	
	
Table	2-2,	primer	sequences	used	for	the	multiplex	analysis	of	the	CTX,	TEM	and	SHV	genes	
(45)	
Primer	Name	 Sequence	5’	to	3’	 Tm	 Amplicon	Size	(bp)	
BlaSHV	Forward	 ATGCGTTATATTCGCCTGTG	 45	 747	
BlaSHV	Reverse	 TGCTTTGTTATTCGGGCCAA	 45	 747	
BlaTEM	Forward	 TCGCCGCATACACTATTCTCAGAATGA	 53	 445	
BlaTEM	Reverse	 ACGCTCACCGGCTCCAGATTTAT	 53	 445	
BlaCTX	Forward	 ATGTGCAGYACCAGTAARGTKATGGC	 54	 593	
BlaCTX	Reverse	 TGGGTRAARTARGTSACCAGAAYCAGCGG	 54	 593	
	
	
	 2.2.5	 Multiplex	PCR	Amplification	of	OXA	Determinant	Groups	
Multiplex	PCR	amplification	for	the	detection	of	OXA	groups	1,	2	and	3	was	performed	on	all	
DNA	samples	[obtained	using	the	heat	method],	25	µl	reactions	were	achieved	by	mixing	10	
µmol/µl	[1	µl]	of	each	forward	and	reverse	primer	[Table	2.3],	12.5	µl	of	2	x	GoTaq	Green	
master	mix	 [Promega]	and	6.5	µl	of	 total	bacterial	DNA.	 	Negative	controls	were	analysed	
with	each	set	of	amplifications;	forward	and	reverse	primers	and	master	mix	were	added	as	
described	 previously,	 the	 final	 volume	 [25	 µl]	was	 achieved	 using	 sterile	molecular	 grade	
distilled	 water.	 	 Gene	 expression	 was	 visualised	 using	 gel	 electrophoresis,	 within	 a	 1%	
agarose	gel.	 	The	template	DNA	was	amplified	using	the	same	conditions	as	the	TEM,	CTX	
and	SHV	multiplex	analysis	[see	section	2.2.4].	
Due	 to	 low	 numbers	 of	 OXA	 expression,	 positive	 PCR	 controls	 were	 also	 added	 to	 this	
analysis	to	ensure	adequate	amplification	was	taking	place.	
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Table	2-3,	primer	sequences	used	for	the	multiplex	PCR	analysis	of	the	OXA	group	1,	2	and	3	genes	
(130)		
Primer	Name	 Sequence	5’	to	3’	 Amplicon	Size	
(bp)	
OXA	Group	1	Forward	 TCA	ACA	AAT	CGC	CAG	AGA	AG	 276	
OXA	Group	1	Reverse	 TCC	CAC	ACC	AGA	AAA	ACC	AG	 276	
OXA	Group	2	Forward	 AAG	AAA	CGC	TAC	TCG	CCT	GC	 478	
OXA	Group	2	Reverse	 CCA	CTC	AAC	CCA	TCC	TAC	CC	 478	
OXA	Group	3	Forward	 TTT	TCT	GTT	GTT	TGG	GTT	TT	 427	
OXA	Group	3	Reverse	 TTT	CTT	GGC	TTT	TAT	GCT	TG	 427	
	 	
2.2.6	 ERIC	PCR	
ERIC	 PCR	 amplification	 of	 genomic	 DNA	 [obtained	 from	 the	 genomic	 DNA	 purification	
method],	was	performed	on	all	samples	in	order	to	obtain	their	genotype	and	identify	clonal	
relationships.		50	µl	reactions	were	achieved	by	mixing	25	µmol/µl	[2.5	µl]	of	each	forward	
and	reverse	primer	[Table	2.4],	25	µl	of	2	x	GoTaq	Green	master	mix	[Promega]	and	5	µl	of	
template	 DNA	 [100	 ng],	 the	 reaction	 was	 then	 made	 up	 to	 50	 µl	 with	 molecular	 grade	
distilled	water.	 	 Negative	 controls	were	 run	with	 each	 set	 of	 amplifications;	 forward	 and	
reverse	primers	and	master	mix	were	added	as	previously	described,	 the	 final	volume	[50	
µl]	 was	 achieved	 using	 molecular	 grade	 sterile	 distilled	 water.	 	 Intergenic	 regions	 were	
visualised	 using	 gel	 electrophoresis,	 within	 a	 1.5%	 agarose	 gel	 [see	 section	 2.3.1].	 	 The	
template	DNA	was	amplified	on	the	Biorad	T100	thermal	cycler	using	the	following	program:	
	
	
Denature	 950C	for	1	minute	
Denature:	 920C	for	45	seconds	
Anneal:	 520C	for	1	minute	 											x	35	cycles	
Extend:	 700C	for	20	minutes	
Extend:	 700C	for	20	minutes	
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Table	2-4,	ERIC	PCR	primer	sequences	used	for	the	amplification	of	intergenic	repeat	units	
(60).	
	
Primer	Name	 Sequence	3’	to	5’	
ERIC	1	 CACTTAGGGGTCCTCGAATGTA	
ERIC	2	 AAGTAAGTGACTGGGGTGAGCG	
	
2.2.7			Molecular	Analysis	of	Animal	Faecal	and	Commercial	Meat	
Product	Samples		
All	 isolates,	 identified	 from	 animal	 faecal	 samples	 and	 commercial	 meat	 products	
demonstrating	 positive	 ESBL	 or	 AmpC	 expression	 were	 analysed	 using	 PCR	 to	 detect	 the	
TEM,	CTX	and	SHV	determinants.	 	DNA	was	extracted	using	 the	heat	method	 [see	section	
2.2.1],	 samples	 were	 analysed	 using	 multiplex	 PCR	 [see	 section	 2.2.4]	 and	 determinant	
expression	visualised	using	gel	electrophoresis,	within	a	1%	agarose	gel.	 	All	animal	 faecal	
samples	demonstrating	positive	results	were	then	prepared	for	sequence	analysis.		Genomic	
DNA	 was	 extracted	 using	 the	 Macherey-Nagel	 Nucleospin	 Tissue	 kit	 [see	 section	 2.2.2],	
amplification	and	PCR	clean	up	carried	out	according	to	sections	2.2.8	and	2.2.9.			
	
2.2.8	 PCR	Amplification	of	the	TEM,	SHV	and	CTX	Determinants	for	
Sequence	Analysis	
PCR	analysis	was	performed,	on	all	animal	faecal	isolates	demonstrating	positive	expression	
of	 the	TEM,	 SHV	and	CTX	 resistance	determinants.	 	High	 fidelity	 taq	polymerase	 [Thermo	
Scientific],	 was	 used	 to	 reduce	 errors	 during	 the	 amplification	 process.	 	 Samples	 were	
analysed	in	triplicate	and	then	pooled	prior	to	PCR	clean	up,	to	dilute	any	misreading	caused	
during	 the	 analysis.	 	 50	 µl	 reactions	 were	 achieved	 by	 mixing	 20	 µmol/µl	 [2	 µl]	 of	 each	
forward	and	reverse	primer,	25	µl	of	2	x	high	fidelity	Taq	polymerase,	10	µl	of	template	DNA	
[obtained	from	the	genomic	DNA	purification	method]	and	13	µl	of	sterile	molecular	grade	
distilled	water.	 	The	 template	DNA	was	amplified	using	 the	same	cycle	programme	as	 the	
multiplex	 PCR	 analysis	 [see	 section	 2.2.4].	 	 Negative	 controls	 were	 run	 with	 each	 set	 of	
amplifications;	 forward	 and	 reverse	 primers	 and	 master	 mix	 were	 added	 as	 previously	
described,	 the	 final	 volume	 [50	 µl]	 was	 achieved	 using	 molecular	 grade	 sterile	 distilled	
water.	
	
46	
	
2.2.9	 PCR	Clean	Up	and	Preparation	for	Sequence	Analysis	
Each	PCR	reaction,	using	the	high	fidelity	taq	polymerase,	was	cleaned	ready	for	sequence	
analysis.	 	 The	Macherey-Nagel	 PCR	 clean-up	Gel	 Extraction	 kit	was	 used	 according	 to	 the	
manufacturer’s	 instructions.	 	 Samples	 were	 then	 diluted,	 using	 molecular	 grade	 sterile	
distilled	water,	to	reach	10	to	50	ng/µl	and	20	µl	of	this	solution	was	separated	into	a	sterile	
eppendorph	tube	and	sent	to	the	GATC	Company	for	sequence	analysis.				
	
2.2.10	 Agarose	Gels	
To	make	an	agarose	gel,	the	gel	tray,	ends	and	comb	were	firstly	cleaned	with	distilled	water	
and	the	ends	were	inserted	into	the	tray,	1-1.5%	agarose	gels	were	achieved	by	mixing	the	
required	amount	of	agarose	with	100	ml	of	1	x	Tris-acetate	EDTA	[TAE]	buffer,	this	was	then	
heated	in	the	microwave	until	all	of	the	agarose	had	completely	dissolved.		Once	cooled	6	µl	
of	 red	safe	gel	 stain	 [Invitrogen]	was	added.	 	The	ends	of	 the	gel	 tray	were	sealed	with	a	
small	 amount	of	agarose	and	when	 this	had	 set	 the	 rest	of	 the	 solution	was	 then	poured	
into	the	tray,	the	comb	was	inserted	and	the	main	gel	was	allowed	to	set.	
Once	set	the	ends	were	removed	from	the	tray	and	the	gel	was	placed	into	the	buffer	tank	
and	covered	with	1	x	TAE	buffer,	the	comb	was	then	removed,	10	µl	of	DNA	ladder	and	each	
PCR	reaction	was	loaded	into	the	gel	via	the	wells	formed	by	the	comb.		Gels	were	typically	
run	 at	 90	 volts	 [ERIC	 analysis]	 and	 150	 volts	 [all	 other	 PCR	 analysis]	 until	 sufficient	
separation	had	occurred.		The	bands	were	visualised	using	the	Alpha	UV	Digi	Doc	system.				
	 	
2.3	Other	Methods	
	 2.3.1	 Ethical	Approval	
Full	ethical	approval	according	to	the	National	Research	Ethics	Service	[NRES]	was	granted	
on	 the	 9th	 of	 August	 2012	 by	 the	 NRES	 South	 Central	 -	 Oxford	 committee,	 reference	
12/SC/0413	[Appendix	1],	allowing	the	detection	of	ESBL	colonisation	within	faecal	samples	
received	 in	 the	 diagnostic	 laboratory	 [Royal	 Hampshire	 County	 Hospital,	 Winchester].		
Samples	could	then	be	included	within	this	study	to	determine	the	MIC	changes	before	and	
after	dosing	with	agents	used	to	treat	a	complicated	urinary	tract	infection.	
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2.4.2	 Statistical	Analysis	
Statistical	 analysis,	 including	 the	 Spearman	 correlation,	 Kruskal-Wallis,	 Chi	 squared	 and		
Mann-Whitney	 tests	 were	 performed	 to	 determine	 statistical	 relevance	 of	 the	 results	
obtained	using	the	software	programmes	Microsoft	Excel	and	Graphpad	Prism	version	6.01	
for	Windows	7.		Values	of	P<0.05	were	used	to	determine	statistical	significance.			
	
2.4.3			 Analysis	of	Sequencing	Results	
Results	obtained	from	sequencing	analysis	were	compared	to	related	sequences	 identified	
by	 the	 completion	 of	 a	 BLAST	 search.	 	 Sequences	 were	 aligned	 using	 the	 computer	
programme,	Seaview,	allowing	nucleotide	substitutions	to	be	identified,	these	could	then	be	
aligned	using	the	amino	acid	sequence	to	determine	if	the	substitutions	were	synonymous.			
	
2.4.4	 Analysis	of	ERIC	PCR	Results	
Multiple	bands	obtained	within	each	gel	were	analysed,	band	sizes	were	calculated	by	the	
distance	 in	which	 each	band	had	migrated,	 in	 relation	 to	 the	DNA	 ladder	 included	within	
each	 analysis.	 	 In	 order	 to	 accurately	 determine	 the	 size	 of	 each	 band	 the	 software	
programme	 Image	 J	was	 used.	 	 Gel	 images	were	 opened	within	 this	 programme	 and	 the	
sample	lanes	highlighted,	a	plot	of	each	lane	was	obtained	and	peaks	relating	to	each	band	
selected.	 	 Microsoft	 Excel	 was	 used	 to	 construct	 a	 spreadsheet,	 where	 the	 X	 value	 [the	
distance	 each	 band	 had	migrated]	was	 used	 to	 calculate	 the	 Rf	 value.	 	 A	 standard	 curve	
graph	was	generated	by	plotting	the	Rf	values	against	the	log	molecular	weights	of	the	DNA	
ladder	and	the	line	of	best	fit	calculated.		The	equation	of	the	line	of	best	fit	was	then	used	
to	calculate	the	molecular	weights	of	all	bands	within	the	gel.	
After	all	band	sizes	were	calculated	a	presence,	absence	framework	was	constructed	using	
Microsoft	 excel.	 	 Band	 sizes	 were	 grouped,	 allowing	 a	 10	 percent	 difference	 within	 the	
different	gel	analysis,	the	presence	of	a	band	was	marked	as	a	1,	and	absence	of	a	band	was	
marked	 as	 a	 0.	 	Once	 completed	 the	 presence,	 absence	 framework	was	 entered	 into	 the	
software	 programme	 PAUP	 in	 order	 to	 generate	 a	 TRE	 file,	 this	 was	 then	 opened	 and	
manipulated	 in	 the	 software	 programme	 FigTree	 to	 obtain	 an	 unweighted	 pair	 group	
method	using	arithmetic	averages	[UMPGA],	phylogenetic	tree.	
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Chapter	3 	
Clinical	Epidemiological	Study	of	ESBL	Producing	Enterobacteriaceae	
within	the	Hampshire	Area	
3.1	Introduction	
Modern	 epidemiology	 uses	 a	 range	 of	 molecular,	 microbiological	 and	 biochemical	
techniques	to	 identify	disease	patterns	amongst	geographical	populations,	enabling	trends	
to	 be	 recognised	 worldwide.	 	 One	 of	 the	 areas	 of	 greatest	 concern	 within	 bacterial	
epidemiology	 is	 the	 incidence	and	spread	of	antibiotic	resistance,	and	within	this	area	the	
occurrence	and	spread	of	ESBL	resistance	determinants	(131).		This	chapter	will	provide	an	
epidemiological	 profile	 of	 ESBL	 infections	 within	 the	 Hampshire	 area	 determined	 using	
primarily	microbiological	techniques,	a	quick	and	cost	effective	way	of	generating	data	that	
can	be	compared	within	the	UK	and	worldwide.	
Hampshire	was	chosen	as	the	study	area	because	of	the	lack	of	information	regarding	ESBL	
infections	 within	 the	 region	 and	 the	 recognition	 that	 these	 infections	 are	 becoming	
problematic	 for	 clinicians,	 as	 well	 as	 the	 close	 availability	 of	 four	 hospitals	 willing	 to	
participate	 in	 the	 study.	 	 Basic	 microbiological	 information,	 such	 as	 ESBL	 pre-dominant	
species,	ESBL	determinant	prevalence,	and	coinciding	multiple	drug	resistance,	were	linked	
to	patient	demographics,	allowing	patterns	to	be	 identified	regarding	resistance	types	and	
patient	age,	gender,	location	and	previous	antimicrobial	treatment.				
	
3.2	Collection	of	Isolates,	Isolate	Identification	and	Patient	
Information	
	 3.2.1	 Isolate	Collection,	Storage	and	Ethical	Approval	
In	order	to	determine	the	epidemiological	profile	of	patients	suffering	from	ESBL	infections	
within	 the	 Hampshire	 area,	 the	 organisms	 responsible,	 type	 of	 resistance	 expressed	 and	
resistance	patterns;	 isolates	were	collected	from	four	hospitals	in	the	region.		The	number	
of	isolates	collected	from	each	hospital,	in	each	year	group	is	presented	in	Table	3.1.	
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Table	3-1,	Number	of	isolates	collected	from	each	hospital	in	each	year	group	for	analysis.	
Year	
Group	
Hospital	Site	 Number	of	Isolates	 Total	Isolates	
	
	
	
2010	
Basingstoke	 and	 North	
Hampshire	Foundation	Trust	
46	 	
Total	235.	
6	 isolates	 failed	 to	
grow,	 leaving	 229	
for	analysis.	
Queen	 Alexandra	 Hospital	
Portsmouth	
54	
University	Hospital	Southampton	 65	
Royal	Hampshire	County	Hospital	
Winchester	
70	
	
	
	
2012	
Basingstoke	 and	 North	
Hampshire	Foundation	Trust	
88	 	
Total	250.	
2	 isolates	 failed	 to	
grow,	 leaving	 248	
for	analysis.	
	
Queen	 Alexandra	 Hospital	
Portsmouth	
40	
University	Hospital	Southampton	 50	
Royal	Hampshire	County	Hospital	
Winchester	
72	
	
Isolates	were	collected	during	the	same	time	period	for	each	year	group,	May	to	August,	the	
number	of	isolates	differed	between	the	hospital	sites	due	to	the	number	of	ESBL	producing	
isolates	detected	within	this	time	period	and	the	member	of	staff	working	on	the	bench.	
In	 order	 to	 determine	 the	 demographic	 of	 patients	 suffering	 from	 ESBL	 infections,	 the	
following	 information,	 relating	 to	 each	 of	 the	 isolates,	 was	 collected	 using	 the	 local	
pathology	 patient	 record	 system,	 patient	 age,	 gender,	 location	 [inpatient,	 General	
Practitioner	 [GP],	 outpatient,	 Intensive	 Care	 Unit	 [ICU]],	 location	 of	 the	 infection	 [for	
example	urinary	tract],	any	clinical	details	received	regarding	the	patient,	and	any	previous	
antimicrobial	 therapy	 that	 the	patient	had	 received,	 if	 stated.	 	Those	 records	 that	did	not	
state	any	previous	antimicrobial	therapy	were	 included	within	the	no	therapy	criteria;	this	
however	was	considered	an	important	variable	in	this	study	for	evaluation.	
Ethical	 approval	 for	 the	 collection	 of	 patient	 information	 and	 ESBL	 producing	 organisms	
from	 the	 clinical	 laboratory	 was	 considered.	 	 As	 all	 patient	 details	 were	 anonymised,	 no	
additional	 clinically	 relevant	 information	 was	 gained	 from	 the	 results	 obtained	 and	 the	
organisms	could	not	be	linked	directly	back	to	the	patients,	ethical	approval	was	considered	
unnecessary.	
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3.2.2	 Patient	Information	
Details	 regarding	 the	 patient,	 that	were	 supplied	with	 the	 samples	 for	 bacterial	 isolation	
included,	 the	 age,	 gender,	 infection	 type,	 location	 and	 clinical	 information	 including	
previous	antimicrobial	therapy.	
	
3.2.2.1	 			Patient	Age	
The	mean	patient	age	for	the	229	isolates	collected	in	2010	was	60,	with	ages	ranging	from	
1	 to	 96.	 	 The	mean	 patient	 age	 for	 the	 248	 isolates	 collected	 in	 2012	was	 62,	with	 ages	
ranging	from	3	months	to	98	years	of	age.		The	mean	age	of	the	patients	within	each	year	
group	was	very	similar	 [60	and	62].	 	The	percentage	resistance	within	each	decade	of	 the	
patients’	age	[Figure	3.1a	and	b]	indicated	that	as	the	patients	age	increased,	so	did	the	risk	
of	multi-resistant	 infection	 [ESBL	or	AmpC],	with	patients	 aged	over	 60	demonstrating	 an	
increased	 susceptibility	 to	 ESBL	 infections	 or	 carriage,	 although	 it	 is	 clear	 that	 ESBL	
producing	bacteria	can	cause	disease	at	any	age.		The	susceptibility	of	ESBL/AmpC	infection	
with	age	has	been	observed	in	other	studies	(105,	132,	133).		Tham	et	al.	(133)	reported	a	
median	 age	 of	 65,	 while	 Auer	 et	 al.	 (105)	 reported	 a	 mean	 age	 of	 58.	 	 Mumtaz	 (132)	
reported	 that	 there	was	 a	 greater	 prevalence	 of	 ESBL	 producing	 organisms	 from	patients	
aged	 over	 60	 years	 and	 drew	 the	 conclusion	 that	 increased	 age	 can	 be	 considered	 as	 a	
susceptibility	risk	factor.			
	
3.2.2.2			Patient	Gender	
Patient	 information	 regarding	 gender	 suggests	 that	 females	 are	 more	 at	 risk	 of	 ESBL	
infections,	with	179	of	the	isolates	collected	in	2010	[78%]	and	192	of	the	isolates	collected	
in	2012	[77%]	resulting	from	infections	suffered	by	female	patients.	
		
3.2.2.3			Infection	Types	
The	majority	of	ESBL	isolates	collected	in	both	year	groups	[96%	within	2010	and	94%	within	
2012]	were	 collected	 from	urinary	 tract	 infections	 [UTI],	of	 these	3%	of	 the	urine	 isolates	
collected	within	2010	and	7%	within	2012	were	catheter	related.			
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(a)	
	
	
(b)	
	
				
Figure	3-1,	The	percentage	resistance	within	each	decade	of	the	patients’	age	within	(a)	
2010	and	(b)	2012;	results	indicate	that,	as	the	patients	age	increases,	they	are	at	an	
increased	risk	of	multi	resistant	infection	(ESBL	or	AmpC).		The	number	provided	above	each	
percentage	demonstrates	the	number	of	isolates	in	each	age	group.	
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Other	 infection	sites	observed	within	this	study	 included	wounds	[2%	within	2010	and	3%	
within	 2012];	 systemic	 infections	 detected	 using	 blood	 culture	 samples	 [1%	 within	 both	
2010	and	2012];	respiratory	tract	infections	detected	from	sputum	samples	[1%	within	both	
2010	and	2012]	and	genital	infections	[1%	within	both	2010	and	2012].			
A	 high	 proportion	 of	 isolates	 collected	 within	 both	 year	 groups	 were	 related	 to	 female	
patients,	suggesting	that	females	may	have	an	increased	risk	of	ESBL	infection.		The	majority	
of	 samples	were	 taken	 from	patients	 suffering	 from	UTIs	 and	 females	 have	 an	 inherently	
greater	risk	of	UTIs	because	of	their	shorter	urethra	and	the	proximity	of	the	urethra	to	the	
anus.	 	 It	has	been	estimated	that	1	 in	3	women	will	suffer	a	UTI	before	the	age	of	24	and	
almost	half	of	the	female	population	will	experience	a	UTI	within	their	 lifetime	(134).	 	The	
preponderance	 of	 female	 patients	 in	 this	 study	 is	 not	 unusual	 when	 considering	 	 ESBL	
infections,	Lee	et	al.	(135)	reported	a	positivity	rate	of	78%	for	females	and	Wani	et	al.	(136)	
recorded	 a	 male	 to	 female	 ratio	 of	 1:16.	 	 Other	 risk	 factors	 for	 ESBL	 infections	 include	
urinary	 catheter	 insertion	 (137),	 however	 the	 number	 of	 samples	 originating	 from	 such	
infection	was	 low	 in	 this	 study.	 	 In	 order	 to	 assess	 if	 the	 ratio	 between	male	 and	 female	
patients	was	significant,	the	other	infection	sites	must	also	be	considered.		Other	infection	
sites	 observed	 within	 this	 study	 included	 wounds,	 with	 an	 equal	 gender	 ratio	 observed	
between	males	and	females	in	2010	and	a	2:1	ratio	of	males	to	females	in	2012.		Systemic	
infections,	 with	 samples	 only	 collected	 from	 female	 patients	 in	 2010	 and	 a	 1:2	 ratio	
between	males	and	females	in	2012.		Respiratory	tract	infections,	with	all	samples	collected	
within	both	year	groups	from	male	patients	and	genital	infections	collected	within	both	year	
groups	 from	females.	 	Considering	 the	gender	 ratio	of	 the	ESBL	 infections	 included	within	
this	 study	 and	 previous	 research	 carried	 out	 regarding	 UTIs,	 it	 can	 be	 concluded	 that	
although	female	patients	are	at	an	increased	risk	of	certain	infections,	ESBL	resistance	can	
affect	either	gender	within	the	Hampshire	area.	
	
	 3.2.2.4			Patient	Location	
The	 patient	 demographic	 information	 collected	 for	 both	 year	 groups	 revealed	 that	 the	
majority	of	isolates	were	collected	within	the	GP	setting	[61%	within	2010	and	77%	within	
2012].	 	 The	 inpatient	 setting	was	 the	 second	most	 common	 patient	 location	 [27%	within	
2010	and	20%	within	2012],	following	by	accident	and	emergency	[7%	within	2010	and	2%	
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within	 2012].	 	 One	 percent	 of	 samples	 within	 both	 2010	 and	 2012	 were	 isolated	 from	
patients	 within	 the	 Intensive	 Care	 Unit	 [ICU].	 	 Within	 2010,	 in	 addition	 to	 the	 locations	
previously	 mentioned,	 2%	 of	 the	 isolates	 were	 collected	 from	 the	 hospital	 outpatients’	
department,	 1%	 from	 the	 antenatal	 department	 and	 1%	 from	 the	 Ministry	 of	 Defence.		
These	 results	 demonstrate	 that	 ESBL	 resistance	 is	 common	 in	 both	 community	 and	
nosocomial	environments.	
	
3.2.2.5		Clinical	Information,	Including	Previous	Antimicrobial					
Therapy	
The	 administration	 of	 antimicrobial	 therapy,	 up	 to	 90	 days	 prior	 to	 patients	 experiencing	
symptoms,	 could	 be	 considered	 as	 a	 potential	 risk	 factor	 for	 acquiring	 an	 ESBL	 infection	
(138).		In	order	to	determine	if	Hampshire	patients	with	a	history	of	previous	antimicrobial	
therapy	 could	 be	 considered	 at	 an	 increased	 risk	 of	 ESBL	 resistance,	 details	 of	 patients’	
previous	antibiotic	therapy	were	collected.			
A	large	proportion	of	patients	[70%	of	the	total	for	2010	and	74%	for	2012]	had	not	recently	
received	any	antimicrobial	therapy,	according	to	the	sample	request	form	completed	by	the	
requesting	clinician.		Within	the	community	setting	[GP,	hospital	outpatients	or	the	accident	
and	emergency	department]	76%	of	the	patients	in	2010	and	79%	in	2012	had	received	no	
recent	antimicrobial	therapy,	where	the	average	age	of	these	patients	was	lower	than	those	
for	 the	whole	year	 sets	 [55	years	of	age	 for	2010	and	59	 for	2012].	 	 Furthermore,	clinical	
records	show	that	only	three	patients	from	these	cohorts	[two	in	2010	and	one	in	2012]	had	
suffered	a	previous	ESBL	infection.	
In	 contrast	 a	 smaller	 number	 of	 patients	 were	 reported	 as	 not	 receiving	 antimicrobial	
therapy	 within	 the	 inpatient	 environment	 [24%	 in	 2010	 [38]	 and	 21%	 in	 2012	 [39]].	 	 In	
comparison	 the	mean	age	of	 these	patients	was	higher	 [71	 in	2010	and	66	 in	2012]	 than	
those	of	the	whole	year	sets.		Clinical	history	also	revealed	that	one	patient	in	2010	and	two	
patients	in	2012	suffered	a	previous	ESBL	infection.	
Current	prescribing	guidelines,	included	within	the	four	hospital	prescribing	policies,	at	the	
time	 of	 analysis,	 advised	 the	 use	 of	 trimethoprim,	 nitrofurantoin	 or	 fosfomycin	 for	 the	
treatment	 of	 uncomplicated	 urinary	 tract	 infections.	 	 The	 agents	 recommended	 for	 the	
treatment	of	complicated	urinary	tract	infections	and	pyelonephritis	included	co-amoxiclav,	
gentamicin,	 meropenem,	 fosfomycin	 and	 temocillin.	 	 Of	 those	 patients	 who	 were	 under	
55	
	
therapy	 or	 had	 recently	 received	 antibiotics,	 61%	 [2010]	 and	 80%	 [2012]	 were	 from	 the	
community	setting.		Within	this	group	of	patients,	54%	[2010]	and	28%	[2012],	had	recently	
received	or	were	currently	 receiving	an	 inappropriate	 therapy	 for	 their	ESBL	 infection.	 	 	A	
similar	 picture	 could	 also	 be	 seen	 when	 analysing	 the	 information	 obtained	 from	 the	
inpatient	setting,	59%	[2010]	and	38%	[2012]	of	 the	patients	were	currently	prescribed	or	
had	 previously	 received	 an	 inappropriate	 agent,	 when	 considering	 the	 resistance	
determinant.			
Comparing	the	patient	cohorts	for	2010	and	2012,	there	is	a	16%	increase	of	ESBL	producing	
organisms	 isolated	 from	patients	within	 the	GP	environment,	although	 it	 should	be	noted	
that	there	was	a	slight	increase	[15%]	in	the	number	of	GP	specimens	collected	between	the	
two	year	groups.		This	observation	supports	previous	research	(105),	indicating	a	rise	in	ESBL	
infections	within	the	community	setting	in	the	Hampshire	area.	 	Based	on	the	observation	
that	 the	 majority	 of	 isolates	 were	 recovered	 from	 patients	 that	 had	 not	 received	 any	
antimicrobial	treatment,	 it	would	appear	that	previous	antibiotic	therapy	within	90	days	is	
not	 a	 risk	 factor	 for	 ESBL	 acquired	 infection	 within	 the	 community.	 	 Although	 this	
observation	should	be	regarded	with	caution,	as	many	prescribing	clinicians	fail	to	complete	
sample	request	forms	correctly,	only	including	the	minimal	amount	of	information	regarding	
the	patient’s	treatment.	
An	age	difference	existed	for	the	cohorts	of	patients	with	no	previous	antimicrobial	therapy,	
with	those	from	the	community	being	younger	and	less	disposed	to	illness	prior	to	the	ESBL	
infection.		Whereas	those	from	the	hospital	environment	represented	the	oldest	age	group,	
with	 a	 greater	 risk	 of	 predisposing	 pathologies	 and	 subsequent	 treatments	 that	 might	
render	 them	 immunocompromised	 and	 at	 an	 increased	 risk	 of	 multi-resistant	 infections.		
Previous	 research	 (139)	 has	 identified	 predisposing	 pathology,	 such	 as	 diabetes	 mellitus,	
chronic	 renal	 failure	 and	 benign	 prostatic	 hyperplasia,	 as	 ESBL	 risk	 factors,	 with	most	 of	
these	being	experienced	at	later	stages	in	life.			
	
	 3.2.3	 Isolate	Identification	
Over	two	year	periods,	229	 isolates	 in	2010	and	248	 isolates	 in	2012,	demonstrating	ESBL	
resistance	were	collected	and	maintained	on	MacConkey	agar.		To	enable	further	analysis	in	
the	 future	 single	 colony	 isolates	 were	 stored	 frozen	 and	 DNA	 was	 extracted	 from	 each	
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bacterium.	 	 The	 identity	 of	 each	 isolate	 was	 obtained	 using	 molecular	 and	 physiological	
methods.		As	the	predominant	species	associated	with	ESBL	production	is	E.	coli	(114,	139,	
140),	 the	 first	 identity	 test	was	molecular,	 the	PCR	amplification	of	 the	beta-galactosidase	
gene,	which	should	be	present	in	E.	coli	and	related	organisms	[Chapter	2,	section	2.2.3].		Of	
the	isolates	tested	402	gave	a	762	base	pair	fragment	when	their	DNA	was	amplified	using	
the	primers	BG-1	and	BG-2	[Figure	3.2]	(129).	
Isolates	 that	 failed	 to	amplify	 the	beta-galactosidase	gene	 from	their	DNA	were	 identified	
using	the	biochemical/physiological	 tests	provided	by	the	API	20e	system	[Biomerieux],	as	
described	in	Chapter	2,	section	2.1.3	and	Section	2.2.10,	and	shown	in	Figure	3.3.		This	is	a	
robust	identification	system	that	is	utilised	in	many	diagnostic	laboratories,	with	a	sensitivity	
of	92.8%.		A	proportion	of	presumptive	E.	coli	isolates	were	also	identified	using	this	system	
to	 confirm	 the	 beta-galactosidase	 PCR	 amplification.	 	 Results	 demonstrated	 that	 the	 PCR	
method	 for	 the	 identification	 of	 E.	 coli	 produced	 100%	 sensitivity,	 with	 all	 PCR	 positive	
samples	being	identified	as	E.	coli	using	the	API	20e	system.		Those	isolates	that	produced	
negative	PCR	results	were	identified	as	other	members	of	the	Enterobacteriaceae	family	and	
are	given	in	Tables	3.2	[2010]	and	3.3	[2012],	including	the	level	of	identification	support	in	
the	form	of	percentage	probability	and	T	value.					
The	pre-dominant	species	identified	was	E.coli	with	85%	[194/229]	of	the	isolates	from	2010	
and	 84%	 [208/248]	 in	 2012	 demonstrating	 positive	 PCR	 analysis.	 	 This	 result	 was	 not	
unexpected,	 as	 E.	 coli	 has	 been	 reported	 as	 the	 most	 common	 cause	 of	 UTIs	 and	 is	
responsible	 for	 other	 systemic	 infections	 ranging	 from	 infective	 arthritis	 to	 septicaemia	
(141).		The	other	bacterial	species	identified	are	those	that	can	be	found	as	normal	resident	
flora	of	the	gastrointestinal	tract	or	are	opportunistic	pathogens.			
Strains	of	Klebsiella	pneumoniae,	Enterobacter	cloacae,	Enterobacter	aerogenes,	Citrobacter	
braakii,	 Proteus	mirabilis	and	Morganella	morganii	 form	part	 of	 the	 larger	 gut	microflora	
comprising	 Firmicutes	 and	 Bacteroidetes	 (142),	 while	 strains	 of	 Klebsiella	 oxytoca,	
Citrobacter	 freundii	 and	 Pantoea	 spp	 can	 often	 cause	 opportunistic	 infection	 which	 are	
particularly	 problematic	 to	 immunocompromised	 and	 hospitalised	 patients	 and	 those	
patient	 with	 co-morbidities.	 	 Strains	 of	 Stenotrophomonas	 maltophilia	 have	 been	
particularly	associated	with	nosocomial	infections,	and	these	are	of	potential	interest	due	to	
their	 inherently	 resistant	 nature	 and	 additional	 spread	 and	 expression	 of	 ESBL	 resistance	
determinants.	
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Figure	3-2,	Image	of	an	agarose	gel	loaded	with	PCR	product	after	amplification	using	beta-
galactosidase	primers	for	the	identification	of	E.coli.		Lane	one	contains	a	positive	E.coli	
marker,	lanes	two	to	eight	contain	patient	samples	(lane	five	demonstrating	a	negative	
result)	and	lane	nine	a	negative	control.		The	762	base	pair	products	in	lanes	1,	2,	3,	4,	6,	7	
and	8	denote	that	these	organisms	can	be	identified	as	E.coli	due	to	their	ability	to	utilise	
the	beta-galactosidase	enzyme.	
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(a)	
	
	
	
(b)	
	
(c)		
 
GOOD IDENTIFICATION 
 
  Strip      API 20 E V4.1 
  Profile      3 3 0 5 5 7 3 
  Note      
 
 
  Significant taxa     % ID     T     Tests against 
  Enterobacter cloacae      95.1      1.0         
 
 
  Next taxon     % ID     T     Tests against 
  Enterobacter sakazakii      3.0      0.75  INO 75%  
 
 SOR 8%  
 
    
 
 	
Figure	3-3,	(a)	An	inoculated	API	20e	strip	after	incubation	illustrating	the	different	test	types;	the	colour	reactions,	after	
addition	of	reagents	to	the	tryptophan	deaminase	(TD),	Indole	(IND)	and	Voges-Proskauer	(VP)	tests,	depict	a	positive	or	
negative	result	producing	a	seven	digit	numerical	profile	to	enable	bacterial	identification.		(b)	The	results	obtained	
(positive	or	negative),	scoring	system	and	seven	digit	numerical	profile	obtained	from	the	API	20e	strip	illustrated	above.	
(c)	the	APIWeb	database	results	from	the	API	20e	strip	illustrated	above,	showing	the	bacterial	identification	(significant	
taxa),	next	best	bacterial	identification	(next	Taxon),	percentage	probability	(%	ID),	T	value,	standard	error	of	identification	
and	any	investigations	that	would	present	against	the	suggested	identification	(Inositol	(INO)	and	Sorbitol	(SOR)).	
	 	
Carbohydrate	fermentation	H2S,	Urease,	Tryptophane	
DeAminase,	Indole,	Acetoin	
and	Gelatinase	production	
Citrate	
utilisation	
Arginine,	
Lysine	and	
Ornithine	De-
Carboxylation	
Β-
galactosidase	
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Table	3-2,	Results	obtained	from	the	isolate	identification	using	the	API20e	system	(Biomerieux)	in	2010,	all	
isolates	producing	negative	PCR	results	and	a	proportion	of	the	positive	samples,	for	isolate	identification	
confirmation,	were	analysed	using	this	method.		Results	include	the	isolate	location,	number	of	the	isolate,	
bacterial	identification,	the	percentage	probability	of	the	identification	and	T	value.	
	
Location	 Isolate	
number	
Identification	 Percentage	
probability	
T	value	
Basingstoke		 8	 Klebsiella	pneumoniae	 97.6%	 1.0	
Basingstoke		 9	 Klebsiella	pneumoniae	 97.6%	 1.0	
Basingstoke		 10	 Klebsiella	pneumoniae	 97.6%	 1.0	
Basingstoke	 13	 Klebsiella	pneumoniae	 97.6%	 1.0	
Basingstoke		 14	 Klebsiella	oxytoca	 97.4%	 1.0	
Basingstoke	 17	 Enterobacter	cloacae	 95.1%	 1.0	
Basingstoke		 18	 Enterobacter	cloacae	 95.1%	 1.0	
Basingstoke		 30	 Citrobacter	freundii	 99.9%	 1.0	
Basingstoke	 34	 Enterobacter	cloacae	 95.1%	 1.0	
Portsmouth	 7	 Klebsiella	pneumoniae	 97.6%	 1.0	
Portsmouth	 10	 Proteus	mirabilis	 99.9%	 0.92	
Portsmouth		 42	 Enterobacter	cloacae	 95.1%	 1.0	
Portsmouth	 48	 Klebsiella	pneumoniae	 98.2%	 0.93	
Portsmouth	 50	 Klebsiella	pneumoniae	 98.2%	 0.93	
Portsmouth	 52	 Klebsiella	pneumoniae	 98.2%	 0.93`	
Southampton	 1	 Enterobacter	cloacae	 97.7%	 1.0	
Southampton	 6	 Klebsiella	pneumoniae	 97.6%	 1.0	
Southampton	 10	 Klebsiella	pneumoniae	 97.6%	 1.0	
Southampton	 18	 Enterobacter	cloacae	 95.1%	 1.0	
Southampton	 41	 Klebsiella	oxytoca	 97.3%	 1.0	
Southampton	 44	 Pantoea	sp	 99.4%	 0.97	
Southampton		 50	 Pantoea	sp	 97.3%	 1.0	
Southampton	 63	 Klebsiella	oxytoca	 97.3%	 1.0	
Winchester	 5	 Klebsiella	oxytoca	 97.4%	 1.0	
Winchester	 6	 Klebsiella	oxytoca	 97.3%	 1.0	
Winchester	 12	 Klebsiella	oxytoca	 97.3%	 1.0	
Winchester	 21	 Enterobacter	aerogenes	 98.9%	 1.0	
Winchester	 27	 Proteus	mirabilis	 99.9%	 1.0	
Winchester	 29	 Enterobacter	cloacae	 98.9%	 0.85	
Winchester	 34	 Klebsiella	pneumoniae	 97.6%	 1.0	
Winchester	 36	 Enterobacter	cloacae	 95.1%	 1.0	
Winchester	 40	 Enterobacter	aerogenes	 98.9%	 1.0	
Winchester	 45	 Klebsiella	pneumoniae	 98.2%	 1.0	
Winchester	 53	 Klebsiella	pneumoniae	 98.2%	 1.0	
Winchester	 66	 Klebsiella	pneumoniae	 97.6%	 1.0	
Basingstoke	 2	 E.coli	 99.5%	 0.96	
Basingstoke		 27	 E.coli	 99.9%	 0.90	
Portsmouth	 1	 E.coli	 99.5%	 0.96	
Portsmouth	 45	 E.coli	 99.8%	 0.94	
Southampton	 13	 E.coli	 99.8%	 0.88	
Southampton	 26	 E.coli	 99.5%	 0.96	
Winchester	 38	 E.coli	 99.5%	 0.96	
Winchester	 68	 E.coli	 99.5%	 0.96	
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Table	3-3,	Results	obtained	from	the	isolate	identification	using	the	API20e	system	(Biomerieux)	in	2012,	all	isolates	
producing	negative	PCR	results	and	a	proportion	of	the	positive	samples,	for	isolate	identification	confirmation,	were	
analysed	using	this	method.		Results	include	the	isolate	location,	number	of	the	isolate,	bacterial	identification,	the	
percentage	probability	of	the	identification	and	T	value.	
			
Location	 Isolate	
number	
Identification	 Percentage	
probability	
T	value	
Basingstoke	 3	 Klebsiella	pneumoniae	 97.6%	 1.0	
Basingstoke	 26	 Enterobacter	cloacae	 97.7%	 1.0	
Basingstoke	 33	 Citrobacter	braakii	 99.8%	 1.0	
Basingstoke	 35	 Citrobacter	freundii	 99.8%	 1.0	
Basingstoke	 36	 Enterobacter	cloacae	 95.1%	 1.0	
Basingstoke	 38	 Citrobacter	freundii	 99.9%	 1.0	
Basingstoke	 48	 Proteus	mirabilis	 99.9%	 1.0	
Basingstoke		 50	 Enterobacter	aerogenes	 98.9%	 1.0	
Basingstoke		 52	 Stenotrophomonas	maltophilia	 99.3%	 0.94	
Basingstoke	 55	 Klebsiella	pneumoniae	 98.2%	 1.0	
Basingstoke		 56	 Klebsiella	oxytoca	 97.4%	 1.0	
Basingstoke	 57	 Enterobacter	cloacae	 97.7%	 1.0	
Basingstoke		 63	 Enterobacter	aerogenes	 98.9%	 1.0	
Basingstoke		 86	 Proteus	mirabilis	 99.9%	 1.0	
Basingstoke	 87	 Klebsiella	pneumoniae	 97.6%	 1.0	
Winchester	 2	 Citrobacter	freundii	 99.9%	 1.0	
Winchester	 10	 Morganella	morganii	 99.9%	 1.0	
Winchester		 13	 Citrobacter	freundii	 99.9%	 1.0	
Winchester	 15	 Proteus	mirabilis	 99.9%	 1.0	
Winchester	 25	 Enterobacter	cloacae	 98.9%	 1.0	
Winchester	 27	 Enterobacter	cloacae	 98.9%	 1.0	
Winchester	 40	 Morganella	morganii	 99.9%	 1.0	
Winchester	 48	 Enterobacter	cloacae	 97.7%	 1.0	
Winchester	 58	 Enterobacter	cloacae	 98.9%	 1.0	
Winchester	 72	 Klebsiella	pneumoniae	 97.6%	 1.0	
Southampton	 1	 Enterobacter	cloacae	 95.1%	 1.0	
Southampton	 3	 Enterobacter	cloacae	 98.9%	 1.0	
Southampton		 4	 Enterobacter	cloacae	 98.9%	 1.0	
Southampton	 7	 Klebsiella	pneumoniae	 98.2%	 1.0	
Southampton		 8	 Enterobacter	cloacae	 95.1%	 1.0	
Southampton		 16	 Enterobacter	cloacae	 95.1%	 1.0	
Southampton		 25	 Klebsiella	pneumoniae	 98.2%	 1.0	
Southampton	 27	 Enterobacter	cloacae	 95.1%	 1.0	
Southampton	 33	 Klebsiella	pneumoniae	 97.6%	 1.0	
Southampton	 40	 Klebsiella	pneumoniae	 97.6%	 1.0	
Southampton	 41	 Klebsiella	pneumoniae	 97.6%	 1.0	
Southampton	 45	 Enterobacter	cloacae	 98.9%	 1.0	
Southampton		 49	 Klebsiella	pneumoniae	 97.6%	 1.0	
Portsmouth	 26	 Proteus	mirabilis	 99.9%	 1.0	
Portsmouth	 32	 Klebsiella	pneumoniae	 98.2%	 1.0	
Basingstoke	 14	 E.coli	 99.9%	 0.90	
Winchester	 28	 E.coli	 99.5%	 0.95	
Southampton	 44	 E.coli	 99.5%	 0.95	
Portsmouth	 27	 E.coli	 99.8%	 0.98	
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3.3	ESBL	and	AmpC	Detection	
All	of	the	isolates	recovered	from	hospital	and	community	infections	were	suspected	to	be	
ESBL	 producing	 organisms;	 nevertheless	 it	 was	 possible	 that	 they	 could	 have	 been	
producing	AmpC	or	dual	 resistance	 [both	AmpC	and	ESBL].	 	 To	distinguish	between	 these	
alternatives,	 the	 ESBL	 and	 AmpC	 disc	 diffusion	 test,	 MAST	 (126),	 was	 employed,	 as	
described	 in	 Chapter	 2,	 section	 2.1.4.	 	 This	 method	 uses	 a	 series	 of	 four	 test	 discs	 [A	 -	
cefpodoxime,	 B	 -	 cefpodoxime	 plus	 an	 ESBL	 inhibitor,	 C	 -	 cefpodoxime	 plus	 an	 AmpC	
inhibitor	and	D	 -	 cefpodoxime	plus	ESBL	and	AmpC	 inhibitors,	 the	nature	of	 the	ESBL	and	
AmpC	 inhibitors	 have	 not	 been	 released	 by	 the	 manufacturer],	 that	 when	 analysed	
according	 to	BSAC	guidelines	 (125),	and	zone	diameters	 calculated	according	 to	 table	3.4,	
will	identify	if	an	isolate	carries	an	ESBL,	AmpC	or	both	ESBL	and	AmpC	determinants	[Figure	
3.4].			
Within	the	Hampshire	isolates,	the	most	prevalent	resistance	mechanism	detected	was	ESBL	
production,	 with	 65%	 of	 the	 total	 2010	 isolates	 and	 79%	 of	 the	 2012	 isolates	 yielding	 a	
positive	set	of	test	reactions.	 	 Isolates	demonstrating	AmpC	production	presented	a	 lower	
proportion	of	 the	 total,	with	 9%	of	 the	 2010	 isolates	 and	6%	of	 the	 2012	 isolates	 testing	
positive.	 	 The	 smallest	proportion	of	 isolates	 [3%	of	 the	2010	 isolates	and	4%	 from	2012]	
demonstrated	production	of	both	resistance	types.		The	difference	between	the	resistance	
determinant	prevalence	was	supported	by	a	Kruskal-Wallis	test	[p=0.0048,	2010	isolates	and	
p=0.0092,	 2012	 isolates].	 	 A	 Dunn’s	 post	 hoc	 analysis	 revealed	 a	 statistically	 significant	
difference,	in	both	year	groups,	between	the	prevalence	of	the	ESBL	determinant	compared	
to	the	ESBL	and	AmpC	determinant	[p=0.0207,	 in	2010	and	p=0.0315],	Figure	3.5	[a]	2010	
and	[b]	2012.		Twenty	three	percent	of	the	2010	isolates	and	11%	of	the	2012	isolates	could	
not	unambiguously	be	categorised	as	either	resistance	type	and	required	further	molecular	
characterisation	to	confirm	ESBL	expression.			
Multiplex	 PCR	 for	 ESBL	 resistance	 determinants	 [detailed	 in	 chapter	 four]	 showed	 that	
45/53	of	the	2010	isolates	and	16/24	of	the	2012	isolates,	requiring	further	work,	expressed	
one	or	more	of	the	ESBL	resistance	determinant	types	[CTX-M,	TEM	or	SHV].	
The	relatively	large	proportion	of	isolates	that	remained	unclassified	after	being	tested	using	
the	MAST	system	suggested	that	 this	system	was	 inadequate	to	distinguish	between	ESBL	
and	AmpC	producing	bacteria	alone.		A	similar	observation	was	reported	by	Halstead	et	al.	
(143)	who	 failed	 to	 detect	 one	 fifth	 of	 the	Klebsiella	 pneumoniae	 isolates	 producing	 SHV	
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enzymes	and	two	isolates	expressing	TEM	and	CTX-M	and	TEM	and	SHV	dual	resistances.		In	
order	 to	 determine	 if	 the	 results	 obtained	 from	 this	 study	 demonstrated	 the	 same	
limitations,	the	isolates	requiring	further	analysis	were	investigated.		Of	the	total	77	isolates	
[53	 in	 2010	 and	24	 in	 2012]	 reported	 as	 requiring	 further	 analysis,	 64%	of	 the	organisms	
were	 identified	 as	 E.	 coli,	 8%	 Klebsiella	 oxytoca,	 4%	 Klebsiella	 pneumoniae,	 3%	 Proteus	
mirabilis	 and	 1%	 Enterobacter	 cloacae.	 	 Thirty	 percent	 of	 the	 isolates	 expressed	 the	 CTX	
enzyme,	30%	both	CTX	and	TEM,	12%	TEM	and	4%	TEM	and	SHV.		Comparing	this	study	to	
the	 published	 data	 revealed	 no	 limitation	 similarities	 when	 considering	 organism	
identification,	 however,	 dual	 expression	 of	 both	 TEM	 and	 CTX	 appear	 to	 be	 problematic	
within	 both	 datasets.	 	 Conclusions	 drawn	 from	 the	 study	 completed	 by	 Halstead	 et	 al.	
suggest	 that	 the	 incorporation	of	 an	AmpC	 inducer	may	mask	ESBL	 activity.	 	 This	may	be	
true	for	this	study	but	was	not	investigated.	
Previous	 research	 was	 considered	 to	 determine	 if	 the	 lower	 AmpC	 and	 dual	 resistance	
prevalence	was	related	to	Hampshire.		Simner	et	al.	(144)	and	Moland	et	al.	(145)	reported	
reduced	prevalence	of	AmpC	production	when	compared	to	ESBL	resistance.		In	comparison	
Masterton	and	Turner	(146)	reported	a	higher	prevalence	of	AmpC	production	[11.3%	rising	
to	16.7%],	in	comparison	to	ESBL	expression	[4.8%	to	7.4%].			
Varying	reports	of	AmpC	prevalence	worldwide	and	within	the	UK,	suggests	that	the	lower	
prevalence	of	AmpC	and	dual	resistance	is	not	geographically	related	to	the	Hampshire	area.		
A	 lack	of	established	guidelines	 for	AmpC	detection	and	 the	associated	 risks	of	producing	
false	negative	results	within	 laboratory	detection	methods,	potentially	highlight	 the	under	
reporting	of	AmpC	resistance	(147).							
	
	 3.3.1	 Hospital	Location	and	Resistance	Type	
When	 the	 hospital	 location	 and	 resistance	 type	 frequency	was	 considered,	 no	 significant	
differences	 between	 the	 resistance	 type	 and	 location,	 according	 to	 a	 Kruskal-Wallis	 test	
[p=0.7231	for	the	2010	data	set	and	p=0.7348	for	the	2012	data	set]	could	be	determined,	
suggesting	that	patient	risk	of	acquiring	an	ESBL	or	AmpC	based	infection	for	any	particular	
year	is	the	same	for	all	four	hospitals.	
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Table	3-4,	The	calculations	used	by	the	MAST	ESBL	and	AmpC	detection	discs	to	determine	
ESBL	or	AmpC	production.		Disc	diffusion	methodology	according	to	the	BSAC	criteria	was	
carried	out	and	agar	plates	were	incubated	for	18-24	hours	in	aerobic	conditions,	after	the	
addition	of	the	four	discs	(A,	B,	C	and	D).		All	zone	diameters	detected	around	the	four	discs	
were	measured	in	millimetres	using	a	ruler.	
	
Resistance	Criteria	 Calculation	 Result	
ESBL	 Zone	diameter	of	Disc	B	–	zone	diameter	of	Disc	A	
and	zone	diameter	of	Disc	D	–	zone	diameter	of	
Disc	C	
	
<5mm	
ESBL	 Zone	diameter	of	Disc	B	–	zone	diameter	of	Disc	D	
and	zone	diameter	of	Disc	A	–	zone	diameter	of	
Disc	C	
	
>4mm	
AmpC	 Zone	diameter	of	Disc	D	-		zone	diameter	of	Disc	B	
and	zone	diameter	of	Disc	C	-		zone	diameter	of	
Disc	A		
	
>5mm	
AmpC	 Zone	diameter	of	Disc	A	-			zone	diameter	of	Disc	B	
and	zone	diameter	of	Disc	C	-		zone	diameter	of	
Disc	D		
	
<4mm	
Dual	Resistance	
(ESBL	and	AmpC)	
Zone	diameter	of	disc	D	-	zone	diameter	of	disc	C		 >5mm	
Dual	Resistance	
(ESBL	and	AmpC)	
Difference	between	the	zone	diameter	of	Discs	A	
and	B.	
<4mm	
Negative	 All	zone	diameters	 Differ	by	<2mm	
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Figure	3-4,	DST	plate	lawned	with	a	0.5	McFarland	standard	bacterial	suspension,	MAST	
ESBL	and	AmpC	detection	discs	labelled	A-D	were	applied	to	the	media	[disc	A	presented	on	
the	left	of	the	plate,	disc	B	to	the	top,	disc	C	to	the	bottom	and	disc	D	to	the	right]	and	
incubated	for	24	hours.		Semi	confluent	growth	was	achieved	and	ESBL	resistance	detected	
as	a	zone	of	clearing	is	evident	around	disc	B	[cefpodoxime	plus	ESBL	inhibitor]	and	disc	D	
[cefpodoxime	plus	ESBL	and	AmpC	inhibitor].		The	calculation	to	determine	the	resistance	
expressed,	revealed	that	this	organism	is	expressing	ESBL	resistance.	
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(a)	
	
(b)	
	
	
Figure	3-5,	The	proportion	of	isolates	within	(a)	2010	and	(b)	2012	demonstrating	ESBL,	AmpC	and	dual	resistance,	Winchester	hospital	is	
depicted	 in	 red,	 Basingstoke	 in	 blue,	 Southampton	 in	 green	 and	 Portsmouth	 in	 yellow.	 	 Kruskal-Wallis	 analysis	 revealed	 significant	
differences	 between	 the	 resistance	 determinant	 prevalence	 (p=0.0048,	 2010	 isolates	 and	 p=0.0092,	 2012	 isolates).	 	 Dunn’s	 post	 hoc	
analysis	revealed	statistical	differences,	in	both	year	groups,	between	the	prevalence	of	the	ESBL	determinant	compared	to	the	ESBL	and	
AmpC	determinant	(p=0.0207,	in	2010	and	p=0.0315).	
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The	differences	in	the	proportion	of	ESBL,	AmpC	and	dual	resistance	within	the	hospitals	for	
the	two	years	varied,	with	Winchester	and	Basingstoke	demonstrating	a	subtle	 increase	 in	
the	ESBL	producing	bacteria	isolated	of	2%	and	6%	respectively,	and	Southampton	having	a	
larger	 increase	 of	 45%.	 	 In	 contrast,	 Portsmouth	 had	 a	 decrease	 of	 9%	 for	 the	 ESBL	
producing	 bacteria	 isolated.	 	 Although	 differences	 existed	 between	 hospitals,	 Mann-
Whitney	test-statistic	 indicated	that	 the	difference	between	the	same	hospital	site,	within	
each	 year	 cohort,	 was	 not	 statistically	 significant	 [p=0.3429].	 	 The	 increase	 noticed	 for	
Southampton	 is	 of	 interest,	 although	 it	 does	 not	 necessarily	 reflect	 an	 increased	 risk	 to	
patients	of	acquiring	an	ESBL	based	infection.		It	may	be	due	to	the	fact	that	this	is	a	larger	
teaching	 hospital,	 accepting	 a	 wider	 range	 of	 severely	 infected	 patients,	 requiring	
alternative	antibiotic	therapies.					
The	 differences	 in	 the	 proportions	 of	 AmpC	 and	 dual	 resistant	 isolates	 between	 the	 data	
sets	 also	 varied,	 with	 Southampton	 and	 Portsmouth	 having	 a	 decrease	 of	 1%	 and	 2%	
respectively	 for	 AmpC	 producing	 isolates,	 Basingstoke	 remained	 stable,	while	Winchester	
exhibited	a	10%	 increase.	 	The	proportions	of	 isolates	exhibiting	dual	 resistance	remained	
stable	at	Winchester,	no	isolates	were	identified	as	exhibiting	dual	resistance	at	Portsmouth	
in	either	2010	or	2012,	while	a	1%	decrease	was	observed	for	Southampton’s	isolates	and	a	
2%	 increase	 noted	 for	 Basingstoke.	 	 Although	 subtle	 differences	 have	 been	 detected	 in	
AmpC	and	dual	expression,	a	Mann-Whitney	test	statistic	determined	that	overall	this	would	
not	be	 considered	an	 increasing	 risk	 factor	 for	patients	 in	 the	Hampshire	 area	 [p=0.5429,	
AmpC	and	p=0.8286,	dual	resistance].	
	
	 3.3.2	 Gender	and	Resistance	Type	
When	 the	 resistance	 type	 and	 patient	 gender	were	 considered,	 no	 significant	 differences	
between	 the	 numbers	 of	 isolates	 with	 different	 resistance	mechanisms	 compared	 to	 the	
patient	gender	could	be	determined.	 	This	was	supported	by	a	Mann-Whitney	 test	with	p	
values	of	p=0.3429	and	p=0.3333	for	the	2010	and	2012	datasets.		No	significant	increases	
or	 decreases	 in	 resistance	 expression	 compared	 to	 patient	 gender	 could	 be	 determined	
between	 the	 two	 year	 sets,	 this	was	 supported	by	 a	Mann-Whitney	 test	with	p	 values	of	
p=0.7778	 for	 females	 and	 p=0.6825	 for	males.	 	 Differences	 between	 the	 genders	 for	 the	
AmpC	determinant	has	been	reported,	but	 these	are	not	consistent.	 	Denisuik	et	al.	 (148)		
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demonstrated	 reduced	 numbers	 of	 AmpC	 production	 within	 the	 male	 population.	 	 	 	 In	
contrast,	 Feglo	 and	Opoku	 (149)	 initially	 reported	a	higher	 incidence	of	AmpC	production	
within	 males	 compared	 to	 females	 [51%	 compared	 to	 42%],	 however	 when	 expression	
levels	for	this	determinant	were	analysed	it	appeared	that	two	forms	existed:	an	inducible	
[the	enzyme	is	only	produced	after	induction]	and	non-inducible	form.		When	the	different	
forms	were	considered	females	had	a	greater	incidence	of	the	inducible	form	compared	to	
males,	 where	 the	 non-inducible	 pre-dominated.	 	 Within	 the	 current	 study,	 males	 were	
observed	 to	 have	 an	 increase	 proportion	 of	 AmpC	 resistance	 within	 the	 2010	 dataset,	
however	this	was	not	observed	in	2012.		It	is	not	possible	to	comment	on	distribution	of	the	
inducible	and	non-inducible	 forms	as	expression	was	not	measured.	 	 It	 should	be	pointed	
out;	however,	that	the	number	of	samples	collected	from	males	and	females	was	not	equal,	
with	the	greater	proportion	of	isolates	originating	from	female	patients	so	that	the	data	is	
skewed.	
	
	 3.3.3	 Patient	Age	and	Resistance	Type	
The	patient	cohorts	for	2010	and	2012	were	separated	into	age	groups	for	each	decade	of	
life	to	compare	the	resistance	mechanism	expressed	by	the	 infection	causing	 isolates.	 	No	
significant	differences	could	be	determined	between	the	patient	age	groups	and	resistance	
type,	 this	was	 supported	 by	 a	 Kruskal-Wallis	 test	with	 p	 values	 of	 p=0.9826	 for	 the	 2010	
isolates	and	p=0.9962	for	2012.		The	percentage	of	each	resistance	type	according	to	each	
age	 range	 is	 shown	 in	 Figure	 3.6.	 	 This	 graph	 reveals,	 in	 greater	 detail,	 the	 similarities	
between	age	groups	11-20,	21-30,	31-40,	51-60	and	61-70	in	2010	and	21-30,	31-40,	41-50	
and	61-70	in	2012.		The	results	obtained	suggest	that	all	age	ranges	are	at	an	equal	risk	of	
ESBL	and	AmpC	producing	organisms,	within	the	Hampshire	area.		Figure	3.6	illustrated	that,	
within	 2010,	 ESBL	 resistance	 appeared	 to	 affect	 all	 age	 ranges	 at	 significant	 percentage	
rates,	AmpC	and	dual	resistance	was	prevalent	in	all	other	age	ranges	at	lower	percentages,	
with	the	exception	of	age	groups	11-20	and	21-30.	 	A	similar	picture	was	observed	within	
2012	 with	 ESBL	 resistance	 affecting	 all	 age	 ranges,	 and	 younger	 patients,	 aged	 1-10,	
appearing	to	have	a	higher	prevalence	of	AmpC	infections.		It	is	important	to	consider	that	
the	 data	 presented	 in	 Figure	 3.6	 is	 that	 of	 percentage.	 	 In	 order	 to	 demonstrate	 if	 the	
percentage	 calculation	has	 skewed	 the	data	 in	anyway,	 in	particular	 for	 those	age	groups	
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with	 small	 sample	numbers,	 the	number	of	 isolates	 in	 each	 age	 group	has	 been	 included	
within	the	graph.		
Although	 not	 detected	 within	 this	 study,	 age	 susceptibility	 to	 AmpC	 resistance	 has	 been	
observed	in	previous	research.	 	Pitout	et	al.	(150)	identified	increased	expression	of	AmpC	
resistance	 in	 young	 patients	 aged	 less	 than	 one	 year	 and	 in	 elderly	 patients	 aged	 70	 or	
above.	 	 Pitout	 also	 identified	 a	 gradual	 increase	 in	 AmpC	 production	 as	 the	 age	 range	
increased.	 	Within	the	Hampshire	area	this	observation	was	not	evident,	 in	2010,	patients	
aged	between	1-10,	71-80	and	91-96	demonstrated	a	higher	prevalence	of	AmpC	expression	
compared	 to	 the	 other	 age	 ranges.	 	 These	 figures	 were	 not	 reproduced	 in	 2012	 and	 a	
significant	decrease	in	AmpC	expression	could	be	observed	within	the	age	groups	71-80	and	
91-98,	suggesting	that	AmpC	resistance,	within	the	elderly	population	in	Hampshire,	is	being	
detected	and	 treated	appropriately.	 	A	 significant	decrease	 in	AmpC	production,	between	
the	two	year	groups,	was	not	observed	in	patients	aged	between	1-10;	although	this	is	not	
considered	a	 statistically	 significant	 risk	 factor,	 these	 results	 suggest	 that	 the	detection	of	
AmpC	 resistance,	 treatment	 options	 and	 prescribing	 policies	 for	 this	 age	 range	 would	
benefit	from	review.		Potential	levels	of	intestinal	AmpC	colonisation,	within	this	age	range,	
could	also	be	assessed,	in	order	to	address	any	potential	increased	risk	of	infection.		When	
comparing	both	 year	 groups,	 the	most	 striking	observation	was	 the	 increased	percentage	
rates	 of	 ESBL	 infections	 through	 all	 age	 groups.	 	 This	 suggests	 that	 ESBL	 infections	 are	
increasing	in	numbers	each	year,	within	the	Hampshire	area.	 	Although	a	slight	increase	in	
AmpC	and	dual	resistance	was	observed,	this	was	not	to	such	a	significant	level.				
	
3.4	Antibiotic	Susceptibility	of	the	Isolates	
Antimicrobial	 susceptibility	 data	 allow	 clinicians	 to	 select	 the	 most	 effective	 antibiotic	
treatment,	 for	 a	 particular	 infection,	 and	 provide	 information	 on	 the	 rise	 of	 particular	
resistance	determinants	within	clinical	isolates.		All	bacterial	isolates	from	the	four	hospitals,	
collected	 over	 two	 years,	 were	 tested	 for	 their	 susceptibility	 to	 thirteen	 antibiotics,	 in	
clinical	use,	as	described	in	Chapter	2,	section	2.1.4,	to	identify	whether	they	had	acquired	
multiple	drug	resistance,		
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(a)	
	
	
(b)	
	
	
Figure	3-6;	(a)	The	proportion	of	ESBL,	AmpC	and	Dual	resistance	within	each	age	group	of	the	patients	within	
2010.		The	graph	illustrates	that	similarities	between	resistance	mechanisms	can	be	determined	within	the	age	
groups	11-20,	21-30,	31-40,	51-60	and	61-70.		Age	ranges	1-10,	71-80	and	91-96	also	demonstrated	higher	
percentage	of	AmpC	resistance.		No	AmpC	or	dual	resistance	was	detected	within	the	age	groups	11-20	and	
21-30.	(b)	The	percentage	ESBL,	AmpC	and	Dual	resistance	within	each	age	group	of	patients	within	2012.		The	
graph	illustrates	similarities	between	the	resistance	mechanisms	within	age	groups	21-30,	31-40,	41-50,	61-70	
and	91-98.		Age	range	1-10	illustrated	a	higher	percentage	of	AmpC	resistance.		Comparison	of	both	years	
revealed	an	increase	in	ESBL	resistance	over	all	age	groups.	
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The	 thirteen	 antibiotics	 screened	 included:	 gentamicin,	 cefotaxime,	 amoxicillin,	 co-
amoxiclav,	 cefuroxime,	 piperacillin-tazobactam,	 ciprofloxacin,	 meropenem,	 ertapenem,	
ceftazidime,	amikacin,	cefepime	and	tigecycline.		The	first	eight	antibiotics	were	considered	
as	either	the	first	or	second	line	treatment	options	for	the	hospitals	in	the	study.		Tigecycline	
was	 added	 on	 the	 advice	 of	 Dr	Matthew	 Dryden,	 [Royal	 Hampshire	 County	 Hospital	 and	
Public	Health	England,	Porton	Down]	as	it	is	a	possible	treatment	for	patients	suffering	from	
a	 carbapenemase	 producing	 ESBL	 infection,	 which	 renders	 carbapenems	 [meropenem,	
ertapenem]	 inactive.	 	 Ceftazidime,	 cefepime,	ertapenem	and	amikacin	were	added	 to	 the	
study	 on	 the	 advice	 of	 Professor	 Neil	 Woodford	 [Head	 of	 Antimicrobial	 Resistance	 and	
Healthcare	 Associated	 Infections	 Reference	 Unit,	 Public	 Health	 England].	 	 Cefepime	
susceptibility	 and	 resistance	 to	 other	 cephalosporins	 provides	 an	 indication	 of	 AmpC	
production;	ertapenem	provides	greater	sensitivity	to	carbapenemase	activity	compared	to	
meropenem.	 	Amikacin	 resistance	with	 gentamicin	 susceptibility	 provides	 an	 indication	of	
CTX-M-15	 plasmid	 expression	 and	 hydrolysation	 of	 cefotaxime	 compared	 to	 ceftazidime	
indicates	CTX-M	expression.		Antimicrobial	susceptibility	disc	diffusion	tests	were	performed	
according	to	BSAC	guidelines	using	a	0.5	McFarland	standard	inoculum,	E.	coli	NCTC	10418	
was	used	as	a	 control	 strain,	and	 results	were	 recorded	 following	 the	BSAC	 format	 [Table	
3.5]	after	measuring	zones	of	inhibition,	Figure	3.7.	
	
3.4.1	 General	Antibiotic	Resistance	Patterns	in	Hampshire	for	2010	
and	2012	
As	 is	 expected	 resistance	 to	 amoxicillin	 was	 found	 in	 99%	 of	 all	 isolates,	 with	 nearly	 all	
isolates	[96%]	being	susceptible	to	meropenem	[Figure	3.8	[a]	and	[c]].		This	is	unsurprising	
because	amoxicillin	is	a	commonly	prescribed	agent	for	UTI	treatment	(151),	with	increased	
resistance	being	recorded	for	E.	coli	isolates	within	the	Hampshire	areas,	and	meropenem	is	
a	less	commonly	used	agent,	reserved	for	complicated	infections	involving	sepsis.	
Of	 greater	 interest	 is	 the	 change	 in	 the	 antibiogram	 over	 the	 two	 years.	 	 Comparing	 the	
resistance	 patterns,	 nine	 antibiotics	 [amoxicillin,	 co-amoxiclav,	 meropenem,	 cefotaxime,	
ertapenem,	 ceftazidime,	 tigecycline,	 cefuroxime	 and	 gentamicin]	 showed	 an	 increase	 of	
resistance	amongst	the	isolates,	while	four	[cefepime,	ciprofloxacin,	piperaillin-tazobactam	
and	amikacin]	showed	a	decrease,	Figure	3.8.		Comparisons	between	the	antibiotic	class	and	
resistance	 results	 in	 each	 of	 the	 year	 cohorts	 were	 considered	 significant.	 	 This	 was	
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supported	by	a	Kruskal-Wallis	 test	 [p=<0.001,	2010	and	2012	 resistance	and	 intermediate	
resistance],	 Dunns	 post	 doc	 tests	 were	 carried	 out	 to	 identify	 the	 significant	 differences	
between	 the	 different	 antibiotic	 classes	 and	 resistance	 prevalence	 [Figures	 3.10,	 2010	
results,	 and	 3.10,	 2012	 results].	 	 Statistically	 supported	 differences	 were	 detected	 for	
changes	in	the	proportion	of	resistance	and	intermediate	resistance	between	the	two	year	
cohorts.		
A	Mann-Whitney	 test	 revealed	 significant	 differences	 between	 the	 resistance	 prevalence	
[p=0.0286]	 and	 the	 intermediate	 resistance	 prevalence	 [p=0.0286]	 of	 cefotaxime.	 	 Other	
studies	 worldwide	 have	 reported	 increases	 in	 resistance	 to	 amoxicillin	 (152-154),	
cefotaxime	(154)	and	ceftazidime	(154,	155),	which	have	been	observed	in	this	study.	
Increases	 in	the	number	of	 isolates	displaying	resistances	to	co-amoxiclav,	gentamicin	and	
tigecycline	 appear	 to	be	 confined	 to	 the	Hampshire	 area.	 	 Possible	 reasons	 for	 this	 could	
include:	 amendments	 to	 hospital	 antimicrobial	 prescribing	 policies	 and	 changes	 in	 the	
British	National	Formulary	[BNF]	regarding	prescribing	within	the	community	setting.	
The	 appearance	 of	 isolates	 resistant	 to	 meropenem	 and	 ertapenem	 [carbapenems],	
including	 those	 showing	 intermediate	 resistance,	 is	of	 concern,	as	 these	are	used	 to	 treat	
complicated	 infections,	 including	 septicaemia.	 	 A	 risk	 factor	 previously	 identified	with	 the	
acquisition	 of	 infections	 caused	 by	 carbapenemase-producing	 bacteria,	 particularly	
Klebsiella	 pneumoniae	 is	 the	 prior	 treatment	with	 a	 beta-lactam/beta-lactamase	 inhibitor	
combination,	 fluoroquinalone	 or	 a	 carbapenem,	 or	 prolonged	 treatment	 with	 a	
fluoroquinalone	 or	 fluoroquinalone,	 carbapenem	 combination.	 In	 contrast	 the	 receipt	 of	
carbapenems	 alone	 proved	 protective	 against	 carbapenem	 resistant	 ESBL	 Klebsiella	
pneumoniae	 (156).	 	 Within	 this	 study	 30%	 and	 25%	 of	 the	 patients	 in	 2010	 and	 2012	
respectively	 received	 previous	 antibiotic	 therapy,	 which	 included	 trimethoprim,	
metronidazole,	amoxicillin,	co-amoxiclav	and	nitrofurantoin	[Section	3.2.2.5].			
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Table	3-5,	An	example	of	the	BSAC	guidelines	including	the	specific	media	requirements	for	bacterial	growth,	the	concentration	of	bacteria	
required	for	semi	confluent	growth,	incubation	conditions	and	the	measurements	of	the	zone	of	inhibition	diameters	to	determine	if	the	
bacteria	were	sensitive	to	the	agent	or	demonstrating	intermediate	resistance	or	complete	resistance	[adapted	from	(125)].			
		
	
	
	
	
	
	
Enterobacteriaceae	(Including	Salmonella,	Shigella	spp	and	Yersinia	enterocolitica)	 BSAC,	Version	14,	January	2012		
The	identification	of	Enterobacteriaceae	to	species	level	is	essential	before	applying	Expert	Rules	for	the	interpretation	of	susceptibility.	
	
Disk	diffusion	method	for	Antimicrobial	Susceptibility	testing	
Medium:	DST	agar	
Inoculum:	McFarland	0.5,	dilute	1:100	
Incubation:	Air,	36±1ºC,	19±1h	
Reading:	Read	zone	edges	as	the	point	showing	no	growth	viewed	from	the	back	of	the	plate	against	a	dark	background	illuminated	with	reflected	light.	
Quality	control:	Escherichia	coli	NCTC	10418	or	ATCC	25922	
	
	 MIC	breakpoint	(mg/L)	 Disc	Content	
µg/ml	
Zone	diameter	Breakpoint	
(mm)	
Agent	Specific	Notes	
S>	 I	 R<	 S	>	 I	 R<	 	
Gentamicin	 2	 4	 4	 10	 20	 17-19	 16	 	
Amoxicillin	 8	 -	 8	 10	 15	 -	 14	 	
Media	requirements,	bacterial	
dilution	requirements	and	
incubation	conditions	 Antibiotic	disc	concentration	
Zone	diameters	20mm	or	greater,	
the	bacteria	would	be	considered	
sensitive	to	the	agent	
Zone	diameters	between	17	and	
19,	the	bacteria	would	be	
considered	as	intermediate	
resistant.	
Zone	diameters	16mm	or	less,	
the	bacteria	would	be	considered	
resistant	to	the	agent.	
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Figure	3-7,	An	illustration	of	antimicrobial	chemotherapy	investigations,	here	a	DST	plate	is	
inoculated	with	a	0.5	McFarland	dilution	of	bacteria	and	impregnated	antibiotic	discs,	
labelled	with	the	appropriate	agents,	are	applied,	the	plate	this	then	incubated	for	18-24	
hours.		The	antibiotic	disc	denoted	by	the	arrow	is	meropenem,	followed	in	a	clock	wise	
direction	by	cefuroxime,	gentamicin,	ceftazidime,	piperacillin/tazobactam,	co-amoxiclav,	
amoxicillin	and	ciprofloxacin.		After	incubation	the	bacterial	zones	of	inhibition	around	the	
different	antibiotic	discs	are	measured	and	interpreted	using	the	BSAC	guidelines.		
Antibiotics	can	be	classified	as	sensitive,	intermediate	or	resistant.		Here	the	bacterium	
demonstrates	sensitivity	to	both	meropenem	and	piperacillin/tazobactam	according	to	the	
BSAC	criteria	however	resistance,	due	to	the	lack	of,	or	reduced	zone	of	inhibition	sizes,	to	
all	of	the	other	agents.	
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(a)	
	
(b)	
	
(c)	
	
Figure	3-8,	Percentage	(a)	resistance,	(b)	intermediate	resistance	and	(c)	sensitivity	of	each	of	the	agents	
included	within	this	study.		Figure	(a)	clearly	demonstrates	a	rise	in	resistance	to	9	of	the	13	antibiotics,	an	
increase	in	intermediate	resistance	was	also	detected	to	4	of	the	13	agents	(b),	however	an	increase	in	
sensitivity	could	be	detected	to	5	of	the	13	agents.		The	number	of	isolates	falling	into	each	category	is	
provided	above	each	bar.	
226
120
188
124
172
1
186 195
62 84
5
247
164
2
227
6
152 179
13
137
232
81
54
40
20
40
60
80
100
Pe
rc
en
ta
ge
Antibiotic
Percentage	Resistance
2010
2012
2
36
27
41
28 21
5
19 179 15
28
48
33 38
5 8 13
0
5
10
15
20
Pe
rc
en
ta
ge
Antibiotic
Percentage	Intermediate
2010
2012
3
109
227
5
202
64
29
207
66 34
148 145
207
1
84
237
6
214
14
36
197
106
16
159 194
231
0
20
40
60
80
100
Pe
rc
en
ta
ge
Antibiotic
Percentage	Sensitive
2010
2012
75	
	
(a)	
A m
o x
ic
ill
in
C o
-A
m
o x
ic
la
v
M
e r
o p
e n
em
C e
fo
ta
x i
m
e
E r
ta
p e
n e
m
C e
fta
z i
d i
m
e
C e
fe
p i
m
e
T i
g e
c y
c l
in
e
C i
p r
o f
lo
x a
c i
n
C e
fu
ro
x i
m
e
G
en
ta
m
ic
in
P i
p e
ra
c i
ll i
n
A m
ik
a c
in
0
5 0
1 0 0
A n tib io tic
 R
e
s
is
ta
n
c
e
 (
%
)
p = 0 .0 0 2
p = 0 .0 0 2
p = 0 .0 0 5
p = 0 .0 2 9
p = 0 .0 4 7
p = 0 .0 4 7
	
(b)	
M
e r
o p
e n
em
C e
fo
ta
x i
m
e
E r
ta
p e
n e
m
C e
fta
z i
d i
m
e
C e
fe
p i
m
e
T i
g e
c y
c l
in
e
C i
p r
o f
lo
x a
c i
n
G
e n
ta
m
ic
in
A m
ik
a c
in
0
1 0
2 0
3 0
4 0
A n tib io tic
In
te
rm
e
d
ia
te
 R
e
s
is
ta
n
c
e
 (
%
) p = 0 .0 2 8 9
	
	
Figure	3-9,	The	proportion	of	 isolates	within	2010	demonstrating	(a)	resistance	and	(b)	 intermediate	resistance.	 	Kruskal-
Wallis	 analysis	 revealed	 significant	 differences	 between	 the	 antibiotic	 classes	 and	 resistance/intermediate	 resistance	
prevalence	(p=<0.001).		Dunn’s	post	hoc	analysis	revealed	statistical	differences,	between	those	classes	of	antibiotics	and	
resistance/intermediate	resistance	prevalence	as	show	on	graphs	(a)	and	(b).		Prevalence	at	Basingstoke	is	depicted	in	red,	
Portsmouth	in	blue,	Southampton	in	Green	and	Winchester	in	yellow.	
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Figure	3-10,	The	proportion	of	isolates	within	2012	demonstrating	(a)	resistance	and	(b)	intermediate	
resistance.		Kruskal-Wallis	analysis	revealed	significant	differences	between	the	antibiotic	classes	and	
resistance/intermediate	resistance	prevalence	(p=<0.001,	resistance	and	p=0.0104	for	intermediate	
resistance).		Dunn’s	post	hoc	analysis	revealed	statistical	differences,	between	those	classes	of	antibiotics	and	
resistance	prevalence	as	show	on	graph	a.		Prevalence	at	Basingstoke	is	depicted	in	red,	Portsmouth	in	blue,	
Southampton	in	Green	and	Winchester	in	yellow.	
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Of	the	 isolates	within	this	study	that	were	associated	with	previous	antimicrobial	 therapy,	
16%	 in	 2010	 and	 14%	 in	 2012	 demonstrated	 intermediate	 resistance	 or	 resistance	 to	 a	
carbapenem.	 	 Of	 all	 the	 patients	 from	 whom	 samples	 were	 taken,	 two	 were	 receiving	
ciprofloxacin	and	two	were	being	treated	with	a	carbapenem	at	the	time	of	sampling.		The	
low	level	of	patients	receiving	pre-treatment	suggests	that	the	conclusions	drawn	regarding	
risk	factors	concerning	any	pre-treatment,	 in	the	afore-mentioned	study,	might	be	specific	
to	the	region	of	Heraklion,	Greece,	from	where	the	isolates	were	recovered.		In	addition,	the	
proportion	 of	 isolates	 identified	 as	 Klebsiella	 pneumoniae,	 the	 organisms	 for	 which	 the	
study	was	primarily	based,	was	low	in	this	study	[10%	of	the	total	in	2010	and	4%	in	2012	–	
Tables	3.1	and	3.2]	
The	increase	in	the	number	of	isolates	resistant	to	tigecycline	was	considered	important	as	
this	antibiotic	may	be	used	to	treat	patients	with	carbapenem-resistant	infections,	creating	
a	possible	route	to	generate	multiple	resistant	organisms.		Of	the	2010	isolates,	seven	[3%]	
exhibited	 a	 resistance	 or	 intermediate	 resistance	 to	 tigecycline	 and	 a	 carbepenem.	 	 This	
number	increased	to	11	[4%]	 in	2012,	suggesting	that	these	organisms	are	certainly	stable	
within	the	population	samples,	and	may	be	on	the	increase.	
The	occurrence	of	intermediate	resistance	amongst	the	isolates	is	of	interest	as	they	might	
indicate	 forthcoming	 patterns.	 	 Four	 antibiotics	 [meropenem,	 ceftazidime,	 cefepime	 and	
tigecycline]	showed	an	increase	in	numbers	with	intermediate	resistance	between	2010	and	
2012.	 	 All	 of	 these	 agents	 are	 delivered	 by	 intravenous	 injection,	 limiting	 their	 use	 to	
hospital	 environments,	 and	 three	 [ceftazidime,	 cefepime	 and	 tigecycline]	 displayed	
increased	levels	of	resistance.		Five	antibiotic	classes,	cefotaxime,	ertapenem,	ciprofloxacin,	
gentamicin	and	amikacin	had	reduced	intermediate	resistance	proportions	of	10%,	1%,	1%,	
5%	and	2%	 respectively.	 	Although	 these	values	were	not	 statistically	 significant,	with	 the	
exception	of	cefotaxime,	the	corresponding	rise	in	the	proportion	of	isolates	with	resistance	
to	 cefotaxime,	 ertapenem	 and	 gentamicin	 [9%,	 2%	 and	 6%];	 suggests	 that,	 for	 these	
antibiotics,	 there	 has	 been	 a	 possible	 change	 in	 the	 expression	 of	 the	 resistance	
determinants	responsible	amongst	a	small	proportion	of	the	populations.		
A	 reduction	 in	 the	 proportion	 of	 isolates	 demonstrating	 resistance	 and	 intermediate	
resistance	 to	 amikacin	 and	 ciprofloxacin	 was	 observed	 between	 2010	 and	 2012.	 	 The	
prescription	 of	 these	 antibiotics	 is	 different	 according	 to	 hospital	 guidelines.	 	 Amikacin	 is	
listed	 in	 the	 prescribing	 guidelines	 of	 one	 hospital	 for	 the	 parenteral	 treatment	 of	
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complicated	 urinary	 tract	 infections.	 	 Although	 it	 is	 included	 within	 the	 BNF	 for	 the	
treatment	 of	 complicated	 Gram	 negative	 infections,	 it	 is	 a	 reserve	 antibiotic	 for	 the	
treatment	 of	multi	 resistant	 infections,	 and	not	 prescribed	within	 the	 community	 setting.		
The	reduction	in	the	proportion	of	isolates	exhibiting	resistance	to	this	antibiotic	may	be	a	
result	 of	 its	 infrequent	 use.	 	 Ciprofloxacin	 is	 listed	 in	 the	 prescribing	 policies	 of	 three	
hospitals	 for	 oral	 and	 parenteral	 use	 when	 treating	 male	 urinary	 tract	 infections,	
pyelonephritis,	 hospital	 acquired	 urinary	 tract	 infections	 and	 catheter	 associated	 sepsis.		
This	antibiotic	can	be	used	orally	in	community	settings,	and	the	observed	decrease	in	the	
proportion	 of	 isolates	 exhibiting	 resistance	 to	 it	 may	 not	 be	 attributed	 to	 limited	 usage.		
Recent	 evidence	 reported	 by	 the	 Department	 of	 Health	 has	 linked	 the	 4C	 antibiotics	
[clindamycin,	 cephalosporins,	 co-amoxiclav	 and	 ciprofloxacin]	 with	 Clostridium	 difficile	
infection.	 	 Research	 has	 demonstrated	 that	 increased	 prescriptions,	 greater	 doses	 and	
prolonged	treatment	duration	all	provide	potential	risk	factors	and	advise	the	reduction	in	
use	 of	 these	 agents	 (157).	 	 This	 additional	 evidence	 may	 suggest	 that	 the	 use	 of	
ciprofloxacin	in	the	Hampshire	region	is	limited	and	further	analysis	should	be	performed	to	
prove	this	theory	.	
	
	 3.4.2	 Hospital	Resistance	Patterns	
The	 antimicrobial	 prescribing	 policy	 of	 a	 hospital	 may	 influence	 the	 level	 of	 antibiotic	
resistance	of	bacteria	present	in	its	patients.		The	general	patterns	observed	in	Section	3.2.1	
could	 therefore	 be	 different	 for	 individual	 hospitals,	 as	 each	 hospital	 follows	 its	 own	
guidelines.	 	 This	 section	 deals	 specifically	 with	 the	 hospitals,	 where	 the	 susceptibility	
information	on	each	isolate	is	considered	according	to	the	hospital	from	where	it	originated.			
The	percentage	of	isolates	exhibiting	antibiotic	resistance	at	each	hospital	location	for	2010	
and	2012	is	shown	in	Figure	3.11	[a]	and	[b].			
Although	 the	 proportions	 of	 resistant	 isolates	 within	 each	 antibiotic	 category	 differed	
[Kruskal-Wallis,	p=<0.001]	 for	both	years,	 there	was	no	significant	difference	between	the	
hospital	 site	 and	 resistance	 to	 each	 agent,	 this	 was	 supported	 by	 	 Kruskal-Wallis	 results	
[amoxicillin	 p=0.657,	 co-amoxiclav	 p=0.952,	 meropenem	 p=>0.999,	 cefotaxime	 p=0.942,	
ertapenem	 p=>0.999,	 ceftazidime	 p=0.91,	 cefipime	 p=0.866,	 tigecycline	 p=0.657,	
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ciprofloxacin	 p=0.542,	 cefuroxime	 p=0.581,	 gentamicin	 p=>0.999,	 piperacillin/tazobactam	
p=0.942	and	amikacin	p=0.342].		
The	proportion	of	 isolates	with	 intermediate	 resistance	 to	 the	antibiotics	at	each	hospital	
location	is	shown	in	Figure	3.12	[a]	and	[b]	and	the	proportion	of	isolates	sensitive	to	each	
antibiotic	is	given	in	Figure	3.13	[a]	and	[b].		The	raw	data	for	all	hospitals	over	the	two	years	
is	given	in	Appendices	2	and	3.		The	Kruskal-Wallis	test	of	both	datasets	revealed	the	same	
pattern	that	was	detected	for	the	resistance	profiles;	with	differences	between	the	different	
antibiotics	 [Figures	3.09	[b]	and	3.10	[b]]	but	none	between	hospital	sites.	 	The	resistance	
and	susceptibility	profiles	for	the	hospital	[Figures	3.11	and	3.13]	are	mirror	images	of	each	
other,	 and	 reveal	 similar	 patterns	 when	 the	 changes	 over	 the	 two	 years	 are	 considered.		
There	 is	a	clear	reduction	or	 increase	 in	susceptibility	or	 resistance	 for	 isolate	proportions	
that	 are	 sensitive	 or	 resistant	 to	 amoxiciliin,	 co-amoxiclav,	 meropenem,	 ertapenem,	
ceftazidime,	 tigecycline,	 cefuroxime	 and	 gentamicin.	 	 The	 exception	 to	 this	 pattern	 is	 the	
susceptibility	to	cefotaxime,	which	has	marginally	increased	[0.24%]	between	the	two	years.		
In	 general,	 this	 pattern	 is	 repeated	 for	 intermediate	 resistance	profiles,	 giving	 the	overall	
impression	 that	 antibiotic	 resistance	 is	 increasing	 in	 Hampshire,	 especially	 for	 those	
antibiotics	 regularly	 used	 clinically.	 	 This	 is	 perhaps	 unsurprising	 when	 the	 Primary	 Care	
Trust	 [PCT]	 prescribing	 data	 for	 Hampshire	 [www.hscic.gov.uk/gpprescribingdata]	 is	
considered.	 	 186,465	 antibiotic	 prescriptions	 were	 dispensed	 within	 the	 first	 quarter	 of	
2010-11,	rising	to	235,909	by	the	fourth	quarter	of	2011	-	2012.		This	represents	an	increase	
of	48,444	[21%]	within	a	two-year	period.	 	The	reasons	for	this	 increase	are	not	especially	
clear	but	must	be	related	to	the	prescribing	policies	of	the	hospitals.	
The	 seriousness	 of	 the	 situation	 is	 clearer	 when	 individual	 antibiotic	 and	 hospitals	 are	
considered.	 	 Co-amoxiclav	 is	 a	 broad	 spectrum	 penicillin	 with	 a	 beta-lactamase	 inhibitor,	
and	 is	 listed	 in	 the	 antimicrobial	 prescribing	 policies	 for	 three	 hospitals	 [Portsmouth,	
Winchester	 and	 Southampton]	 for	 the	 treatment	 of	 urinary	 tract	 infections	 or	
pyelonephritis.		Overall,	the	resistance	to	this	antibiotic	has	increased	by	14%	between	2010	
and	2012,	however	when	the	isolate	resistance	proportions	are	considered	for	an	individual	
hospital	compared	to	the	others	the	increases	are	more	striking.		Queen	Alexandra	Hospital	
[Portsmouth]	and	Basingstoke	&	North	Hampshire	Hospital	had	an	increase	of	resistance	to	
co-amoxiclav	of	42%	and	38%	respectively.					
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(a)	
	
	
(b)	
	
	
	
Figure	3-11,	Percentage	resistance	against	each	of	the	antimicrobial	agents	tested	according	
to	the	hospital	site	within	(a)	2010	and	(b)	2012.		Results	indicate	that	overall	resistance	is	
increasing	however	greater	resistance	within	certain	hospitals	could	be	determined	within	
co-amoxiclav,	tigecycline,	meropenem	and	ertapenem.		The	number	of	isolates	relating	to	
the	percentage	calculation	is	listed	above	each	bar.	
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	(a)	
	
	
(b)	
	
	
Figure	3-12,	Percentage	intermediate	resistance	against	each	of	the	antimicrobial	agents	tested	according	to	
the	hospital	site	within	(a)	2010	and	(b)	2012.		Results	indicate	that	a	significant	increase	in	meropenem	
intermediate	resistance	could	be	observed	within	the	Portsmouth	area	and	Tigecycline	intermediate	resistance	
could	be	seem	in	higher	percentage	both	within	Basingstoke	and	North	Hampshire	Hospital	and	University	
Hospital	Southampton.		An	increase	in	ertapenem	intermediate	resistance	could	also	be	determined	at	
Basingstoke	and	North	Hampshire	Hospital;	this	could	suggest	an	early	indication	of	increasing	carbapenem	
resistance.	The	number	of	isolates	relating	to	the	percentage	calculation	is	listed	above	each	bar.	
	
	
6 7 7
3
13
5 5
7
6
10
9
1 1 1
2
14
7
13
7
6 5
12 7
4
9
7
11
9
1 1
4
0
2
4
6
8
10
12
14
16
0
5
10
15
20
25
30
35
Pe
rc
en
ta
ge
Antibiotic
Percentage	Intermediate	by	Hospital	2010
Basingstoke
Portsmouth
Southmpton
Winchester
2
8
19
13 6
6 3
76
2
3
7
6 3 2 11
2
2
9 10
24
11
3
5
19
11
5 2 4
6
0
5
10
15
20
25
30
0
5
10
15
20
25
30
35
40
45
50
Pe
rc
en
ta
ge
Antibiotic
Percentage	Intermediate	by	Hospital	2012
Basingstoke
Portsmouth
Southmpton
Winchester
82	
	
(a)	
	
	
(b)	
	
	
Figure	3-13,	Percentage	sensitivity	for	each	of	the	antimicrobial	agents	tested	according	to	
the	hospital	site	within	(a)	2010	and	(b)	2012.		Results	indicate	organisms	expressing	ESBL	
resistance	remain	susceptible	to	ciprofloxacin	and	amikacin.		Ciprofloxacin	is	still	widely	
used	as	an	antimicrobial	agent	however	reduced	use	compared	to	other	agents	has	perhaps	
lead	to	an	increase	in	susceptibility	rates.		The	number	of	isolates	relating	to	the	percentage	
calculation	is	listed	above	each	bar.	
	
1
27
42
1
35
9
4
29
18
3
26
35 35
25
53
2
47
16
7
52
6
15
38
32
52
1
28
62 57
16
3
57
9 3
42
40
55
1
29
66
2
63
23
15
69
33
13
42
38 65
0
20
40
60
80
100
Pe
rc
en
ta
ge
Antibiotic
Percentage	Sensitive	by	Hospital	2010
Basingstoke
Portsmouth
Southmpton
Winchester
1
23
84
2
64
19 18
77
37
11
55 58
79
2
33 36
5 3
35
20
2
24
38 39
22
49
1
47
5
7
19 17
1
28
38 50
37
71
3
67
19
8
66
32
2
52
60 63
0
20
40
60
80
100
Pe
rc
en
ta
ge
Antibiotic
Percentage	Sensitive	by	Hospital	2012
Basingstoke
Portsmouth
Southmpton
Winchester
83	
	
The	differences	in	prescribing	policy	between	the	hospitals	may	help	explain	this	particular	
rise	in	resistant	organisms.		In	the	other	hospitals	co-amoxiclav	is	limited	for	the	treatment	
of	lower	UTIs	during	pregnancy,	second	to	amoxicillin,	whereas	at	Queen	Alexandra	Hospital	
and	Basingstoke	&	North	Hampshire	Hospital	it	is	used	for	the	treatments	of	pyelonephritis,	
hospital	acquired	UTI’s	and	catheter	associated	infections.		
The	 susceptibility	 of	 isolates	 to	 the	 carbapenems	 [meropenem	 and	 ertapenem]	 has	
decreased	 between	 2010	 and	 2012,	 with	 small	 increases	 in	 the	 proportion	 of	 resistant	
organisms	 found	 at	 University	 Hospital	 Southampton	 [2%	 increase	 for	 ertapenem	 from	
2010-2012]	and	Basingstoke	&	North	Hampshire	hospital	 [5%	 increase	 for	ertapenem	and	
1%	 increase	 for	 meropenem	 from	 2010-2012].	 	 Organisms	 demonstrating	 intermediate	
resistance	 to	meropenem	were	 also	 found	 in	 all	 four	 hospitals	 at	 the	 time	 of	 analysis	 in	
2012.	 	 To	 identify	 if	 the	organisms	with	 these	 resistance	determinants	 is	of	 interest,	 they	
were	 considered	 further.	 	 One	 meropenem	 resistant	 isolate	 from	 an	 elderly	 patient	 at	
Basingstoke	&	North	Hampshire	hospital	was	identified	as	Stenotrophomonas	maltophilia,	a	
species	 often	 associated	 with	 hospital	 acquired	 infections.	 	 Meropenem	 and	 ertapenem	
resistant	 organisms,	 recovered	 from	 patients	 at	 University	 Hospital	 Southampton	 and	
Basingstoke	 &	 North	 Hampshire	 hospital,	 were	 identified	 as	 Enterobacter	 cloacae,	 a	
member	 of	 the	 normal	 gastrointestinal	 flora.	 	 The	 presence	 of	 carbepenem	 resistant	
determinants	 in	 an	 organism	 that	 is	 the	 cause	 of	 hospital	 acquired	 infections	 and	 in	 a	
bacterium	 that	 normally	 inhabits	 the	 gastrointestinal	 tract	 is	 of	 concern	 regarding	 the	
spread	of	these	determinants.		Schwaber	and	Carmeli	(158)	highlighted	the	increased	threat	
of	 carbapenem	 resistant	 Enterobacteriaceae	worldwide,	 in	 particular	 the	 risk	 of	 potential	
horizontal	 spread	 to	 different	 bacterial	 species	 and	 intestinal	 colonisation.	 	 Increasing	
resistance	 to	 carbapenems	within	ESBL	 intestinal	 colonisation	could	potentially	 lead	 to	an	
increased	 risk	 of	 urinary	 tract	 infections	 caused	 by	 these	 organisms,	 particularly	 within	
female	 patients.	 	 The	 increase	 in	 the	 proportion	 of	 intermediate	 carbapenem	 resistant	
bacteria,	particularly	at	Queen	Alexandra	Hospital,	could	be	an	early	warning	sign	that	these	
resistance	 determinants	 are	 responding	 to	 antibiotic	 selection.	 	 Interestingly,	 only	 one	
hospital	 [University	 Hospital	 Southampton]	 has	 listed	 ertapenem	 in	 its	 antimicrobial	
prescribing	 policy,	 for	 the	 treatment	 of	 known	 ESBL	 urinary	 tract	 infections	with	 signs	 of	
systemic	complications.	
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The	proportion	of	isolates	with	tigecycline	resistance	has	increased	in	every	hospital	within	
this	study,	with	 increases	of	5%	at	Basingstoke	&	North	Hampshire	Hospital,	3%	at	Queen	
Alexandra	 Hospital,	 1%	 at	 the	 Royal	 Hampshire	 County	 Hospital	 Winchester	 and	 12%	 at	
University	Hospital	Southampton.		This	antibiotic	appears	to	be	little	used	within	the	study	
hospitals,	 with	 no	 prescribing	 policies	 listing	 this	 agent	 as	 a	 treatment	 option	 for	
complicated	 urinary	 tract	 infections.	 	 The	 BNF	 also	 only	 recommends	 this	 agent	 to	 be	
reserved	for	skin	and	soft	tissue	infections	as	a	result	of	multi-resistant	organisms,	requiring	
admission,	due	 to	parenteral	 administration.	 	Antimicrobial	pre-treatment	may	encourage	
tigecycline	resistance	if	it	interferes	with	the	AcrAB	efflux	pump,	which	has	previously	been	
implicated	in	this	resistance	in	E.	coli	(159).		Hornsey	et	al.	(160)	reported	that	treatment	of	
Enterobacter	cloacae	with	ciprofloxacin,	a	substrate	for	the	AcrAB	system,	up-regulated	the	
RamA	regulatory	protein	leading	to	a	cross	resistance	to	tigecycline.		Sheng	et	al.	(161)	also	
related	up-regulation	of	the	RamA	protein,	due	to	a	mutation	in	the	gene,	with	tigecycline	
resistance	 in	 Klebsiella	 pneumoniae.	 	 This	 does	 not	 explain	 the	 increase	 of	 tigecycline	
resistance	observed	in	this	study,	as	none	of	the	isolates	exhibiting	this	resistance	originated	
from	patients	with	known	exposure	to	ciprofloxacin,	however,	46%	of	the	isolates	showing	
resistance	 were	 identified	 as	 Klebsiella	 pneumoniae.	 	 It	 is	 possible	 that	 a	 spontaneous	
mutation	might	be	responsible	 for	 tigecycline	resistance	 in	some	 isolates.	 	These	resistant	
organisms	would	be	 expected	 to	be	 clonal,	 spreading	 the	 resistant	 determinant	 relatively	
slowly,	as	opposed	to	the	rapid	spread	of	a	plasmid	born	resistant	determinant	to	sensitive	
cells,	 and	 they	 could	 easily	 be	 lost	 from	 the	 population	 if	 they	 are	 at	 a	 selective	
disadvantage	in	the	absence	of	the	antibiotic.		In	this	respect,	the	patterns	of	intermediate	
resistance	 of	 this	 antibiotic	 are	 of	 interest.	 	 During	 2010	Basingstoke	&	North	Hampshire	
Hospital	had	a	high	 incidence	of	 intermediate	resistant	organisms,	which	reduced	in	2012.		
In	contrast	University	Hospital	Southampton	had	a	 low	incidence	of	 intermediate	resistant	
isolates	 in	2010,	which	 increased	dramatically	 in	2012.	 	Although	 this	behaviour	might	be	
accounted	for	by	the	appearance	and/or	loss	of	a	spontaneous	mutant,	it	should	be	noted	
that	organisms	fully	resistant	to	the	antibiotic	have	increased	greatly	at	University	Hospital	
Southampton	 along	 with	 the	 increase	 of	 intermediate	 resistance,	 suggesting	 that	 the	
expression	of	this	resistant	determinant	is	stable.	
Gentamicin	was	included	in	all	of	the	hospitals	antimicrobial	prescribing	policies	for	treating	
complicated	 urinary	 tract	 infections,	 associated	 with	 inpatient	 care	 due	 to	 parenteral	
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administration	of	the	drug.	 	Resistance	to	this	antibiotic	amongst	 isolates	has	 increased	 in	
three	hospitals,	with	a	7%	 increased	at	Basingstoke	and	North	Hampshire	Hospital,	a	10%	
increase	 at	 Queen	 Alexandra	 Hospital	 Portsmouth	 and	 a	 28%	 increase	 at	 the	 University	
Hospital	 Southampton.	 	 BSAC	 bacteraemia	 data	 indicates	 that	 gentamicin	 resistance	 has	
risen	within	the	United	Kingdom	and	Ireland,	with	40%	of	ESBL	producing	Enterobactericeae	
and	11%	of	ESBL	negative	isolates	exhibiting	gentamicin	resistance	(162).		This	information	
suggests	 that	 the	 increase	 in	 gentamicin	 resistance	 amongst	 isolates	 is	 not	 necessarily	
related	 to	 ESBL	 production	 in	 Hampshire,	 but	 could	 be	 linked	 to	 the	 inpatient	 use	 of	
gentamicin	for	Enterobacteriaceae	infections.	
Not	all	isolates	from	the	hospitals	exhibited	increased	resistance	numbers;	some	maintained	
or	 had	 an	 increase	 in	 the	 number	 that	were	 susceptible,	 such	 as	 those	 for	 amikacin	 and	
ciprofloxacin.	 	 Two	 hospitals,	 University	 Hospital	 Southampton	 and	 Queen	 Alexandra	
Hospital	Portsmouth,	generated	 isolates	 that	 showed	 increased	numbers	 for	 susceptibility	
to	ciprofloxacin.		This	antibiotic	was	included	in	all	of	the	hospitals	prescribing	policies,	but	it	
was	 limited	 for	 empirical	 therapy	 of	 upper	 UTIs	 and	 pyelonephritis	 with	 systemic	
complications	 resulting	 from	an	unknown	agent	or	 if	 the	patient	was	allergic	 to	penicillin.		
Within	all	of	 the	prescribing	policies	 ciprofloxacin	would	only	be	considered	 if	 the	patient	
was	suitable	for	treatment	within	the	community	setting.				
	
	 3.4.3	 Prescribing	Treatments	within	the	Community	
When	 considering	 antibiotic	 resistance	 patterns	 in	 a	 region,	 it	 is	 important	 to	 assess	 the	
number	 of	 antimicrobial	 drug	 prescriptions	 issued	 within	 the	 community	 by	 the	 GP	
surgeries,	 served	 by	 the	 hospital	 pathology	 laboratories.	 	 The	 Health	 and	 Social	 Care	
Information	 Centre	 holds	 the	 prescribing	 by	 GP	 practice	 database	
[www.hscic.gov.uk/gpprescribing	data],	from	which	information	on	Hampshire	GP	surgeries	
was	obtained	 for	 the	month	of	 June,	 the	mid-point	 for	 sampling,	 for	both	 years.	 	 In	 June	
2010,	2636	doses	of	co-amoxiclav	were	prescribed	within	the	Hampshire	areas,	 increasing	
to	 2953	 in	 June	 2012	 –	 a	 rise	 of	 10%.	 	 During	 2010,	 10,616	 doses	 of	 amoxicillin	 were	
prescribed,	 rising	 to	12,076	 in	2012.	 	The	 increased	use	of	 these	drugs	 in	nosocomial	and	
community	 environments	 could	 be	 a	 contributing	 factor	 in	 keeping	 and	 increasing	 the	
observed	level	of	resistance	to	co-amoxiclav	and	amoxicillin.	
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In	 contrast	 to	 co-amoxiclav	 and	 amoxicillin,	 the	 overall	 proportion	 of	 isolates	 resistant	 to	
ciprofloxacin	dropped,	with	a	corresponding	rise	in	sensitivity	to	the	drug.	In	June	2010,	GP	
surgeries	 in	 Hampshire	 prescribed	 1578	 ciprofloxacin	 treatments,	 which	 rose	 to	 1690	 in	
2012,	an	increase	of	112.		The	prescription	rate	of	increase	is	approximately	one	third	less	
for	 ciprofloxacin	 than	 for	 co-amoxiclav,	 while	 the	 prescription	 rate	 each	 year	 is	
approximately	 60%	 less.	 	 Ciprofloxacin	 is	 clearly	 used	 to	 a	 far	 lesser	 extent	 than	 co-
amoxiclav.	 	 Other	 antimicrobial	 drugs,	 such	 as	 meropenem,	 ertapenem,	 gentamicin,	
amikacin	 and	 tigecycline,	 are	 rarely	 prescribed	 within	 the	 community	 setting	 [one	
prescription	 for	 meropenem	 in	 2010,	 six	 and	 eight	 for	 gentamicin	 in	 2010	 and	 2012	
respectively	 and	 one	 for	 amikacin	 in	 2010],	 and	 it	 can	 be	 concluded	 that	 prescribing	 for	
these	 in	the	community	does	not	 influence	the	observed	rise	of	resistance	to	these	 in	the	
hospital	environment.		In	general,	these	observations	support	the	idea	that	the	occurrences	
of	some	antibiotic	resistances	in	Hampshire	are	associated	with	over	prescribing	of	selected	
antimicrobial	agents.	 	 If	resistances	to	antibiotics	are	to	be	reduced	in	Hampshire,	hospital	
antimicrobial	prescribing	policies	and	GP	prescribing	in	the	community	should	be	reviewed	
to	 take	 into	 account	 alternative	 strategies.	 	 These	 may	 include	 the	 use	 of	 a	 range	 of	
antibiotic	agents,	as	first	line	therapies,	a	mosaic	approach,	alternating	the	agents	to	reduce	
over	prescribing	of	one	antibiotic,	or	considering	therapies	other	than	antimicrobial	agents,	
such	as	alkalising	agents,	in	the	case	of	UTIs,	if	the	patient	has	only	experienced	symptoms	
within	the	last	24	hours.	
	
3.5	Conclusion	
This	 section	of	 the	 study	has	highlighted	 the	 rising	 levels	of	ESBL	 resistance	 in	Hampshire	
and	how	this	could	lead	to	increased	levels	of	ESBL	intestinal	colonisation,	and	the	potential	
increased	 risk	of	multi-resistant	 infections.	 	 Evaluation	of	hospital	prescribing	policies,	 the	
BNF	recommendations,	 resistance	changes	between	the	 two	year	groups	and	prescription	
numbers	 in	 the	Hampshire	 areas	 suggest	 that	 increasing	 resistance	 could	 be	 related	 to	 a	
number	of	factors,	such	as	horizontal	transfer	of	resistance	determinates	between	species,	
previous	 antibiotic	 therapy	 leading	 to	 potential	 cross	 resistance	 and	 over	 prescribing	 of	
different	antimicrobial	agents.		It	was	very	difficult	to	evaluate	the	numbers	of	inappropriate	
prescribing	within	the	two	year	cohorts,	as	the	ESBL	producing	organisms	may	be	present	as	
87	
	
a	result	of	colonisation	in	comparison	to	causing	infection.		However	prescribing	should	be	
monitored	 within	 each	 of	 the	 hospitals,	 as	 the	 use	 of	 inappropriate	 agents	 may	 also	
contribute	to	future	resistances.		Results	obtained	from	this	study	highlight	the	importance	
of	 sample	 collection	 and	 analysis,	 and	 how	 prompt	 diagnosis	 potentially	 using	 a	 point	 of	
care	method	would	benefit	patients	at	risk	of	multi-resistant	organisms.	 	Timely	receipt	of	
results	 may	 encourage	 the	 prescribing	 of	 appropriate	 antimicrobial	 agents,	 potentially	
reducing	antimicrobial	resistance	and	enhancing	patient	care.	
Clinicians	 and	 prescribing	 pharmacists	 within	 the	 Hampshire	 area	 should	 receive	 further	
education	 regarding	 the	 increasing	 resistance	 levels	 of	 ESBL	 infections	 and	 should	 ensure	
appropriate	antimicrobial	stewardship	at	all	 times.	 	Patients	should	also	be	advised	of	 the	
importance	 of	 appropriate	 prescribing	 and	 should	 be	 aware	 that	 all	 infections	 may	 not	
require	antibiotic	 therapy;	 in	 the	 cases	where	antibiotics	 are	 required,	patients	 should	be	
advised	 of	 the	 importance	 of	 completing	 the	 entire	 course,	 to	 reduce	 the	 potential	 of	
further	resistance.	
Limitations	within	this	area	of	the	study	have	been	identified	and	should	also	be	considered.		
The	use	of	the	pathology	information	system	for	gaining	patient	information	only	provides	
details	of	the	patient	at	that	point	in	time.		In	addition	to	this	limitation	the	study	is	reliant	
on	 the	 requesting	 clinician	 completing	 all	 areas	 of	 the	 sample	 request	 form	
comprehensively.	 	 Previous	 antibiotic	 therapy	 may	 not	 be	 listed	 correctly	 and	 details	
regarding	the	patient’s	location	prior	to	the	sample	collection	[patients	recently	discharged	
from	hospital]	were	not	available,	potentially	affecting	the	results	obtained.		Future	analysis	
should	seek	ethical	approval	to	obtain	this	information.		This	would	provide	a	more	accurate	
account	of	the	patient	demographic	in	the	Hampshire	area.		Identification	of	E.	coli	using	the	
molecular	PCR	method	to	detect	the	beta-galactosidase	gene	allowed	for	the	analysis	of	a	
large	 number	 of	 samples,	 in	 a	 cost	 effective	manner.	 	 Care	 should	 be	 taken	 however,	 as	
other	members	of	the	Enterobacteriaceae	family	may	produce	the	beta-galactosidase	gene,	
potentially	producing	false	positive	results.		To	ensure	the	correct	identity	of	the	organisms,	
a	 number	 of	 isolates	 identified	 as	 E.	 coli	 were	 confirmed	 using	 the	 API20e	 system	
(Biomerieux).	 	 The	API20e	 system	 is	 also	not	without	 issues.	 	 Interpreting	an	API20e	 strip	
requires	 user	 expertise	 and	 results	 may	 differ	 between	 different	 individuals.	 	 To	 ensure	
reliability	of	the	results	obtained,	any	identification	demonstrating	a	percentage	of	less	than	
95%	 was	 discarded	 and	 repeated.	 	 Limitations	 were	 also	 noted	 within	 the	 susceptibility	
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testing	methodology,	 although	 the	 standard	method	provided	by	BSAC	was	 followed,	 this	
method	 suggests	 that	 one	 control	 plate	 at	 the	 beginning	 of	 each	 set	 of	 experiments	 is	
sufficient.	 	 Although	 the	 use	 of	 a	 control	 plate	 identifies	 if	 the	media,	 for	 that	 particular	
plate,	 and	 the	 antibiotic	 and	 identification	 discs	 are	 working	 appropriately,	 it	 does	 not	
ensure	 this	 for	every	media	plate	used	 in	 the	analysis	of	 isolates.	 	An	alternative	method,	
the	Stokes	method,	incorporates	the	use	of	a	control	strain,	in	addition	to	the	test	isolate,	in	
every	analysis,	ensuring	that	all	media	plates	produce	accurate	results.		The	Stokes	method	
has	been	previously	criticised,	with	research	suggesting	that	use	of	the	Stokes	method	may	
promote	 inaccuracies	 in	 interpretation	 of	 the	 results	 obtained	 (163).	 	 Increases	 in	
carbapenem	resistance	were	 identified,	through	the	use	of	antibiotic	susceptibility	testing,	
within	the	two	year	cohorts	studied;	the	potential	mechanisms	however	for	this	resistance	
were	not	identified.		A	modified	Hodge	test	could	have	been	incorporated	into	this	area	of	
the	study,	 to	simply	and	cost	effectively	detect	carbapenemase	activity.	 	 Interpretation	of	
the	data	within	the	figures	should	also	be	considered;	due	to	differing	numbers	of	isolates	
falling	 within	 the	 different	 categories	 the	 percentage	 was	 calculated.	 	 This	 however	 can	
influence	 the	 results	 obtained,	 with	 lower	 number	 isolate	 categories	 potentially	
demonstrating	 statistically	 significant	 differences,	 even	 though	 only	 one	 isolate	 may	 be	
demonstrating	 resistance	 or	 sensitivity.	 	 In	 order	 to	 highlight	 if	 this	 was	 apparent,	 the	
number	of	isolates	within	each	category	was	included	within	the	graphs	presented.				
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Chapter	4 	
Molecular	Epidemiological	Study	of	ESBL	Producing	Enterobacteriaceae	
	
4.1	Introduction	
Microbiological	techniques,	such	as	antimicrobial	susceptibility	testing,	allow	the	detection,	
isolation	and	identification	of	bacteria	that	exhibit	resistance	or	sensitivity	to	antibiotics	but	
they	do	not	accurately	identify	the	mechanism	of	the	resistance	or	how	it	may	be	spread	in	
the	population.	 	The	nature	of	the	resistance	determinant,	 its	 location	within	the	genome,	
its	 origin	 and	 frequency	 within	 a	 population	 can	 only	 be	 estimated	 using	 molecular	
techniques.				This	information	has	been	used	to	design	rapid	PCR	identification	procedures,	
such	as	multiplex	PCR,	 to	distinguish	 the	different	determinant	 types	 [SHV,	TEM,	CTX	and	
OXA].		
In	 this	 chapter	 the	 enterobacterial	 isolates,	 previously	 obtained	 from	 patients	 in	 four	
hospitals,	were	 further	 characterised	 for	 their	 resistance	 determinant[s]	 at	 the	molecular	
level.	 	This	 information	was	used	to	 identify	relationships	between	resistance	determinate	
and	 hospital	 sites,	 patient	 age,	 gender,	 previous	 antimicrobial	 therapy	 and	 resistance	
patterns.		
	
4.2	Polymerase	Chain	Reaction	Analysis	for	the	Detection	of	TEM,	
CTX	and	SHV	Genes	
A	three	primer,	multiplex	PCR	system	was	used	to	detect	the	TEM,	CTX	and	SHV	genes.		The	
primers	used	were	BlaSHV,	BlaTEM	and	BlaCTX,	 giving	products	of	445bp	 for	 TEM,	593bp	 for	
CTX	and	747bp	for	SHV.	The	protocol	of	Monstein	et	al.	 (45),	was	 initially	used	to	 identify	
the	presence	of	the	determinants	from	ten	isolates.	Once	this	had	been	achieved,	the	assay	
was	 optimised	 using	 temperature	 gradient	 PCR,	 initially	 for	 the	BlaCTX	to	 amplify	 the	 CTX	
gene,	 followed	 by	 primers	 BlaCTX	 and	 BlaTEM	 for	 the	 CTX	 and	 TEM	 genes.	 	 Annealing	
temperatures	of	500C	to	550C	were	suitable	to	amplify	the	TEM	and	CTX	targets,	with	540C	
being	 chosen	 as	 the	 optimal	 temperature	 to	 amplify	 both	 genes	 [Figure	 4.1].	 	 This	
temperature	was	also	suitable	to	amplify	the	SHV	gene	[Figure	4.2].	
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4.2.1	 Detection	of	CTX,	TEM	and	SHV	Genes	from	Isolates	of	the	2010	and	
2012	Cohorts	
Multiplex	PCR	of	DNA,	described	in	Chapter	2,	section	2.2.4	and	agarose	gel	electrophoresis,	
described	in	Chapter	2	section	2.2.10,	from	all	of	the	isolates	showed	that	within	the	2010	
collection,	9%	[20]	of	 the	 isolates	amplified	the	TEM	determinant	alone,	38%	[87	 isolates]	
produced	the	CTX	determinant	and	1%	SHV	[2	 isolates].	 	 Joint	amplification	was	observed	
from	a	number	of	 isolates,	34%	[79	 isolates]	gave	the	TEM	and	CTX	determinants,	6%	[13	
isolates]	 SHV	 and	 TEM	 and	 1	 isolate	 amplified	 all	 three	 resistance	 determinants.	 	 Twelve	
percent	[27]	of	the	isolates	failed	to	amplify	any	gene	studied.		The	2012	collection	showed	
a	 slight	 decrease	 in	 the	 proportion	 of	 isolates	 amplifying	 the	 CTX	 [27%,	 66	 isolates]	
determinant	with	a	slight	increase	in	the	proportion	of	SHV	[2%,	4	isolates]	and	TEM	[22%,	
54	isolates].		There	was	also	a	decrease	in	the	proportion	amplifying	the	CTX	and	TEM	[23%,	
58	 isolates],	 and	 SHV	 and	 TEM	 [2%,	 5	 isolates]	 determinants,	 however,	 there	 was	 an	
increase	in	the	proportion	amplifying	all	three	resistance	determinants	[2%,	4	isolates]	and	
the	joint	amplification	of	the	SHV	and	CTX	[1%,	3	isolates],	not	seen	within	the	2010	cohort.		
Twenty	 two	 percent	 [54]	 of	 the	 isolates	 failed	 to	 amplify	 any	 gene	 studied.	 	 These	
observations	 are	 consistent	 with	 other	 epidemiological	 studies	 (22,	 42,	 75),	 where	 the	
number	of	ESBL	infections	caused	by	the	CTX	determinant	dominate,	over	those	caused	by	
TEM	and	SHV.		Within	the	Hampshire	area,	although	the	numbers	of	 isolates	with	the	CTX	
resistance	 determinant	 is	 greater	 compared	 to	 those	with	 the	 other	 resistance	 genes,	 an	
increase	in	the	proportion	of	isolates	bearing	the	SHV	gene	and	double	presence	of	SHV	and	
CTX,	as	well	as	an	overall	increase	for	all	resistance	determinants	between	the	two	cohorts	
was	 observed.	 	 This	 suggests	 that	 in	 accordance	 with	 published	 literature	 CTX	 is	 the	
predominant	 resistance	 mechanism	 within	 the	 Hampshire	 area,	 however	 the	 increased	
proportions	of	SHV	and	TEM	joint	resistance	within	the	2012	cohort	suggests	that	there	 is	
an	 increasing	 risk,	 with	 time,	 of	 acquiring	 an	 ESBL	 infection,	 contributing	 to	 antibiotic	
resistance	within	this	geographical	region.		The	nature	of	this	risk	was	examined	in	relation	
to	patient	age	and	gender.	
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Figure	4-1,	(a)	Temperature	gradient	for	CTX	analysis	alone,	producing	a	593bp	product,	
L=100	base	pair	DNA	ladder,	Promega,	1=50	OC,	2=51	OC,	3=52	OC,	4=53	OC,	5=54	OC,	6=55	
OC,	7=56	OC,	8=57	OC,	9=58	OC,	10=59	OC,	11=60	OC	and	N=negative	control.		This	analysis	
illustrates	that	for	TEM	alone	all	temperatures	were	suitable	for	TEM	detection.	(b)	
Temperature	gradient	for	TEM	and	CTX	analysis,	producing	593	and	443bp	products,	L=	100	
base	pair	DNA	ladder,	Promega,	all	temperatures	were	identical	to	those	within	the	TEM	
analysis	and	N=negative	control.		This	analysis	illustrates	that	temperatures	between	50	OC	
and	55	OC	were	suitable	for	TEM	and	CTX	detection	however	54	OC	was	selected	as	the	
optimal	temperature	due	to	the	clear	visualisation	of	both	DNA	bands.					
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Figure	4-2,	Results	obtained	from	multiplex	PCR	analysis	and	1%	agarose	gel	electrophoresis	
analysed	at	150	volts	for	45	minutes	allowing	adequate	separation	of	the	different	
resistance	genes.		The	marker	demonstrates	SHV	expression	by	a	747bp	DNA	fragment	
(higher	marker),	CTX	by	a	593bp	DNA	fragment	(middle	marker)	and	TEM	by	a	445bp	DNA	
fragment	(lower	marker).		Lanes	1	to	12	demonstrate	sample	analysis,	including	all	of	the	
resistance	determinants;	the	neg	lane	demonstrates	the	negative	control.	
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	 4.2.2	 Patient	Age	and	ESBL	Resistance	Determinants	
Bacteria	 isolated	 from	patients	 of	 all	 ages	 amplified	 the	 CTX,	 SHV	 and	 TEM	determinants	
and	 jointly	 amplified	 the	 CTX	 and	 TEM	 genes.	 	 Within	 the	 2010	 cohort,	 isolates	 jointly	
amplifying	the	TEM	and	SHV	genes	came	from	patients	aged	over	60	years	[non-parametric	
Spearman	correlation	p=0.0174],	whereas	within	the	2012	cohort	such	 isolates	came	from	
younger	 patients	 [<10	 years],	 those	 aged	 under	 40	 years	 as	 well	 as	 those	 aged	 over	 60	
[Figure	4.3	a	and	b].	 	The	joint	amplification	of	the	CTX	and	SHV	genes	was	observed	from	
isolates	that	came	from	patients	aged	over	80	years	in	the	2012	cohort	[Figure	4.4],	which	
was	 not	 observed	 at	 all	 from	 the	 2010	 cohort	 of	 isolates.	 	 With	 the	 exception	 of	 the	
occurrence	of	the	double	resistances	TEM	and	SHV,	and	CTX	and	SHV,	no	difference	could	
be	 detected	 between	 the	 patient	 age	 and	 the	 presence	 of	 particular	 resistance	
determinants,	 suggesting	 that	 all	 age	 ranges	 are	 at	 an	 equal	 risk	 of	 CTX,	 SHV	 or	 TEM	
resistance.	 	 When	 comparing	 these	 results	 with	 previously	 described	 research,	 it	 is	 very	
difficult	 to	 determine	 if	 these	 findings	 are	 geographically	 related.	 	 Previous	 studies	 have	
isolated	different	resistance	determinant	strains	associated	with	ESBL	production;	however	
they	have	not	considered	whether	different	ages	are	susceptible	to	different	determinants	
(76,	82).		Results	obtained	from	this	study	do	suggest	that	resistance	determinants	initially	
present	within	the	elderly	population	once	established	spread	to	a	more	diverse	age	range.	
	
	 4.2.3	 Patient	Gender	and	ESBL	Resistance	Determinants	
Interpretation	of	the	data	indicated	that	all	SHV	bearing	isolates	came	from	female	patients	
of	 the	 2010	 cohort;	 a	 similar	 observation	 was	 made	 for	 isolates	 bearing	 the	 double	
resistance	of	SHV	and	TEM,	and	SHV	and	CTX	for	the	2012	cohort.		Although	the	numbers	of	
isolates	 carrying	 different	 resistance	 determinants	 did	 differ,	 no	 relationship	 could	 be	
determined	between	patient	gender	and	resistance	determinant	[Mann-Whitney	tests,	TEM	
p=0.67,	CTX	p=0.67,	SHV	p=>0.99,	CTX	and	TEM	p=0.67,	TEM	and	SHV	p=>0.99,	TEM,	CTX	
and	SHV	p=0.67	and	CTX	and	SHV	p=>0.99].		These	results	suggest	that	patient	gender	does	
not	appear	to	influence	resistant	determinant	expression.			
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Figure	4-3,	(a)	The	correlation	in	graphical	form	between	patient	age	and	dual	expression	of	TEM	
and	SHV,	all	patients	experiencing	infections	due	to	bacteria	expressing	dual	resistance	with	these	
enzymes	are	aged	60	or	above.		(b)	The	correlation	could	not	be	seen	in	2012,	suggesting	an	increase	
in	susceptibility	to	dual	TEM	and	SHV	expression	in	a	wider	age	population.	
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Figure	4-4,	Graphical	illustration	of	the	correlation	between	patient	age	and	joint	CTX	and	
SHV	expression,	all	patients	suffering	infections	caused	by	bacteria	demonstrating	dual	
expression	of	these	enzymes	are	aged	80	or	above.	
	
	
	
	
	
	
	
	
	
	
97	
	
No	other	study	has	looked	at	this	aspect	for	comparison,	and	it	is	concluded	that	within	the	
Hampshire	 area,	 although	 a	 higher	 prevalence	 of	 female	 ESBL	 infections	 were	 sampled	
within	both	year	groups,	susceptibility	to	resistance	gene	expression	could	not	be	linked	to	
gender,	 rendering	 both	 males	 and	 females	 at	 equal	 risk	 of	 developing	 ESBL	 infections	
expressing	a	range	of	resistance	determinants.		
	
	 4.2.4	 Hospital	Location	and	ESBL	Resistance	Determinants	
The	prevalence	of	antibiotic	 resistance	determinants	at	hospital	 locations	was	determined	
over	the	two	year	study	period.		Within	both	year	groups	statistical	differences	according	to	
a	Kruskal-Wallis	test	could	be	determined	between	the	presence	of	the	different	resistance	
determinants	 [p=0.0003	 for	 2010	 and	 p=0.0038	 for	 2012,	 with	 a	 Dunns	 post	 hoc	 test	
showing	statistical	differences	between	CTX	and	CTX	&	SHV	expression	p=0.029,	CTX	 	and	
CTX,	TEM	&	SHV	expression	p=0.012,	TEM	&	SHV	and	CTX	&	SHV	expression	p=0.039	and	
TEM	&	 SHV	 and	 TEM,	 CTX	&	 SHV	p=0.015	 for	 2010],	 	 but	 no	 significant	 differences	were	
determined	 between	 the	 different	 hospital	 sites.	 	 Figure	 4.5	 shows	 [a]	 the	 proportion	 of	
resistant	 determinants	 for	 each	 of	 the	 different	 hospital	 sites	 within	 2010	 and	 [b]	 the	
proportion	of	resistance	determinants	for	each	hospital	 in	2012.	 	Although	not	considered	
statistically	significant	the	data	suggests	that	in	2010,	Southampton	University	hospital	had	
a	 greater	number	of	 joint	 TEM	and	 SHV	 resistant	 infections,	with	 a	 lower	number	of	 CTX	
infections	 compared	 to	 the	 other	 hospitals.	 	 The	 Royal	 Hampshire	 County	 Hospital,	
Winchester,	also	had	a	higher	 level	of	 joint	TEM	and	CTX	resistant	 infections.	 	The	overall	
levels	 of	 infections	 caused	 by	 TEM	 carrying	 determinants	 increased	 in	 2012,	 with	 the	
greatest	proportion	found	at	Queen	Alexandra	Hospital	Portsmouth.		Infections	due	to	the	
double	 resistance	 TEM	 and	 SHV	 increased	 in	 proportion	 at	 the	 Royal	 Hampshire	 County	
Hospital	Winchester	but	decreased	at	the	University	Hospital	Southampton.			
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Figure	4-5,	the	proportion	of	each	resistance	determinant	separated	by	hospital	site	for	(a)	2010	and	
(b)	2012	(Basingstoke	represented	in	red,	Portsmouth	in	green,	Southampton	in	pink	and	
Winchester	in	blue).		Statistical	analysis	revealed	significant	differences	between	the	resistance	
determinants	in	both	year	groups	however	no	significant	differences	could	be	determined	between	
the	hospital	sites.		Within	2012,	although	a	significant	difference	was	determined	between	the	
resistance	determinants,	using	a	Kruskal-Wallis	test,	the	Dunn’s	post	hoc	test	did	not	reveal	specific	
differences	when	comparing	the	resistance	determinants	with	each	other.		
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4.3	Resistance	Determinants	and	their	Isolate	Antibiotic	
Susceptibility	
The	relationship	between	isolate	antibiotic	susceptibility	and	the	resistance	determinant	 it	
carries	 is	 important	because	 it	signals	 the	occurrence	of	multiple	drug	resistant	organisms	
and	 identifies	 potential	 empirical	 therapy	 options,	 if	 the	 resistance	 determinant	 could	 be	
identified	using	rapid	point	of	care	testing	methodologies.	 	The	susceptibility	profile	for	13	
antibiotics	 [Section	 3.4]	 was	 determined	 for	 each	 isolate	 according	 to	 the	 resistance	
determinant	 it	 carried.	 	 In	 general,	 this	 rearrangement	 of	 the	 susceptibility	 data	 revealed	
that	all	of	the	resistance	determinants	were	expressed	in	organisms	that	were	resistant	to	
amoxicillin.	
Organisms	 expressing	 the	 TEM	determinant	 alone	 exhibited	 susceptibility	 to	meropenem,	
ertapenem,	 gentamicin,	 amikacin	 and	 tigecycline	 in	 high	 proportions	 [Figure	 4.6a].	 	 The	
Mann-Whitney	statistic	for	the	difference	between	the	sensitivity	and	resistance,	including	
intermediate	 resistance,	 for	 each	 antibiotic	was	 significant	 at	 p	 values	 of	 0.0028,	 0.0001,	
0.0299,	0.0256	and	0.0022	respectively,	suggesting	that	these	drugs	are	potential	empirical	
treatment	options	 for	ESBL	organisms	expressing	 the	TEM	determinant,	 in	 the	Hampshire	
area.	 	 The	 level	 of	 ciprofloxacin,	 cefuroxime,	 piperacillin/tazobactam,	 co-amoxiclav,	
ceftazadime	 and	 cefipime	 susceptibilities	 in	 TEM	 carrying	 isolates	 gave	 Mann-Whitney	
results	 that	were	not	 statistically	different	 compared	 to	 resistances.	 	Cefotaxime	 resistant	
isolates	 with	 the	 TEM	 determinant	 did	 produce	 significant	 Mann-Whitney	 statistics	
[p0.0005],	making	this	an	inappropriate	treatment	option.	
The	 CTX	 determinant	 bearing	 isolates	 exhibited	 susceptibilities	 in	 high	 proportions	 to	
meropenem,	piperacillin/tazobactam,	ertapenem,	amikacin	and	tigecycline	[Figure	4.6b],	all	
of	 which	 gave	 significant	Mann-Whitney	 statistics	 at	 p	 values	 of	 0.0001,	 0.0093,	 0.0016,	
0.0003	and	0.0275	respectively,	and	could	be	considered	as	potential	empirical	 treatment	
options.	 	Ciprofloxacin,	 cefuroxime,	 ceftazidime	and	cefepime	 resistant	organisms	were	 in	
higher	 proportions	 compared	 to	 their	 sensitive	 CTX-bearing	 counterparts	 with	 significant	
Mann-Whitney	 statistics	 making	 them	 inappropriate	 therapy	 choices.	 	 Gentamicin,	 co-
amoxiclav	 and	 cefotaxime	 also	 proved	 to	 be	 inappropriate	 treatment	 options	 for	 CTX	
infections,	based	on	the	high	proportion	of	resistance	to	these	drugs	[60%,	60%	and	100%	
respectively].			
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(a)	
	
	
(b)	
	
Figure	4-6	(a)	The	percentage	resistance,	intermediate	resistance	and	sensitivity	for	each	antibiotic	
in	each	year	group	of	all	the	organisms	expressing	TEM	alone,	(b)	the	percentage	resistance,	
intermediate	resistance	and	sensitivity	for	each	antibiotic	in	each	year	group	of	all	the	organisms	
expressing	CTX	alone.		Results	indicate	that	meropenem,	ertapenem,	amikacin	and	tigecycline	could	
be	considered	as	blind	therapy	for	both	of	these	resistance	genes.		Gentamicin	revealed	sensitivity	
to	TEM	expression	alone	and	piperacillin/tazobactam	to	CTX	expression	alone.	
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Isolates	 bearing	 the	 SHV	 determinant	 exhibited	 a	 high	 level	 of	 resistance	 to	 all	 of	 the	
antibiotics	 tested,	 except	 meropenem	 and	 amikacin,	 to	 which	 all	 of	 the	 isolates	 were	
sensitive,	 	 [Figure	 4.7a],	 limiting	 the	 potential	 treatment	 options.	 	 The	 double	 resistance	
TEM	 and	 CTX	 determinants	 occurred	 in	 organisms	 that	 exhibited	 sensitivities	 to	
meropenem,	 ertapenem,	 amikacin	 and	 tigecycline	 [Figure	 4.7b],	 with	 significant	 Mann-
Whitney	statistics	at	p	values	of	0.0001,	0.0058,	0.0001	and	0.0025	respectively,	rendering	
these	as	potential	treatment	options.		Significant	Mann-Whitney	statistics	were	obtained	for	
cefuroxime,	 cefotaxime,	 ceftazidime	 and	 cefepime	 resistant	 organisms,	 making	 them	
inappropriate	 as	 empirical	 therapy	 choices.	 	 All	 other	 agents	 were	 not	 considered	 as	
potential	therapy	choices	due	to	the	statistically	insignificant	results	obtained.				
Meropenem	 and	 amikacin	 sensitive	 isolates	 bearing	 the	 SHV	 and	 TEM	 double	 resistance	
determinants	 totally	 dominated	 this	 group	 [Figure	 4.8a],	 so	 these	 can	 be	 considered	 as	
appropriate	treatment	choices.		High	proportions	of	cefuroxime,	cefotaxime	and	ceftazidime	
resistances	were	 present	 in	 this	 group,	 supported	 by	 significant	Mann-Whitney	 statistics,	
suggesting	 that	 these	 agents	 are	 inappropriate	 as	 treatment	 options.	 	 All	 other	 agents	
included	within	 this	 study	 produced	 insignificant	 statistical	 results.	 	 These	 results	 support	
the	 notion	 that	 SHV	 expression	 within	 the	 Hampshire	 area	 is	 associated	 with	 increased	
antimicrobial	resistance.	
Organisms	with	all	 three	 resistance	determinants	 [TEM,	CTX	and	SHV],	also	demonstrated	
increased	resistance	levels	to	the	majority	of	the	agents	included	within	this	study,	with	the	
exception	of	ertapenem	and	amikacin	[Figure	4.8b];	with	all	isolates	being	sensitive	to	these	
antibiotics.	 	 These,	 however,	 were	 the	 only	 agents	 to	 demonstrate	 a	 high	 level	 of	
susceptibility;	 all	 other	 agents	 produced	 statistically	 insignificant	 results,	 suggesting	 all	
except	ertapenem	and	amikacin	are	inappropriate	as	empirical	therapies	for	ESBL	infections	
expressing	all	three	resistance	enzymes.			
Isolates	with	 the	 determinants	 for	 the	 SHV	 and	 CTX	 enzymes	were	 obtained	 in	 the	 2012	
cohort	 only.	 	 The	 number	 of	 isolates	 showing	 susceptibility	 to	meropenem	 and	 amikacin	
within	 this	 group	 gave	 significant	 Mann-Whitney	 statistics	 at	 p=0.0071	 and	 p=0.0001	
respectively,	indicating	that	these	antibiotics	could	be	considered	as	appropriate	treatment	
for	 infections	 caused	by	 these	double	 resistant	bacteria	 [Figure	4.9].	 	All	 other	 antibiotics	
were	 found	 to	 be	 inappropriate,	 especially	 ciprofloxacin	 for	 which	 there	 was	 a	 high	
proportion	of	resistant	isolates.	
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(a)	
	
(b)	
	
Figure	4-7	(a)	The	percentage	resistance,	intermediate	resistance	and	sensitivity	for	each	antibiotic	
in	each	year	group	of	all	the	organisms	expressing	SHV	alone,	(b)	the	percentage	resistance,	
intermediate	resistance	and	sensitivity	for	each	antibiotic	in	each	year	group	of	all	the	organisms	
expressing	the	TEM	and	CTX	enzymes.		Results	indicated	that	meropenem	and	amikacin	could	be	
potential	empirical	therapies	for	both	set	of	gene	expression.		Ertapenem	and	tigecycline	could	also	
be	considered	for	the	joint	expression	of	TEM	and	CTX.	
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	(a)	
	
(b)	
	
Figure	4-8	(a)	The	percentage	resistance,	intermediate	resistance	and	sensitivity	for	each	antibiotic	in	each	
year	group	of	all	the	organisms	expressing	the	SHV	and	TEM	enzymes,	(b)	the	percentage	resistance,	
intermediate	resistance	and	sensitivity	for	each	antibiotic	in	each	year	group	of	all	the	organisms	expressing	all	
three	resistance	enzymes	(TEM,	CTX	and	SHV).		Results	suggest	that	amikacin	could	be	considered	as	empirical	
therapy	for	both	sets	of	gene	expression.		Meropenem	could	also	be	considered	for	SHV	and	TEM	expression	
and	Ertapenem	for	expression	of	all	three	resistance	genes.		
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Figure	4-9,	The	percentage	resistance,	intermediate	resistance	and	sensitivity	for	each	
antibiotic	in	2012	of	all	the	organisms	expressing	the	SHV	and	CTX	enzymes.		Statistical	
analysis	suggests	that	ertapenem	and	amikacin	are	potential	empirical	therapy	options	for	
the	expression	of	SHV	and	CTX.		Observation	of	the	graph	also	suggest	that	meropenem,	
amikacin	could	also	provide	additional	options.	
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Distinct	 differences	 could	 be	 seen	 between	 antibiotic	 susceptibility	 and	 ESBL	 presence	
within	 the	 Hampshire	 area.	 	 Only	 one	 antibiotic,	 amikacin,	 could	 be	 considered	 as	 a	
treatment	 option	 for	 all	 types	 of	 ESBL	 infection.	 	 Five	 agents	 could	 be	 considered	 for	
potential	empirical	 therapy	options	 if	 the	TEM	or	CTX	determinants	alone	were	detected;	
four	agents	for	joint	expression	of	TEM	and	CTX	and	two	agents	for	expression	of	SHV,	SHV	
and	 TEM,	 SHV	 and	 CTX	 and	 all	 three	 resistance	 determinants.	 	 Care	 should	 be	 taken,	
however,	when	interpreting	these	results;	bacteria	carrying	the	SHV,	SHV	and	TEM,	SHV	and	
CTX	and	all	three	resistance	determinants	were	isolated	in	smaller	numbers	in	comparison	
to	the	other	individual	determinants	and	determinant	combinations	identified.		Low	cohort	
numbers	 converted	 into	percentage	can	give	 the	 impression	 that	high	 levels	of	 resistance	
are	 present,	 when	 potentially	 only	 one	 isolate	 may	 be	 demonstrating	 resistance	 to	 a	
particular	antimicrobial	agent.				
These	observations	cannot	be	easily	compared	to	those	described	by	others,	as	most	studies	
do	 not	 link	 susceptibility	 to	 a	 range	 of	 antibiotics	 to	 particular	 determinants.	 	 Rezi	 et	 al.	
(164)	did	consider	resistance	percentages	and	resistance	gene	presence	within	North	 Iran,	
concluding	that	resistance	levels	were	dependent	on	geographical	location,	resistance	gene	
expression	and	 local	prescribing	guidelines,	and	reported	 increased	resistance	 to	amikacin	
associated	 with	 the	 CTX	 determinant.	 	 In	 Hampshire	 very	 low	 levels	 of	 resistance	 and	
intermediate	 resistance	 to	 amikacin	were	observed	within	 both	 year	 cohorts	 [Figure	 3.8],	
with	 it	 being	 suggested	as	 a	potential	 empirical	 treatment	option	 for	 all	 of	 the	 resistance	
genes	 expressed.	 	 Resistances	 to	 aminoglycosides	 and	 ciprofloxacin	were	 associated	with	
the	SHV	determinant	in	both	studies,	although	these	antibiotics	were	considered	unsuitable	
as	empirical	treatment	options.	 	Furthermore,	the	rise	in	infections	caused	by	SHV	bearing	
organisms	is	linked	to	increased	antimicrobial	resistance.	
The	difference	in	antimicrobial	susceptibility	profiles	for	the	ESBL	determinant	variants	is	a	
reason	 for	 concern,	 and	 it	 is	 suggested	 that	 prompt	 identification	 of	 the	 resistance	
determinant	 should	 be	 included	 in	 potential	 point	 of	 care	 testing	 methodologies.	 	 The	
inclusion	of	molecular	techniques	in	the	point	of	care	testing	field	has	been	successful	in	the	
past,	 such	 as	 the	 Cepheid	 GeneXpert	 (used	 in	 the	 diagnosis	 of	 Methicillin	 Resistant	
Staphylococcus	aureus	 (MRSA),	Clostridium	difficile	 and	Norovirus),	 the	Cobas	Liat	 system,		
enabling	 the	 molecular	 detection	 of	 Influenza	 A	 and	 B,	 and	 the	 Nanogen,	 a	 NanoChip	
microarray	 system	used	 for	 the	diagnosis	of	 Influenza	A	and	B,	 respiratory	Syncytial	Virus	
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(RSV)	 and	 Parainfluenza	 virus	 (165).	 	 With	 increases	 in	 mutations	 reported	 for	 all	 ESBL	
resistance	 genes	 (166),	 target	 sites	 for	 molecular	 point	 of	 care	 testing	 techniques	 must	
incorporate	 constant	 regions	 to	 ensure	 reliable	 gene	 detection.	 	 In	 addition,	 regular	
epidemiological	information	should	also	be	collected	to	identify	any	shift	in	resistance	prior	
to	treatment	failure.	
	
	 4.3.1	 Previous	Antibiotic	Therapy	and	Resistance	Determinants	
It	was	 suggested	 in	Chapter	 three	 that	 the	 increased	use	of	 certain	 antibiotics	within	 the	
Hampshire	area	has	led	to	an	increase	in	the	number	of	infections	caused	by	ESBL	producing	
bacteria.		The	profile	of	antibiotic	susceptibility	for	isolates	carrying	different	ESBL	resistance	
determinants	is	different	for	each	determinant	or	combination	of	determinants.		In	order	to	
determine	 if	 exposure	 to	previous	antibiotic	 therapy	has	an	effect	on	 the	 resistance	gene	
expressed,	the	proportion	of	isolates	with	different	resistance	determinants	was	compared	
for	 those	patients	 that	had	received	previous	 treatment	with	 those	that	had	not.	 	 In	both	
year	 cohorts,	 although	no	 significant	differences	between	 the	presences	of	 the	 resistance	
determinants	 could	 be	 identified,	 a	 Mann-Whitney	 test	 supported	 statistically	 significant	
differences	 between	 infections	 associated	with	 no	 previous	 antibiotic	 therapy	with	 those	
that	 had	 recently	 received	 treatment,	 p=0.0003	 for	 2010	 and	 2012	 [Figure	 4.10],	 with	
greater	 levels	 of	 infections	 caused	 by	 resistant	 organisms	 from	 patients	 previously	
untreated	 with	 antibiotics.	 	 The	 exception	 to	 this	 was	 the	 infections	 caused	 by	 bacteria	
expressing	the	SHV	determinant,	which	increased	in	patients	previously	treated	in	2010	and	
2012.	 	 These	 results	 suggest	 that	 previous	 exposure	 to	 antibiotics	 associated	 with	 the	
infections	investigated	in	this	study,	do	not	influence	the	resistance	determinant	expression	
within	the	Hampshire	area.	
	
4.4	Multiplex	PCR	for	the	Detection	of	OXA	Groups	1,	2	and	3	
With	 reports	 of	 OXA	 resistance	 being	 expressed	 in	 1-10%	 of	 Enterobacteriaceae,	 it	 was	
important	to	identify	the	level	of	OXA	presence	in	the	Hampshire	area.	
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Figure	4-10,	The	proportion	of	isolates	expressing	resistance	determinants	associated	with	current	or	recent	antimicrobial	
therapy	compared	to	those	associated	with	no	previous	treatment	in	(a)	2010	and	(b)	2012	(TEM	represented	by	orange,	
CTX	pink,	SHV	blue,	CTX	&	TEM	red,	TEM	&	SHV	yellow,	SHV	&	CTX	purple,	all	three	pink	and	negative	isolates	dark	red.		
Results	show	that	the	highest	percentage	of	resistance	gene	expression	is	associated	with	infections	that	have	not	be	
exposed	to	current	or	previous	antibiotic	therapy,	with	the	exception	being	the	SHV	determinant.	
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Oxacillinase	enzymes	can	be	divided	into	five	distinct	groups	according	to	their	amino	acid	
sequences:	OXA	group	1,	including	OXA-5,	OXA-7,	OXA-10	and	its	derivatives	[OXA-11,	OXA-
14,	OXA-16	and	OXA-17]	and	OXA-13	and	its	derivatives	[OXA-19	and	OXA-28];	OXA	Group	2	
including	the	enzymes	OXA-2,	OXA-3,	OXA-15	and	OXA-20	and	Group	3,	OXA-1,	OXA-4,	OXA-
30	and	OXA-31.	 	Other	groups	 included	within	 the	oxacillinases	are	OXA	group	4	which	 is	
defined	by	OXA-9	and	OXA	group	five	that	consists	of	only	enzyme	LCR-1.		When	considering	
the	different	amino	acid	sequences	between	the	OXA	enzymes,	OXA-18	does	not	fit	within	
any	of	 these	groups	as	 it	has	a	very	 low	amino	acid	similarity	compared	to	the	other	OXA	
types	(167).			
The	multiplex	 PCR	 used	 in	 this	 study,	 described	 in	 Chapter	 2,	 section	 2.2.5,	 incorporated	
OXA	 groups	 1,	 2	 and	 3	 as	 these	 groups	 contain	 the	 largest	 amount	 of	 OXA	 enzymes	
compared	to	the	others,	as	previously	described	by	Bert	et	al.	(130).		Only	one	isolate	from	
both	year	cohorts	amplified	a	 fragment	 that	belonged	 to	OXA	group	1	 [Figure	4.11].	 	This	
gives	this	resistance	type	the	potential	identification	of	OXA-5,	OXA-7,	OXA-10	or	OXA-13	or	
a	derivative	of	either	OXA-10	or	OXA-13.	 	When	considering	 the	 isolate	 in	which	 the	OXA	
resistance	was	 detected,	 the	 patient	was	 female	 and	 82	 years	 of	 age,	 her	 clinical	 details	
revealed	that	she	was	generally	unwell	and	she	had	not	received	any	previous	antimicrobial	
therapy.		As	previously	stated	in	Chapter	three,	these	details	must	be	considered	carefully,	
as	 the	 information	 provided	 only	 gives	 a	 snap	 shot	 of	 the	 patients’	 circumstances	 at	 the	
time	of	 sample	collection.	 	Although	 this	patient	was	 recorded	as	being	a	GP	patient,	 she	
may	 well	 have	 resided	 in	 a	 care	 home	 or	 may	 have	 just	 been	 discharged	 from	 hospital	
rendering	her	at	an	increased	risk	of	multi-resistant	infections.		Observing	the	antimicrobial	
resistance	 pattern	 of	 the	 isolate	 expressing	 the	 OXA	 enzyme,	 resistance	 to	 the	 following	
agents	 were	 identified,	 cefuroxime,	 cefotaxime,	 piperacillin-tazobactam,	 co-amoxiclav,	
amoxicillin	and	ceftazidime.		Low	level	or	intermediate	resistance	was	also	observed	against	
cefepime;	 however	 the	 organism	was	 sensitive	 to	 ciprofloxacin,	meropenem,	 gentamicin,	
ertapenem,	amikacin	and	tigecycline,	limiting	this	patient	to	only	one	oral	therapy	option.			
Although	 OXA	 type	 resistance	 has	 been	 documented	 in	 Enterobacteriaceae	 including	
reports	of	OXA-48,	also	included	in	OXA	group	one,	in	E.	coli	and	K.	pneumoniae	 in	the	UK	
(168)	and	in	Turkey	(169).		Within	the	Hampshire	region	OXA,	appears	at	present,	to	be	less	
of	a	problem.			
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Figure	4-11,	Results	obtained	from	the	PCR	analysis	to	amplify	OXA	groups	1,	2	and	3.		
Sample	lane	1	contains	a	1kb	plus	DNA	ladder	present	for	band	size	detection,	sample	
analysis	runs	from	2-14,	and	positive	and	negative	controls	are	present	in	sample	lanes	15	
and	16.		The	positive	control,	a	CTX	determinant,	demonstrates	a	593	bp	size,	this	provided	
evidence	that	the	PCR	analysis	had	worked.			Sample	lane	14	demonstrates	a	276bp	band	
identifying	an	OXA	enzyme	that	falls	within	OXA	group	one.			
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OXA	expression	within	this	geographical	 location	however	should	be	monitored	as	OXA-48	
has	 been	 associated	with	 plasmid	mediated	 transmission,	 allowing	 the	 rapid	 transfer	 and	
dissemination	 of	 OXA	 resistance	 through	 different	 bacterial	 species.	 	 Raw	 data	 collected	
from	the	analysis	of	isolates	and	discussed	in	Chapters	3	and	4	can	be	found	in	Appendix	2	
and	3.	
	
4.5	Conclusions	
Identifying	the	molecular	characteristics	of	the	ESBL,	AmpC	and	dual	resistant	bacteria	in	the	
Hampshire	area	complemented	the	phenotypic	information	previous	obtained.			
Detection	 of	 the	 resistance	 determinant[s]	 expressed	 within	 the	 isolates	 enhanced	 the	
epidemiological	 knowledge	 in	 this	 location	 and	 identified	 potential	 shifts	 in	 resistance	
determinant	 expression,	 initiating	within	 the	elderly	 population.	 	 PCR	 results	 suggest	 that	
OXA	expression	was	not	a	concern	in	the	two	year	cohorts	analysed,	with	only	one	isolate	
amplifying	 an	 OXA-group	 one	 resistance	 determinant.	 	 Nevertheless	 this	 resistance	 type	
should	continue	to	be	monitored	to	detect	an	increase	in	expression	and	resistance	changes	
due	to	this	enzyme.				
Molecular	techniques	are	not	routinely	used	for	the	diagnosis	of	ESBL	or	AmpC	resistance	in	
clinical	 practice.	 	 Results	 obtained	 from	 this	 area	 of	 the	 study	 suggest	 that	 molecular	
techniques	 could	 provide	 potential	 point	 of	 care	 testing	 methodologies	 to	 identify	 the	
resistance	 determinant[s]	 expressed.	 	 When	 coupled	 with	 epidemiological	 resistance	
information	 the	most	appropriate	agent,	according	 to	 the	 resistance	determinant[s]	 could	
then	 be	 administered	 to	 the	 patient,	 potentially	 improving	 patient	 diagnosis,	 care	 and	
treatment.	
Limitations	were	 identified	within	 this	 area	 of	 the	 study	 and	 should	 be	 considered	when	
determining	the	results	obtained.		The	primers	used	for	the	multiplex	PCR	detection	of	the	
TEM,	SHV	and	CTX	resistance	determinants	were	reported	in	2007,	and,	those	for	the	OXA	
group	analysis	in	2002.		With	increasing	evidence	that	resistance	determinants	are	evolving	
at	a	rapid	rate,	the	potential	for	these	primers	to	fail	to	detect	certain	mutations	within	the	
resistance	determinants,	increases	with	time.		In	addition	a	number	of	isolates	in	each	year	
cohort	failed	to	detect	any	of	the	resistance	determinants	tested	for,	suggesting	that	other	
determinants	are	responsible	for	the	ESBL	resistance	identified.		This	study	focused	on	the	
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epidemiological	profile	of	ESBL	producing	bacteria	within	the	Hampshire	area	and	although	
AmpC	 enzymes	 were	 identified,	 no	 further	 work	 was	 carried	 out	 to	 further	 characterise	
these.		As	AmpC	expression	is	thought	to	be	under	reported,	it	could	also	be	concluded	that	
further	analysis	of	these	isolates	should	take	place	to	identify	the	prevalent	determinant[s]	
responsible	for	AmpC	resistance	in	this	area.		
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Chapter	5 	
Typing	of	Isolates	to	Determine	Clonal	Relationships	
5.1	Introduction	
In	addition	to	the	molecular	classification	of	the	resistance	determinants,	it	is	also	important	
to	 be	 able	 to	 detect	 the	 clonal	 relationship	 between	 isolates	 carrying	 extended	 spectrum	
beta-lactamases.	 	 Molecular	 typing	 techniques,	 such	 as	 pulse	 field	 gel	 electrophoresis	
[PFGE],	and	arbitrary	primed	PCR	techniques,	 such	as	enterobacterial	 repetitive	 intergenic	
consensus	[ERIC]	PCR,	can	be	used	to	identify	clonal	origins	and	relationships	of	isolates.			
In	 this	 chapter,	 clonal	 relationships	 will	 be	 determined	 through	 typing	 techniques,	
potentially	 identifying	 resistance	 spread	within	 the	 geographical	 location.	 	 Comparison	 of	
the	results	obtained	from	the	2010	and	2012	cohorts	will	allow	patterns	or	distinct	shifts	in	
the	spread	of	ESBL	resistance	to	be	identified.	
	
5.2	Enterobacterial	Repetitive	Intergenic	Consensus	[ERIC]	Profiles	
of	isolates	
The	spread	of	resistance	determinants	within	a	population	may	be	through	conjugation,	or	
other	 gene	 transfer	mechanisms,	 and/or	 by	 clonal	 growth,	where	 a	 resistant	 clone	 has	 a	
selective	 advantage	 in	 environments	 challenged	 by	 the	 antibiotic.	 	 Determining	 whether	
isolates	are	clonal	or	not	involves	comparing	their	genotypes,	either	using	PFGE	techniques	
or	arbitrary	primed/microsatellite-based	PCR	techniques.	 	Although	PFGE	techniques,	such	
as	Clamped	Homogeneous	Electric	Fields	[CHEF],	represent	a	gold	standard	for	this	type	of	
work,	it	is	time	consuming	and	reliant	upon	specialised	equipment.		Arbitrary/microsatellite-
based	 primer	 PCR	 techniques,	 by	 comparison,	 allow	 a	 large	 number	 of	 isolates	 to	 be	
screened	quickly	using	standard	equipment.		In	this	study	no	PFGE	equipment	was	available	
for	use	at	the	time,	and	it	was	decided	to	use	a	microsatellite-based	primed	PCR	technique,	
ERIC,	to	generate	genotypic	information	on	the	isolates	for	comparison.			
ERIC-PCR	is	designed	to	generate	a	banding	profile	for	enterobacterial	species	based	upon	
the	presence	of	intergenic	repeat	units	(IRUs)	within	the	genome.		IRUs	are	127	nucleotide	
long	 imperfect	 palindromic	 sequences	 that	 vary	 in	 number	 depending	 on	 the	 bacterial	
strains	within	a	species.		In	the	majority	of	cases	these	repeat	units	are	found	in	extra-genic	
areas,	occurring	outside	of	genes	expressed	within	the	bacterial	chromosome.		Forward	and	
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reverse	primers	target	the	inverted	repeat	of	the	IRU	element	in	both	orientations,	so	that	
selective	 areas	 of	 the	 genome	 are	 amplified	 that	 represent	 the	 region	 between	 the	
elements	(170).		PCR	using	these	primers,	as	described	in	Chapter	2,	section	2.2.6,	results	in	
the	amplification	of	a	series	of	fragments	that	are	specific	to	the	strain	under	investigation.		
Strains	 with	 identical	 or	 similar	 profiles	 are	 considered	 to	 be	 clonal.	 	 	 	 	 	 	 ERIC-PCR	
amplification	products	were	separated	by	agarose	gel	electrophoresis,	described	in	Chapter	
2,	section	2.2.10.		In	order	to	ensure	consistency	when	estimating	the	size	of	each	amplified	
fragment,	 profiles	 from	 each	 isolate	 were	 repeated	 independently	 three	 times	 and	 only	
those	 fragments	 consistently	 observed	 were	 counted.	 	 The	 size	 of	 each	 fragment	 was	
estimated	using	Image	J	software	from	a	standard	set	of	DNA	size	fragments	after	an	image	
density	scan	had	been	produced.		A	typical	example	of	such	a	gel	and	its	densitometer	scan	
is	shown	in	Figure	5.1.		All	isolates	within	both	cohorts	were	screened	using	ERIC-PCR.		ERIC	
profiles	were	obtained	for	351	[206	in	2010	and	145	in	2012]	of	the	hospital	isolates.		One	
hundred	 and	 forty	 one	 of	 the	 isolates	 collected	 in	 2010	 and	 103	 from	 2012	 produced	
between	2	and	12	fragments,	giving	68	bands	in	total	for	both	years	of	study.		From	these	
fragments	10	groups	with	similar	banding	profiles	were	detected	[Figure	5.2].		In	addition	to	
these	groups,	65	isolates	in	2010	and	42	in	2012	were	recovered	that	gave	unique	ERIC-PCR	
profiles,	the	samples	analysed	in	each	cohort	are	summarised	in	Table	5.1.		The	ERIC	profiles	
for	isolates	recovered	from	the	2010	and	2012	cohorts	were	analysed	separately,	in	order	to	
detect	any	changes	in	the	spread	of	clonal,	or	genetically	related,	groups.			
	
	
Table	5-1,	A	summary	of	the	number	of	isolates	within	each	year	cohort	that	fell	within	the	
clonal	groups,	in	the	non-clonal	group	or	provided	negative	result.		
	
Year	 Total	 Number	
of	Isolates	
Number	 Within	
the	 Clonal	
Groups	
Number	 Within	
the	 Non-Clonal	
Group	
Number	 Providing	 a	
Negative	Result	
2010	 229	 141	 65	 23	
2012	 248	 103	 42	 103	
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Figure	5-1,	(a)	An	example	of	an	ERIC	PCR	agarose	gel	demonstrating	sample	analysis	in	
triplicate,	Lane	1	to	15	contain	isolate	sample	PCR	products	and	lane	16	contains	the	1kb	
DNA	marker	fragments.		(b)	The	plot	of	the	different	bands	obtained	from	the	image	j	
software	in	the	analysis	of	the	above	ERIC	PCR	gel,	the	lane	numbers	associated	with	each	
plot	are	given	above	the	diagram.	
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Figure	5-2,	ten	clonal	groups	identified	from	ERIC-PCR	analysis	of	the	2010	and	2012	
isolates.	
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5.2.1	 ERIC	profiles	for	the	2010	cohort	of	hospital	isolates	
Nine	of	 the	 clonal	 groups	 shown	 in	 Figure	 5.2	 [Groups	 1,	 2,	 3,	 4,	 5,	 6,	 7,	 8	 and	10]	were	
present	in	the	2010	cohort.		Figure	5.3	shows	the	UPGMA	dendrogram	that	summarises	the	
relationship	 between	 these	 groups	 based	 on	 the	 presence	 or	 absence	 of	 ERIC-amplified	
fragments.	 	Group	1	 isolates	pre-dominated	 this	 cohort,	 representing	48%	of	 the	 isolates.			
This	group	comprised	isolates	from	all	of	the	hospitals	[Table	5.2]	that	carried	CTX-M	or	TEM	
and	CTX-M	determinants	pre-dominantly	[Figure	5.4].		Other	determinants	found	within	this	
group	 included	TEM	and	Amp	C,	but	no	SHV.	 	Although	 this	 group	would	appear	 to	have	
been	 of	 clonal	 origin,	 the	 presence	 of	 different	 determinants	 suggests	 that	 genetic	
differences	do	exist,	presumably	due	to	the	presence	of	different	R	plasmids,	encoding	for	
multiple	resistances.			
Isolates	 from	Southampton	hospital	 [S13,	 S14,	 S15,	 S16,	 S17,	 S19,	 S47,	 S57,	 S59,	 S60	 and	
S64]	and	one	from	Winchester	[W23]	formed	a	clade	within	group	1,	which	differed	by	the	
presence	of	a	single	fragment	for	isolates	S16,	S17,	S19,	S47,	S57,	S59,	S60,	S64	and	W23.					
The	other	ERIC	groups	contain	a	smaller	number	of	isolates	that	primarily	carry	the	CTX-M	
determinant	 or	 CTX-M	 and	 TEM	 double	 determinants.	 	 Groups	 2,	 3	 and	 6	 appear	 to	 be	
related	[Figure	5.3],	all	of	which	have	the	CTX-M/TEM	double	determinant	pre-dominantly.		
Group	3	 contains	 isolates	 from	Portsmouth	Queen	Alexandra	Hospital,	while	Group	6	has	
isolates	 from	 University	 Hospital	 Southampton.	 	 Group	 2	 had	 isolates	 from	 Basingstoke,	
Winchester	and	Southampton	Hospitals,	with	two	separate	clades	comprising	isolates	from	
Basingstoke	 hospital.	 	 The	 remaining	 groups	 [4,	 7,	 8	 and	 10],	 except	 group	 5,	 comprised	
isolates	from	single	hospitals	[Basingstoke	–	Groups	4	and	7;	Winchester	–	Groups	8	and	10].		
Group	5	contained	isolates	from	Winchester,	Southampton	and	Portsmouth,	but	all	of	these	
share	 a	 single	 ERIC	 fragment,	with	 isolates	 S30	 and	P4	 sharing	 an	 additional	 band.	 	 Their	
relationship	with	the	other	groups	is	not	clear.	
The	other	group	identified	by	the	ERIC	analysis	was	the	one	containing	isolates	that	shared	
no	ERIC	fragments	with	each	other	or	the	other	groups.		This	represented	the	second	largest	
group	 of	 isolates,	 and	 it	 contained	 those	 that	 carried	 all	 of	 the	 resistance	 determinants	
except	AmpC.			
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Figure	5-3,	UPGMA	tree	of	the	2010	isolates	ERIC	profiles.		Isolate	identification	is	provided	
and	the	end	of	each	branch	and	the	different	clonal	groups	have	been	identified	in	
accordance	with	the	gel	pictures	obtained	from	the	ERIC-PCR	analysis.	Bootstrap	values	are	
given	above	the	branches.	
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Table	5-2,	clonal	groups	identified	in	2010	along	with	the	resistance	determinant	expressed	and	identification	
through	sequence	analysis	(TEM	depicted	by	orange	text,	CTX	by	yellow	and	SHV	by	green).		Results	
demonstrate	the	diverse	nature	of	the	different	clonal	groups	with	the	exception	of	group	8,	suggesting	that	
the	clonal	nature	of	ESBL	producing	organisms	is	not	related	to	the	resistance	determinant	expressed		
			
Clonal	Groups	from	2010	Isolates	
Group	 Resistance	Determinant	 Isolates	
	
	
	
	
1	
TEM	 B7,	W7,	W41,	S43,	P1,	P38,	P44	
CTX	 B28,	B29,	B31,	B32,	B35,	S8,	S9,	S28,	S32,	S34,	S46,	S47,	S53,	S54,	W1,	
W15,	W25,	W23,	W31,	W42,	W43,	W44,	W48,	W54,	W56,	W59,	P2,	P3,	
P8,	P13,	P15,	P18,	P19,	P20,	P21,	P22,	P24,	P29,	P30,	P31,	P32,	P35,	
P36,	P39,	P40,	P41,	P42,	P49,	P53		
CTX	and	TEM	 B3,	B10,	B37,	S19,	S20,	S22,	S23,	S24,	S26,	S27,	S31,	S33,	S35,	S36,	S39,	
S40,	S42,	S57,	S60,	S64,	W16,	W46,	W50,	W51,	W52,	W55,	W57,	W61,	
W62,	W64,	W65,	W69,	W70,	P9,	P23,	P26,	P27,	P28,	P33,	P37,	P43	
AmpC	 W2	
Neg	 B11,	S21,	S52,	S59,	P47	
	
2	
CTX	 B19,	B21,	B23,	B26,	W11,	W14,	B43,	B44,	S14,	W60	
CTX	and	TEM	 B22,	B45,	S13,	S15,	S25	
AmpC	 W3	
3	 TEM	 P54	
CTX	 P46		
4	 CTX	and	TEM	 B15	
Neg	 B25	
	
10	
CTX	 W19,	W20	
AmpC	 W22	
Neg	 W18,	W21	
	
5	
TEM	 S58,	P4	
CTX	 W24,	W47	
CTX	and	TEM	 W17,	W39,	S30		
6	 TEM	 S65	
CTX	and	TEM	 S56,	S60,	S62,	S51		
7	 TEM	 B13	
TEM	and	SHV	 B9		
8	 CTX	 W5,	W6	
	
	
No	
Group	
TEM	 B5,	W4,	W10,	S17,	S45,	W27,	W38,	W41,	P10,	P25	
CTX	 B14,	B27,	B40,	S41,	S63,	W33,	W37,	P5,	P11,	P12,	P45	
SHV	 S18	
TEM	and	SHV	 B8,	B16,	W12,	S11,	W34,	W53,	W58	
CTX	and	TEM	 B18,	B24,	B30,	B38,	W9,	W13,	S4,	S10,	S12,	S16,	S29,	S49,	S55,	W32,	
W35,	W67,	P16	
AmpC	 B17,	B30,	S44,	S50,	W26,	W28,	W29,	W30,	W36	
Neg	 B33,	B34,	S1,	S5,	S48,	W40	
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Figure	5-4,	frequency	of	resistance	determinants	present	in	each	ERIC	group	identified	
within	the	2010	cohort.	
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This	was	 the	 only	 group	 that	 had	 isolates	 carrying	 the	 SHV	 determinant	 or	 the	 TEM/SHV	
double	determinants,	although	 these	were	present	at	 low	 frequencies	 [0.54%	of	 the	 total	
for	the	SHV	determinant	and	3%	for	the	TEM/SHV	double	determinants].		The	pre-dominant	
determinants	 within	 this	 group	 were	 CTX-M	 and	 CTX-M/TEM	 [6%	 of	 the	 total	 and	 7%	
respectively].	
Six	 isolates	 were	 recovered	 as	 ESBL-producing	 organisms	 but	 they	 did	 not	 produce	 any	
products	when	their	DNA	was	amplified	with	 the	 three	primer	pairs	used	 in	 the	multiplex	
PCR	assay.	 	Five	of	these	 isolates	produced	ERIC	profiles	for	Group	1,	and	one	produced	a	
profile	 for	Group	 4.	 	 It	 is	 presumed	 that	 these	 isolates	 carry	 determinants	 that	were	 not	
amplified	by	the	multiplex	primers.	
The	 association,	 or	 not,	 between	 the	 clonal	 and	 non-clonal	 groups	 to	 patient	 gender,	
location,	antimicrobial	resistance	profile	and	the	presence	of	resistance	determinant	types	
was	considered	to	identify	if	any	potential	relationship	existed.		Observation	of	the	patient	
gender	within	the	clonal	groups	revealed	that	although	female	isolates	predominated,	male	
isolates	were	distributed	in	four	of	the	nine	groups	[Groups	1,	2,	6	and	10].		This	observation	
was	 supported	 by	 a	 Chi-squared	 analysis	 which	 demonstrated	 no	 statistically	 significant	
differences	 between	 the	 patient	 gender	 within	 the	 clonal	 groups	 and	 the	 calculated	
expected	 values	 [p=0.123].	 	 Although	 there	 appeared	 to	 be	 no	 relationship	 between	 the	
clonal	groups	and	patient	gender,	this	was	not	true	for	the	non-clonal	group.		The	number	of	
isolates	 from	 male	 patients	 in	 the	 non-clonal	 category	 represented	 72%	 of	 the	 total	
compared	 to	 18%	 from	 the	 clonal	 groups.	 	 This	 suggested	 that	 the	 isolates	 from	 male	
patients	 demonstrated	 limited	 or	 no	 clonality,	 which	 may	 have	 resulted	 from	 sporadic	
infections	from	a	wider	range	of	sources	[potentially	the	community].	
The	 outpatient	 environment	 was	 dominated	 by	 isolates	 that	 fell	 within	 both	 the	 clonal	
groups	 and	 those	 present	 in	 the	 non-clonal	 category.	 	 Isolates	 from	 in-patients	 were	
distributed	 in	 four	 clonal	 groups	 [Groups	 1,	 2,	 5	 and	 7]	 and	 the	 non-clonal	 cohort.	 	 Chi-
squared	 analysis	 revealed	 statistical	 differences	 between	 the	 patient	 location	within	 both	
clonal	and	non-clonal	groups	compared	to	the	calculated	expected	values	[p=0.026].		These	
results	 suggest	 that	patient	 location	within	 the	different	groups	 is	not	a	 result	of	 random	
distribution.	 	 Combining	 the	 ERIC	 results	 for	 patient	 location	 and	 gender	 revealed	 that	
within	 both	 the	 clonal	 and	 non-clonal	 groups,	 female	 in-patients	 had	 a	 greater	 isolate	
prevalence	 than	males	 [15%	 compared	 to	 8%	 in	 the	 clonal	 groups	 and	 26%	 compared	 to	
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14%	 in	 the	non-grouping	 category].	 	 These	 results	 support	 the	notion	 that	 female	patient	
isolates	may	have	originated	from	a	limited	number	of	sources,	compared	to	more	sporadic	
infections	experienced	by	males.	
Identifying	 relationships	 between	 clonal	 groups	 and	 antibiotic	 resistance	 patterns	 would	
allow	the	spread	of	resistance	between	different	locations	to	be	monitored	over	prolonged	
periods.	 	Observation	of	 the	 resistance	prevalence	within	 the	 clonal	 groups	 revealed	high	
levels	of	amoxicillin,	cefuroxime,	cefotaxime	and	co-amoxiclav	resistance	and	high	levels	of	
meropenem,	 ertapenem	 and	 amikacin	 sensitivity.	 	 Kruskal-Wallis	 analysis	 revealed	 no	
statistical	differences	between	antibiotic	resistance	prevalence	and	clonal	group	[p=0.796].		
Statistical	differences	were	however	determined,	using	the	Kruskal-Wallis	test,	between	the	
clonal	 groups	 and	 antibiotic	 intermediate	 resistance	 prevalence	 at	 P=0.002,	 [Figure	 5.5].		
Although	 not	 all	 antibiotic	 classes	 demonstrate	 intermediate	 resistance,	 these	 results	
suggest	 that	 monitoring	 the	 clonal	 spread	 of	 low	 level	 resistance	 may	 aid	 in	 predicting	
resistance	 patterns	 in	 the	 future.	 	 In	 addition	 monitoring	 the	 spread	 of	 intermediate	
resistance	 would	 also	 provide	 potential	 theories	 as	 to	 the	 mechanisms	 responsible	 for	
increases	in	antibiotic	resistance.	
Resistance	determinant	presence	within	organisms	falling	into	the	clonal	groups	and	those	
that	did	not	was	dominated	by	 the	CTX-M	and	CTX-M/TEM	enzymes	 [Table	5.2],	however	
the	 TEM	 and	 SHV	 determinants	were	 also	 observed	 to	 a	 lesser	 extent.	 	 This	 information	
suggests	 that	 clonality	 may	 not	 be	 related	 to	 a	 particular	 resistance	 determinant	 and,	
although	 selective	 advantage	 may	 be	 playing	 a	 role	 in	 the	 spread	 of	 resistance	
determinants,	 other	 mechanisms	 of	 gene	 transfer	 such	 as	 conjugation	 may	 also	 be	
occurring.	 	 Combining	 resistance	 determinant	 type	 and	 patient	 location	 revealed	 that	 all	
resistance	 determinants	 [TEM,	 CTX-M,	 TEM/CTX-M	 and	 TEM/SHV]	 detected	 in	 the	 clonal	
groups	were	observed	in	higher	percentages	in	the	community	compared	to	the	nosocomial	
environment	[77%	community	and	23%	in-patient].		A	similar	picture	was	also	observed	for	
those	 isolates	 that	 fell	 within	 the	 non-clonal	 category,	 with	 the	 out-patient	 environment	
demonstrating	higher	frequency	of	the	resistance	determinants,	with	the	exception	of	joint	
expression	of	TEM	and	SHV	[61%	community	and	39%	in-patient].	 	Comparison	of	the	two	
data	sets	revealed	that	those	isolates	in	the	non-clonal	category	were	having	an	impact	on	
the	nosocomial	environment	to	a	greater	extent	compared	to	the	clonal	groups.		This	may	
123	
	
suggest	 that	 sporadic	 infections	 are	 entering	 the	 nosocomial	 environment	 from	 potential	
community	sources.				
	
	 5.2.2	 ERIC	Profiles	for	the	2012	Cohort	of	Hospital	Isolates	
The	ERIC	profiles	for	103	isolates	from	the	2012	cohort	represented	seven	clonal	groups	[1,	
3,	6,	7,	8,	9	and	10]	and	42	isolates	fell	within	one	non-clonal	group,	where	unique	profiles	
were	observed	[Figure	5.6].	 	 Isolates	with	profiles	for	groups	2,	4	and	5	were	not	present.		
The	 isolates	 also	 showed	 different	 distributions	 within	 the	 clonal	 groups,	 with	 fewer	
belonging	to	Group	1,	although	this	was	still	the	pre-dominant	group	[Figure	5.7].			
A	greater	number	of	isolates	were	recovered	with	profiles	associated	with	Groups	7	and	10,	
both	of	which	were	close	matches	to	the	number	recovered	for	Group	1,	while	a	new	group	
of	 clonal	 isolates	were	detected	–	Group	9.	 	 The	overall	proportion	of	 isolates	 falling	 into	
one	 of	 the	 clonal	 groups	was	 76%,	which	 is	marginally	 lower	 that	 that	 observed	 in	 2010	
[79%].	 	 The	 change	 in	 distribution	 amongst	 the	 clonal	 groups	 represents	 a	 division	 of	
isolates,	some	of	which	were	novel	while	others	not,	from	one	pre-dominant	group	to	three,	
rather	than	a	change	in	the	rates	of	nosocomial	or	community-based	infection.	
The	UMPGA	 tree	 [Figure	 5.7]	 identified	 six	 of	 the	 seven	 clonal	 groups,	with	 the	 Group	 6	
isolates	[P8	and	P11]	being	placed	within	Group	1.		Three	main	clades,	Group	1,	Group	7	and	
Group	 10	 were	 identified.	 	 Groups	 7	 and	 10	 had	 isolates	 that	 formed	 separate	 clades,	
suggesting	a	spread	of	these	within	the	hospital	environment.		Groups	3,	8	and	9	comprised	
a	 small	 number	 of	 isolates	 that	 originated	 primarily	 from	 Queen	 Alexandra	 Hospital,	
Portsmouth.	 	 Isolates	belonging	 to	Groups	7	and	10	originated	primarily	 from	Winchester	
and	Basingstoke	hospitals,	whereas	 the	 isolates	 from	Group	1	were	 from	Portsmouth	and	
Southampton	 hospitals.	 	 This	 had	 changed	 from	 2010,	 when	 Group	 1	 had	 isolates	 from	
Basingstoke	 and	Winchester	 as	well	 as	 those	 from	 Portsmouth	 and	 Southampton	 [Figure	
5.8].	 	Groups	7	and	10	were	also	present	 in	the	2010	cohort.	 	 Isolates	 forming	Group	7	 in	
2010	 originated	 from	 Southampton,	whereas	 in	 2012	 this	 had	 changed,	with	 the	 isolates	
coming	from	Basingstoke	and	Winchester.		In	2010	the	isolates	that	formed	Group	10	came	
exclusively	from	Winchester.	 	 In	2012	the	number	of	Winchester	isolates	within	this	group	
increased	and	they	were	joined	by	isolates	from	Basingstoke.		The	only	group	that	contained	
isolates	from	all	of	the	hospitals	for	both	years	was	the	non-clonal	one.	
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Figure	5-5,	Statistical	differences,	identified	by	a	Kruskal-Wallis	test,	between	the	clonal	
groups	identified	in	2010	and	antibiotic	intermediate	resistance	prevalence	p=0.002.		Here	
significant	differences	could	also	be	seen	between	clonal	groups	1	and	4,	p=0.017.		In	this	
graph	the	prevalence	of	ciprofloxacin	intermediate	resistance	is	depicted	by	red	colour,	
meropenem	blue,	gentamicin	green,	cefotaxime	yellow,	ertapenem	pink,	ceftazidime	
purple,	amikacin	orange,	cefepime	brown	and	tigecycline	dark	green.					
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Figure	5-6,	distribution	of	isolates	amongst	the	ERIC	clonal	and	non-clonal	groups	in	the	
2010	and	2012	cohorts.	
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Figure	5-7,	UPGMA	tree	of	the	2012	isolates	ERIC	profiles,	demonstrating	the	different	clonal	groups.			
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The	most	 common	 resistance	 determinant	 amongst	 the	 isolates	 was	 CTX-M	 [29%	 of	 the	
total)	followed	by	TEM	[25%],	with	SHV	being	present	at	1%.		This	order	was	similar	to	the	
one	 observed	 in	 2010,	 but	 with	 an	 increase	 of	 the	 TEM	 determinant	 from	 11%	 and	 a	
decrease	of	 CTX-M	 from	38%.	 	 The	TEM-CTX-M	double	 resistance	was	 the	most	 common	
double	resistance	at	29%,	with	the	other	double	resistance	determinants	being	represented	
at	much	lower	frequencies	[2%	for	TEM/SHV	and	1%	for	CTX-M/SHV].		Once	again,	the	order	
was	 similar	 to	 that	 of	 2010,	 but	 with	 a	 decrease	 for	 the	 TEM-CTX-M	 double	 resistance	
determinants	from	41%.	
The	 distribution	 of	 determinants	 within	 the	 clonal	 groups	 had	 changed	 compared	 to	 the	
2010	cohort.		All	of	the	groups	had	isolates	with	the	TEM	determinant.		Those	belonging	to	
Group	1	had	the	TEM	and	CTX-M	determinants	in	equal	proportion,	as	did	those	in	Groups	8	
and	 9.	 	 Members	 of	 Groups	 3,	 6,	 and	 10	 had	 the	 TEM	 determinant	 in	 the	 greatest	
proportions.		The	AmpC	determinant	was	present	in	Groups	7	and	10.		In	contrast	the	SHV	
determinant	 was	 not	 present	 in	 any	 members	 from	 the	 clonal	 groups.	 	 The	 double	
resistance	determinants	TEM	and	CTX-M	was	found	in	members	of	Groups	1,	7,	8,	9	and	10,	
with	the	greatest	proportion	within	Group	7,	followed	by	Groups	10	and	1	[Table	5.2].			
The	non-clonal	group	represented	24%	of	the	isolates	and	contained	members	that	carried	
all	of	the	resistance	determinants	and	double	resistance	determinants	[Figure	5.9],	with	the	
greatest	proportion	for	the	CTX-M	determinant,	followed	by	TEM	and	the	double	resistance	
determinants	TEM	and	CTX-M.		The	proportion	of	resistance	determinants	within	this	group	
was	similar	to	that	found	in	2010.	
The	loss	of	clonal	groups	and	the	change	in	the	makeup	of	each	group	between	the	cohorts	
suggests	that	there	is	a	continual	turn-over	of	isolates	that	cause	infection.		Comparison	of	
the	ERIC	profiles	within	Group	1	for	2010	and	2012	[Figure	5.10]	indicates	that	there	is	no	
carry-over	of	isolates	from	2010	to	those	isolated	in	2012.		This	suggests	that	novel	isolates	
continually	enter	the	hospital	systems,	and	that	some	of	these	spread	establishing	a	colony.			
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Figure	5-8,	Comparison	of	ERIC	group	memberships	from	the	2010	and	2012	cohorts	by	
hospital	of	origin.	
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The	2012	clonal	groups	mirrored	those	of	2010,	displaying	no	differences	between	gender	
and	 clonal	 group	 [Chi-squared	 analysis	 p=0.113]	 and	 a	 statistically	 significant	 difference	
between	 the	proportions	of	 in-patient	 and	out-patient	 isolates	within	 the	different	 clonal	
groups	 [Chi-squared	 analysis	 p=0.013].	 	 Combination	 of	 the	 patient	 gender	 and	 location	
results	revealed	that	although	females	again	demonstrated	a	greater	number	of	 in-patient	
isolates	compared	to	males,	 the	prevalence	had	declined	compared	to	 those	calculated	 in	
2010	 [12%	 females	and	5%	males	 in	 clonal	 groups	and	15%	 females	and	6%	males	 in	 the	
non-grouping	category].	
Subtle	 differences	 were	 identified	 in	 the	 2012	 resistance	 and	 intermediate	 resistance	
prevalence	 compared	 to	 those	 found	 in	 the	 2010	 data.	 	 No	 statistically	 significant	
differences	could	be	determined	between	the	clonal	groups	and	antibiotic	resistance,	or	the	
intermediate	resistance	frequency	[Kruskal-Wallis	test,	p=0.980	for	resistance	and	p=0.838	
for	 intermediate	resistance].	 	This	contradicts	the	observed	relationship	of	the	2010	clonal	
groups	with	intermediate	resistance	levels,	and	does	not	give	credence	to	the	idea	that	low	
level	 resistance	 differences	 provide	 an	 indication	 of	 the	 clonal	 spread	 of	 complete	
resistance.	
The	 presence	 of	 ESBL	 resistance	 determinants	was	 diverse	within	 the	 2012	 cohort	 [Table	
5.3],	with	two	or	more	determinants	present	in	all	but	one	group	and	all	present	within	the	
non-clonal	category.	 	The	CTX-M	and	TEM	determinants	were	the	most	common,	with	the	
double	 combination	 of	 TEM	 and	 CTX-M	 determinants	 being	 the	 pre-dominant	 class	 of	
multiple	resistances.		Isolates	forming	groups	7	and	10	showed	the	greatest	increase	in	the	
proportion	of	this	double	resistance	determinant	combination	compared	to	those	from	the	
2010	 cohort.	 	 By	 comparison,	 the	proportion	of	 isolates	 from	Group	1	 that	displayed	 this	
double	determinant	class	fell	compared	to	that	from	the	2010	cohort	[Figure	6.11].	
The	other	class	 that	displayed	an	 increase	 in	 frequency	compared	to	the	2010	cohort	was	
the	 group	 of	 isolates	 that	 failed	 to	 amplify	 a	 product	with	 the	multiplex	 primers.	 	 These	
isolates	 were	 recovered	 as	 ESBL	 producing	 bacteria,	 and	 it	 is	 possible	 that	 they	 possess	
variant	ESBL	determinants	that	failed	to	be	amplified	using	the	existing	primers.	
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Table	5-3,	clonal	groups	identified	in	2012	along	with	the	resistance	determinant	expressed	and	identification	
through	sequence	analysis	(TEM	depicted	by	orange	text,	CTX	by	yellow	and	SHV	by	green).		Results	
demonstrate	the	diverse	nature	of	the	different	clonal	groups	suggesting	that	the	clonal	nature	of	ESBL	
producing	organisms	is	not	related	to	the	resistance	determinant	expressed		
	
Clonal	Groups	from	2012	Isolates	
Group	 Resistance	Determinant	 Isolates	
	
	
1	
TEM	 P3,	P8,	P14,	P17,	P18,	P20,	P22,	P35,	S6,	S22,	S36	
CTX	 P15,	P16,	S2,	S11,	S12,	S17,	S19,	S23,	S24,	S30,	S48		
CTX	and	TEM	 P4,	P5,	P7,	S9,		
CTX	and	SHV	 P33	
CTX,	TEM	and	SHV	 P40,	P28	
Neg	 P12,	P19,	P23,	P29,	P37,	S20,	S28,	S42,	S44,	S47	
6	 TEM	 P8,	P11	
9	
	
TEM	 P10	
CTX	 S50	
CTX	and	TEM	 P24	
Neg	 P21,	S14	
3	 TEM	 P30,	P31	
	
8	
TEM	 P27	
CTX	 P36	
CTX	and	TEM	 B67	
	
	
10	
TEM	 W47,	W49,	B4,	B85	
CTX	 W46,	W3,	W12	
CTX	and	TEM	 W7,	W17,	W18,	W30,	W45,	B31,	B77,	B1,	B2,	B88,	W16,	W36		
SHV	and	TEM	 W11	
AmpC	 W4	
Neg	 W5	
	
	
7	
TEM	 B17,	B51,	B53,	W63,	W65,	W50	
CTX	 W19,	W20,	W22,	W32,	W33,	B18,	B20,	B28,	B30,	B65,	B66,	W64,	
W44,	B12	
CTX	and	TEM	 W8,	W21,	W34,		W60,	B74,	B76,	B5,	B6,	W9,	W14,	W42,	W43,	
B7,	B8	
AmpC	 B27	
	
	
No	
Group	
TEM	 P22,	S40,	W62,	B44,	B79,	W66,	W24,	B10	
CTX	 P34,	W1,	W3,	W6,	W59,	B42,	B47,	W26,	W28,	W39	
SHV	 B54,	S33	
TEM	and	SHV	 P39,	P32	
CTX	and	TEM	 P7,	W31,	W57,	W61,	B68,	W38,	W52,	W56,	W58,	S37		
CTX	and	SHV	 W35,	S49	
AmpC	 W4	
Neg	 S18,	S39,	W5,		
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Figure	5-9,	Prevalence	of	resistance	determinant	types	expressed	within	the	clonal	and	non-
clonal	groups	in	the	2012	cohort.		The	blue	column	demonstrates	TEM	resistance,	green	
CTX,	purple	AmpC,	light	brown	SHV,	light	blue	TEM	and	SHV,	orange	CTX	and	TEM,	dark	blue	
CTX	and	SHV	and	brown	negative.				
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Figure	5-10,	Phylogenetic	analysis	of	the	2010	and	2012	isolates	falling	in	clonal	group	1.		
Results	suggest	that	although	banding	patterns	are	very	similar,	there	are	differences	
between	the	isolates	analysed	in	each	year	cohort.	
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Figure	5-11,	Comparison	of	the	resistance	determinant	frequency	within	the	clonal	groups	
found	within	both	the	2010	and	2012	cohorts	and	the	non-clonal	category.		Results	
demonstrate	the	reduction	of	TEM	expression	within	Group1	and	the	slight	increase	of	CTX-
M	in	Group	10.	
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5.3	Conclusions	
The	 mode	 of	 infection	 by	 ESBL-producing	 bacteria	 had	 changed	 since	 2000,	 when	 the	
presence	of	these	bacteria	in	the	community	was	detected.		Up	until	1992,	ESBL	infections	
were	 caused	 primarily	 by	 bacteria	 carrying	 the	 determinants	 TEM	 and	 SHV	 and	 spread	
clonally.		The	increased	incidence	of	community	acquired	ESBL	infections	after	2000	meant	
that	 these	bacteria	 from	alternative	origins	entered	hospital	environments,	 increasing	 the	
diversity	of	ESBL-producing	bacteria.		With	this	increased	diversity,	the	spread	of	the	CTX-M	
determinant	was	noted	amongst	hospital	 isolates	 so	 that	 it	became	 the	 commonest	 form	
detected.	
The	 ERIC	 profiles	 generated	 for	 isolates	 from	 four	 Hampshire	 hospitals	 revealed	 the	
presence	of	groups	that	have	a	possible	clonal	origin	and	a	group	of	non-related	bacteria,	
which	was	 the	most	 diverse	 for	 ESBL	 resistance	 determinants.	 	 This	 pattern	 is	 consistent	
with	ESBL-producing	bacteria	entering	the	hospital	environments	from	the	community,	with	
some	 being	 spread	 clonally.	 	 The	 presence	 of	 potential	 clonal	 groups	 indicates	 that	 this	
infection	 mechanism	 is	 still	 important	 in	 hospital	 environments.	 	 The	 majority	 of	 these	
clonal	groups	are	mostly	specific	to	a	hospital,	but	some	are	general	to	all	hospitals,	such	as	
group	1	in	2010.		This	suggests	that	isolates	may	be	transferred	between	hospitals.					
The	pre-dominant	resistance	determinant	was	CTX-M,	inherited	singularly	or	together	with	
TEM.	 	 The	 presence	 of	 more	 than	 one	 determinant	 in	 a	 clonal	 group	 is	 not	 especially	
surprising.	 	 Clonal	 isolates	 carrying	 different	 resistance	 determinants	 may	 be	 introduced	
into	 a	 hospital	 system,	 or	 genetic	 exchanges	 may	 take	 place	 between	 and	 within	 clonal	
groups.	 	Within	Group	1	 in	2010	and	2012,	 there	appeared	to	be	no	overlap	between	the	
cohorts,	 suggesting	 that	 there	may	have	been	a	 turnover	with	 isolate	 replacement,	and	a	
possible	loss	of	clonal	diversity.	
Genotyping	 isolates	 collected	 in	 2010	 and	 2012	 has	 demonstrated	 that	 although	 clonal	
spread	is	not	dependent	on	patient	gender,	location,	antimicrobial	resistance	or	resistance	
determinant	expression,	the	diversity	of	organisms	expressing	ESBL	resistance	has	changed	
in	the	two	year	cohorts	studied.		These	results	are	significant	as	this	could	indicate	that	as	
ESBL	resistance	prevalence	increases,	so	does	the	chance	of	sporadic	infections.	
Adding	ERIC	analysis	to	this	study	has	provided	further	information	regarding	the	potential	
exchange	of	resistance	determinants	between	the	four	hospitals	studied,	and	identified	that	
both	 clonal	 and	 plasmid	 spread	 is	 occurring	within	 the	 Hampshire	 region.	 	 Although	 this	
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method	has	been	reported	as	quick,	easy	and	cost	effective,	 limitations	have	been	noted.		
ERIC-PCR,	 as	 the	 name	 suggests	 was	 designed	 for	 the	 typing	 of	 enterobacterial	 isolates,	
research	now	suggests	 that	 this	method	can	also	be	used	 for	 the	 typing	of	Gram	positive	
organisms,	 such	 as	 Streptococcus	 pyogenes	 (171),	 Bacillus	 anthracis	 and	 Bacillus	 cereus	
(172)	 and	 yeasts	 (173),	 questioning	 its	 specificity	 to	 enteric	 organisms.	 	 Banding	 pattern	
variation	between	 analyses	 has	 also	 been	 reported,	 and	 this	was	 certainly	 evident	 in	 this	
study,	 with	 darker	more	 prominent	 bands	 reported	 as	 consistent,	 however	 lighter	 bands	
having	 the	 potential	 to	 be	 misinterpreted	 and	 in	 some	 cases	 absent	 from	 the	 gel	 (60).		
Potential	 limitations	 were	 also	 observed	 within	 the	 analysis	 of	 the	 banding	 patterns,	
although	the	image	J	software	was	used	to	construct	the	presence/absence	framework	for	
phylogenetic	analysis,	 the	 initial	 grouping	of	 the	clonal	 categories	was	carried	out	by	eye,	
allowing	 subtle	 banding	 differences	 to	 be	 misinterpreted.	 	 Within	 this	 study	 a	 high	
proportion	 of	 isolates	 demonstrated	 negative	 results	 when	 amplified	 using	 the	 ERIC-PCR	
primers,	 even	 though	 a	 known	 quantity	 of	 DNA	 was	 analysed	 during	 each	 amplification.		
This	observation	has	not	been	reported	in	other	literature	(174)	and	questions	the	suitability	
of	the	primer	sequences	used	within	this	analysis.		Other	methods	using	the	PCR	technique	
could	have	been	considered,	an	example	including	Multilocus	Sequence	Typing	[MLST],	used	
by	 PHE	 for	 the	 typing	 of	 E.	 coli.	 	 This	 method	 amplifies	 multiple	 housekeeping	 genes,	
approximately	 450	 –	 500	 bp	 in	 length	 and	 has	 been	 compared	 to	 PFGE	with	 conclusions	
drawn	that	MLST	has	a	greater	ability	and	reproducibility	to	discriminate	between	bacterial	
species	(175)	
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Chapter	6 	
Pilot	Analysis	of	Antimicrobial	Resistance	within	a	ESBL	Colonised	Gut	
Model	
	
6.1	Introduction	
Research	 has	 identified	 an	 increase	 in	 the	 incidence	 of	 intestinal	 colonisation	 with	 ESBL	
producing	organisms	since	2002	(176).		Although	colonisation	will	not	routinely	cause	harm	
to	these	individuals,	this	could	potentially	increase	the	risk	of	contracting	an	ESBL	infection,	
particularly	 urinary	 tract	 infections.	 	 Knowledge	 of	 ESBL	 colonisation	 within	 the	 hospital	
environment	 should	aid	 in	prompt	 infection	 control	management	of	 the	patient,	 and	also	
appropriate	prescribing	of	antimicrobial	agents,	if	and	when	needed.		It	has	been	suggested	
that	routine	screening	techniques	would	be	beneficial	to	patients	entering	the	nosocomial	
environment	 (176,	 177).	 	When	 comparing	 to	 pre-screening	methods	 for	 other	 causes	 of	
hospital	 acquired	 infections,	 for	 example	 Methicillin	 Resistant	 Staphylococcus	 aureus	
[MRSA],	 this	 improved	 diagnosis	 and	 eradication,	 reducing	 infection	 numbers	 (177).	 	 It	 is	
also	 important	 to	understand	the	effects	antimicrobial	 treatment	has	on	 the	resistance	of	
the	 intestinal	 microbiota,	 including	 any	 resident	 or	 transient	 ESBL	 producing	 organisms	
present.		Previous	research	has	identified	loss	of	colonisation	resistance,	antibiotic	selection	
and	 the	 plasmid	 exchange	 of	 resistance	 determinants	within	 the	microbiota,	 all	 of	which	
have	been	associated	with	antimicrobial	prescribing	(117).				
The	simulated	colon	can	be	used	to	identify	the	effects	of	antimicrobial	chemotherapy,	on	
the	 minimum	 inhibitory	 concentration	 [MIC]	 of	 ESBL	 colonising	 organisms.	 	 	 	 The	 colon	
model	was	constructed	to	mimic	a	patient	receiving	therapy	at	set	dose	times	over	a	period	
of	 5	 days.	 	 This	 model	 was	 used	 to	 identify	 changes	 in	 the	 minimum	 inhibitory	
concentrations	of	ESBL	colonising	organisms	before	and	after	treatment.		Such	a	study	will	
help	reveal	the	potential	of	current	prescribing	guidelines	in	the	contribution	to	resistance	
changes	within	the	gut	microflora.	
	
6.2		Construction	of	Simulated	Colon	
In	 order	 to	 determine	 the	 effects	 of	 antimicrobial	 agents	 on	 the	 intestinal	 microbiota,	
including	ESBL	producing	bacteria,	a	continuous	culture	system	was	required.		The	use	of	a	
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solo	series	bioreactor	was	initially	planned,	however	due	to	faults	within	this	equipment	a	
novel	 system	 was	 designed.	 	 A	 simplified	 adaptation	 of	 the	 colon	 model	 described	 by	
Edwards	et	al.	 (127)	was	designed	with	the	equipment	available.	 	 	The	artificial	colon	was	
constructed	using	a	peristaltic	pump	to	pass	sterile	gut	mimicking	media	(127),	at	a	rate	of	3	
ml	per	minute,	 into	 the	 simulated	colon	vessel	and	simultaneously	out	 for	discard	 [Figure	
6.1].	 	 The	 size	 of	 this	 vessel	 was	 determined	 using	 the	 mean	 volume	 of	 the	 ascending,	
transverse	and	descending	colon	[300	ml,	500	ml	and	500	ml]	(178).		The	quantity	of	media	
added	to	the	simulated	colon	ranged	between	1500-2000	ml;	this	represented	all	areas	of	
the	colon	and	allowed	a	degree	of	media	fluctuation.		Media	within	the	simulated	colon	was	
heated	to	370C	and	continuously	agitated	using	a	magnetic	stirrer.			
	
6.3	Screening	and	Collection	of	Faecal	Samples	
To	 simulate	 the	 gut	microflora	within	 the	 colon,	 including	 the	 carriage	 of	 ESBL	 producing	
organisms,	 faecal	 samples	 from	 colonised	 individuals	 were	 required.	 	 To	 include	 faecal	
matter,	 ethical	 approval	 was	 required	 from	 the	 NHS	 National	 Research	 Ethics	 Service	
[NRES].		Approval	was	granted	on	the	9th	of	August	2012	by	the	NRES	South	Central	-	Oxford	
committee,	reference	number	12/SC/0413	(Appendix	1).	
Screening	of	 faecal	 samples	 received	 in	 the	 laboratory,	 for	 ESBL	 colonisation,	was	 carried	
out	 at	 the	 Royal	 Hampshire	 County	 Hospital	 Winchester.	 	 Over	 a	 one	 month	 period	 80	
samples	were	 screened	 using	 ESBL	 brilliance	 chromogenic	media	 (179).	 	 Samples	 proving	
positive	 for	 other	 infectious	 diseases	 [Salmonella	 sp,	 Shigella	 sp,	 Campylobacter	 sp	 or	
Clostridium	difficille]	were	discarded.	Six	samples	demonstrated	positive	ESBL	carriage	and	
were	collected,	transported	and	stored	at	-80OC	prior	to	analysis.		
	
6.4	Selection	of	Antimicrobial	Agents	
Dosing	 regimens	 adopted	 for	 the	 treatment	 of	 pyelonephritis	 or	 upper	 urinary	 tract	
infections	were	used	to	determine	the	effects	of	antimicrobial	treatment	on	the	minimum	
inhibitory	concentration	of	the	gut	microflora,	including	an	ESBL	producing	organism.			
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Figure	6-1,	a	demonstration	of	the	simulated	colon,	continuously	agitated	using	a	magnetic	
stirrer	and	maintained	at	370C.		Simultaneously	sterile	gut	mimicking	media	was	pumped	
into	the	simulated	colon	and	waste	products	pumped	out	at	3ml	per	minute.		Antibiotic	
agents,	according	to	local	prescribing	policies,	were	administered	to	the	colon,	for	the	
treatment	of	an	upper	urinary	tract	infection.	
	
Sterile	gut	mimicking	
media	continuously	
being	pumped	at	3ml	
per	minute		
Peristaltic	pump,	
simultaneously	
pumping	sterile	media	
into	and	waste	
products	out	of	the	
simulated	colon	
Simulate	colon,	ESBL	
bacterial	cultures	were	
continuously	grown	and	
subjected	to	antimicrobial	
agents,	according	to	patient	
protocol.	
Simulated	colon	was	
maintained	at	37	OC	and	
continuously	agitated	
using	a	magnetic	stirrer	
Peristaltic	pump	attached	to	
a	timer	socket,	administering	
antibiotic	doses	out	of	
working	hours.		
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Therapy	 would	 commence	 for	 approximately	 48	 hours	 comprising	 parenteral	 gentamicin	
(once	daily	 dosing	 according	 to	 the	patients	weight)	 and	 co-amoxiclav	 [1.2	 g,	 three	 times	
daily	[tds]]	until	 the	patient’s	temperature	had	returned	within	normal	parameters.	 	Upon	
hospital	 discharge	 one	 of	 three	 different	 oral	 agents	may	 be	 considered,	 these	 included,	
amoxicillin	1	g	tds,	co-amoxiclav	625	mg	tds	or	trimethoprim	200	mg	twice	daily	[bd].	
	
6.5	Calculation	of	Antibiotic	Concentrations	Reaching	the	Colon	
The	 pharmacokinetic	 and	 pharmacodynamic	 properties	 of	 each	 antimicrobial	 agent	 were	
evaluated	and	calculations	performed	to	determine	the	amount	of	each	antibiotic	reaching	
the	colon.			
	
	 6.5.1	 Parenterally	Administered	Antibiotics	
As	gentamicin	dosing	 is	dependent	on	 the	patient’s	weight,	 the	patient	demographic	of	a	
healthy	6ft	tall	male,	aged	67	was	used	[chosen	as	all	samples	collected	were	from	patients	
over	the	age	of	65].		The	NHS	choices,	body	mass	index	calculator	determined	that	patients	
fitting	 this	 category	 should	have	a	healthy	weight	of	around	75	kg.	Recommended	dosing	
regimens	of	once	daily	 gentamicin	are	5-7	mg	per	 kg,	 considering	a	dose	of	6	mg/kg,	 the	
simulated	colon	would	be	administered	450	mg	daily.		Values	of	gentamicin	being	excreted	
through	 the	 bile	 have	 been	 estimated	 between	 30%	 to	 40%	 of	 the	 dose	 (180),	 with	 this	
information	 the	dosage	 calculation	 could	 then	be	modified,	 reducing	 the	dose	 to	 135	mg	
daily.		
Dosing	 regimens	of	co-amoxiclav	are	not	dependent	on	 the	patient	weight.	 	Values	of	co-
amoxiclav	being	excreted	within	 the	bile	or	 faeces	have	been	estimated	at	40%	or	higher	
(181,	182).		This	knowledge	allowed	the	dosage	calculation	of	co-amoxiclav	to	be	modified	
to	480mg,	intravenously	tds.		
	
6.5.2		Orally	Administered	Antibiotics	
After	 48	 hours	 of	 parenteral	 therapy	 the	 simulated	 colon	 was	 administered	 orally	 active	
agents	 to	mimic	dosing	 regimens	 considered	after	hospital	 discharge.	 	 These	 included	 co-
amoxiclav,	amoxicillin	or	trimethoprim.		As	the	values	of	co-amoxiclav	being	excreted	within	
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the	bile	or	faeces	had	already	been	estimated,	the	dosage	calculation	could	be	modified	to	
250	mg	tds.			
Amoxicillin	demonstrated	similar	amounts	of	excretion	within	the	bile	or	faeces	compared	
to	co-amoxiclav.		Reports	state	that	levels	of	30%	or	higher	have	been	identified	in	the	bile	
and	to	a	lesser	extent	in	the	faeces	(182).		This	information	allowed	the	dosage	calculation	
to	be	modified	to	300mg	tds.	
The	 third	 choice	of	oral	 therapy,	 trimethoprim,	had	 reported	excretion	 levels	of	10%-20%	
within	 the	 bile	 and	 faeces	 (182).	 	 This	 knowledge	 allowed	 the	 dosage	 calculation	 to	 be	
modified	to	30	mg	bd.	
	
6.6	Selection	and	Analysis	of	Pure	Cultures	
In	order	to	compare	the	effects	of	different	antimicrobial	agents	on	the	minimum	inhibitory	
concentration	of	pure	ESBL	 cultures	and	 intestinal	microflora	 including	an	ESBL	producing	
organism,	pure	cultures	from	previous	investigations	were	selected.		Isolates	Basingstoke	16	
[carrying	a	TEM	determinant]	and	Basingstoke	31	[carrying	the	TEM	and	CTX	determinants],	
collected	within	2012,	were	 chosen	as	 the	pure	 cultures	 for	analysis	within	 the	 simulated	
colon.			
Basingstoke	 16	was	 chosen,	 for	 analysis	 of	 parenteral	 therapy	 and	 oral	 amoxicillin	 or	 co-
amoxiclav	treatment,	because	it	represented	a	typical	ESBL	profile	for	the	Hampshire	region,	
exhibiting	 resistance	 to	amoxicillin	 [as	demonstrated	by	99%	of	 isolates	 in	both	2010	and	
2012]	 and	 lower	 level	 resistance	 [zone	 of	 inhibition	 on	 the	 cut	 off]	 to	 co-amoxiclav	 [as	
demonstrated	 by	 53%	 of	 the	 isolates	 in	 2010	 and	 66%	 of	 the	 isolates	 in	 2012].		
Determination	of	the	minimum	inhibitory	concentration	of	each	of	the	agents	against	B16	
revealed	that,	clinically	these	antibiotics	would	be	deemed	unsuitable.					
Basingstoke	 31,	was	 chosen	 for	 the	 analysis	 of	 parenteral	 therapy	 and	 oral	 trimethoprim	
treatment,	as	a	counterbalance	to	Basingstoke	16,	which	demonstrated	complete	resistance	
to	this	agent.		
A	negative	control	in	the	form	of	an	E.	coli	strain	held	within	the	University	culture	collection	
was	analysed	prior	to	either	of	the	samples.		This	analysis	was	performed	to	identify	if	the	
colon	model	would	ensure	continuous	growth,	the	gut	mimicking	media	would	support	the	
growth	of	the	bacteria,	if	the	dosing	regimens	were	achievable	and	provide	a	growth	curve	
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for	 a	 non	 ESBL	 producing	 bacteria.	 	 Sample	 analysis	 was	 carried	 out	 in	 duplicate	 and	 an	
average	of	each	 spectrophotometry	 reading	plotted	 to	determine	 the	pattern	of	bacterial	
growth.	
Prior	 to	 analysis	 both	 ESBL	 carrying	 isolates	 were	 cultured	 onto	 nutrient	 agar,	 to	 ensure	
purity.		A	six	McFarland	standard	dilution	was	performed	in	sterile	distilled	water	and	added	
to	 the	 sterile	 gut	 mimicking	 media	 within	 the	 simulated	 colon.	 	 Bacterial	 growth	 was	
measured	using	spectrophotometry	[at	625	nm],	with	samples	collected	hourly	for	the	first	
eight	hours,	followed	by	three	collections	daily,	with	the	exception	of	weekends	when	one	
measurement	was	collected,	for	the	remainder	of	the	experiment.			
Spectrophotometry	 readings,	 from	 the	 analysis	 of	 B16,	 revealed	 a	 lag	 phase,	 clear	
exponential	phase,	with	the	stationary	phase	of	bacterial	growth	being	observed	between	
48	and	72	hours.		After	two	days	of	bacterial	growth,	parenteral	therapy	[co-amoxiclav	and	
gentamicin]	 commenced,	 followed	 immediately	 by	 oral	 therapy	 of	 amoxicillin	 or	 co-
amoxiclav.		Bacterial	growth	was	significantly	inhibited	after	24	hours	of	parenteral	therapy,	
after	24	hours	of	oral	therapy	[amoxicillin	or	co-amoxiclav]	bacterial	growth	increased	at	a	
significant	 rate,	 returning	 to	 the	 levels	 observed	prior	 to	 the	 administration	of	 antibiotics	
before	the	full	course	of	oral	therapy	had	been	completed	[Figure	6.2].	
The	spectrophotometry	results	obtained	from	the	analysis	of	B31,	using	parenteral	therapy	
followed	by	trimethoprim,	revealed	similar	results	to	the	analysis	of	B16.		Differences	could	
however	be	determined	 in	 the	 length	of	bacterial	 inhibition	observed	during	oral	 therapy,	
after	which	significant	bacterial	growth	occurred	returning	the	density	to	 levels	equivalent	
to	those	observed	prior	the	administration	of	antibiotics	[Figure	6.3].		Such	differences	could	
be	explained	by	the	sensitivity	of	B31	to	trimethoprim	and	resistance	of	B16	to	amoxicillin	
and	 co-amoxiclav,	 however	 B31	 was	 able	 to	 repopulate	 the	 simulated	 colon	 after	
completion	 of	 the	 recommended	 dose,	 suggesting	 that	 these	 bactericidal	 agent	 regimens	
merely	 inhibit	 rather	 than	 eradicate	 ESBL	 colonisation.	 	 The	 minimum	 inhibitory	
concentration,	of	all	four	antibiotics,	against	B16	and	B31	was	determined	before	and	after	
dosing	 with	 antimicrobial	 agents.	 	 E	 Test	 strip	 methodology	 [Biomerieux]	 was	 used	 to	
provide	 quantitative	 analysis	 so	 that	 comparisons	 could	 then	 determine	 if	 the	
administration	 of	 antimicrobial	 agents	 potentially	 contribute	 to	 resistance	 within	 ESBL	
organisms	 colonising	 the	 intestinal	 tract.	 	 Pure	 culture	 E.test	 strip	 analysis	 results	 are	
presented	in	Table	6.1.		
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	(a)	
	
	
(b)		
	
Figure	6-2,	The	bacterial	growth	of	a	pure	culture	of	ESBL	producing	E.coli	(Basingstoke	16)	when	exposed	to	IV	
gentamicin	and	co-amoxiclav	and	(a)	oral	amoxicillin	and	(b)	oral	co-amoxiclav.		Results	demonstrate	that	in	
both	analyses	bacterial	growth	was	inhibited	after	24	hours	of	parenteral	therapy,	however	during	the	
administration	of	oral	therapy	bacterial	growth	was	observed	as	increasing.		
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Figure	6-3,	The	bacterial	growth	of	a	pure	culture	of	ESBL	producing	E.coli	(Basingstoke	31)	when	
exposed	to	IV	gentamicin	and	co-amoxiclav	and	oral	trimethoprim.		Results	demonstrate	that	
bacterial	growth	was	inhibited	after	24	hours	of	parenteral	therapy	and	the	switch	to	oral	therapy	
maintained	the	bacterial	inhibition	until	the	dosing	period	was	reached.		After	finishing	the	course	of	
treatment	bacterial	growth	was	observed	to	increase,	reaching	levels	equal	to	those	obtained	prior	
to	treatment.			
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Table	 6-1,	 E.test	 results	 for	 the	 pure	 culture	 analysis	 within	 the	 simulated	 colon	 model	
demonstrating	 the	MIC	of	 the	organisms	tested	both	before	and	after	 treatment	using	gentamicin	
and	 co-amoxiclav	 (IV)	 for	 48	 hours	 followed	by	 oral	 therapy	 of	 either	 amoxicillin,	 co-amoxiclav	 or	
trimethoprim.		Results	illustrate	a	rise	in	MIC	against	all	agents	with	the	exception	of	gentamicin.	
	
Organism	Tested	 Dosing	Regimen	 MIC	Prior	to	Dosing	 MIC	After	Dosing	
B16	 Parenteral:	gentamicin	
																					co-amoxiclav	
Oral:												amoxicillin	
0.5	µg/ml		
6	µg/ml		
24	µg/ml					
0.5	µg/ml	
12	µg/ml	
Complete	resistance	
B16	 Parenteral:	gentamicin	
																					co-amoxiclav	
Oral:												co-amoxiclav	
0.5	µg/ml		
6	µg/ml		
6	µg/ml					
0.5	µg/ml	
12	µg/ml	
12	µg/ml	
B31	 Parenteral:	gentamicin	
																					co-amoxiclav	
Oral:												trimethoprim	
0.5	µg/ml		
6	µg/ml		
3	µg/ml					
0.5	µg/ml	
12	µg/ml	
Complete	resistance	
	
	
Analysis	 of	 all	 the	 treatment	 regimens	 revealed	 an	 increase	 in	 the	 minimum	 inhibitory	
concentration	 of	 co-amoxiclav	 from	 6	 µg/ml	 before	 dosing	 to	 12	 µg/ml	 after	 dosing.		
Interpretation	of	these	results	using	the	BSAC	guidelines	revealed	that	the	increase	in	MIC	
would	not	be	considered	clinically	significant	if	used	for	the	oral	treatment	of	urinary	tract	
infections.	 	However	 if	co-amoxiclav	was	considered	as	treatment	for	a	systemic	 infection,	
the	 breakpoint	 cut	 off	 is	 8	 µg/ml,	 with	 B16	 demonstrating	 a	 sensitive	 result	 prior	 to	 the	
administration	 of	 antimicrobial	 agents	 and	 a	 resistant	 result	 after	 treatment	 had	 been	
administered.			
The	minimum	inhibitory	concentration	of	gentamicin	did	not	appear	to	be	affected	by	the	
treatment	with	antimicrobial	agents	and	remained	stable	at	0.5	µg/ml	during	all	analyses.		
Interpretation	 of	 the	 results	 revealed	 that	 both	 B16	 and	 B31	 remained	 sensitive	 to	 this	
agent	(breakpoint	2	µg/ml).	
Prior	 to	 treatment	 the	 MIC	 of	 amoxicillin	 for	 B16	 was	 high	 at	 24	 µg/ml;	 this	 was	 not	
unexpected	as	the	organism	had	previously	been	reported	as	resistant	to	this	agent.		After	
treatment	 however	 B16	 demonstrated	 complete	 resistance	 with	 no	 zone	 of	 clearing	
observed	around	the	E	Test	strip.	 	Although	clinically	both	sets	of	results	[before	and	after	
dosing]	would	indicate	resistance	and	this	agent	would	be	avoided,	this	result	suggests	that	
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treatment	with	 amoxicillin	 could	 be	 a	 contributing	 factor	 to	 the	 high	 levels	 of	 resistance	
observed	within	the	Hampshire	area.		
The	minimum	concentration	of	 trimethoprim	required	to	 inhibit	B31	was	determined	as	2	
µg/ml.	 	 This	 would	 be	 considered	 to	 be	 clinically	 sensitive,	 potentially	 rendering	 this	 a	
treatment	option.	 	 After	 the	 full	 dosing	 regimen	had	been	 administered	 to	 the	 simulated	
colon,	total	resistance	was	noted	with	no	zone	of	clearing	observed	around	the	E	Test	strip.	
	
6.7	Selection	and	Analysis	of	Mixed	Cultures	
Samples	 demonstrating	 positive	 screening	 results	 for	 ESBL	 carriage	 were	 stored	 at	 -800C	
prior	 to	analysis.	 	All	 samples	were	then	cultured	onto	Brilliance	ESBL	chromogenic	media	
[Oxoid],	to	ensure	the	presence	of	the	ESBL	producing	organism,	and	a	blood	agar	plate	to	
allow	 the	 growth	 of	 most	 of	 the	 bacteria	 present	 in	 the	 sample.	 	 From	 the	 samples	
collected,	two	isolates,	one	isolate	demonstrating	sensitivity	to	co-amoxiclav	and	the	other	
exhibiting	 sensitivity	 to	 trimethoprim	 and	 amoxicillin,	 were	 used	 for	 the	 simulated	 colon	
analysis.	 	A	 six	McFarland	 standard	dilution	was	performed	 in	 sterile	distilled	water,	 from	
the	blood	agar	plate	to	ensure	the	majority	of	intestinal	microflora	was	included,	and	added	
to	 the	 sterile	gut	mimicking	media	already	within	 the	 simulated	colon.	 	The	growth	curve	
analysis	 results,	 from	 the	mixed	 cultures,	mirrored	 those	 obtained	 from	 the	 pure	 culture	
analysis.		Clear	lag	and	exponential	phases	were	observed	with	a	second	exponential	phase	
apparent	 between	 36	 and	 48	 hours	 of	 bacterial	 growth.	 	 Twenty-four	 hours	 after	 the	
administration	 of	 parenteral	 therapy	 a	 rapid	 decline	 of	 bacterial	 growth	 was	 observed.		
When	 either	 of	 the	 three	 oral	 therapies	 [co-amoxiclav,	 amoxicillin	 or	 trimethoprim]	were	
considered	as	part	of	the	treatment	regimen,	an	increase	in	bacterial	growth	was	observed	
after	36	hours	of	oral	 therapy	commencing	 [Figure	6.4	and	6.5].	 	This	 result	 suggests	 that	
any	bacteria	within	 the	 samples	demonstrating	 resistance	could	 repopulate	 the	 simulated	
colon	at	a	significant	rate.		In	addition,	the	conjugative	transfer	of	resistance	determinants	
may	be	taking	place,	increasing	the	overall	resistance	of	the	gut	microbiota,	but	this	was	not	
investigated.					
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	(a)	
	
(b)		
	
	
Figure	6-4,	The	bacterial	growth	of	a	mixed	culture	including	an	ESBL	producing	bacteria	when	exposed	to	IV	
gentamicin	and	co-amoxiclav	and	(a)	oral	co-amoxiclav	and	(b)	oral	amoxicillin.		Results	demonstrate	that	in	
both	analyses	bacterial	growth	was	inhibited	after	24	hours	of	parenteral	therapy,	however	during	the	
administration	of	oral	therapy	bacterial	growth	was	observed	as	increasing.		
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Figure	6-5,	The	bacterial	growth	of	a	pure	culture	of	mixed	intestinal	population	of	
organisms	including	an	ESBL	producing	bacteria	when	exposed	to	IV	gentamicin	and	co-
amoxiclav	and	oral	trimethoprim.		Results	demonstrate	that	bacterial	growth	was	inhibited	
after	24	hours	of	parenteral	therapy	and	the	switch	to	oral	therapy	maintained	the	bacterial	
inhibition	for	36	hours	after	which	bacterial	growth	was	observed	to	increase,	reaching	
levels	equal	to	those	obtained	prior	to	treatment.			
	
	
	
	
	
	
		
		
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
09
:3
0
10
:3
0
11
:3
0
12
:3
0
13
:3
0
14
:3
0
15
:3
0
16
:3
0
09
:0
0
12
:0
0
16
:0
0
09
:0
0
12
:0
0
16
:0
0
09
:0
0
12
:0
0
16
:0
0
09
:0
0
12
:0
0
16
:0
0
12
:0
0
11
:0
0
12
:0
0
09
:0
0
12
:0
0
16
:0
0
09
:0
0
12
:0
0
16
:0
0
Day	1 Day	2 Day	3 Day	4 Day	5 Day	
6
Day	
7
Day	
8
Day	9 Day	10
Op
tic
al
	D
en
sit
y	a
t	6
25
nm
Day	and	Time	of	Reading
Mixed	Bacterial	Growth	Measured	at	625nm	after	dosing	
with	IV	Gentamicin	and	co-amoxiclav	followed	by	oral	
Trimethoprim
Dose	Gent	and	
Co-amoxiclav	
for	48	hours Dose	oral	
Trimethoprim	
for	3	days 
149	
	
The	concentration	of	each	of	the	different	agents	required	to	inhibit	the	mixed	cultures	was	
also	 determined	 before	 and	 after	 antimicrobial	 treatment,	 using	 the	 E.test	methodology.		
This	would	identify	differences	that	could	account	for	increases	in	antimicrobial	resistance.		
Results	of	the	mixed	culture	analysis	prior	to	and	after	dosing	are	presented	in	Table	6.2.	
	
Table	 6-2,	 E.test	 results	 for	 the	 mixed	 culture	 analysis	 within	 the	 simulated	 colon	 model	
demonstrating	 the	MIC	of	 the	organisms	tested	both	before	and	after	 treatment	using	gentamicin	
and	 co-amoxiclav	 (IV)	 for	 48	 hours	 followed	by	 oral	 therapy	 of	 either	 amoxicillin,	 co-amoxiclav	 or	
trimethoprim.		Results	illustrate	a	rise	in	MIC	against	all	agents	with	the	exception	of	gentamicin.	
	
Organism	Tested	 Dosing	Regimen	 MIC	Prior	to	Dosing	 MIC	After	Dosing	
Mixed	 culture	
analysis	1	
	
Parenteral:	gentamicin	
																					co-amoxiclav	
Oral:												co-amoxiclav	
	
Parenteral:	gentamicin	
																					co-amoxiclav	
Oral:												co-amoxiclav	
Isolate	1	
2	µg/ml		
24	µg/ml		
24	µg/ml	
Isolate	2	
0.5	µg/ml		
4	µg/ml	
4	µg/ml	
Isolate	1	
Not	detected	
Complete	resistance	
Complete	resistance	
Isolate	2	
0.5	µg/ml		
Complete	resistance	
Complete	resistance	
Mixed	 culture	
analysis	2	
	
Parenteral:	gentamicin	
																					co-amoxiclav	
Oral:												amoxicillin	
	
Parenteral:	gentamicin	
																					co-amoxiclav	
Oral:												amoxicillin	
Isolate	1	
2	µg/ml		
24	µg/ml		
Complete	resistance				
Isolate	2	
0.5	µg/ml		
4	µg/ml	
3	µg/ml	
Isolate	1	
Not	detected	
Complete	resistance	
Complete	resistance	
Isolate	2	
0.5	µg/ml		
Complete	resistance	
Complete	resistance	
Mixed	 culture	
analysis	3	
	
Parenteral:	gentamicin	
																					co-amoxiclav	
Oral:												trimethoprim	
	
Parenteral:	gentamicin	
																					co-amoxiclav	
Oral:												trimethoprim	
	
Isolate	1	
2	µg/ml		
24	µg/ml		
Complete	resistance			
Isolate	2	
0.5	µg/ml		
4	µg/ml	
2	µg/ml		
	
Isolate	1	
Not	detected	
Complete	resistance	
Complete	resistance	
Isolate	2	
0.5	µg/ml		
Complete	resistance	
Complete	resistance	
	
				
Differences	 in	 the	 MIC	 of	 co-amoxiclav	 were	 observed	 before	 and	 after	 dosing,	 when	
compared	 to	 the	 results	 obtained	 from	 the	 pure	 culture	 analysis.	 	 The	 main	 difference	
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observed	was	the	degree	in	which	the	MIC	had	increased.		Prior	to	antibiotic	treatment	two	
distinct	zones	of	inhibition	could	be	observed	around	the	E	Test	strip,	one	producing	an	MIC	
of	 24	 µg/ml	 and	 the	 other	 an	 MIC	 of	 4	 µg/ml.	 	 After	 treatment	 however	 no	 zones	 of	
inhibition	around	the	E	Test	strip	could	be	observed	from	any	of	the	bacteria	making	up	the	
gut	 microflora	 suggesting	 complete	 resistance	 to	 this	 agent.	 	 These	 results	 support	 the	
findings	of	a	previous	study	suggesting	that	exposure	to	co-amoxiclav	could	be	a	potential	
risk	factor	for	co-amoxiclav	resistant	E.	coli	(183).		
Two	 distinct	 zones	 of	 inhibition	 [MIC	 of	 0.5	 µg/ml	 and	 2	 µg/ml]	 were	 observed	 when	
determining	 the	MIC	of	 gentamicin	prior	 to	 antimicrobial	 treatment.	 	After	 completion	of	
the	 treatment	 regimen	 only	 one	 zone	 of	 inhibition	 could	 be	 determined	 at	 0.5	 µg/ml,	
suggesting	 that	 the	 second	 bacterial	 population	 had	 been	 inhibited	 completely.		
Interpretation	 of	 these	 findings	 demonstrate	 that	 potentially	 both	 populations	 of	 gut	
microbiota	 remained	 susceptible	 to	 gentamicin	 after	 the	 dosing	 period,	 these	 results	
suggest	 that	 the	 increase	 in	 gentamicin	 resistance	 observed	 in	 the	 Hampshire	 area	 are	
unlikely	 to	 be	 attributed	 to	 over	 prescribing	 and	 over	 exposure	 to	 this	 agent.	 	 Previous	
studies	 have	 linked	 an	 increase	 in	 gentamicin	 resistance	with	 expression	 of	 CTX-M-1	 like	
genes,	 SHV	 and	 VEB	 (184),	 when	 considering	 this	 concept	 in	 the	 Hampshire	 area	 some	
similarities	 could	 be	 determined.	 	 Fifteen	 percent	 of	 organisms	 in	 2010	 and	 6%	 in	 2012	
expressing	 the	 SHV	 determinant	 demonstrated	 gentamicin	 resistance,	 these	 percentages	
increased	 significantly	when	 considering	 gentamicin	 resistance	 and	 expression	 of	 the	 CTX	
determinant	 [71%	 in	 2010	 and	 49%	 in	 2012].	 	 In	 comparison	 a	 smaller	 percentage	 of	
organisms	 expressing	 the	 TEM	 determinant	 demonstrated	 resistant	 to	 gentamicin	 [8%	 in	
2010	 and	 26%	 in	 2012].	 	 Vaidya	 (185)	 reported	 the	 conjugative	 transfer	 of	 gentamicin	
resistance	from	K.	pneumoniae	to	E.	coli,	indicating	that	such	resistance	can	be	easily	spread	
between	 bacterial	 populations.	 	 Other	 considerations	 for	 the	 increases	 in	 gentamicin	
resistance	include	the	potential	co-expression	of	another	resistance	mechanism	in	addition	
to	 ESBL	 production.	 	 Vliegenthart	 et	 al.	 (186)	 identified	 and	 sequenced	 the	 aacC2	 gene	
within	members	of	the	Enterobacteriaceae	family.		This	gene	has	previously	been	associated	
with	gentamicin	resistance	in	other	bacterial	species.		As	this	resistance	mechanism	was	not	
included	 in	 this	 study,	 further	 research	 is	 required,	 to	highlight	 if	 this	 is	another	potential	
resistance	mechanism	contributing	to	the	 increasing	 levels	of	gentamicin	resistance	within	
the	Hampshire	area.				
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The	minimum	 inhibitory	 concentrations	 of	 amoxicillin	 observed	within	 the	mixed	 culture,	
prior	 to	 dosing,	 revealed	 two	 distinct	 groups	 of	 organisms:	 one	 group	 demonstrating	
complete	 resistance,	 the	 other	 an	MIC	 of	 3	 µg/ml.	 	 After	 the	 dosing	 regimen,	 complete	
resistance	was	apparent	within	both	of	the	bacterial	populations,	with	no	zone	of	clearing	
observed	 around	 the	 E	 Test	 strip.	 	 This	 suggests	 that	 the	 high	 levels	 of	 prescribing,	
calculated	 for	 the	 Hampshire	 region,	 may	 have	 a	 potential	 effect	 on	 the	 high	 levels	 of	
amoxicillin	resistance	observed.			
Analysis	 of	 the	 MIC	 for	 trimethoprim	 prior	 to	 dosing	 revealed	 two	 colonial	 types,	 one	
completely	resistant	to	the	agent	and	the	other	demonstrating	an	MIC	of	2	µg/ml.		After	the	
dosing	regimen,	complete	resistance	was	observed	in	both	sets	of	organisms.		Trimethoprim	
resistance	 has	 been	 considered	 by	 other	 studies	 (187)	 and	 the	 mechanisms	 identified	
include	 the	 potential	 co-expression	 of	 resistance	 determinants,	 for	 example	 dfr	
(dihydrofolate	reductase)	genes	expressed	by	E.	coli.	 	Other	studies	(188)	have	considered	
the	synthesis	of	dihydropteroate	synthetase,	causing	metabolic	alteration	of	the	drug,	and	
the	hyperproduction	of	p-aminobenzoic	acid	which	has	been	associated	with	 the	 reduced	
effects	 of	 oral	 trimethoprim.	 	 In	 addition	 to	 the	 potential	 mechanisms	 of	 trimethoprim	
resistance	described,	previous	exposure	to	 this	agent	may	also	be	a	contributing	 factor	 to	
resistance.	 	 When	 considering	 possible	 resistance	 mechanisms	 the	 evaluation	 of	
trimethoprim	prescribing	 in	 the	Hampshire	 region	was	necessary.	 	Using	 the	Primary	Care	
Trust	prescribing	data	for	Hampshire,	the	number	of	prescriptions	within	the	month	of	June	
could	be	determined.	 	 The	 results	obtained	 from	 this	 analysis	 revealed	 that	 trimethoprim	
prescribing	fell	between	those	levels	observed	for	amoxicillin	[10,616	in	2010	and	12,076	in	
2012]	 and	 co-amoxiclav	 [2636	 in	 2010	 and	 2953	 in	 2012],	 with	 6086	 prescriptions	
administered	to	patients	in	June	2010	and	6612	in	June	of	2012.			
Although	 not	 included	 within	 this	 study,	 trimethoprim	 resistance	 was	 also	 commonly	
reported	 within	 urinary	 isolates	 in	 the	 Hampshire	 region	 and	 has	 also	 been	 reported	 in	
hospital	 infection	 control	 policies,	 including	 those	 of	 Hampshire	 hospitals	 trust.	 	 These	
results	 suggest	 that	 alongside	 of	 other	 resistance	 mechanisms	 the	 level	 of	 previous	
exposure	to	trimethoprim	may	have	a	potential	effect	on	the	resistance	patterns	observed	
within	this	geographical	region.	
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6.8	Conclusions	
The	results	obtained	from	this	part	of	the	study	strongly	suggest	that	previous	exposure	to	
antibiotics,	at	the	concentrations	advised	for	complicated	urinary	tract	 infections,	 increase	
the	 resistance	 of	 the	 intestinal	 microbiota	 to	 Gram	 negative	 active	 antibiotics,	 including	
ESBL	colonising	organisms.		Knowledge	of	ESBL	intestinal	colonisation	would	not	only	aid	in	
the	 clinical	 management	 of	 the	 patient	 but	 could	 also	 influence	 the	 agents	 used,	 to	
potentially	reduce	the	increase	in	resistance	demonstrated	within	the	simulated	colon.	
This	 preliminary	 study	 has	 also	 highlighted	 the	 need	 to	 evaluate	 and	 review	 the	 current	
treatment	regimens.		Potential	changes	in	antibiotic	dosages	and	the	duration	of	treatment	
may	have	a	beneficial	effect,	reducing	the	resistance	of	the	intestinal	microbiota,	potentially	
decreasing	the	risk	of	further	resistant	infections	to	the	patient.					
Although	 significant	 findings	 were	 produced,	 limitations	 within	 this	 study	 must	 be	
considered.		The	intestinal	microbiota	changes	associated	with	age	and	different	conditions	
may	have	effects	on	the	MICs	produced.		Further	analysis	using	a	range	of	age	groups	should	
be	considered	in	order	to	determine	if	the	results	observed	are	consistent	over	all	ranges	of	
micro	flora,	including	ESBL	producing	organisms.		In	addition	this	basic	colon	model	did	not	
consider	 the	 inhibitory	 substances	 and	 immunological	 response	 produced	 within	 the	
intestinal	tract	of	a	healthy	individual.		Substances,	for	example,	secretory	IgA,	non-specific	
fatty	acids,	peroxidases,	specific	bacteriocins	and	low	levels	of	antibodies	produced	against	
components	of	the	normal	microbiota,	may	affect	the	MICs	observed,	and	in	future	analysis,	
these	 must	 be	 considered.	 	 The	 surface	 area	 of	 the	 intestinal	 tract	 enable	 bacteria	 to	
populate	niches	and	form	biofilms,	this	is	a	limitation	of	the	current	colon	model	and	could	
be	addressed	by	 the	use	of	beads	within	 the	colon	vessel.	 	The	current	culture	conditions	
within	 the	 colon	 model	 select	 for	 the	 growth	 of	 aerobic	 organisms	 [although	 a	 natural	
atmospheric	gradient	within	the	liquid	media	will	be	present],	this	 is	not	representative	of	
the	 human	 intestinal	 tract.	 	 Future	 studies	 using	 this	 method	 should	 be	 carried	 out	 in	
anaerobic	 conditions,	 to	 allow	 the	 growth	 of	 both	 facultative	 and	 obligate	 anaerobes	
present	within	any	stool	samples.		Results	do	suggest	that	dosing	regimens	may	contribute	
to	 increasing	 resistance,	however	statistical	analysis	was	not	able	 to	be	performed	due	to	
the	 limited	 number	 of	 repeat	 analyses.	 	 As	 this	 was	 only	 considered	 a	 pilot	 study	 to	
determine	 if	 future	 research	 in	 this	 area	 is	 necessary,	 further	 studies	 should	 ensure	
adequate	repeat	sample	analysis	to	determine	statistically	significant	differences	in	the	MIC	
153	
	
prior	 to	 and	 after	 treatment.	 	 Spectrophotometry	 analysis	 allowed	 the	 growth	 of	 the	
bacteria	to	be	identified	and	illustrated	the	effects	of	the	different	antimicrobial	agents	on	
the	 bacterial	 growth.	 	 Limitations	 within	 the	 sampling	 of	 the	 liquid	 media	 for	
spectrophotometry	 analysis	may	have	 failed	 to	 identify	 subtle	 differences	 in	 the	bacterial	
growth.	 	 Although	 hourly	 readings	were	 taken	 during	 the	 first	 eight	 hours,	 this	was	 then	
reduced	to	three	readings	every	24	hours.		At	the	weekend,	analysis	comprised	of	only	one	
reading.		In	order	to	determine	subtle	differences	in	the	bacterial	growth	with	consistency,	
samples	should	be	taken	at	the	same	time	points	throughout	the	whole	analysis.		E.test	strip	
methodology	allowed	the	easy	determination	of	 the	organisms	MIC	both	before	and	after	
dosing	 to	 that	 particular	 agent.	 	 Nevertheless	 further	 identification	 analysis	 should	 be	
carried	out	on	the	organism[s]	isolated	post	dosing	to	ensure	they	are	comparable	to	those	
inoculated	into	the	colon	model,	prior	to	dosing.		Molecular	analysis	should	also	be	carried	
out	 on	 the	organisms	 isolated	post	 dosing	 to	 determine	 any	 differences	 in	 the	 resistance	
determinant	expressed,	as	this	could	suggest	resistance	exchange,	within	the	colon	model,	
through	 conjugation.	 It	 should	 also	 be	 noted	 that	 when	 considering	 the	 mixed	 culture	
analysis,	 organisms	 demonstrating	 MIC	 levels	 prior	 to	 dosing,	 that	 are	 then	 absent	 post	
dosing	may	be	responding	to	antibiotic	selection.	
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Chapter	7 	
Potential	Sources	of	Intestinal	Colonisation	with	ESBL	Producing	
Organisms	
	
7.1	Introduction	
The	 transmission	 of	 ESBL	 producing	 bacteria	 has	 been	 complicated	 by	 the	 reports	 of	
increasing	intestinal	colonisation	of	healthy	individuals.		If	colonised	individuals	act	as	ESBL	
reservoirs	then	it	is	possible	that	human	to	human	contact,	foreign	travel,	and	the	over	use	
of	 antimicrobial	 agents	within	 agriculture	will	 represent	 potential	modes	 of	 transmission.		
Studies	have	reported	ESBL	and	AmpC	within	the	normal	intestinal	microbiota	of	a	range	of	
animals,	including	pigs,	poultry	and	rabbits	(189).		ESBL	producing		organisms	have	also	been	
isolated	from	a	selection	of	food	types	(190)	and	the	Food	Standards	Agency	are	currently	
evaluating	 the	 prevalence	 of	 E.coli,	 producing	 ESBL	 resistance,	 in	 commercially	 available	
food	products,	within	the	UK.		The	likelihood	of	transmission,	between	human	and	animals	
through	 the	 consumption	 or	 handling	 of	 contaminated	 food	 products	 has	 also	 been	
considered.		The	consumption	of	Salmonella	sp,	expressing	ESBL	or	AmpC	resistance,	within	
poultry	 has	 been	 associated	 with	 such	 transmission	 (191),	 however	 other	 evidence	
considering	the	spread	of	these	organisms	from	direct	contact	with	animals	is	limited	(192).	
In	 this	 chapter,	 healthy	 animal	 faecal	 samples	 and	 commercially	 available	 fresh	 meat	
products	were	screened	for	ESBL	presence,	in	order	to	identify	susceptibility	profiles	as	well	
as	the	resistance	determinants	responsible.		
	
7.2	Collection	and	Analysis	of	Animal	Faecal	Samples	
One	 hundred	 animal	 faecal	 samples,	 from	 multiple	 locations	 within	 Hampshire	 were	
collected	from	domestic	and	farm	animals	[47	horse,	2	sheep,	5	chicken,	4	cow,	28	dog,	1	
rat,	8	cat,	1	guinea	pig,	1	 turkey,	1	parrot,	1	hamster	and	1	rabbit],	 that	had	not	received	
antibiotic	therapy	in	the	past	month.		After	incubation	in	enrichment	broth	[as	described	in	
Chapter	 2,	 section	 2.1.8],	 samples	 were	 cultured	 onto	 one	 quarter	 of	 an	 ESBL	 brilliance	
media	 plate	 [Oxoid],	 a	 chromogenic	 media	 containing	 an	 antibiotic	 mix	 allowing	 for	 the	
selection	of	ESBL	producing	organisms.		A	selection	of	chromogens	is	also	contained	within	
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the	 media,	 allowing	 different	 coloured	 colonies	 to	 be	 generated	 depending	 on	 the	
chromogens	cleaved,	providing	bacterial	species	identification.			
After	incubation	32	of	the	100	animal	faecal	samples	revealed	no	bacterial	growth.		Of	these	
samples	 53%	were	 collected	 from	 dogs,	 22%	 from	 cats,	 9%	 from	 horses	 and	 one	 sample	
from	a	sheep,	a	rat,	a	guinea	pig,	a	cow	and	a	hamster.		All	other	faecal	samples	isolated	one	
or	 more	 species	 of	 bacteria,	 potentially	 expressing	 ESBL,	 AmpC	 or	 dual	 resistance.	 	 One	
hundred	 and	 fifteen	 organisms	 were	 isolated	 on	 the	 ESBL	 brilliance	 media	 from	 the	
remaining	68	samples	[Figure	7.1],	of	these	isolates	68%	originated	from	horses,	11%	from	
dogs,	9%	 from	chicken,	3%	 from	sheep,	4%	 from	cows	1%	 from	rabbits,	 cats,	 turkeys	and	
parrots.	 	 If	 multiple	 species	 were	 isolated	 from	 one	 sample,	 all	 colonial	 types	 were	 sub-
cultured	onto	nutrient	agar	to	ensure	purity,	prior	to	further	analysis.			
	 	
	 7.2.1	 ESBL	and	AmpC	Detection	
ESBL	 and	 AmpC	 production	 was	 confirmed	 using	 the	 ESBL	 and	 AmpC	 discs	 [MAST]	 as	
described	in	Chapter	2,	Section	2.1.4	and	Chapter	3,	Section	3.3.		Results	revealed	that	32%	
of	 the	organisms	 expressed	 ESBL	 resistance,	 15%	AmpC,	 32%	of	 the	organisms	 expressed	
joint	 resistance	 [ESBL	 and	 AmpC],	 15%	 required	 further	 work	 to	 identify	 the	 type	 of	
resistance	expressed	and	17%	demonstrated	a	negative	result.	 	Observation	of	 the	animal	
species	 in	 which	 the	 resistance	 type	 was	 identified	 revealed	 that	 horses	 had	 a	 higher	
prevalence	 of	 dual	 resistance,	 compared	 to	 the	 other	 animals	 included	within	 this	 study.		
This	 observation	 was	 supported	 by	 a	 Kruskal-Wallis	 test,	 which	 revealed	 statistically	
significant	differences	between	resistance	type	and	animal	species	[p=0.0041],	[Figure	7.2].			
No	ESBL	or	AmpC	producing	organisms	were	isolated	from	guinea	pigs,	rats	or	rabbits.		This	
may	be	related	to	the	small	number	of	samples	collected	from	these	animal	types,	however	
ESBL	resistance	[CTX	determinant]	has	been	identified	in	rabbit	farms	(189)	and	the	CTX-M-
15	determinant	has	also	been	isolated	from	the	microbiota	of	guinea	pigs	(193).		No	reports	
have	been	published	regarding	domestic	rat	colonisation;	however	high	levels	of	faecal	ESBL	
carriage	have	been	related	to	brown	rats.		High	levels	of	rat	population	within	urban	areas,	
increasing	the	potential	for	rat	faeces	contamination	could	provide	zoonotic	risks	associated	
with	multi-resistant	bacteria	(194).		
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Figure	7-1,	bacteria	isolated	on	the	ESBL	brilliance	chromogenic	media,	demonstrating	
different	colours	depending	on	the	different	bacterial	species	isolated.		Due	to	the	isolation	
of	mixed	cultures,	all	bacteria	were	then	cultured	onto	nutrient	agar	to	ensure	purity,	prior	
to	being	analysed	further.		Brown	isolates	demonstrated	in	the	top	left	corner	and	bottom	
right	corner	of	the	plate	could	be	identified	as	Proteus	sp,	Morganella	sp	or	Providencia	sp.		
The	white	colonies,	in	the	top	left,	were	potential	Salmonella	sp	or	Acinetobacter	sp.		Blue	
and	pink	colonies	illustrated	in	the	top	right	of	the	plate,	identify	E.	coli	and	green	colonies,	
bottom	left	were	potential	Klebsiella	sp,	Enterobacter	sp,	Serratia	sp	or	Citrobacter	sp.		
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Figure	7-2,	the	proportion	of	ESBL,	AmpC,	dual	resistance,	isolates	that	required	further	
work	and	those	producing	negative	results	compared	to	the	animal	species	in	which	they	
were	isolated.		Statistically	significant	differences	could	be	determined	between	horses	and	
cats,	horses	and	turkeys	and	horses	and	rabbits.		ESBL	resistance	is	depicted	by	a	red	colour,	
AmpC	by	blue,	dual	resistance	by	green,	negative	result	by	orange	and	those	requiring	
further	analysis	by	purple.	
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	 7.2.2	 Organism	Identification	
Organisms	were	identified	to	species	level	by	the	use	of	the	chromogenic	media,	or,	in	cases	
where	 identification	 could	 not	 be	 determined,	 by	 the	 API20e	 identification	 system	
[Biomerieux],	 as	 described	 in	 Chapter	 2,	 Section	 2.1.3	 and	 Chapter	 3,	 Section	 3.2.3.		
Identification	results	revealed	11	different	bacterial	species	expressing	ESBL,	AmpC	or	dual	
resistance.		The	most	prevalent	organism	identified	was	E.	coli	[56%],	16%	of	the	organisms	
were	identified	as	Pseudomonas	spp,	15%	Ochrobacterium	anthropi,	4%	Acinetobacter	spp,	
3%	Providencia	spp,	2%	Morganella	morganii,	and	Citrobacter	freundii,	Escherichia	vulneris,	
Hafnia	 alvei,	 Pantoea	 spp	 and	 Proteus	 penneri	 all	 demonstrated	 a	 prevalence	 of	 1%.		
Comparing	 these	results	 to	 those	obtained	 in	Chapter	3,	Citrobacter	 freundii,	Pantoea	spp	
and	Morganella	 morganii	 were	 all	 isolated	 from	 patients	 suffering	 ESBL,	 AmpC	 and	 dual	
resistant	infections.			
Organisms	that	were	only	associated	with	animal	colonisation	in	this	study,	have	also	been	
reported	as	causing	human	infections.		Pseudomonas	spp	and	Acinetobacter	spp	have	been	
associated	with	multiple	resistance	for	many	years	(195),	however	were	not	included	in	this	
study	 due	 to	 not	 being	 members	 of	 the	 Enterobacteriaceae	 family.	 	 Strains	 of	 Proteus	
penneri,	 Providencia	 spp	 (196)	 and	Ochrobacterium	 anthropi	 (197)	 have	 been	 associated	
with	 opportunistic	 infections,	 particularly	 in	 immunocompromised,	 hospitalised	 patients,	
while	Escherichia	vulneris	can	colonise	wounds	(198).			
	
7.2.3	 Antibiotic	Susceptibility	of	the	Animal	Isolates	
Disc	diffusion	methodology	was	performed	on	all	 isolates	demonstrating	ESBL,	AmpC,	dual	
resistance	and	those	requiring	 further	work,	 to	obtain	the	organisms	susceptibility	profile,	
using	 the	 same	 thirteen	 antibiotics	 and	method	 as	 listed	 in	 Chapter	 2,	 Section	 2.1.4	 and	
Chapter	 3,	 Section	 3.4.	 	 Comparisons	 could	 then	 be	 made	 to	 determine	 similarities	 or	
differences	between	 the	organisms	associated	with	animal	colonisation	and	 those	causing	
human	infection.			
Antimicrobial	susceptibility	testing	revealed	that	the	highest	resistance	rates	were	observed	
against	amoxicillin.	 	 In	contrast	piperacillin-tazobactam	demonstrated	 the	 least	 resistance.		
The	Kruskal-Wallis	test	identified	statistical	differences	between	the	resistance	percentages	
observed	 against	 the	 different	 agents,	 p=0.0004	 [Figure	 7.3a],	 and	 resistance	 prevalence	
compared	to	the	different	animal	species	p=<0.0001	[Figure	7.3b].			
160	
	
(a)	
G
en
ta
m
ic
in
C e
fo
ta
x i
m
e
P i
p e
ra
c i
ll i
n -
T a
zo
b a
c t
am
E r
ta
p e
n e
m
C e
fta
z i
d i
m
e
C e
fe
p i
m
e
M
e r
o p
e n
em
c e
fu
ro
x i
m
e
C o
-a
m
o x
ic
la
v
A m
o x
ic
ill
in
T i
g e
c y
c l
in
e
C i
p r
o f
lo
x a
c i
n
A m
ik
a c
in
-1 0
0
1 0
2 0
3 0
4 0
5 0
6 0
 R e s is ta n c e  F re q u e n c y  w ith in  A n im a l G u t C o lo n is a tio n
A n tib io tic
P
e
rc
e
n
ta
g
e
 R
e
s
is
ta
n
c
e
p = 0 .0 3 5 2
p = 0 .0 2 7 9
p = 0 .0 4 9 6
	
(b)	
H o
rs
e
S h
e e
p
C h
ic
k e
n
C o
w
D o
g
T u
rk
e y
P a
rr
o t
R a
b b
it
0
2 0
4 0
6 0
 R e s is ta n c e  F re q u e n c y  C o m p a re d  b y  A n im a l S p e c ie s
A n im a l S p e c ie s
P
e
rc
e
n
ta
g
e
 R
e
s
is
ta
n
c
e
p=0 .0 091
p=0 .0 004
p=0 .0 048
p=0 .0 293
p=<0 .0001
p=0 .0 406
	
Figure	7-3,	(a)	Prevalence	resistance	of	animal	intestinal	colonisation,	significant	differences	could	be	determined	between	
piperacillin-tazobactam	and	cefuroxime,	piperacillin-tazobactam	and	co-amoxiclav	and	amoxicillin	and	amikacin.		
Observing	the	graph	horses	are	depicted	in	blue,	sheep	in	red,	chicken	in	orange,	cow	yellow,	dogs	green,	turkeys	pink,	
parrots	purple	and	rabbits	brown.	(b)	Prevalence	resistance	compared	to	animal	species,	significant	differences	could	be	
determined	between	horses	and	sheep,	cows,	turkeys,	parrots	and	rabbits	and	between	dogs	and	rabbits.		Gentamicin	is	
depicted	in	blue,	cefotaxime	in	red,	piperacillin-tazobactam	orange,	ertapenem	yellow,	ceftazidime	green,	cefepime	pink,	
meropenem	purple,	cefuroxime	brown,	co-amoxiclav	light	blue,	tigecycline	light	brown,	ciprofloxacin	light	purple	and	
amikacin	black.	
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A	 similar	 picture	 could	 also	 be	 observed	 when	 considering	 the	 intermediate	 resistance	
results,	 with	 the	 Kruskal-Wallis	 test	 supporting	 statistical	 differences	 between	 the	
intermediate	 resistance	 percentages	 against	 the	 different	 agents	 p=0.0300	 [Figure	 7.4a],	
and	 intermediate	 resistance	prevalence	 compared	 to	 the	 animal	 species	p=0.0005	 [Figure	
7.4b].			
Results	suggested	that	organisms	isolated	from	horses	demonstrated	higher	proportions	of	
gentamicin,	 cefotaxime,	 ceftazidime,	 cefepime,	 cefuroxime,	 co-amoxiclav	 and	 amoxicillin	
resistance	and	cefotaxime,	ertapemen,	ceftazidime,	cefepime,	tigecycline	and	ciprofloxacin	
intermediate	 resistance.	 	 Increased	 levels	 of	 amoxicillin	 resistance	were	 also	 observed	 in	
isolates	associated	with	intestinal	colonisation	in	dogs.			
The	collection	of	zoonotic	resistance	data	identified	commensal	E.	coli	exhibiting	increased	
resistance	to	ampicillin,	sulphonamides	and	tetracyclines,	and	lower	levels	of	resistance	to	
gentamicin,	 cefotaxime	 and	 chloramphenicol	 in	 pigs	 and	 cattle.	 	 In	 addition	 resistance	 to	
ampicillin,	 ciprofloxacin,	nalidixic	acid,	 streptomycin,	 sulphonamides	and	 tetracyclines	was	
also	 reported	 in	broiler	 chicken	 (199).	High	 levels	of	multi-resistant	E.	 coli	have	also	been	
isolated	 from	 horses	 in	 the	 north	 west	 of	 England;	 conclusions	 drawn	 from	 this	 study	
highlighted	 concerns	 regarding	 antibiotic	 use	 in	 veterinary	 practice	 and	 the	 potential	
zoonotic	risk	that	horses	could	prove	to	humans	(200).	 	With	grazing	animals,	 in	particular	
horses,	 demonstrating	 ESBL	 and	 AmpC	 colonisation,	 studies	 have	 suggested	 the	
epidemiological	profile	of	ESBL	and	AmpC	is	changing	and	could	be	related	to	the	ability	of	
E.	coli	to	survive	in	a	range	of	different	environments	(201).			
Similarities	 and	 differences	 could	 be	 determined	 when	 comparing	 human	 infection	 and	
animal	intestinal	colonisation	resistance	patterns.		In	both	cohorts	high	levels	of	amoxicillin	
resistance	were	observed.	 	Alongside	of	 the	high	amoxicillin	prescribing	rates	discussed	 in	
Chapter	3,	penicillin’s	have	also	been	described	as	the	most	popular	choice	of	antibiotic	in	
veterinary	practice	for	conditions	including	mastitis	and	uterine	infections	(202),	potentially	
contributing	 to	 the	 high	 level	 of	 resistance	 observed	 in	 the	 animal	 isolates.	 	 Very	 similar	
results	 were	 also	 obtained	 when	 comparing	 co-amoxiclav,	 with	 30-40%	 of	 the	 animal	
microbiota	samples	demonstrating	resistance	to	this	agent.		As	co-amoxiclav	falls	within	the	
penicillin	class	of	antimicrobials,	prescribing	within	the	veterinary	field	may	also	contribute	
to	the	levels	of	resistance	observed.		Cephalosporin	resistance	was	expected	in	both	cohorts	
due	to	the	mode	of	action	of	ESBL	and	AmpC	resistance.			
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Figure	7-4,	(a)	Percentage	intermediate	resistance	of	animal	intestinal	colonisation,	although	statistical	analysis	
revealed	an	overall	significant	difference	between	the	different	antibiotic	intermediate	resistance	percentages,	
no	specific	differences	could	be	determined	between	the	individual	antibiotics.		Observing	the	graph	horses	
are	depicted	in	blue,	sheep	in	red,	chicken	in	orange,	cow	yellow,	dogs	green,	turkeys	pink,	parrots	purple	and	
rabbits	brown.	(b)	Percentage	intermediate	resistance	compared	to	animal	species,	significant	differences	
could	be	determined	between	horses	and	cows,	turkeys,	parrots	and	rabbits.		Here	gentamicin	is	depicted	in	
blue,	cefotaxime	in	red,	ertapenem	yellow,	ceftazidime	green,	cefepime	pink,	meropenem	purple,	tigecycline	
light	brown,	ciprofloxacin	light	purple	and	amikacin	black.	
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High	 levels	of	 sensitivity	 to	meropenem,	ertapenem	and	amikacin	were	observed	 in	all	of	
the	isolates.		This	is	unsurprising	as	these	agents	are	reserved	for	complicated	infections	and	
are	 delivered	 via	 parenteral	 or	 intramuscular	 methods	 requiring	 veterinary	 hospital	
admission.	 	Carbapenems	are	also	unlicensed	for	uses	in	veterinary	practice	however	have	
been	considered	in	specific	cases	when	a	multi-drug	resistant	organism	has	been	suspected	
(203).	 	 Amikacin	 is	 licensed	 and	 is	 used	 to	 treat	 Gram	 negative	 infections,	 the	 mode	 of	
delivery,	however	does	limit	its	use	to	the	clinic/veterinary	practice	environment.	
Higher	levels	of	susceptibility	to	gentamicin	were	also	observed	within	the	animal	intestinal	
microbiota.	 	Prescribing	of	gentamicin	in	veterinary	practice	is	 licenced	however	the	mode	
of	 delivery	 and	 potential	 toxicity	 reduces	 it	 use.	 	 Increases	 in	 the	 use	 of	 piperacillin-
tazobactam	in	the	clinical	field,	as	an	attempt	to	reduce	the	prescribing	of	cephalosporins,	
does	 not	 appear	 to	 be	 mirrored	 in	 the	 veterinary	 field	 with	 animal	 intestinal	 isolates	
demonstrating	higher	levels	of	sensitivity	(204).		Higher	levels	of	sensitivity	to	ciprofloxacin	
were	also	observed	in	the	animal	isolates,	this	agent	however	is	used	regularly	in	veterinary	
practice	for	the	treatment	of	urinary	tract	and	skin	infections.		Theories	for	the	increase	in	
susceptibility	to	this	and	other	agents	may	highlight	the	more	prudent	use	of	antimicrobial	
agents	within	animals,	potentially	reducing	levels	of	resistance.		In	comparison	higher	levels	
of	animal	 intestinal	 resistance	was	observed	against	 tigecycline,	 this	observation	 is	a	 little	
more	challenging	to	define	as	there	are	currently	no	tigecycline	containing	products	licenced	
for	veterinary	practice	in	the	EU.		Suggestions	for	such	resistance	include	the	increased	use	
of	other	tetracyclines	and	the	expression	of	other	resistance	determinants.													
	
7.2.4	 Polymerase	Chain	Reaction	Analysis	for	the	Detection	of	TEM,	
SHV	and	CTX	Determinants	
All	organisms	demonstrating	positive	results	for	ESBL,	AmpC	and	dual	resistance	or	requiring	
further	 work	 to	 identify	 the	 resistance	 mechanism	 expressed	 were	 analysed	 using	 the	
multiplex	PCR	method,	as	described	in	Chapter	2,	section	2.2.4	and	Chapter	4,	Section	4.2.		
PCR	amplification	revealed	that	22	of	the	113	isolates	were	identified	as	expressing	one	or	
more	 resistance	 determinant,	 with	 the	 highest	 proportion	 being	 CTX	 [eight	 isolates],	
followed	by	SHV	[seven	isolates]	and	seven	isolates	were	identified	as	expressing	both	the	
CTX	 and	 TEM	 determinants.	 	 Ninety-one	 of	 the	 isolates	 produced	 negative	 results,	
suggesting	that	another	ESBL	resistance	determinant	may	be	more	prevalent	within	animal	
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intestinal	microbiota.	 	Relating	animal	species	to	the	resistance	determinant	revealed	that	
100%	of	the	organisms	demonstrating	SHV	resistance	were	isolated	in	horses,	as	were	50%	
expressing	 CTX	 and	 43%	 expressing	 both	 CTX	 and	 TEM.	 	 Other	 animal	 species	 associated	
with	 CTX	 resistance	 included	 sheep	 and	 parrots,	with	 equal	 distribution	 of	 the	 remaining	
50%.		Joint	expression	of	the	CTX	and	TEM	determinants	were	also	associated	with	chicken	
and	 dogs	 (29%	 and	 28%),	 raw	 data	 for	 the	 analysis	 of	 animal	 samples	 can	 be	 found	 in	
Appendix	4.		Due	to	the	small	amount	of	samples	demonstrating	positive	gene	expression	all	
samples	were	prepared	and	sent	for	sequence	analysis,	as	per	Chapter	2,	Sections	2.2.8	and	
2.2.9.										
	
	 7.2.4.1			SHV	Sequence	Analysis	Results	
Samples	 sent	 for	 sequence	 analysis	 were	 coded	 according	 to	 the	 number	 faecal	 sample	
received	 in	 the	 laboratory	 and	 the	 colour	 of	 the	 colony	 isolated	 onto	 the	 chromogenic	
media.	 	 Isolates	 sent	 for	 SHV	 analysis	 revealed	 two	 unique	 sequences,	 with	 samples	 5	
White,	 8	 Blue	 and	 16	 Blue	 forming	 sequence	 group	 1	 and	 sample	 15	 White	 forming	
sequence	 group	 2.	 	 Differences	 could	 be	 identified	 between	 the	 groups	 by	 a	 G	 to	 A	
transition	at	position	91,	a	C	to	A	transition	at	position	92	and	T	to	A	transitions	at	position	
347	and	767.		Blast	searches	of	these	sequences	matched	them	to	a	range	of	bla-SHV	alleles	
at	the	99%	and	98%	level,	with	e-values	of	0	[Table	7.1].		The	commonest	allele[s]	identified	
are	highlighted	 in	bold,	 however	 the	greater	 frequency	of	 these	matches	may	 just	 reflect	
that	 there	 are	more	 of	 these	 sequences	 present	 in	 the	 database	 rather	 than	 a	bone	 fide	
match.	 	 Previous	 analysis	 aligning	 and	 editing	 82	bla-SHV	 alleles	 [out	 of	 a	 possible	 87]	 to	
include	the	coding	region	only,	and	transcribed	into	their	amino	acid	sequence	revealed	ten	
amino	acid	substitutions,	within	the	coding	region	of	the	SHV	gene,	at	positions	3,	4,	14,	31,	
39,	142,	183,	198,	234	and	235	defining	15	allelic	variants.		Amino	acid	substitutions	at	these	
positions	were	determined	 in	order	better	 identify	 the	SHV	determinant	expressed.	 	Both	
isolates	 gave	 the	 same	 substitution	 patterns	 for	 the	 amino	 acid	 residues	 at	 the	 variable	
positions	with	 group	 one	 potentially	matching	 the	 profile	 of	 the	bla-SHV-12	 determinant	
and	group	two	potentially	matching	the	profiles	of	either	bla-SHV-5,	12	or	55,	both	groups	
however	were	 identified	 as	 producing	 an	 ESBL	 enzyme	 [Table	 7.2].	 	 These	 identifications	
are,	 however,	 estimates	 as	 the	 5’-end	 of	 the	 gene	 had	 an	 incomplete	 sequence	 so	 that	
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amino	acid	positions	3,	4	and	14	were	missing	for	the	analysis	of	group	1,	and	positions	3,	4,	
14,	31	and	39	 for	 the	analysis	of	group	2.	 	Comparison	of	 these	results	 to	studies	relating	
SHV-12	with	human	infections	revealed	the	identification	of	SHV-12	in	a	range	of	countries,	
including	 Thailand	 (205),	 Nigeria	 (206)	 and	 the	 Philippines	 (207),	 all	 of	 which	 report	 the	
conjugative	 and	 non-conjugative	 spread	 of	 this	 plasmid	 mediated	 enzyme.	 	 Liu	 et	 al.	
reported	 the	 expression	 of	 SHV-12,	 SHV-1	 and	 SHV-28	within	 the	UK	 and	 concluded	 that	
SHV-12	was	 extensively	 distributed	 in	 both	 the	 community	 and	 nosocomial	 setting	 (208).		
These	results	suggest	that	the	SHV-12	determinant	can	be	related	to	animals	and	humans,	
and	 animals	 could	 be	 identified	 as	 possible	 reservoirs,	 potentially	 increasing	 the	 risk	 of	
colonisation	with	bacteria	carrying	the	SHV-12	determinant.	
	
	 7.2.4.2			CTX	Sequence	Analysis	Results	
Isolates	sent	for	CTX	sequence	analysis	revealed	three	unique	groups,	with	isolates	2	Blue,	
10	Blue,	13	Brown,	19	Green,	96	Brown,	96	Blue,	100	Blue	and	100	Purple	forming	group	1,	
isolates	88	Green	and	89	Blue	forming	group	2	and	10	Brown	forming	group	3.		Differences	
could	be	 identified	between	 the	groups	by	a	G	 to	A	or	T	 transition	at	position	66,	 T	 to	G	
transition	 at	 positions	 144	 and	 299,	 a	 T	 to	 C	 transition	 at	 position	 326	 and	 an	 A	 to	 G	
transition	at	position	442.	 	Blast	searches	of	these	sequences	matched	them	to	a	range	of	
bla-CTX	 alleles	 at	 the	 99%	 level,	with	 e-values	 of	 0	 [Table	 7.3].	 	 Those	 allele[s]	 that	were	
identified	 in	 larger	 numbers	 are	 highlighted	 in	 bold;	 however,	 the	 greater	 frequency	 of	
these	matches	may	 just	 reflect	a	greater	number	of	 these	sequences	being	present	 in	 the	
database	 rather	 than	 a	 bone	 fide	 match.	 	 In	 order	 to	 determine	 if	 the	 nucleotide	
substitutions	 observed	 were	 synonymous,	 the	 amino	 acid	 sequences	 of	 each	 animal	 CTX	
group	 were	 also	 considered	 and	 compared	 to	 known	 CTX	 types	 [Table	 7.4].	 	 Results	
demonstrated	that	the	group	3	nucleotide	substitution	at	alignment	position	349	(G	or	A	to	
T)	 resulted	 in	 a	 non-synonymous	 amino	 acid	 expression	 unlike	 any	 of	 the	 other	 CTX	
sequences	(tyrosine	at	alignment	position	117).	 	Although	the	other	amino	acid	sequences	
were	 able	 to	 narrow	 down	 the	 potential	 CTX	 determinants	 isolated	 within	 the	 animal	
samples,	 these	 were	 only	 estimates	 as	 the	 whole	 gene	 sequence	 was	 incomplete	 with	
positions	16,	39,	42	and	289	missing	from	all	three	sequence	groups.			
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Table	7-1,	Animal	sequence	groups	and	BLAST	Sequence	matches.	SHV	alleles	in	bold	
represent	the	most	commonly	match	SHV	types.	
	
Sequence	
Group	
SHV	allele	 OTU	ID	from	BLAST	and	
(percentage	number	of	hits)		
BLAST	
sequence	%	
	
	
	
	
Group	1	
12,	5,	160,	5a,	
134,	31,	2a,	
66,	56,	86,	71,	
165,	154,	11,	
7,	64,	183	
	Klebsiella	pneumoniae	(50%),	E.	
coli	(26%),	Raoultella	terrigena	
(4%),	Enterobacter	cloacae	(6%),	
Citrobacter	freundii	(2%),	
Pseudomonas	aeruginosa	(4%),	
Acinetobacter	baumannii	(6%),	
Proteus	mirabilis	(2%)	
99%	(E	value	
–	0)	
1,	2a,	185,	7,	
161,	148,	12,	
120,	2,	129,	
11,	61,	31,	70,	
5,	13,	1a,	189,	
180,	199,	26,	
179,	173,	172	
Klebsiella	pneumoniae	(74%),	E.	
coli	(15%),	Raoultella	terrigena	
(2%),	Enterobacter	cloacae	(3%),	
Pseudomonas	aeruginosa	(1%),	
Shigella	flexneri	(1%),	Salmonella	
enterica	serovar	typhimurium	(1%),	
Klebsiella	ozaenae	(1%),	
Enterococcus	faecalis	(1%),	Serratia	
liquefaciens	(1%)	
98%	(E	value	
–	0)	
	
Group	2	
12,	5,	160,	5a,	
134,	31,	2a,	
66,	56,	86,	71,	
165,	154,	11,	
7,	64,	183	
Klebsiella	pneumoniae	(48%),	E.coli	
(26%),	Raoultella	terrigena	(4%),	
Enterobacter	cloacae	(8%),	
Citrobacter	freundii	(2%),	
Pseudomonas	aeruginosa	(4%),	
Acinetobacter	baumannii	(6%),	
Proteus	mirabilis	(2%)		
99%	(E	value	
–	0)	
1,	12,	2a,	185,	
7,	161,	148,	
120,	2,	129,	
11,	61,	31,	70,	
5,	13,	1a,	189,	
180,	119,	26,	
179,	173,	172		
Klebsiella	pneumoniae	(78%),	E.coli	
(10%),	Enterobacter	cloacae	(3%),	
Raoultella	terrigena	(3%),				
Pseudomonas	aeruginosa	(2%),	
Shigella	flexneri	(2%),	Klebsiella	
ozaenae	(1%),	Salmonella	enterica	
serovar	typhimurium	(1%)	
98%	(E	value	
–	0)	
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Table	7-2,	the	amino	acid	substitutions	at	positions	3,	4,	14,	31,	39,	142,	183,	198,	234	and	235	for	
the	15	SHV	alleles	and	the	two	animal	sequence	groups.	
	
SHV	Group	 Codon	position	and	amino	acid	residue	 Isolate	
3*	 4	 14*	 31*	 39	 142	 183	 198	 234*	 235*	 	
SHV-1	(non-ESBL)	 Y	 I	 T	 L	 R	 A	 A	 R	 G	 E	 	
SHV-2a	(ESBL)	 Y	 I	 T	 L	 R	 A	 A	 R	 S	 E	 	
SHV-5	(ESBL)	 Y	 I	 T	 L	 R	 A	 A	 R	 S	 K	 	
SHV-11	(non-ESBL)	 Y	 I	 T	 Q	 R	 A	 A	 R	 G	 E	 	
SHV-12	(ESBL)	 Y	 I	 T	 Q	 R	 A	 A	 R	 S	 K	 	
SHV-18	(ESBL)	 Y	 F	 T	 L	 S	 A	 A	 R	 A	 K	 	
SHV-25	(non-ESBL)	 Y	 I	 A	 Q	 R	 A	 A	 R	 G	 E	 	
SHV-26	(non-ESBL)	 Y	 I	 T	 L	 R	 A	 T	 R	 G	 E	 	
SHV-28	(non-ESBL)	 F	 I	 T	 L	 R	 A	 A	 R	 G	 E	 	
SHV-30	(ESBL)	 Y	 F	 T	 L	 S	 A	 A	 R	 S	 E	 	
SHV-31	(ESBL)	 Y	 I	 T	 Q	 R	 A	 A	 R	 G	 K	 	
SHV-36	(non-ESBL)	 Y	 I	 T	 Q	 R	 A	 A	 R	 G	 E	 	
SHV-38	(non-ESBL)	 Y	 I	 T	 L	 R	 V	 A	 R	 G	 E	 	
SHV-55	(ESBL)	 F	 I	 T	 L	 R	 A	 A	 R	 S	 K	 	
SHV-104	(non-ESBL)	 Y	 I	 T	 L	 R	 A	 A	 S	 G	 E	 	
	 	 	 	 	 	 	 	 	 	 	 	
SHV-12	 -	 -	 -	 Q	 R	 A	 A	 R	 S	 K	 Gp	1	
SHV-5/12/55	 -	 -	 -	 -	 -	 A	 A	 R	 S	 K	 GP	2	
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Table	7-3,	animal	sequence	groups	and	BLAST	Sequence	matches.	CTX	alleles	in	bold	
represent	the	most	common	matches.	
	
	
Sequence	
Group	
CTX	allele	 OTU	ID	from	BLAST	and	
(percentage	number	of	hits)		
BLAST	
%	homology	
	
	
	
	
Group	1	
1,	61,	138,	36	 E.	coli	(86%),	Klebsiella	
pneumoniae	(8%),	Proteus	mirabilis	
(3%),	Salmonella	enterica	serovar	
typhimurium	(3%)	
	
99%	(E	value	
–	0)	
3,	175,	166,	
158,	1,	58,	32,	
29,	22,	116,	
15,	66,	30	
E.	coli	(57%),	Klebsiella	
pneumoniae	(20%),	Enterobacter	
cloacae	(5%),	Proteus	mirabilis	
(7%),	Morganella	morganii	(2%),	
Aeromonas	hydrophila	(7%),	
Citrobacter	freundii	(2%)			
	
98%	(E	value	
–	0)	
	
Group	2	
15,	164,	163,	
55,	1,	3,	142,	
79,	109,	108	
E.	coli	(84%),	Klebsiella	
pneumoniae	(7%),	Enterobacter	
cloacae	(1%),	Proteus	mirabilis	
(4%),	Enterobacter	aerogenes	(1%),	
Salmonella	enterica	serovar	
typhimurium	(1%),	Shigella	sp	(2%)		
99%	(E	value	
–	0)	
Group	3	 15,	1,	61,	138,	
36,	175,	166,	
158,	32,	58,	3,	
22,	116	
E.	coli	(90%),	Klebsiella	
pneumoniae	(3%),	Enterobacter	
cloacae	(1%),	Proteus	mirabilis	
(2%),	Morganella	morganii	(1%),	
Aeromonas	hydrophila	(2%),	
Salmonella	enterica	serovar	
typhimurium	(1%)			
99%	(E	value	
–	0)	
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Table	7-4,	the	amino	acid	substitutions	at	positions	16,	39,	42,	117,	122,	143,	242	and	289	for	19	CTX	
alleles,	plus	the	three	animal	sequence	groups.	
	
Enzyme	 Amino	Acid	Residue	Position	Number	 	
16	 39	 42	 117	 122	 143	 242	 289	 	
CTX-M-01	 T	 E	 R	 D	 L	 S	 D	 ?	 	
CTX-M-55	 T	 E	 R	 N	 L	 A	 G	 D	 	
CTX-M-57	 T	 E	 R	 N	 L	 A	 G	 D	 	
CTX-M-61	 T	 E	 R	 D	 L	 S	 D	 D	 	
CTX-M-32	 T	 E	 R	 D	 L	 S	 G	 N	 	
CTX-M-138	 T	 E	 R	 D	 L	 S	 D	 N	 	
CTX-M-142	 T	 E	 R	 N	 L	 A	 G	 D	 	
CTX-M-156	 T	 E	 R	 N	 L	 A	 G	 D	 	
CTX-M-30	 A	 E	 R	 D	 L	 A	 D	 D	 	
CTX-M-29	 A	 E	 R	 D	 L	 A	 G	 N	 	
CTX-M-10	 T	 E	 Q	 N	 L	 A	 D	 D	 	
CTX-M-34	 T	 E	 Q	 N	 L	 A	 D	 D	 	
CTX-M-11	 T	 G	 R	 N	 P	 A	 D	 ?	 	
CTX-M-22	 T	 E	 R	 N	 L	 A	 D	 N	 	
CTX-M-15	 T	 E	 R	 N	 L	 A	 G	 D	 	
CTX-M-33	 T	 E	 R	 N	 L	 A	 G	 D	 	
CTX-M-28	 T	 E	 R	 N	 L	 A	 G	 N	 	
CTX-M-3	 T	 E	 R	 N	 L	 A	 D	 D	 	
CTX-M-12	 A	 E	 R	 N	 L	 A	 D	 D	 	
	 	 	 	 	 	 	 	 	 	
CTX-M-1/	61/	
138	
?	 ?	 ?	 D	 L	 S	 D	 ?	 Group	1	
CTX-M-13/15	
/28/55/57	
/142/156	
?	 ?	 ?	 N	 L	 A	 G	 ?	 Group	2	
No	CTX	group	
identified	
?	 ?	 ?	 Y	 L	 S	 D	 ?	 Group	3	
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Comparing	 the	 potential	 identifications	 of	 the	 animal	 CTX	 determinants	 with	 research	
associated	 with	 human	 infections	 revealed	 that	 animal	 sequence	 group	 one	 potentially	
matched	those	of	CTX-M-1	and	CTX-M-61.		CTX-M-1	was	the	first	CTX	type	to	be	reported	in	
the	1980’s	in	Europe	and	is	now	associated	in	a	wider	geographical	range	including	Turkey	
(209),	Russia	(210)	and	the	USA	(211).		The	prevalence	of	determinant	CTX-M-61	is	less	than	
that	for	CTX-M-1,	and	it	has	not	been	reported	in	the	UK	but	was	originally	discovered	in	the	
Champagne-Ardenne	region	of	France	(212).		
Animal	sequence	group	two,	potentially	matched	CTX-M-15,	CTX-M-28	and	CTX-M-55.		CTX-
M-15	has	been	classified	as	one	of	the	most	important	CTX	resistance	types	due	to	its	ability	
to	cause	resistance	in	humans,	animals	and	the	environment	(213).	 	 It	was	not	possible	to	
distinguish	 the	 amplified	 sequences	 between	 determinant	 CTX-M-15	 and	 CTX-M-28	 from	
the	 data	 produced,	 however	 CTX-M-28	 has	 been	 reported	 in	 Brazil	 (214),	 Lebanon	 (215),	
Tunisia	(216)	and	India	(217),	with	few	reports	in	Europe;	the	first	description	of	its	presence	
being	 in	 2015	 in	 Bosnia-Herzegovina	 (218).	 	 In	 contrast	 determinant	 CTX-M-55	 has	 been	
reported	with	greater	 frequency	 in	Korea	and	China,	where	 it	poses	a	 significant	problem	
(219,	220),	than	Europe.			
Although	both	the	nucleotide	and	amino	acid	analysis	of	the	animal	faecal	isolates	identified	
a	potentially	new	variant	of	 the	CTX-M	enzyme,	 the	 identity	of	 sequence	groups	one	and	
two	have	been	associated	with	human	infections.		These	results	suggest	that	animal	contact	
could	be	a	potential	source	of	intestinal	colonisation	with	CTX-M	producing	organisms.	
	
7.3	Collection	and	Analysis	of	Commercial	Meat	and	Egg	Products	
Thirteen	individually	packed	fresh	meat	and	egg	products	were	purchased	from	two	leading	
supermarkets	 [Tesco	 PLC	 and	 Asda	 Stores	 Limited].	 	 Products	 included	 British	 chicken	
breast,	eggs	[to	include	analysis	with	egg	yolk	and	white,	and	egg	and	shell],	British	turkey	
breast	mince,	British	and	Irish	beef	mince,	unsmoked	bacon	from	British	and	Dutch	origin,	
British	 lamb	 mince,	 diced	 lamb	 from	 New	 Zealand,	 British	 pork	 mince	 and	 pork	 chops	
sourced	 from	Denmark.	 	 Food	 samples	were	 analysed	 in	 the	 same	manner	 as	 the	 faecal	
samples,	and	as	described	in	Chapter	2,	section	2.1.9,	with	the	addition	of	homogenisation	
in	 a	 stomacher	 prior	 to	 enrichment	 and	 culture.	 	 Organism	 identification,	 susceptibility	
profiles,	resistance	type	and	determinant	were	all	obtained	to	identify	if	fresh	food	products	
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could	 be	 a	 potential	 source	 of	 intestinal	 colonisation.	 	 After	 incubation	 four	 of	 the	 13	
commercial	 meat	 and	 egg	 products	 demonstrated	 no	 bacterial	 growth,	 two	 of	 these	
samples	were	from	eggs	[egg	yolk	and	white,	and	egg	and	shell],	one	from	unsmoked	bacon	
originating	in	the	UK	and	one	from	diced	lamb	originating	from	outside	of	the	UK.		All	other	
commercial	meat	samples	 isolated	one	or	more	species	of	bacteria,	potentially	expressing	
ESBL,	AmpC	or	dual	resistance.	Twenty-five	organisms	were	isolated	on	the	ESBL	brilliance	
media	from	the	remaining	nine	samples,	36%	of	these	were	isolated	from	chicken,	16%	from	
UK	 lamb	mince,	 4%	 from	 UK	 beef	mince,	 12%	 from	 UK	 turkey	mince	 and	 8%	 from	 beef	
mince,	unsmoked	bacon	and	pork	chop	originating	from	outside	of	the	UK	and	from	UK	pork	
mince.	 	 Prior	 to	 further	 analysis	 all	 organisms	 isolated	 on	 the	 chromogenic	 agar	 were	
cultured	onto	nutrient	agar	to	ensure	purity.			
	
7.3.1	 	ESBL	and	AmpC	Detection	
ESBL	and	AmpC	production	was	confirmed	 in	the	same	manner	as	 the	 faecal	samples	and	
described	in	Chapter	2,	section	2.1.4.		Results	revealed	that	60%	of	the	organisms	expressed	
ESBL	 resistance,	 12%	 AmpC	 and	 28%	 demonstrated	 a	 negative	 result,	 no	 organisms	
expressed	joint	resistance	[ESBL	and	AmpC].		Observation	of	the	food	product	in	which	the	
resistant	 bacteria	 were	 identified	 revealed	 that	 chicken	 had	 a	 higher	 prevalence	 of	 ESBL	
resistance	compared	to	the	other	products	analysed.		Organisms	expressing	ESBL	or	AmpC	
were	isolated	in	all	other	meat	products,	to	a	lesser	extent,	with	the	exception	of	pork	chops	
originating	 from	outside	of	 the	UK.	 	Although	a	higher	percentage	of	ESBL	 resistance	was	
observed	 in	 chicken	 samples,	 a	 Kruskal-Wallis	 test	 revealed	 no	 statistical	 differences	
between	the	frequency	of	the	different	resistance	mechanisms	[p=0.7857]	or	the	between	
the	resistance	expressed	within	the	different	meat	products	[p=0.7630].				
Consideration	of	the	risks	associated	with	the	handling	and	consumption	of	ESBL	or	AmpC	
contaminated	food	products	and	inadequate	hand	washing	has	identified	the	possibility	of	
resistance	being	transmitted	from	food	sources	to	humans.		Contaminated	poultry	has	been	
associated	with	 an	 outbreak	 of	 E.	 coli,	 carrying	 ESBL	 resistance	 (221).	 	Molecular	 studies	
have	also	identified	ESBL	resistance	determinants	originally	associated	with	poultry,	isolated	
from	 bacteria	 resulting	 in	 human	 infections	 (96).	 	 Conclusions	 drawn	 from	 these	 studies	
suggest	that	the	transmission	of	ESBL	resistance	from	poultry	to	humans	is	most	likely	to	be	
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through	the	food	chain.		Food	processing	and	preservation	techniques	aim	to	extend	the	life	
of	food	products	however	have	varying	effects	on	bacterial	contamination.		Many	bacterial	
species	are	merely	 inhibited	during	 these	 techniques,	 resulting	 in	 stress	or,	 in	 some	cases	
damage	to	the	cellular	structure.		Bacterial	lysis	may	also	occur,	resulting	in	DNA,	including	
potential	 resistance	 determinants,	 being	 present	 within	 the	 environment,	 potentially	
increasing	the	risk	of	resistance	transfer	(222).		
	
	 7.3.2	 Organism	Identification	
Organisms	demonstrating	ESBL	or	AmpC	resistance	were	identified	to	species	level	using	the	
same	 techniques	 as	 described	 for	 the	 animal	 faecal	 analysis	 and	 provided	 in	 Chapter	 2,	
Section	2.1.3.		The	most	prevalent	organism	identified	within	the	food	products	was	E.	coli	
[56%],	11%	of	the	organisms	were	identified	as	Salmonella	enterica	and,	Kluyvera	ascorbata,	
Hafina	 alvei,	 Pseudomonas	 aeruginosa,	 Pseudomonas	 luteola,	 Serratia	 marcescens	 and	
Serratia	fonticola	all	demonstrated	a	prevalence	of	6%.			
E.	coli	has	proven	to	be	the	most	prevalent	organism	in	all	areas	of	this	study	and	has	been	
identified	as	one	of	the	most	common	animal	and	human	pathogens.		Organisms	limited	to	
food	 products	 include	 Salmonella	 enterica,	 Kluyvera	 ascorbata,	 Serratia	 marcescens	 and	
Serratia	 fonticola	 all	 of	 which	 have	 been	 associated	 with	 opportunistic	 and	 nosocomial	
human	infections	(223-226).			
	
7.3.3	 Antibiotic	Susceptibility	of	the	Food	Product	Isolates	 	
Antibiotic	susceptibility	profiles	of	the	ESBL	and	AmpC	producing	bacteria	isolated	from	the	
food	products	were	determined	in	order	to	identify	similarities	or	differences	compared	to	
those	organisms	causing	human	infection.		High	levels	of	resistance	were	observed	against	
amoxicillin	and	co-amoxiclav;	in	contrast	meropenem	and	amikacin	demonstrated	the	least	
resistance.	 	 These	 differences	 were	 supported	 by	 a	 Kruskal-Wallis	 test	 which	 identified	
statistically	 significant	 differences	 between	 the	 resistance	 prevalence	 of	 the	 different	
antimicrobial	 agents	 p=<0.0001	 [Figure	 7.5a].	 	 The	 Kruskal-Wallis	 test	 however	 failed	 to	
identify	 any	 statistically	 significant	differences	between	 the	meat	products	 and	 resistance	
prevalence	[p=0.0931]	suggesting	that	the	risk	of	antimicrobial	 resistance	 is	not	related	to	
specific	food	types.		Similar	results	were	also	observed	for	the	intermediate	resistance,	with	
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the	 Kruskal-Wallis	 test	 identifying	 statistically	 significant	 differences	 between	 the	
intermediate	 resistance	 prevalence	 of	 the	 different	 antimicrobial	 agents	 p=0.0465	 [Figure	
7.5b]	 but	no	 relationship	between	 the	different	meat	products	 [p=0.0722].	 	 Although	not	
considered	 significant,	 organisms	 isolated	 from	 chicken	 and	 lamb	 mince	 demonstrated	
higher	proportions	of	cefotaxime,	co-amoxiclav	and	amoxicillin	resistance,	with	higher	levels	
of	cefuroxime	resistance	also	associated	with	 lamb	mince.	 	 In	comparison	higher	 levels	of	
cefepime	intermediate	resistance	was	observed	in	bacteria	isolated	from	chicken	and	lamb	
mince	 isolates	 demonstrated	 an	 increase	 intermediate	 resistance	 to	 ertapenem	 and	
tigecycline.	
Amalgamation	 of	 the	 results	 with	 those	 obtained	 from	 the	 animal	 and	 human	 samples	
revealed	 that	 all	 isolates	 relating	 to	 the	 meat	 products	 demonstrated	 resistance	 to	 co-
amoxiclav,	however	only	30%	to	40%	resistance	was	observed	in	animal	and	human	isolates.		
Considerations	 as	 to	 the	 cause	 of	 this	 increased	 resistance	 should	 not	 rule	 out	 over	
prescribing	of	co-amoxiclav,	however	if	this	was	the	case,	a	higher	level	of	resistance	may	be	
expected	 in	 the	 animal	 faecal	 samples.	 	 Cephalosporin	 resistance	 was	 expected	 in	 both	
cohorts	due	to	the	mode	of	action	of	ESBL	and	AmpC	resistance,	however	high	percentages	
of	cefotaxime	resistance	was	observed	in	the	animal	faecal	samples	compared	to	the	meat	
products.			
Bacteria	 isolated	 from	 chicken	 samples	 demonstrated	 the	 greatest	 incidence	 of	 antibiotic	
sensitivity	against	amikacin,	gentamicin,	tigecycline,	ciprofloxacin,	meropenem,	ertapenem,	
piperacillin-tazobactam	and	ceftazadime.		Lamb	mince	also	demonstrated	higher	incidence	
of	 sensitivity	 against	 amikacin,	 gentamicin,	 ciprofloxacin,	 meropenem	 and	 piperacillin-
tazobactam.			
High	 incidence	of	 sensitivity	 to	meropenem,	 ertapenem	and	 amikacin	were	 suspected,	 as	
previously	discussed,	carbepenems	are	unlicensed	in	veterinary	practice	and	the	limitations	
of	parenteral	administration	of	gentamicin	and	amikacin	will	potentially	affect	commercial	
meat	 in	 the	 same	manner	 as	 animal	 intestinal	 colonisation.	 	 The	 higher	 susceptibility	 of	
organisms	to	piperacillin-tazobactam	and	ciprofloxacin	within	food	products,	mirrored	that	
seen	in	the	animal	faecal	samples,	this	was	not	observed	in	the	human	isolates.			
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Figure	7-5,	(a)	Percentage	resistance	in	commercial	meat	products,	here	statistical	differences	can	be	
determined	between	co-amoxiclav	and	piperacillin-tazobactam,	ertapenem,	meropenem	and	amikacin,	and	
amoxicillin	and	piperacillin-tazobactam,	ertapenem,	meropenem	and	amikacin.		(b)	Percentage	intermediate	
resistance	in	commercial	meat	products,	although	an	overall	statistical	difference	was	determined,	the	Dunns	
post	hoc	test	did	not	identify	specific	differences.		Here	chicken	is	depicted	in	blue,	turkey	mince	in	red,	beef	
mince	in	yellow,	bacon	in	green,	lamb	mince	in	pink	and	pork	mince	in	purple.	
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This	 again	 may	 suggest	 more	 prudent	 use	 of	 antimicrobial	 agents	 within	 veterinary	
medicine,	potentially	reducing	levels	of	resistance.		Tigecycline	resistance	was	also	observed	
at	a	similar	level	to	those	determined	in	the	animal	faecal	samples;	this	again	is	difficult	to	
explain	due	to	the	lack	of	products	containing	tigecycline	licenced	for	veterinary	use	in	the	
EU.	 	 Further	 suggestions	 for	 this	 resistance	 include	 the	 expression	 of	 other	 resistance	
determinants	and	the	use	of	other	antibiotics	falling	within	the	tetracycline	category.					
	
7.3.4	 Polymerase	Chain	Reaction	Analysis	for	the	Detection	of	TEM,	
SHV	and	CTX	Determinants	
Those	 organisms	 demonstrating	 ESBL	 or	 AmpC	 production	 were	 also	 analysed	 using	
molecular	 techniques,	 to	 identify	 the	 resistance	 determinants	 expressed,	 as	 described	 in	
Chapter	2,	section	2.2.4.	 	The	multiplex	PCR	method,	as	previously	discussed,	was	used	to	
detect	 the	 TEM,	 SHV	 and	 CTX	 determinants,	 which	 would	 in-turn	 identify	 if	 resistance	
associated	 with	 human	 infection	 could	 be	 identified	 in	 isolates	 collected	 from	 food	
products.		Of	the	15	isolates	analysed,	14	expressed	the	SHV	determinant	and	one	the	CTX-
M	 determinant.	 	 Breaking	 the	 data	 down	 into	 meat	 product	 revealed	 that	 all	 samples	
[chicken,	 turkey	 mince,	 beef	 mince,	 unsmoked	 bacon,	 lamb	 mince	 and	 pork	 mince]	
contained	 bacteria	 that	 expressed	 the	 SHV	 determinant.	 	 The	 one	 sample	 demonstrating	
CTX	expression	was	isolated	from	chicken.	 	Due	to	lack	of	viable	sample	sequence	analysis	
was	unable	to	be	performed	on	the	resistance	determinants	isolated	from	the	food	samples.		
This	is	a	limiting	area	of	the	study	and	should	be	considered	in	future	experiments,	however	
results	 have	 highlighted	 that	 ESBL	 determinants	 can	 be	 isolated	 within	 commercially	
available	meat	products.	
	
7.4	Conclusions	
The	 results	 obtained	 from	 this	 area	 of	 the	 study	 have	 revealed	 that	 ESBL	 and	 AmpC	
resistance	can	be	isolated	from	healthy	animal	faeces	and	commercial	meat	products	within	
the	 Hampshire	 area,	 potentially	 rendering	 either	 of	 these	 sources	 of	 human	 intestinal	
colonisation.		Contact	with	animal	faeces	in	the	form	of	cage,	stable	or	litter	tray	cleaning,	
could	 result	 in	 contamination	 of	 the	 hands	 and	 if	 inadequate	 hand	washing	 is	 performed	
could	be	a	source	of	ESBL	or	AmpC	intestinal	colonisation.		Clinical	management	[infection	
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control,	barrier	nursing	and	potential	separation]	of	patients	regularly	handling	animals	may	
potentially	 be	 considered,	 as	 this	 could	 be	 considered	 an	 additional	 risk	 factor	 for	multi-
resistant	infections.									
The	effects	of	multi-resistant	organisms	within	commercial	food	products	are	more	difficult	
to	determine,	as	cooking	and	some	preservation	techniques	may	render	organisms	inactive.		
However	strict	hygiene	within	the	kitchen	is	paramount	and	individuals	should	be	advised	to	
cook	their	food	types	thoroughly	prior	to	consumption,	especially	in	the	case	of	chicken	to	
not	only	reduce	the	risks	of	infection	but	colonisation	with	multi-resistant	organisms.	
Limitations	were	also	identified	in	this	area	of	the	study	and	should	be	addressed	if	further	
analysis	 is	 to	 be	 performed	 in	 the	 future.	 	 Brain	 heart	 infusion	 both	was	 used	within	 the	
animal	 faecal	 analysis	 to	 enhance	 the	 growth	 of	 low	 numbers	 of	 bacteria	 and	 provide	 a	
media	to	dilute	the	sample.	This	is	a	limiting	factor	as	the	enrichment	of	the	sample	in	this	
media	may	promote	the	growth	of	bacteria	 in	 larger	numbers	and	encourage	sample	bias,	
as	those	bacteria	present	in	lower	numbers	may	be	selected	against.		The	use	of	this	media	
for	a	sample	diluent	is	also	questionable,	as	this	 is	an	enrichment	media	that	will	enhance	
the	bacterial	growth	rather	than	dilute	it.		Although	the	use	of	the	ESBL	chromogenic	media	
allows	 for	 the	 selection	 of	 ESBL	 resistant	 organisms,	 isolate	 identification	 could	 be	
questioned	using	 this	 technique.	 	 Figure	7.1	demonstrates	 the	different	 coloured	colonies	
produced	 by	 the	 organisms,	 however	 when	 a	 mixed	 population	 is	 isolated	 the	 colours	
combine	making	 identification	 difficult.	 	 High	 levels	 of	 organisms	 isolated	may	 also	 effect	
the	selectivity	of	the	media,	as	any	antibiotic	present	may	be	diluted	by	the	over	growth	of	
organisms,	 allowing	 sensitive	 isolates	 to	 survive.	 	 Sequence	 analysis	 of	 the	 animal	 faecal	
samples	related	two	groups	of	isolates	to	resistance	determinants	expressed	within	bacteria	
associated	with	human	infection.		Limitations	were	however	identified	as	the	primers	used	
within	the	sequence	analysis	failed	to	amplify	the	whole	gene	sequence,	particularly	the	5’	
end,	 resulting	 incomplete	 sequencing.	 	 In	 order	 to	 obtain	 unambiguous	 identifications	 of	
future	isolates,	primers	should	be	designed	to	incorporate	the	entire	gene	sequence.	
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8.0	Future	Work	
Both	 the	 results	 obtained	 and	 the	 limitations	 identified	 in	 this	 study	 suggest	 that	 future	
work	 in	 the	 area	 of	 ESBLs	 would	 be	 beneficial.	 	 As	 this	 study	 has	 highlighted,	 the	
epidemiological	 profile	 of	 ESBL	 producing	 bacteria	 is	 continuously	 evolving	 and	
epidemiological	 data	 should	 be	 collected	 yearly	 in	 an	 attempt	 to	 predict	 antimicrobial	
resistance	patterns	and	identify	potential	shifts	in	resistant	determinant	expression.			
Prior	 to	 the	analysis	 of	more	 recent	 isolates,	 those	 collected	 in	2010	and	2012	 should	be	
analysed	 further.	 	 Although	 AmpC	 expression	 was	 detected	 using	 the	 disc	 diffusion	
methodology	 (MAST)	 no	 further	 classification	 was	 performed.	 	 All	 isolates	 should	 be	
screened	 for	 the	 common	AmpC	 resistance	 determinants	 in	 order	 to	 assess	 the	 levels	 of	
AmpC	 resistance	expressed	within	 the	Hampshire	 region.	 	 Further	 analysis	 should	also	be	
carried	out	on	 those	 isolates	expressing	 resistance	 to	 the	carbapenem	class	of	antibiotics.		
Determinants	 responsible	 for	 resistance	 to	 these	 agents	 should	 be	 amplified	 and	 if	 not	
present	 further	 analysis	 should	 be	 carried	 out	 to	 identify	 the	 potential	 mechanism	
responsible	 for	 the	 increased	 resistance.	 	Other	 resistance	mechanisms	 including	 reduced	
porin	production	and	activity	 should	also	be	 investigated,	potentially	by	 the	use	of	whole	
genome	 sequencing.	 	 These	 results	 could	 then	 be	 related	 to	 resistance	 patterns	 to	
determine	if	altered	porin	production	contributes	to	antimicrobial	resistance	in	Hampshire.		
Future	 cohort	 analysis	 should	 include	 full	 ethical	 approval,	 in	 order	 to	 obtain	 improved	
patient	 information.	 	Although	 the	 laboratory	 information	 system	provides	a	 snap	 shot	of	
the	 patient’s	 status	 at	 the	 time	 of	 sampling,	 it	 does	 not	 provide	 information	 regarding	
previous	hospitalisation	or	long	term	antibiotic	therapy.		Gaining	this	additional	information	
will	provide	a	more	accurate	ESBL	epidemiological	profile	within	the	Hampshire	area.	
Molecular	 typing	 of	 the	 ESBL	 producing	 organisms	 highlighted	 a	 number	 of	 limitations.		
Further	analysis	 should	be	carried	out	 to	 compare	 the	ERIC-PCR	 technique	with	 the	MLST	
and	PFGE	methods	to	determine	if	MLST	is	a	more	appropriate,	time	efficient,	cost	effective	
way	in	which	to	identify	clonal	relationships.	
The	pilot	 colon	model	 study	 results	 suggest	 that	 the	prescribing	of	different	antimicrobial	
agents	may	be	contributing	to	the	antimicrobial	resistance	within	the	intestinal	microbiota.		
This	theory	requires	further	research	modifying	the	analysis	to	include	anaerobic	conditions,	
178	
	
greater	 surface	 area	 within	 the	 colon	 vessel	 and	 the	 inclusion	 of	 inhibitory	 and	
immunological	 substances.	 	 Once	 these	 modifications	 have	 been	 successfully	 implicated	
other	 alternative	 therapies	 can	 be	 investigated	 alongside	 of	 antimicrobial	 agents.	 	 These	
include	 bisphosphonates,	 thought	 to	 reduce	 the	 conjugative	 transfer	 of	 resistance	
determinants	 and	 Chinese	 herbal	 therapies	 with	 the	 potential	 to	 have	 synergistic	 effects	
with	 antimicrobial	 agents,	 potentially	 reducing	 the	 dose	 or	 duration	 of	 antimicrobial	
therapy.	 	 Future	 ethical	 approval	 should	 also	 be	 obtained	 to	 identify	 the	 level	 of	 ESBL	
colonisation	 within	 the	 Hampshire	 region,	 linking	 this	 to	 patient	 information	 in	 order	 to	
determine	 any	 risk	 factors,	 associated	 infections	 or	 antimicrobial	 therapy	 that	 may	
predispose	 individuals	 to	 ESBL	 carriage.	 	 The	 use	 of	 bacteriophages	 has	 also	 been	
considered	 as	 an	 alternative	 treatment	 for	 ESBL	 infections.	 	 Bacteriophages	 capable	 of	
inhibiting	 the	 growth	 of	 ESBL	 producing	 organisms	 have	 been	 isolated	 from	 a	 number	 of	
sources,	including	sewage.		Further	analysis	of	these	bacteriophages	should	be	carried	out	in	
the	 simulated	 colon	model	 to	 determine	 the	 dosage	 requirements	 and	 the	 antimicrobial	
activity	of	these	viruses.			
The	 identification	 of	 ESBL	 producing	 organisms	 within	 environmental	 samples,	 including	
sewage	should	continue	to	the	carried	out	as	these	are	potential	sources	of	ESBL	intestinal	
colonisation.	 	 Identification	of	the	potential	sources	of	multi-resistant	organisms	will	aid	in	
identifying	patient	risk	factors	and	overall	patient	care.	
It	 is	 evident	 that	 the	 prompt	 diagnosis	 and	 treatment	 of	 patients	 suffering	 from	 multi-
resistant	 infections	 reduces	mortality	 rates.	 	 Point	 of	 care	 testing	methodologies	 for	 the	
identification	of	ESBL	and	AmpC	resistance,	at	the	patients	bed	side,	would	be	beneficial	to	
both	clinicians	and	patients.		This	study	suggests	that	molecular	methods	for	the	detection	
of	 the	resistance	determinant	expressed,	alongside	epidemiological	 resistance	 information	
may	promote	 informed	prescribing	within	 the	 clinical	 setting.	 	Challenges	are	 faced	when	
considering	molecular	methods	such	as	this,	in	particular	ESBL	producing	organisms,	as	the	
resistance	 determinants	 expressed	 are	 evolving	 at	 a	 rapid	 pace.	 	 Further	 research	 in	 this	
area	should	be	considered,	and	although	this	is	thought	to	be	a	distant	possibility,	if	a	stable	
constant	 region	 within	 the	 resistance	 determinant[s]	 can	 be	 identified,	 this	 may	 be	 a	
potential	 target	 for	diagnostic	methodologies.	 	Methods	 for	 the	extraction	of	 appropriate	
concentrations	of	bacteria	DNA,	direct	 from	patient	samples	 [urine	or	 faeces],	should	also	
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be	 investigated.	 	Currently	molecular	methods	are	utilised	after	the	manual	culture	of	 the	
organism.		 If	point	of	care	testing	methods	are	to	be	identified	and	explored,	a	method	of	
directly	extracting	bacterial	DNA	from	the	clinical	specimen	is	imperative.				
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Discussion/Final	Conclusions	
	
Findings	generated	from	this	study	reveal	that	the	frequency	of	ESBL	and	AmpC	producing	
organisms,	in	Hampshire,	has	risen	over	the	two	year	cohorts	studied,	with	the	potential	to	
rise	 further	 in	 coming	 years.	 	 Although	 increases	 in	 age	 have	 been	 associated	 with	 risk	
factors	for	resistant	organisms,	it	is	clear	that	ESBL	and	AmpC	resistance	can	cause	disease	
in	a	wide	age	range.		Results	obtained	from	this	study	concur	with	previous	research	(105,	
132,	133)	with	patients’	ages	averaging	60	in	2010	and	62	in	2012.		Nevertheless	when	the	
data	 was	 analysed	 further,	 those	 patients	 located	 within	 the	 community	 demonstrated	
lower	 ages	 and,	 those	 in	 the	 nosocomial	 environment	 higher	 ages	 compared	 to	 the	 year	
averages.		These	results	demonstrated	that,	within	Hampshire,	younger,	potentially	healthy	
individuals	are	suffering	ESBL	or	AmpC	resistance	outside	of	the	hospital	environment.				
Female	patients	appear	to	be	more	at	risk	of	ESBL	or	AmpC	resistance	compared	to	males,	
and	this	finding	is	not	confined	to	the	Hampshire	region	(135,	136).		However	consideration	
of	 the	 site	 of	 infection	 combined	with	 the	 patient	 gender,	 provided	 conclusions	 that	 the	
preponderance	 of	 female	 isolates	 compared	 to	 males	 resulted	 from	 the	 inherent	 risk	 of	
UTIs,	and	that	risk	is	not	associated	with	gender	in	this	area.							
The	 receipt	 of	 previous	 antibiotic	 therapy	 could	 not	 be	 considered	 a	 risk	 factor	 for	 ESBL	
resistance	in	Hampshire.		Scrutiny	of	the	data	obtained	from	both	year	cohorts	also	revealed	
that	 a	 proportion	 of	 patients	 were	 currently	 or	 had	 previously	 received	 inappropriate	
therapy	for	their	ESBL	infection	[54%	-	2010	and	28%	-	2012	in	the	community	setting,	59%	-	
2010	and	38%	-	2012].		Inappropriate	prescribing	however	is	very	difficult	to	define,	as	many	
of	 the	 therapies	administered	 to	 the	patients	are	appropriate	 to	other	conditions	and	 the	
presence	 of	 an	 ESBL	 producing	 organism	may	 be	 as	 a	 result	 of	 colonisation,	 rather	 than	
infection.		Within	the	Hampshire	area	prescribing	should	be	continually	monitored	to	ensure	
appropriate	 antimicrobial	 stewardship,	 as	 inappropriate	 prescribing	 has	 been	 linked	 to	
increases	in	antimicrobial	resistance.				
In	the	Hampshire	area	ESBL	resistance	demonstrated	higher	prevalence	compared	to	AmpC	
and	dual	 resistance,	 these	 findings	do	not	appear	 to	be	geographically	 related	 (144,	145).		
The	lower	number	of	AmpC	resistance	however,	may	be	a	result	of	under-reporting	due	to	
disc	 diffusion	 techniques	 failing	 to	 accurately	 detect	 this	 type	 of	 resistance.	 	 Due	 to	 the	
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multiple	antibiotic	resistances	associated	with	the	AmpC	determinant,	accurate	reporting	is	
essential	to	ensure	appropriate	prescribing	for	both	community	and	nosocomial	infections.				
E.	 coli	 was	 the	 most	 prevalent	 organism	 expressing	 ESBL,	 AmpC	 and	 dual	 resistance	 in	
Hampshire.	 	This	 result	was	not	surprising	and	correlated	with	previous	studies	 (114,	139,	
140);	 nevertheless	 what	 is	 of	 concern	 is	 the	 diverse	 range	 of	 infections	 caused	 by	 this	
bacterial	 species.	 	 In	 addition	 E.	 coli	 represents	 a	 large	 proportion	 of	 the	 normal	 human	
intestinal	 microbiota,	 increasing	 the	 potential	 for	 individuals	 to	 carry	 ESBL	 producing	
organisms	as	normal	flora.	
One	 of	 the	 most	 significant	 findings	 in	 this	 study	 was	 the	 increase	 in	 resistance	
demonstrated	against	nine	of	the	13	antibiotics	investigated.		Of	considerable	concern	was	
the	 increase	 in	 intermediate	 resistance	 and	 resistance	 to	 the	 carbapenems,	 used	 as	
treatment	options	 for	complicated	ESBL	 infections	resulting	 in	septicaemia.	 	Prescribing	of	
different	antimicrobial	agents	through	the	use	of	policies	and	guidelines	that	are	reviewed	
unfrequently	may	encourage	increased	antibiotic	resistance.		This	study	has	identified	using	
both	hospital	policies	and	the	guidelines	listed	in	the	BNF,	alongside	community	prescribing	
numbers	 that	 commonly	 used	 agents,	 such	 as	 co-amoxiclav	 demonstrated	 the	 highest	
resistance	increase.		In	contrast	those	agents	used	to	a	lesser	extent,	such	as	ciprofloxacin,	
demonstrated	 a	 decrease	 in	 resistance	 frequency.	 	 These	 results	 suggest	 that,	within	 this	
region,	prescribing	policies	would	benefit	 from	more	 frequent	 review,	potentially	 rotating	
antibiotics,	to	reduce	overprescribing	of	a	limited	number	of	antimicrobial	agents.	
Molecular	 analysis	 allowed	 for	 the	 identification	 of	 the	 resistance	 determinant[s]	 and	
genotyping	 to	 determine	 clonal	 relationships.	 	 Resistance	 determinant	 identification	
revealed	that	the	CTX	enzyme	dominated	in	both	year	cohorts.		This	shift	was	also	observed	
worldwide,	with	the	CTX	determinant	being	reported	as	the	pre-dominant	ESBL	resistance	
gene.	 	 Combining	 resistance	 determinant	 identification	 and	 patient	 age	 revealed	 that	
resistance	 appears	 to	 initiate	 in	 the	 elderly	 population	 (>70	 years).	 	 Those	 determinants	
identified	in	the	elderly	alone	during	2010,	were	detected	in	the	very	young	and	middle	age	
groups	in	2012.		These	results	suggest	that	although	age	was	not	considered	a	risk	factor	in	
the	 Hampshire	 area,	 epidemiological	 information	 regarding	 the	 resistance	 determinants	
identified	within	 the	 elderly	 population	 should	 continue	 to	 be	 collected.	 	 This	will	 enable	
shifts	 in	 resistance	 determinants	 to	 be	 identified	 early	 and	 suitable	 treatment	 options	
initiated.					
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Analysis	 of	 the	 resistance	 determinant	 and	 antimicrobial	 susceptibility	 patterns	 revealed	
subtle	differences	between	determinant	 type	and	antibiotic	 resistance.	 	These	differences	
suggest	 that	 identification	 of	 the	 resistance	 determinant,	 through	 point	 of	 care	
methodologies,	 could	 provide	 rapid	 identification	 of	 ESBL	 or	 AmpC	 resistance	 and	 when	
coupled	 with	 resistance	 patterns	 could	 indicate	 the	 most	 appropriate	 treatment	 for	 the	
patient.		Nevertheless	monitoring	of	resistance	prevalence	should	be	carried	out	regularly	in	
order	to	identify	shifts	in	antimicrobial	resistance.	
Genotyping	of	 the	ESBL	 isolates	 in	both	year	cohorts	 revealed	a	number	of	clonal	groups,	
suggesting	 clonal	 growth	 of	 resistant	 organisms	 that	 have	 a	 distinct	 advantage	 when	
challenged	by	selective	antibiotic	pressure.	A	percentage	of	isolates	also	fell	within	the	non-
clonal	 category,	 demonstrating	 no	 relationship	 between	 the	 clonal	 groups	 or	 each	 other,	
potentially	arising	from	sporadic	infections.		Nevertheless	further	analysis	combining	clonal	
group	 and	 resistance	 determinant	 revealed	 no	 relationship,	 suggesting	 that	 other	
mechanisms	of	gene	transfer,	such	as	conjugation,	are	also	present.		A	shift	in	clonal	groups	
was	observed	between	the	two	year	cohorts	studied,	suggesting	that	the	diversity	of	ESBL	
producing	 organisms	 is	 changing	 and	 multiple	 resistances	 are	 being	 transferred	 from	
different	hospitals	in	the	Hampshire	region.	
The	 construction	 of	 a	 simulated	 colon	model,	 although	 limited,	 suggests	 that	 the	 current	
antibiotic	 dosing	 regimens	 for	 the	 treatment	 of	 complicated	UTIs	may	 be	 contributing	 to	
increased	 gastrointestinal	 colonisation	 resistance.	 	 Further	 analysis	 should	 now	 be	
completed	to	include	an	anaerobic	atmosphere,	greater	surface	area,	inhibitory	substances	
and	antibiotic	peptides,	found	within	the	normal	intestinal	tract,	to	determine	if	these	have	
an	 inhibitory	 effect	 on	 antibiotic	 agents.	 	 Dosing	 regimens	 should	 also	 be	 reviewed	 to	
determine	 if	 higher	 doses	 of	 antibiotics	 should	 be	 used	 for	 a	 shorter	 period	 of	 time,	 to	
reduce	the	increases	in	resistance.		Nevertheless	considerations	must	to	given	to	the	risk	of	
antibiotic	 associated	 diarrhoea	 caused	 by	 Clostridium	 difficile	 to	 potentially	 vulnerable	
patients.						
This	study	has	also	highlighted	that	ESBL	producing	organisms	can	be	found	within	a	variety	
of	sources.		Isolating	and	identifying	organisms	expressing	ESBL	resistance	in	healthy	animal	
faeces	and	in	commercially	available	meat	products	support	the	theory	that	food	types	and	
animal	contact	may	be	a	source	of	ESBL	contamination.		Sequence	analysis	revealed	that	a	
high	proportion	of	resistance	determinant	types	identified	in	animal	faeces	matched	those	
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found	within	human	infections.		This	suggests	that	contact	with	domestic	and	farm	animals	
in	 the	Hampshire	area	may	put	 individuals	at	an	 increased	risk	of	 infections	and	 intestinal	
colonisation.		Animal	species	also	revealed	that	grazing	animals	demonstrated	greater	levels	
of	ESBL	colonisation	compared	to	dogs	and	cats,	these	results	suggest	that	ESBL	producing	
organisms	may	be	surviving	in	the	environment	allowing	grazing	animals	to	continuously	re-
contaminate	their	gastrointestinal	tracts.	
The	information	gained	from	this	study	may	aid	in	the	evaluation	and	review	of	prescribing	
and	 infection	 control	 policies.	 	 Understanding	 the	 epidemiological	 profile,	 antibiotic	
resistance	 patterns,	 prescribing	 choices	 and	 doses,	 and	 mechanisms	 in	 which	 resistance	
determinants	 are	 spread	 between	 bacterial	 species,	 aid	 in	 the	 attempt	 to	 reduce	 ESBL	
infections.	 	 Identifying	 potential	 sources	 of	 intestinal	 colonisation	 may	 also	 highlight	
patients	 in	 at	 risk	 groups,	 and	 screening	 for	 potential	 ESBL	 colonisation	 may	 reduce	 the	
spread	of	 resistant	organisms.	 	The	 importance	of	antibiotic	 stewardship	by	clinicians	and	
pharmacists	and	the	education	of	patients	in	the	principles	of	appropriate	prescribing	may	
also	 aid	 in	 reducing	 the	 increasing	 levels	 of	 antibiotic	 resistance	 observed	 in	 this	
geographical	region.	
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Isolate	 Identity	 Sex	 Age	
Isolate	
Obtained	
From	 Clinical	Details	 Location	
Antibiotic	
History	
CIP	
(R<16	
-	
S>20)	
MEM	
(R<19	
-	
S>27)	
CXM	
(R<19	
-	
S>20)	
CN	
(R<16	
-	
S>20)	
CTX	
(R<23	
-	
S>30)	
PTZ	
(R<20	
-	
S>21)	
AMC	
(R<14	
-	
S>15)	
AML	
(R<14	
-	
S>15)	
ETP	
(R<15	
-	
S>28)	
CAZ	
(R<22	
-	
S>27)	
AK	
(R<15	
-	
S>19)	
FEP	
(R<26	
-	
S>32)	
TIG	
(R<19	
-	
S>24)	 A	 B	 C	 D	 ESBL/AMPC	
Multiplex	
PCR	
Result	
Multiplex	PCR	
Result2	
Basingstoke	
1	 E.coli	 Female	 66	 Urine	
Leucocytes,	
nitrites,	pre	op	
In	
patient	 None	 14	R	 29	S	 17	R	 22	S	 20	R	 25	S	 12	R	 11	R	 16	I	 0	R	 16	I	 21	R	 22	I	 11	 24	 14	 28	 ESBL	 CTX	 NEG	
Basingstoke	
10	
Klebsiella	
Pneumoniae	 Female	 82	 Urine	 No	clinical	details	 GP	 Nitrofurantoin	 0	R	 35	S	 0	R	 16	R	 18	R	 21	S	 14	R	 0	R	 36	S	 26	I	 18	I	 27	I	 22	I	 9	 27	 16	 29	 ESBL	
CTX	&	
TEM	 NEG	
Basingstoke	
11	 E.coli	 Female	 77	 Urine	
Follow	up,	
previous	UTI	 GP	 Nitrofurantoin	 0	R	 32	S	 0	R	 22	S	 19	R	 22	S	 12	R	 0	R	 32	S	 27	S	 21	S	 26	I	 22	I	 8	 28	 14	 29	
Further	
work	
required	 NEG	 NEG	
Basingstoke	
12	
No	growth	
from	slope	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
Basingstoke	
13	
Klebsiella	
Pneumoniae	 Female	 76	 Urine	 ?	UTI	 GP	 None	 24	S	 29	S	 15	R	 19	I	 19	R	 22	S	 22	S	 0	R	 32	S	 0	R	 19	S	 31	I	 21	I	 11	 31	 12	 30	 ESBL	 TEM	 NEG	
Basingstoke	
14	
Klebsiella	
Oxytoca	 Male	 86	 Urine	
Abnormal	U/A,	
?UTI	 GP	 None	 32	S	 28	S	 0	R	 19	I	 28	I	 15	R	 16	S	 0	R	 28	S	 30	S	 21	S	 18	R	 21	I	 18	 21	 18	 17	
Further	
work	
required	 CTX	 NEG	
Basingstoke	
15	 E.coli	 Female	 63	
Urine	
(catheter)	
Leucocytes,	Hae,	
Protein	 GP	 None	 40	S	 39	S	 0	R	 27	S	 16	R	 31	S	 23	S	 0	R	 36	S	 28	S	 21	S	 22	R	 30	S	 0	 23	 9	 26	 ESBL	
CTX	&	
TEM	 NEG	
Basingstoke	
16	 E.coli	 Male	 71	
Urine	
(catheter)	 Persistant	uti		 GP	 Trimethoprim	 11	R	 33	S	 19	R	 13	R	 22	R	 27	S	 19	S	 0	R	 22	I	 31	S	 20	S	 21	R	 26	S	 11	 24	 16	 27	 ESBL	
TEM	&	
SHV	 NEG	
Basingstoke	
17	
Enterobacter	
Cloacae	 Male	 1	
Urine	
(clean	
catch)	 Previous	ESBL	
In	
patient	 Metronadizole	 41	S	 27	S	 0	R	 21	S	 0	R	 14	R	 0	R	 0	R	 17	I	 0	R	 23	S	 26	I	 21	I	 0	 0	 19	 18	 AMPC	 NEG	 NEG	
Basingstoke	
18	
Enterobacter	
Cloacae	 Male	 15	 Wound	 Slough	
Out	
patient	 Augmentin	 26	S	 31	S	 0	R	 7	R	 0	R	 24	S	 0	R	 0	R	 33	S	 13	R	 25	S	 18	R	 21	I	 0	 22	 0	 24	 ESBL	
CTX	&	
TEM	 NEG	
Basingstoke	
19	 E.coli	 Female	 92	 Urine	
^	incontence,	prev	
ESBL	
In	
patient	 Nitrofurantoin	 13	R	 33	S	 0	R	 21	S	 0	R	 26	S	 21	S	 0	R	 38	S	 22	R	 27	S	 22	R	 28	S	 0	 20	 0	 23	 ESBL	 CTX	 NEG	
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Basingstoke	
2	 E.coli	 Female	 56	 Urine	
Leucocytes,	
nitrites,	hae	
In	
patient	 Clarithromycin	 23	S	 30	S	 16	R	 14	R	 21	R	 23	S	 10	R	 12	R	 33	S	 26	I	 24	S	 17	R	 22	I	 0	 18	 0	 20	 ESBL	
CTX	&	
TEM	 NEG	
Basingstoke	
20	
No	growth	
from	slope	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
Basingstoke	
21	 E.coli	 Male	 88	 Urine	 No	clinical	details	
In	
patient	 None	 0	R	 36	S	 0	R	 12	R	 11	R	 27	S	 17	S	 0	R	 38	S	 18	R	 23	S	 19	R	 26	S	 0	 24	 0	 24	 ESBL	 CTX	 NEG	
Basingstoke	
22	 E.coli	 Female	 10	 Urine	
Ab	pain,	dysuria,	
protein	 GP	 Trimethoprim	 0	R	 34	S	 0	R	 19	I	 9	R	 23	S	 16	S	 0	R	 36	S	 12	R	 21	S	 17	R	 24	S	 0	 21	 0	 22	 ESBL	
CTX	&	
TEM	 NEG	
Basingstoke	
23	 E.coli	 Female	 85	 Urine	 Previous	ESBL	
In	
patient	 None	 16	R	 37	S	 0	R	 23	S	 14	R	 33	S	 27	S	 0	R	 35	S	 18	R	 23	S	 21	R	 25	S	 0	 28	 0	 29	 ESBL	 CTX	 NEG	
Basingstoke	
24	 E.coli	 Female	 72	 Urine	 ?	UTI	 GP	 None	 39	S	 42	S	 0	R	 27	S	 24	I	 35	S	 22	S	 0	R	 36	S	 28	S	 28	S	 25	R	 33	S	 0	 31	 15	 32	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Basingstoke	
25	 E.coli	 Female	 19	 Urine	
Nitrites,	Hae,	Self	
Catheterises	 GP	 None	 36	S	 35	S	 0	R	 26	S	 19	R	 34	S	 24	S	 0	R	 31	S	 14	R	 21	S	 15	R	 26	S	 0	 27	 0	 27	 ESBL	 NEG	 NEG	
Basingstoke	
26	 E.coli	 Female	 83	
Urine	
(catheter)	 Previous	E.Coli	
In	
patient	 None	 0	R	 39	S	 0	R	 24	S	 24	I	 26	S	 14	R	 0	R	 36	S	 24	I	 20	S	 25	R	 31	S	 0	 30	 14	 30	
Further	
work	
required	 CTX	 NEG	
Basingstoke	
27	 E.coli	 Female	 88	 Urine	
Hae,	Protein,	ward	
test	+ve	
In	
patient	 None	 0	R	 35	S	 0	R	 9	R	 0	R	 23	S	 0	R	 0	R	 25	I	 11	R	 19	I	 14	R	 34	S	 0	 0	 0	 19	
ESBL	and	
AMPC	 CTX	 NEG	
Basingstoke	
28	 E.coli	 Male	 54	 Urine	
UTI,	ESBL	1	year	
previously	 GP	 Ciprofloxacin	 0	R	 39	S	 8	R	 22	S	 25	I	 27	S	 17	S	 0	R	 36	S	 19	R	 20	S	 21	R	 31	S	 9	 28	 13	 28	 ESBL	 CTX	 NEG	
Basingstoke	
29	 E.coli	 Male	 78	 Urine	 Dip	=	positive	
In	
patient	 None	 0	R	 37	S	 0	R	 24	S	 14	R	 25	S	 16	S	 0	R	 26	I	 11	R	 18	I	 16	R	 30	S	 0	 26	 0	 27	 ESBL	 CTX	 NEG	
Basingstoke	
3	 E.coli	 Male	 87	 Urine	
Haem,	positive	
dipstick	
In	
patient	 Tazocin	 14	R	 29	S	 18	R	 23	S	 21	R	 23	S	 12	R	 13	R	 33	S	 12	R	 22	S	 15	R	 21	I	 0	 21	 0	 23	 ESBL	
CTX	&	
TEM	 NEG	
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Basingstoke	
30	
Citrobacter	
Freundii	 Female	 86	 Urine	 ?	Infection	
In	
patient	 None	 39	S	 41	S	 27	S	 25	S	 34	S	 37	S	 18	S	 15	S	 36	S	 28	S	 24	S	 40	S	 32	S	 14	 15	 31	 29	 AMPC	
CTX	&	
TEM	 NEG	
Basingstoke	
31	 E.coli	 Female	 56	 Urine	
Leucocytes,	
nitrites,	haem	
In	
patient	 None	 41	S	 39	S	 26	S	 26	S	 0	R	 34	S	 27	S	 0	R	 35	S	 21	R	 19	S	 22	R	 35	S	 0	 30	 10	 31	 ESBL	 CTX	 NEG	
Basingstoke	
32	 E.coli	 Male	 71	 Urine	 Recurrent	UTI	
Out	
patient	 Gentamicin	 14	R	 36	S	 0	R	 24	S	 20	R	 34	S	 28	S	 0	R	 36	S	 28	S	 17	I	 26	I	 28	S	 0	 28	 14	 29	
Further	
work	
required	 CTX	 NEG	
Basingstoke	
33	 E.coli	 Female	 43	 Urine	 Recurrent	UTI	
Out	
patient	 None	 37	S	 39	S	 0	R	 20	S	 24	I	 29	S	 21	S	 0	R	 32	S	 17	R	 18	I	 15	R	 34	S	 0	 24	 0	 26	 ESBL	 NEG	 NEG	
Basingstoke	
34	
Enterobacter	
Cloacae	 Male	 53	 Urine	 Nitrites	+++	 GP	 None	 26	S	 32	S	 0	R	 11	R	 0	R	 25	S	 0	R	 0	R	 39	S	 16	R	 26	S	 18	R	 25	S	 0	 23	 0	 24	 ESBL	 NEG	 NEG	
Basingstoke	
35	 E.coli	 Female	 85	 Urine	 Positive	UTI	
In	
patient	 Trimethoprim	 0	R	 37	S	 0	R	 21	S	 13	R	 21	S	 14	R	 0	R	 38	S	 28	S	 20	S	 27	I	 28	S	 0	 26	 0	 27	 ESBL	 CTX	 NEG	
Basingstoke	
36	 E.coli	 Female	 21	 Urine	 Dysuria,	frequency	 GP	 Trimethoprim	 10	R	 28	S	 0	R	 9	R	 0	R	 21	S	 16	S	 0	R	 30	S	 17	R	 21	S	 18	R	 29	S	 0	 19	 0	 21	 ESBL	 CTX	 NEG	
Basingstoke	
37	 E.coli	 Male	 89	 Urine	 ?	UTI	
In	
patient	 None	 31	S	 28	S	 0	R	 7	R	 0	R	 17	R	 18	S	 0	R	 34	S	 15	R	 26	S	 18	R	 29	S	 0	 21	 0	 22	 ESBL	
CTX	&	
TEM	 NEG	
Basingstoke	
38	 E.coli	 Female	 86	 Urine	 ?	Infection	
In	
patient	 None	 0	R	 32	S	 0	R	 21	S	 21	R	 21	S	 13	R	 0	R	 36	S	 25	I	 23	S	 42	S	 28	S	 0	 26	 10	 27	 ESBL	
CTX	&	
TEM	 NEG	
Basingstoke	
39	 E.coli	 Female	 71	
Blood	
Culture	
Spiking	
temperature,	?	
Sepsis	
In	
patient	 None	 40	S	 33	S	 8	R	 20	S	 22	R	 24	S	 13	R	 0	R	 34	S	 23	I	 21	S	 35	S	 30	S	 9	 11	 20	 18	 AMPC	 NEG	 NEG	
Basingstoke	
4	 E.coli	 Female	 83	 Urine	
Haem,	previous	
E.coli	
In	
patient	 Amoxicillin	 13	R	 29	S	 17	R	 22	S	 20	R	 19	R	 12	R	 13	R	 22	I	 0	R	 21	S	 12	R	 23	I	 0	 0	 0	 17	
ESBL	and	
AMPC	 CTX	 NEG	
Basingstoke	
40	 E.coli	 Female	 26	
Blood	
Culture	 ^	temp,	unwell	 A	and	E	 None	 34	S	 35	S	 0	R	 9	R	 12	R	 32	S	 25	S	 0	R	 29	S	 14	R	 21	S	 15	R	 33	S	 0	 24	 6	 23	 ESBL	 CTX	 NEG	
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Basingstoke	
41	 E.coli	 Female	 92	 Urine	
^	urinary	inc,	
nitrites	
In	
patient	 Nitrofurantoin	 0	R	 36	S	 0	R	 21	S	 21	R	 22	S	 16	S	 0	R	 29	S	 22	R	 14	R	 18	R	 31	S	 0	 26	 13	 27	
Further	
work	
required	 CTX	 NEG	
Basingstoke	
42	
No	growth	
from	slope	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
Basingstoke	
43	 E.coli	 Female	 5	 Urine	 ?	UTI	 GP	 None	 0	R	 37	S	 0	R	 18	I	 23	R	 24	S	 16	S	 0	R	 31	S	 15	R	 20	S	 16	R	 28	S	 10	 25	 15	 26	 ESBL	 CTX	 NEG	
Basingstoke	
44	 E.coli	 Female	 21	 Urine	 F/U	after	nasty	UTI	 GP	 Nitrofurantoin	 0	R	 41	S	 0	R	 20	S	 25	I	 22	S	 15	S	 0	R	 35	S	 23	S	 21	S	 23	R	 31	S	 0	 29	 0	 29	 ESBL	 CTX	 NEG	
Basingstoke	
45	 E.coli	 Male	 54	 Urine	
UTI,	ESBL	1	year	
previously	 GP	 Ciprofloxacin	 9	R	 35	S	 0	R	 21	S	 14	R	 28	S	 18	S	 0	R	 36	S	 21	R	 22	S	 22	R	 28	S	 0	 23	 9	 25	 ESBL	
CTX	&	
TEM	 NEG	
Basingstoke	
46	
No	growth	
from	slope	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
Basingstoke	
5	 E.coli	 Female	 56	 Urine	 No	clinical	details	 A	and	E	 None	 23	S	 35	S	 23	S	 22	S	 21	R	 18	R	 11	R	 10	R	 35	S	 28	S	 23	S	 36	S	 25	S	 12	 14	 28	 27	 AMPC	 TEM	 NEG	
Basingstoke	
6	 E.coli	 Female	 82	 Urine	 Dysuria,	Frequency	 GP	 Nitrofurantoin	 25	S	 32	S	 18	R	 23	S	 22	R	 17	R	 17	S	 9	R	 31	S	 23	I	 22	S	 18	R	 22	I	 0	 19	 0	 21	 ESBL	 CTX	 NEG	
Basingstoke	
7	 E.coli	 Female	 28	 Urine	
Dysuria,	
Frequency,	loin	
pain	 A	and	E	 None	 12	R	 36	S	 17	R	 24	S	 20	R	 25	S	 18	S	 11	R	 31	S	 20	R	 15	R	 0	R	 20	I	 9	 27	 15	 27	
Further	
work	
required	 TEM	 NEG	
Basingstoke	
8	
Klebsiella	
Pneumoniae	 Female	 75	 Urine	
Recurrent	UTI,	
prev	ESBL	
Out	
patient	 None	 31	S	 28	S	 9	R	 18	I	 16	R	 24	S	 18	S	 0	R	 30	S	 0	R	 21	S	 0	R	 24	S	 0	 31	 0	 32	 ESBL	
TEM	&	
SHV	 NEG	
Basingstoke	
9	
Klebsiella	
Pneumoniae	 Female	 82	 Urine	
Recurrent	UTI,	?	
+ve	culture	 GP	 Augmentin	 11	R	 35	S	 15	R	 15	R	 21	R	 18	R	 18	S	 10	R	 18	I	 0	R	 22	S	 22	R	 23	I	 0	 27	 11	 28	 ESBL	
TEM	&	
SHV	 NEG	
Portsmouth	1	 E.coli	 Female	 66	 Urine	 Pyrexia,	unwell	
In	
patient	 None	 0	R	 34	S	 20	S	 10	R	 0	R	 22	S	 17	S	 0	R	 31	S	 12	R	 21	S	 0	R	 31	S	 0	 26	 0	 26	 ESBL	 TEM	 NEG	
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Portsmouth	
10	
Proteus	
mirabilis	 Female	 95	 Urine	 PUO,	?	UTI	
In	
patient	 Ciprofloxacin	 30	S	 34	S	 30	S	 28	S	 20	R	 29	S	 23	S	 0	R	 36	S	 38	S	 25	S	 38	S	 30	S	 41	 40	 39	 38	
Further	
work	
required	 TEM	 NEG	
Portsmouth	
11	 E.coli	 Male	 50	 Urine	 No	clinical	details	 GP	 None	 0	R	 39	S	 19	R	 25	S	 10	R	 20	R	 13	R	 0	R	 32	S	 34	S	 23S	 34S	 29	S	 0	 20	 0	 19	 ESBL	 CTX	 NEG	
Portsmouth	
12	 E.coli	 Female	 72	 Urine	 PUO		 A	and	E	 None	 0	R	 35	S	 0	R	 10	R	 0	R	 15	R	 12	R	 0	R	 20	I	 13	R	 21	S	 12	R	 29	S	 0	 18	 0	 18	 ESBL	 CTX	 NEG	
Portsmouth	
13	 E.coli	 Female	 50	 Urine	 No	clinical	details	 GP	 None	 9	R	 41	S	 25	S	 25	S	 18	R	 30	S	 28	S	 0	R	 34	S	 22	R	 22	S	 23	R	 30	S	 0	 23	 9	 23	 ESBL	 CTX	 NEG	
Portsmouth	
14	 E.coli	 Female	 48	 Urine	
Recurrent	
infection	 GP	 Augmentin	 10	R	 35	S	 20	S	 23	S	 0	R	 26	S	 18	S	 0	R	 34	S	 18	R	 22	S	 19	R	 28	S	 0	 18	 0	 20	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
15	 E.coli	 Female	 45	 Urine	 ?	UTI	 GP	 None	 0	R	 34	S	 25	S	 23	S	 28	I	 20	R	 15	S	 0	R	 35	S	 26	I	 21	S	 27	I	 28	S	 0	 24	 0	 25	 ESBL	 CTX	 NEG	
Portsmouth	
16	 E.coli	 Female	 20	 Urine	
Spiking	
temperature,	?	
Sepsis	
In	
patient	 None	 0	R	 38	S	 15	R	 10	R	 10	R	 20	R	 13	R	 0	R	 38	S	 37	S	 25	S	 41	S	 28	S	 0	 20	 0	 20	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
17	
No	growth	
from	slope	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
Portsmouth	
18	 E.coli	 Female	 75	 Urine	 Unwell	 GP	 Augmentin	 11	R	 41	S	 18	R	 16	R	 21	R	 31	S	 25	S	 0	R	 36	S	 25	I	 24	S	 25	S	 32	S	 0	 25	 10	 25	 ESBL	 CTX	 NEG	
Portsmouth	
19	 E.coli	 Female	 27	 Urine	 PUO	
In	
patient	 Pre		 9	R	 36	S	 0	R	 8	R	 0	R	 23	S	 18	S	 0	R	 34	S	 13	R	 25	S	 17	R	 28	S	 0	 18	 0	 19	 ESBL	 CTX	 NEG	
Portsmouth	2	 E.coli	 Female	 78	 Urine	 No	clinical	details	 GP	 None	 0	R	 34	S	 30	S	 25	S	 21	R	 24	S	 12	R	 0	R	 33	S	 26	I	 19	S	 26	I	 29	S	 0	 27	 11	 30	 ESBL	 CTX	 NEG	
Portsmouth	
20	 E.coli	 Female	 21	 Urine	 No	clinical	details	 GP	 Ciprofloxacin	 9	R	 38	S	 19	R	 25	S	 18	R	 31	S	 23	S	 0	R	 38	S	 23	I	 25	S	 25	R	 29	S	 0	 24	 11	 24	 ESBL	 CTX	 NEG	
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Portsmouth	
21	 E.coli	 Female	 89	 Urine	 Confusion	 GP	 Ciprofloxacin	 0	R	 40	S	 17	R	 23	S	 23	R	 20	R	 14	R	 0	R	 37	S	 28	S	 21	S	 27	I	 29	S	 0	 28	 0	 27	 ESBL	 CTX	 NEG	
Portsmouth	
22	 E.coli	 Female	 89	 Urine	 No	clinical	details	 GP	 None	 0	R	 42	S	 21	S	 23	S	 24	I	 22	S	 15	S	 0	R	 35	S	 30	S	 20	S	 30	I	 29	S	 0	 28	 0	 28	 ESBL	 CTX	 NEG	
Portsmouth	
23	 E.coli	 Female	 84	 Urine	 ?	UTI	 GP	 None	 13	R	 42	S	 25	S	 26	S	 16	R	 29	S	 24	S	 0	R	 27	I	 0	R	 24	S	 0	R	 32	S	 0	 26	 0	 27	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
24	 E.coli	 Female	 70	 Urine	 Pyrexia	 GP	 Augmentin	 9	R	 38	S	 19	R	 24	S	 13	R	 27	S	 21	S	 0	R	 36	S	 21	R	 25	S	 24	R	 30	S	 0	 21	 0	 22	 ESBL	 CTX	 NEG	
Portsmouth	
25	 E.coli	 Male	 75	 Urine	
Frequency,	
Proteinuria	 GP	 None	 0	R	 36	S	 0	R	 25	S	 0	R	 21	S	 13	R	 0	R	 30	S	 9	R	 25	S	 10	R	 28	S	 0	 19	 0	 19	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
26	 E.coli	 Female	 95	 Urine	
Pyrexia,	
incontinence	 GP	
Pre	
Augmentin	 0	R	 41	S	 20	S	 24	S	 23	R	 14	R	 11	R	 0	R	 37	S	 27	S	 20	S	 28	I	 30	S	 0	 22	 0	 21	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
27	 E.coli	 Female	 78	 Urine	
Dysuria,	
Frequency,	?UTI	
In	
patient	 Gentamicin	 0	R	 41	S	 16	R	 25	S	 20	R	 24	S	 18	S	 0	R	 36	S	 29	S	 24	S	 20	R	 29	S	 0	 21	 0	 21	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
28	 E.coli	 Female	 85	 Urine	 PUO	
In	
patient	 None	 43	S	 36	S	 22	S	 28	S	 20	R	 22	S	 16	S	 0	R	 33	S	 17	R	 21	S	 21	R	 32	S	 0	 24	 0	 24	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
29	 E.coli	 Female	 86	 Urine	
Pyrexia,	
Frequency,	Unwell	
In	
patient	 Amoxicillin	 9	R	 46	S	 18	R	 23	S	 23	R	 28	S	 25	S	 0	R	 38	S	 26	I	 24	S	 30	I	 30	S	 9	 28	 0	 29	 ESBL	 CTX	 NEG	
Portsmouth	3	 E.coli	 Female	 76	 Urine	
Protein,	dysuria	
and	frequency	 GP	
Pre	
Augmentin	 12	R	 31	S	 15	R	 11	R	 0	R	 27	S	 22	S	 0	R	 30	S	 16	R	 22	S	 17	R	 29	S	 0	 24	 0	 27	 ESBL	 CTX	 NEG	
Portsmouth	
30	 E.coli	 Female	 83	 Urine	 Confusion,	Unwell	
In	
patient	 None	 11	R	 42	S	 20	S	 25	S	 18	R	 31	S	 28	S	 0	R	 39	S	 34	S	 26	S	 36	S	 31	S	 0	 28	 0	 29	 ESBL	 CTX	 NEG	
Portsmouth	
31	 E.coli	 Female	 21	 Urine	 Protein,	leucocytes	 GP	 None	 0	R	 43	S	 19	R	 24	S	 24	I	 21	S	 13	R	 0	R	 40	S	 35	S	 25	S	 42	S	 30	S	 0	 28	 0	 29	 ESBL	 CTX	 NEG	
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Portsmouth	
32	 E.coli	 Female	 18	 Urine	 Post	op,	?UTI	
In	
patient	 Gentamicin	 0	R	 40	S	 21	S	 23	S	 23	R	 19	R	 18	S	 0	R	 38	S	 28	S	 21	S	 28	S	 28	S	 0	 27	 11	 27	 ESBL	 CTX	 NEG	
Portsmouth	
33	 E.coli	 Female	 57	 Urine	 No	clinical	details	 GP	 None	 0	R	 39	S	 11	R	 22	S	 25	I	 22	S	 18	S	 0	R	 34	S	 19	R	 19	S	 23	R	 28	S	 0	 27	 12	 28	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
34	 E.coli	 Female	 77	 Urine	
Generally	unwell,	
Frequency	 GP	 None	 0	R	 36	S	 0	R	 21	S	 13	R	 23	S	 16	S	 0	R	 33	S	 24	I	 25	S	 20	R	 27	S	 0	 18	 10	 19	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
35	 E.coli	 Female	 28	 Urine	
Recurrent	
infection	 GP	 Augmentin	 10	R	 39	S	 0	R	 23	S	 17	R	 29	S	 26	S	 0	R	 38	S	 23	I	 24	S	 26	I	 30	S	 0	 24	 0	 25	 ESBL	 CTX	 NEG	
Portsmouth	
36	 E.coli	 Female	 37	 Urine	 No	clinical	details	 GP	 None	 0	R	 40	S	 11	R	 22	S	 24	I	 21	S	 14	R	 0	R	 36	S	 30	S	 21	S	 28	I	 28	S	 0	 25	 11	 26	 ESBL	 CTX	 NEG	
Portsmouth	
37	 E.coli	 Female	 81	 Urine	
	
GP	 None	 0	R	 38	S	 17	R	 23	S	 30	S	 20	R	 15	S	 0	R	 34	S	 30	S	 21	S	 28	I	 27	S	 16	 27	 19	 28	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
38	 E.coli	 Male	 85	 Urine	 PUO,	?	UTI	
In	
patient	 Gentamicin	 0	R	 39	S	 21	S	 18	I	 28	I	 22	S	 13	R	 0	R	 31	S	 13	R	 16	I	 25	R	 32	S	 11	 30	 18	 32	
Further	
work	
required	 TEM	 NEG	
Portsmouth	
39	 E.coli	 Female	 89	 Urine	 Unwell,	?UTI	 GP	 None	 0	R	 33	S	 0	R	 24	S	 0	R	 16	R	 9	R	 0	R	 33	S	 18	R	 22	S	 21	R	 28	S	 0	 15	 0	 16	 ESBL	 CTX	 NEG	
Portsmouth	4	 E.coli	 Female	 55	 Urine	 Frequency	 GP	 None	 20	S	 31	S	 19	R	 21	S	 0	R	 22	S	 19	S	 0	R	 30	S	 17	R	 21	S	 0	R	 28	S	 0	 25	 0	 24	 ESBL	 TEM	 NEG	
Portsmouth	
40	 E.coli	 Female	 75	 Urine	 No	clinical	details	 GP	 Augmentin	 0	R	 36	S	 0	R	 24	S	 14	R	 28	S	 15	S	 0	R	 36	S	 25	I	 25	S	 25	R	 29	S	 0	 22	 8	 23	 ESBL	 CTX	 NEG	
Portsmouth	
41	 E.coli	 Male	 67	 Urine	 Dysuria	 GP	 None	 0	R	 34	S	 0	R	 22	S	 20	R	 18	R	 0	R	 0	R	 35	S	 27	S	 21	S	 26	I	 28	S	 0	 22	 0	 23	 ESBL	 CTX	 NEG	
Portsmouth	
42	
Enterobacter	
Cloacae	 Female	 28	 Urine	
Dysuria,	
frequency,	
haematuria	 GP	 None	 0	R	 33	S	 0	R	 22	S	 12	R	 27	S	 13	R	 0	R	 38	S	 30	S	 26	S	 31	I	 27	S	 0	 22	 0	 24	 ESBL	 CTX	 NEG	
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Portsmouth	
43	 E.coli	 Female	 57	 Urine	 No	clinical	details	 GP	 None	 0	R	 36	S	 0	R	 11	R	 0	R	 19	R	 0	R	 0	R	 30	S	 12	R	 21	S	 13	R	 28	S	 0	 17	 0	 21	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
44	 E.coli	 Female	 83	 Urine	
Raised	
temperature,	?UTI	 GP	 Amoxicillin	 0	R	 29	S	 0	R	 23	S	 0	R	 18	R	 0	R	 0	R	 25	I	 0	R	 22	S	 0	R	 29	S	 0	 16	 0	 17	 ESBL	 TEM	 NEG	
Portsmouth	
45	 E.coli	 Male	 59	 Urine	 ?	Infection	 GP	 None	 0	R	 29	S	 0	R	 8	R	 0	R	 18	R	 0	R	 0	R	 35	S	 23	I	 24	S	 21	R	 32	S	 0	 18	 0	 15	 ESBL	 CTX	 NEG	
Portsmouth	
46	 E.coli	 Female	 66	 Urine	 Protein,	leucocytes	 GP	 None	 0	R	 29	S	 0	R	 0	R	 0	R	 17	R	 0	R	 0	R	 34	S	 17	R	 21	S	 20	R	 33	S	 0	 17	 0	 19	 ESBL	 CTX	 NEG	
Portsmouth	
47	 E.coli	 Female	 94	 Urine	 Confusion	
In	
patient	 None	 0	R	 29	S	 0	R	 13	R	 0	R	 15	R	 0	R	 0	R	 35	S	 23	I	 24	S	 22	R	 31	S	 0	 17	 0	 18	 ESBL	 NEG	 NEG	
Portsmouth	
48	
Klebsiella	
Pneumoniae	 Female	 78	 Urine	
Raised	
temperature,	?UTI	
In	
patient	 Augmentin	 0	R	 29	S	 0	R	 0	R	 0	R	 18	R	 0	R	 0	R	 31	S	 16	R	 22	S	 20	R	 28	S	 0	 20	 0	 21	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	
49	 E.coli	 Female	 68	 Urine	 No	clinical	details	 GP	 None	 0	R	 35	S	 0	R	 25	S	 20	R	 33	S	 15	S	 0	R	 39	S	 31	S	 26	S	 36	S	 32	S	 0	 28	 0	 30	 ESBL	 CTX	 NEG	
Portsmouth	5	 E.coli	 Female	 44	 Urine	
Haematuria,	
protein		 GP	 Amoxicillin	 0	R	 33	S	 16	R	 29	S	 0	R	 25	S	 18	S	 0	R	 30	S	 12	R	 23	S	 14	R	 28	S	 0	 24	 0	 23	 ESBL	 CTX	 NEG	
Portsmouth	
50	
Klebsiella	
Pneumoniae	 Female	 71	
Urine	
(catheter)	
Temperature,	?	
Infection	 GP	 none	 0	R	 31	S	 0	R	 12	R	 0	R	 17	R	 0	R	 0	R	 31	S	 20	R	 28	S	 24	R	 28	S	 0	 21	 0	 20	 ESBL	
TEM	&	
SHV	 NEG	
Portsmouth	
51	 E.coli	 Male	 50	
Urine	
(catheter)	
Recurrent	
infection	 GP	 Augmentin	 0	R	 28	S	 0	R	 24	S	 18	R	 18	R	 0	R	 0	R	 31	S	 19	R	 26	S	 20	R	 32	S	 0	 0	 21	 20	 AMPC	 NEG	 NEG	
Portsmouth	
52	
Klebsiella	
Pneumoniae	 Male	 31	
Urine	
(catheter)	
Dysuria,	?	
Infection	 MOD	 None	 21	S	 37	S	 0	R	 11	R	 0	R	 21	S	 0	R	 0	R	 34	S	 22	I	 25	S	 19	R	 21	I	 0	 22	 0	 23	 ESBL	
SHV,	TEM	
&	CTX	 NEG	
Portsmouth	
53	 E.coli	 Female	 88	 Urine	
Pyrexia	post	
surgery	
In	
patient	 None	 0	R	 39	S	 0	R	 25	S	 0	R	 26	S	 0	R	 0	R	 34	S	 16	R	 26	S	 15	R	 28	S	 0	 22	 0	 21	 ESBL	 CTX	 NEG	
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Portsmouth	
54	 E.coli	 Female	 24	 Urine	 Cystitis	 GP	 None	 20	S	 39	S	 20	S	 28	S	 28	I	 28	S	 0	R	 0	R	 38	S	 37	S	 28	S	 39	S	 27	S	 0	 31	 0	 30	 ESBL	 TEM	 NEG	
Portsmouth	6	 E.coli	 Male	 75	 Urine	 Unwell,	pyrexia	 GP	 None	 0	R	 40	S	 10	R	 28	S	 0	R	 25	S	 13	R	 0	R	 23	I	 0	R	 28	S	 0	R	 31	S	 0	 16	 0	 17	 ESBL	
CTX	&	
TEM	 NEG	
Portsmouth	7	
Klebsiella	
Pneumoniae	 Male	 75	 Urine	 No	clinical	details	 GP	 None	 20	S	 40	S	 36	S	 28	S	 36	S	 0	R	 0	R	 0	R	 22	I	 22	R	 23	S	 19	R	 30	S	 34	 35	 34	 35	
Further	
work	
required	
TEM	&	
SHV	 NEG	
Portsmouth	8	 E.coli	 Female	 25	 Urine	
Dysuria,	frequency	
and	haem	 GP	 None	 0	R	 36	S	 15	R	 23	S	 0	R	 19	R	 11	R	 0	R	 28	S	 11	R	 20	S	 13	R	 28	S	 0	 17	 0	 18	 ESBL	 CTX	 NEG	
Portsmouth	9	 E.coli	 Female	 90	 Urine	
Temperature,	?	
Infection	 GP	 None	 0	R	 39	S	 9	R	 0	R	 10	R	 19	R	 10	R	 0	R	 25	I	 0	R	 27	S	 25	R	 30	S	 0	 14	 0	 14	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
1	
Enterobacter	
Cloacae	 Female	 58	 Urine	 ?	UTI	 GP	 None	 10	R	 32	S	 0	R	 19	I	 0	R	 30	S	 15	S	 0	R	 34	S	 22	R	 21	S	 23	R	 32	S	 0	 22	 13	 23	
Further	
work	
required	 NEG	 NEG	
Southampton	
10	
Klebsiella	
Pneumoniae	 Female	 37	 Urine	 ?	UTI	 GP	 Ciprofloxacin	 18	I	 36	S	 0	R	 0	R	 0	R	 17	R	 0	R	 0	R	 29	S	 11	R	 21	S	 14	R	 20	I	 0	 23	 0	 22	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
11	 E.coli	 Male	 67	 Urine	 No	clinical	details	 GP	 None	 34	S	 35	S	 0	R	 0	R	 25	I	 22	S	 0	R	 0	R	 39	S	 32	S	 26	S	 40	S	 25	S	 0	 0	 15	 31	
ESBL	and	
AMPC	
TEM	&	
SHV	 NEG	
Southampton	
12	 E.coli	 Female	 41	 Wound	 Offensive	wound	
In	
patient	 Augmentin	 0	R	 45	S	 0	R	 20	S	 0	R	 17	R	 0	R	 0	R	 23	I	 0	R	 24	S	 23	R	 26	S	 0	 18	 0	 17	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
13	 E.coli	 Female	 93	 Urine	 Recurrent	UTI	 GP	 Ciprofloxacin	 0	R	 41	S	 0	R	 0	R	 0	R	 17	R	 0	R	 0	R	 29	S	 9	R	 20	S	 11	R	 23	I	 0	 19	 0	 20	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
14	 E.coli	 Female	 75	
Blood	
Culture	 ?	Sepsis,	PUO	 A	and	E	 None	 0	R	 36	S	 0	R	 20	S	 0	R	 22	S	 0	R	 0	R	 19	I	 15	R	 21	S	 12	R	 27	S	 0	 22	 0	 22	 ESBL	 CTX	 NEG	
Southampton	
15	 E.coli	 Female	 25	 Urine	 No	clinical	details	 GP	 None	 0	R	 36	S	 16	R	 0	R	 0	R	 21	S	 0	R	 0	R	 32	S	 11	R	 21	S	 15	R	 28	S	 0	 21	 0	 24	 ESBL	
CTX	&	
TEM	 NEG	
216	
	
Southampton	
16	 E.coli	 Female	 56	 Urine	 ?	UTI	 GP	 None	 42	S	 35	S	 0	R	 21	S	 9	R	 22	S	 0	R	 0	R	 28	S	 0	R	 26	S	 0	R	 27	S	 0	 17	 0	 18	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
17	 E.coli	 Male	 68	 Urine	 Recurrent	UTI	
In	
patient	 None	 18	R	 42	S	 0	R	 21	S	 20	R	 13	R	 0	R	 0	R	 32	S	 19	R	 24	S	 25	R	 28	S	 0	 0	 25	 25	 AMPC	 TEM	 NEG	
Southampton	
18	
Enterobacter	
Cloacae	 Female	 39	 Urine	 Frequency,	Dysuria	 GP	 Trimethoprim	 17	I	 30	S	 0	R	 16	I	 0	R	 0	R	 0	R	 0	R	 19	I	 15	R	 27	S	 25	R	 20	I	 0	 0	 8	 13	
ESBL	and	
AMPC	 SHV	 NEG	
Southampton	
19	 E.coli	 Female	 47	 Urine	 No	clinical	details	 GP	 None	 0	R	 36	S	 0	R	 19	I	 21	R	 21	S	 0	R	 0	R	 31	S	 0	R	 22	S	 0	R	 26	S	 0	 24	 0	 26	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
2	 E.coli	 Female	 82	 Urine	 Unwell	 GP	 None	 38	S	 36	S	 16	R	 22	S	 21	R	 16	R	 0	R	 0	R	 29	S	 8	R	 24	S	 28	I	 30	S	 0	 25	 14	 27	
Further	
work	
required	
TEM	&	
SHV	 OXA	Group	1	
Southampton	
20	 E.coli	 Female	 18	 Urine	 ?	Infection	 GP	 Trimethoprim	 0	R	 37	S	 0	R	 19	I	 20	R	 20	R	 0	R	 0	R	 29	S	 31	S	 26	S	 25	R	 22	I	 0	 26	 14	 26	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
21	 E.coli	 Female	 29	 Urine	 ?	UTI	 GP	 None	 0	R	 44	S	 0	R	 23	S	 27	I	 18	R	 0	R	 0	R	 28	S	 22	R	 18	I	 22	R	 29	S	 0	 31	 15	 36	
Further	
work	
required	 NEG	 NEG	
Southampton	
22	 E.coli	 Female	 82	 Urine	 No	clinical	details	
In	
patient	 None	 13	R	 41	S	 0	R	 21	S	 24	I	 27	S	 11	R	 0	R	 28	S	 0	R	 30	S	 0	R	 25	S	 10	 29	 16	 31	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
23	 E.coli	 Male	 55	 Urine	
Frequency,	Loin	
pain	 GP	 Augmentin	 0	R	 39	S	 0	R	 19	I	 23	R	 18	R	 0	R	 0	R	 24	I	 0	R	 28	S	 0	R	 22	I	 0	 28	 16	 29	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
24	 E.coli	 Female	 34	 Urine	 Recurrent	UTI	 GP	 None	 0	R	 38	S	 0	R	 21	S	 21	R	 17	R	 0	R	 0	R	 35	S	 23	R	 20	S	 23	R	 23	I	 0	 27	 9	 27	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
25	 E.coli	 Female	 79	 Urine	
Frequency,	
Proteinuria	
In	
patient	 Gentamicin	 0	R	 40	S	 0	R	 19	I	 19	R	 18	R	 0	R	 0	R	 32	S	 0	R	 22	S	 0	R	 24	S	 0	 27	 11	 28	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
26	 E.coli	 Male	 67	 Urine	 Offensive	urine	 GP	 Trimethoprim	 0	R	 35	S	 0	R	 21	S	 13	R	 20	R	 0	R	 0	R	 38	S	 27	S	 21	S	 28	I	 26	S	 0	 22	 14	 24	
Further	
work	
required	
CTX	&	
TEM	 NEG	
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Southampton	
27	 E.coli	 Female	 9	 Urine	 Unwell,	?	Infection	 A	and	E	 None	 0	R	 34	S	 0	R	 20	S	 21	R	 19	R	 18	S	 0	R	 36	S	 24	I	 22	S	 25	R	 25	S	 0	 22	 14	 26	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
28	 E.coli	 Male	 58	 Urine	 No	clinical	details	
In	
patient	 Amoxicillin	 0	R	 32	S	 0	R	 19	I	 17	R	 23	S	 15	S	 0	R	 32	S	 24	I	 18	I	 25	R	 26	S	 0	 22	 13	 23	
Further	
work	
required	 CTX	 NEG	
Southampton	
29	 E.coli	 Male	 46	 Urine	 Pyrexia	 GP	 None	 0	R	 34	S	 0	R	 22	S	 19	R	 20	R	 14	R	 0	R	 37	S	 16	R	 22	S	 17	R	 25	S	 0	 22	 14	 24	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
3	 E.coli	 Female	 70	 Urine	 Pyrexia	 GP	 Ciprofloxacin	 14	R	 33	S	 0	R	 21	S	 0	R	 23	S	 12	R	 0	R	 31	S	 13	R	 25	S	 15	R	 29	S	 0	 23	 0	 22	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
30	 E.coli	 Female	 51	 Urine	
Loin	pain,	
frequency	 GP	 None	 0	R	 38	S	 0	R	 8	R	 11	R	 22	S	 19	S	 0	R	 34	S	 19	R	 21	S	 20	R	 28	S	 0	 25	 0	 26	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
31	 E.coli	 Female	 67	 Urine	
Frequency,	
haematuria	 GP	 None	 0	R	 37	S	 0	R	 22	S	 24	I	 21	S	 17	S	 0	R	 37	S	 18	R	 24	S	 20	R	 24	S	 8	 26	 14	 29	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
32	 E.coli	 Female	 80	 Urine	 Pyrexia,	off	food	
In	
patient	 Gentamicin	 0	R	 38	S	 0	R	 21	S	 23	R	 22	S	 14	R	 0	R	 33	S	 24	I	 18	I	 24	R	 28	S	 9	 28	 12	 29	 ESBL	 CTX	 NEG	
Southampton	
33	 E.coli	 Male	 73	 Urine	 Frank	Haematuria	
In	
patient	 None	 0	R	 39	S	 0	R	 19	I	 23	R	 24	S	 15	S	 0	R	 30	S	 25	I	 15	R	 23	R	 27	S	 0	 28	 13	 30	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
34	 E.coli	 Female	 26	 Urine	
Abdominal	pain,	
pyrexia	 A	and	E	 None	 0	R	 38	S	 0	R	 22	S	 24	I	 25	S	 16	S	 0	R	 28	S	 13	R	 22	S	 13	R	 26	S	 9	 31	 15	 31	
Further	
work	
required	 CTX	 NEG	
Southampton	
35	 E.coli	 Female	 38	 Urine	 No	clinical	details	 GP	 None	 0	R	 39	S	 0	R	 21	S	 24	I	 24	S	 13	R	 0	R	 33	S	 28	S	 21	S	 26	I	 28	S	 0	 29	 11	 31	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
36	 E.coli	 Female	 41	 Urine	
Proteinuria,	
haematuria	 GP	 Trimethoprim	 0	R	 41	S	 0	R	 23	S	 23	R	 22	S	 14	R	 0	R	 36	S	 28	S	 19	S	 28	I	 27	S	 0	 28	 9	 29	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
37	 E.coli	 Female	 54	 Urine	 Previous	ESBL	 GP	 None	 0	R	 35	S	 8	R	 22	S	 25	I	 22	S	 26	S	 0	R	 37	S	 26	I	 17	I	 25	R	 28	S	 10	 30	 17	 31	
Further	
work	
required	
CTX	&	
TEM	 NEG	
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Southampton	
38	 E.coli	 Male	 34	 Urine	 Frequency	 GP	 Trimethoprim	 0	R	 36	S	 8	R	 23	S	 28	I	 22	S	 20	S	 0	R	 30	S	 23	I	 20	S	 19	R	 26	S	 0	 26	 14	 27	
Further	
work	
required	 CTX	 NEG	
Southampton	
39	 E.coli	 Male	 71	 Urine	 Recurrent	UTI	
In	
patient	 Ciprofloxacin	 0	R	 37	S	 12	R	 24	S	 26	I	 23	S	 18	S	 0	R	 36	S	 28	S	 11	R	 23	R	 26	S	 0	 26	 15	 27	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
4	 E.coli	 Female	 65	 Urine	 Recurrent	UTI	 GP	 None	 19	I	 38	S	 0	R	 25	S	 0	R	 24	S	 10	R	 0	R	 36	S	 18	R	 28	S	 22	R	 31	S	 0	 26	 0	 26	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
40	 E.coli	 Female	 29	 Urine	 Abdominal	Pain	 GP	 None	 0	R	 43	S	 0	R	 23	S	 25	I	 19	R	 16	S	 0	R	 35	S	 25	I	 20	S	 24	R	 27	S	 0	 24	 11	 26	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
41	
Klebsiella	
Oxytoca	 Female	 52	 Urine	 Cystitis	symptoms	 GP	 None	 0	R	 31	S	 14	R	 22	S	 23	R	 0	R	 11	R	 0	R	 29	S	 34	S	 21	S	 24	R	 29	S	 15	 17	 14	 18	
Further	
work	
required	 CTX	 NEG	
Southampton	
42	 E.coli	 Female	 49	 Urine	 No	clinical	details	 GP	 None	 0	R	 36	S	 0	R	 19	I	 21	R	 25	S	 16	S	 0	R	 35	S	 25	I	 18	I	 22	R	 27	S	 9	 27	 13	 29	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
43	 E.coli	 Male	 60	 Urine	
Temperature,	
unwell	
In	
patient	 Amoxicillin	 0	R	 34	S	 10	R	 20	S	 23	R	 24	S	 16	S	 0	R	 36	S	 26	I	 18	I	 23	R	 32	S	 9	 25	 14	 26	 ESBL	 TEM	 NEG	
Southampton	
44	 Pantoea	sp	 Male	 39	 Urine	 ?	Infection	 GP	 None	 37	S	 27	S	 0	R	 28	S	 15	R	 24	S	 0	R	 0	R	 29	S	 0	R	 29	S	 11	R	 27	S	 0	 0	 44	 46	 AMPC	 NEG	 NEG	
Southampton	
45	 E.coli	 Female	 18	 Urine	 Unwell,	pyrexia	 A	and	E	 None	 0	R	 36	S	 0	R	 22	S	 24	I	 21	S	 16	S	 0	R	 28	S	 29	S	 23	S	 19	R	 28	S	 0	 29	 14	 31	
Further	
work	
required	 TEM	 NEG	
Southampton	
46	 E.coli	 Female	 40	 Urine	 Recurrent	UTI	 GP	 None	 0	R	 37	S	 0	R	 23	S	 16	R	 27	S	 22	S	 0	R	 33	S	 15	R	 24	S	 16	R	 29	S	 0	 26	 15	 26	
Further	
work	
required	 CTX	 NEG	
Southampton	
47	 E.coli	 Male	 61	 Urine	 No	clinical	details	 GP	 None	 19	I	 39	S	 0	R	 24	S	 19	R	 30	S	 26	S	 0	R	 35	S	 22	R	 23	S	 24	R	 32	S	 0	 27	 14	 28	
Further	
work	
required	 CTX	 NEG	
Southampton	
48	 E.coli	 Female	 37	 Urine	
Protein,	dysuria	
and	frequency	 GP	 None	 0	R	 40	S	 9	R	 20	S	 8	R	 24	S	 14	R	 0	R	 31	S	 0	R	 31	S	 0	R	 27	S	 9	 28	 14	 27	 ESBL	 NEG	 NEG	
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Southampton	
49	 E.coli	 Female	 10	 Urine	 ?	Infection	
In	
patient	 None	 0	R	 32	S	 0	R	 10	R	 0	R	 22	S	 0	R	 0	R	 39	S	 43	S	 28	S	 44	S	 29	S	 0	 18	 10	 19	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
5	 E.coli	 Female	 27	 Urine	 Unwell	
In	
patient	 None	 36	S	 38	S	 0	R	 18	I	 18	R	 31	S	 0	R	 0	R	 18	I	 28	S	 26	S	 30	I	 14	R	 0	 0	 0	 0	
Further	
work	
required	 NEG	 NEG	
Southampton	
50	 Pantoea	sp	 Female	 80	 Urine	
Frequency	and	
pyrexia	 GP	 Trimethoprim	 33	S	 33	S	 16	R	 24	S	 11	R	 21	S	 26	S	 22	S	 26	I	 0	R	 32	S	 0	R	 28	S	 0	 0	 42	 43	 AMPC	 NEG	 NEG	
Southampton	
51	 E.coli	 Female	 67	 Urine	 ?	UTI	 GP	 None	 0	R	 39	S	 0	R	 20	S	 20	R	 20	R	 13	R	 0	R	 35	S	 22	R	 20	S	 23	R	 39	S	 0	 26	 11	 26	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
52	 E.coli	 Female	 70	 Urine	 No	clinical	details	 GP	 None	 0	R	 39	S	 0	R	 21	S	 19	R	 19	R	 17	S	 0	R	 29	S	 0	R	 23	S	 13	R	 29	S	 0	 26	 15	 27	
Further	
work	
required	 NEG	 NEG	
Southampton	
53	 E.coli	 Female	 48	 Urine	 Frequency	 GP	 None	 0	R	 38	S	 11	R	 22	S	 22	R	 23	S	 18	S	 0	R	 33	S	 26	I	 19	S	 26	I	 27	S	 0	 26	 14	 27	
Further	
work	
required	 CTX	 NEG	
Southampton	
54	 E.coli	 Female	 29	 Urine	 Pain	passing	urine	 GP	 None	 0	R	 38	S	 0	R	 19	I	 21	R	 24	S	 16	S	 0	R	 35	S	 28	S	 22	S	 27	I	 27	S	 0	 27	 14	 29	
Further	
work	
required	 CTX	 NEG	
Southampton	
55	 E.coli	 Female	 72	 Urine	 Pyrexia	
In	
patient	 Ciprofloxacin	 0	R	 38	S	 0	R	 24	S	 24	I	 22	S	 17	S	 0	R	 30	S	 32	S	 22	S	 23	R	 25	S	 0	 26	 14	 28	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
56	 E.coli	 Female	 66	 Urine	 Recurrent	UTI	 GP	 None	 0	R	 26	I	 0	R	 20	S	 21	R	 23	S	 16	S	 0	R	 30	S	 31	S	 23	S	 24	R	 28	S	 0	 26	 14	 28	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
57	 E.coli	 Male	 71	 Urine	
Self	
catheterisation	 GP	 None	 0	R	 35	S	 9	R	 19	I	 23	R	 22	S	 16	S	 0	R	 34	S	 28	S	 19	S	 26	I	 26	S	 10	 27	 15	 28	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
58	 E.coli	 Female	 42	 Urine	 ?	UTI	 GP	 Trimethoprim	 0	R	 37	S	 20	S	 20	S	 23	R	 20	R	 16	S	 0	R	 36	S	 11	R	 24	S	 36	S	 28	S	 13	 27	 17	 27	 ESBL	 TEM	 NEG	
Southampton	
59	 E.coli	 Female	 33	 Urine	 No	clinical	details	 GP	 None	 10	R	 30	S	 0	R	 13	R	 13	R	 24	S	 15	S	 0	R	 29	S	 11	R	 21	S	 11	R	 28	S	 0	 11	 0	 17	 ESBL	 NEG	 NEG	
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Southampton	
6	
Klebsiella	
Pneumoniae	 Female	 45	 Urine	 ?	Infection	
In	
patient	 Trimethoprim	 45	S	 39	S	 0	R	 24	S	 27	I	 26	S	 0	R	 0	R	 33	S	 36	S	 26	S	 27	I	 28	S	 17	 22	 20	 22	
Further	
work	
required	 CTX	 NEG	
Southampton	
60	 E.coli	 Male	 82	 Wound	 Offensive	wound	
In	
patient	 Gentamicin	 0	R	 32	S	 19	R	 20	S	 20	R	 22	S	 16	S	 0	R	 35	S	 26	I	 21	S	 25	R	 27	S	 11	 27	 14	 26	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
61	
No	growth	
from	slope	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
Southampton	
62	 E.coli	 Female	 69	 Urine	 Cystitis	 GP	 None	 0	R	 35	S	 0	R	 22	S	 22	R	 20	R	 19	S	 0	R	 30	S	 26	I	 20	S	 23	R	 28	S	 28	 26	 30	 30	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Southampton	
63	
Klebsiella	
Oxytoca	 Female	 58	 Wound	 ?	Infected	wound	 GP	 None	 33	S	 26	I	 21	S	 21	S	 0	R	 0	R	 11	R	 0	R	 33	S	 32	S	 24	S	 25	R	 29	S	 0	 20	 12	 23	
Further	
work	
required	 CTX	 NEG	
Southampton	
64	 E.coli	 Female	 63	 Urine	 ?	Urine	infection	 GP	 None	 0	R	 33	S	 22	S	 17	I	 18	R	 18	R	 0	R	 0	R	 31	S	 12	R	 23	S	 15	R	 26	S	 0	 16	 0	 15	 ESBL	
CTX	&	
TEM	 NEG	
Southampton	
65	 E.coli	 Female	 38	 Urine	
Pyrexia,	pain	
passing	urine	 A	and	E	 None	 0	R	 35	S	 16	R	 22	S	 16	R	 19	R	 18	S	 0	R	 31	S	 0	R	 25	S	 0	R	 25	S	 0	 29	 15	 28	
Further	
work	
required	 TEM	 NEG	
Southampton	
7	 E.coli	 Male	 67	 Urine	 ?	UTI	 GP	 None	 46	S	 45	S	 18	R	 23	S	 25	I	 21	S	 13	R	 0	R	 41	S	 10	R	 24	S	 28	I	 25	S	 12	 35	 15	 35	 ESBL	
TEM	&	
SHV	 NEG	
Southampton	
8	 E.coli	 Male	 76	 Urine	 No	clinical	details	 GP	 None	 0	R	 37	S	 0	R	 8	R	 9	R	 25	S	 8	R	 0	R	 30	S	 16	R	 22	S	 17	R	 28	S	 0	 28	 0	 30	 ESBL	 CTX	 NEG	
Southampton	
9	 E.coli	 Male	 53	 Urine	 ^	temp,	unwell	 A	and	E	 None	 0	R	 38	S	 0	R	 0	R	 0	R	 20	R	 0	R	 0	R	 25	I	 9	R	 18	I	 18	R	 33	S	 0	 18	 0	 19	 ESBL	 CTX	 NEG	
Winchester	1	 E.coli	 Female	 38	 Urine	 2/52	Dysuria	 GP	 None	 0	R	 27	S	 0	R	 15	R	 0	R	 27	S	 19	S	 0	R	 31	S	 15	R	 22	S	 16	R	 27	S	 0	 18	 0	 19	 ESBL	 CTX	 NEG	
Winchester	
10	 E.coli	 Female	 76	 urine	
Blood	++++,	Leus	
+++,	Nitrates	
In	
patient	 None	 0	R	 32	S	 27	S	 0	R	 0	R	 22	S	 21	S	 0	R	 31	S	 11	R	 18	I	 15	R	 26	S	 0	 26	 0	 27	 ESBL	 TEM	 NEG	
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Winchester	
11	 E.coli	 Female	 56	 urine	 Previous	UTI	 GP	 None	 39	S	 35	S	 20	S	 0	R	 0	R	 26	S	 21	S	 0	R	 34	S	 25	I	 23	S	 18	R	 25	S	 0	 24	 0	 26	 ESBL	 CTX	 NEG	
Winchester	
12	
Klebsiella	
Oxytoca	 Male	 78	 urine	 Dip	=	positive	
In	
patient	 Flucloxacillin	 35	S	 34	S	 35	S	 0	R	 26	I	 25	S	 24	S	 0	R	 35	S	 12	R	 26	S	 28	I	 25	S	 0	 30	 12	 35	
Further	
work	
required	
TEM	&	
SHV	 NEG	
Winchester	
13	 E.coli	 Female	 30	 urine	
Frequency	and	
dysuria	
In	
patient	
Post	
Trimethrprim	 35	S	 35	S	 21	S	 21	S	 0	R	 23	S	 19	S	 0	R	 33	S	 24	I	 24	S	 16	R	 26	S	 0	 21	 0	 24	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
14	 E.coli	 Female	 35	 urine	
Frequency,	Blood,	
Leucocytes	 GP	 None	 0	R	 34	S	 10	R	 12	R	 0	R	 21	S	 18	S	 0	R	 29	S	 13	R	 18	I	 14	R	 23	I	 0	 21	 0	 22	 ESBL	 CTX	 NEG	
Winchester	
15	 E.coli	 Female	 73	 urine	 No	clinical	details	 GP	 None	 8	R	 30	S	 0	R	 0	R	 0	R	 27	S	 22	S	 0	R	 32	S	 23	I	 21	S	 23	R	 26	S	 0	 24	 14	 29	
Further	
work	
required	 CTX	 NEG	
Winchester	
16	 E.coli	 Male	 49	 urine	 Dysuria	 GP	 None	 0	R	 33	S	 0	R	 0	R	 0	R	 17	R	 15	S	 0	R	 33	S	 16	R	 19	S	 16	R	 24	S	 0	 22	 0	 21	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
17	 E.coli	 Female	 65	 urine	 No	clinical	details	 GP	
Pre	
Trimethoprim	 32	S	 30	S	 13	R	 20	S	 0	R	 21	S	 22	S	 0	R	 36	S	 24	I	 24	S	 23	R	 26	S	 0	 26	 0	 25	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
18	 E.coli	 Female	 65	 urine	 No	clinical	details	 GP	
Post	
Amoxicillin	 32	S	 33	S	 27	S	 21	S	 30	S	 20	R	 24	S	 19	S	 36	S	 33	S	 23	S	 37	S	 27	S	 29	 29	 31	 27	
Further	
work	
required	 NEG	 NEG	
Winchester	
19	 E.coli	 Female	 18	 urine	
Dysuria,	UTI,	
D.O.O	1	week	 GP	 None	 0	R	 32	S	 22	S	 21	S	 0	R	 28	S	 24	S	 0	R	 33	S	 23	I	 22	S	 22	R	 28	S	 0	 26	 13	 25	
Further	
work	
required	 CTX	 NEG	
Winchester	2	 E.coli	 Male	 46	 Urine	 UTI	 A	and	E	 None	 0	R	 35	S	 23	S	 23	S	 0	R	 14	R	 0	R	 0	R	 29	S	 0	R	 26	S	 10	R	 31	S	 0	 0	 17	 16	 AMPC	 NEG	 NEG	
Winchester	
20	 E.coli	 Female	 36	 urine	
Loin	pain,	
frequency	 GP	 None	 15	R	 31	S	 31	S	 22	S	 22	R	 30	S	 21	S	 0	R	 31	S	 27	S	 24	S	 35	S	 26	S	 0	 26	 15	 30	
Further	
work	
required	 CTX	 NEG	
Winchester	
21	
Enterobacter	
aerogenes	 Male	 44	 urine	
Long	term	ICU	
patient	 ICU	 None	 21	S	 28	S	 22	S	 21	S	 21	R	 23	S	 0	R	 0	R	 27	I	 31	S	 25	S	 35	S	 24	S	 21	 20	 25	 26	
Further	
work	
required	 NEG	 NEG	
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Winchester	
22	 E.coli	 Female	 71	 urine	 No	clinical	details	 GP	 None	 31	S	 38	S	 16	R	 26	S	 28	I	 23	S	 0	R	 0	R	 35	S	 27	S	 24	S	 41	S	 30	S	 11	 10	 34	 31	 AMPC	 NEG	 NEG	
Winchester	
23	 E.coli	 Female	 43	 urine	 Renal	pain,	UTI	 GP	 None	 37	S	 34	S	 0	R	 24	S	 14	R	 24	S	 0	R	 0	R	 34	S	 27	S	 24	S	 20	R	 27	S	 0	 0	 0	 11	
ESBL	and	
AMPC	 CTX	 NEG	
Winchester	
24	 E.coli	 Female	 9	 urine	 Nitrates	 GP	
Post	
Trimethrprim	 35	S	 34	S	 0	R	 22	S	 13	R	 22	S	 0	R	 0	R	 38	S	 34	S	 25	S	 40	S	 27	S	 0	 0	 0	 14	
ESBL	and	
AMPC	 CTX	 NEG	
Winchester	
25	 E.coli	 Female	 71	 urine	 No	clinical	details	 GP	
Post	
Trimethrprim	 0	R	 33	S	 0	R	 8	R	 0	R	 18	R	 0	R	 0	R	 32	S	 16	R	 22	S		 16	R	 26	S	 0	 0	 0	 12	
ESBL	and	
AMPC	 CTX	 NEG	
Winchester	
26	 E.coli	 Female	 91	 urine	
Leucocytes,	
nitrates,	blood	 A	and	E	 None	 36	S	 34	S	 0	R	 24	S	 10	R	 17	R	 0	R	 0	R	 28	S	 11	R	 23	S	 29	I	 29	S	 0	 0	 17	 18	 AMPC	 NEG	 NEG	
Winchester	
27	
Proteus	
mirabilis	 Male	 47	 urine	
Daibetes,	
proteinuria,	
nitrates	 GP	 None	 30	S	 36	S	 15	R	 16	R	 28	I	 20	R	 0	R	 0	R	 36	S	 39	S	 25	S	 35	S	 26	S	 22	 21	 23	 24	
Further	
work	
required	 TEM	 NEG	
Winchester	
28	 E.coli	 Female	 92	 urine	
Proteinuria,	
leucocytes,	
keytones	
In	
patient	 Penicillin	 39	S	 33	S	 10	R	 24	S	 21	R	 21	S	 0	R	 0	R	 30	S	 14	R	 25	S	 29	I	 28	S	 0	 0	 17	 18	 AMPC	 NEG	 NEG	
Winchester	
29	
Enterobacter	
Cloacae	 Female	 89	 urine	 No	clinical	details	 GP	 None	 32	S	 33	S	 10	R	 21	S	 28	I	 24	S	 0	R	 0	R	 22	I	 19	R	 21	S	 20	R	 26	S	 0	 0	 25	 24	 AMPC	 NEG	 NEG	
Winchester	3	 E.coli	 Female	 9	
Genital	
Swab	 Sore	Vulva	 GP	 None	 0	R	 23	I	 12	R	 16	R	 21	R	 24	S	 0	R	 0	R	 37	S	 27	S	 23	S	 40	S	 27	S	 11	 12	 23	 19	 AMPC	 NEG	 NEG	
Winchester	
30	 E.coli	 Female	 73	 urine	 No	clinical	details	 GP	 None	 35	S	 34	S	 16	R	 24	S	 28	I	 20	R	 0	R	 0	R	 31	S	 27	S	 24	S	 34	S	 28	S	 9	 8	 26	 27	 AMPC	 NEG	 NEG	
Winchester	
31	 E.coli	 Female	 96	 urine	 No	clinical	details	 GP	 None	 10	R	 36	S	 0	R	 23	S	 13	R	 29	S	 9	R	 0	R	 39	S	 29	S	 25	S	 31	I	 29	S	 0	 12	 10	 19	 ESBL	 CTX	 NEG	
Winchester	
32	 E.coli	 Female	 75	 urine	 No	clinical	details	 GP	
Post	
Trimethrprim	 11	R	 33	S	 14	R	 9	R	 21	R	 15	R	 0	R	 0	R	 31	S	 22	R	 22	S	 36	S	 24	S	 0	 0	 21	 22	 AMPC	
CTX	&	
TEM	 NEG	
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Winchester	
33	 E.coli	 Female	 81	 urine	 TKR,	21.02.11	
In	
patient	 None	 8	R	 36	S	 11	R	 21	S	 23	R	 22	S	 0	R	 0	R	 38	S	 30	S	 21	S	 33	S	 27	S	 10	 19	 15	 22	 ESBL	 CTX	 NEG	
Winchester	
34	
Klebsiella	
Pneumoniae	 Male	 72	 urine	 Pre	Op	catheter	
In	
patient	 None	 25	S	 32	S	 18	R	 0	R	 21	R	 19	R	 0	R	 0	R	 35	S	 27	S	 26	S	 28	I	 26	S	 9	 17	 13	 20	 ESBL	
TEM	&	
SHV	 NEG	
Winchester	
35	 E.coli	 Female	 1	 urine	 No	clinical	details	
In	
patient	 None	 7	R	 33	S	 0	R	 9	R	 0	R	 20	R	 0	R	 0	R	 31	S	 10	R	 24	S	 14	R	 27	S	 0	 10	 0	 15	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
36	
Enterobacter	
Cloacae	 Female	 73	 urine	 No	clinical	details	 GP	 Cefalexin	 35	S	 36	S	 12	R	 25	S	 26	I	 29	S	 12	R	 0	R	 27	I	 16	R	 25	S	 21	R	 26	S	 0	 0	 22	 21	 AMPC	 NEG	 NEG	
Winchester	
37	 E.coli	 Female	 58	 urine	
Leucocytes,	
Nitratesm	
Proteinuria	
In	
patient	 Flucloxacillin	 13	R	 34	S	 0	R	 21	S	 9	R	 24	S	 18	S	 9	R	 32	S	 21	R	 27	S	 18	R	 28	S	 0	 0	 0	 16	
ESBL	and	
AMPC	 CTX	 NEG	
Winchester	
38	 E.coli	 Male	 88	 Sputum	 Productive	 ICU	 None	 32	S	 36	S	 18	R	 24	S	 33	S	 16	R	 11	R	 0	R	 37	S	 27	S	 25	S	 37	S	 28	S	 14	 13	 26	 27	 AMPC	 TEM	 NEG	
Winchester	
39	 E.coli	 Female	 66	 urine	 No	clinical	details	 GP	 None	 37	S	 34	S	 9	R	 23	S	 10	R	 13	R	 11	R	 0	R	 31	S	 14	R	 25	S	 16	R	 27	S	 0	 20	 0	 21	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	4	 E.coli	 Female	 93	 Urine	
Nitrates,	
Protein,leucoctyes,	
blood	
In	
patient	 Amoxicillin	 0	R	 29	S	 13	R	 0	R	 18	R	 19	R	 0	R	 0	R	 30	S	 12	R	 23	S	 31	I	 29	S	 0	 0	 16	 17	 AMPC	 TEM	 NEG	
Winchester	
40	
Enterobacter	
aerogenes	 Male	 44	 urine	 Brain	stem	infarct	 ICU	 None	 25	S	 31	S	 14	R	 20	S	 28	I	 20	R	 0	R	 0	R	 29	S	 30	S	 22	S	 35	S	 25	S	 20	 18	 24	 24	
Further	
work	
required	 NEG	 NEG	
Winchester	
41	 E.coli	 Female	 78	 urine	 No	clinical	details	 GP	
Pre	
Nitrofurantoin	 34	S	 34	S	 16	R	 23	S	 28	I	 21	S	 10	R	 0	R	 36	S	 28	S	 25	S	 39	S	 26	S	 10	 10	 24	 26	 AMPC	 TEM	 NEG	
Winchester	
42	 E.coli	 Female	 88	 urine	
Vascular	
dementia,	fits	 GP	 Trimethoprim	 0	R	 35	S	 12	R	 21	S	 22	R	 18	R	 12	R	 0	R	 34	S	 30	S	 20	S	 29	I	 26	S	 9	 21	 9	 22	 ESBL	 CTX	 NEG	
Winchester	
43	 E.coli	 Female	 84	 urine	
Recurrent	UTI,	
Prot,	Leu,	Nitrates	 GP	 None	 0	R	 34	S	 0	R	 21	S	 10	R	 18	R	 13	R	 0	R	 32	S	 16	R	 23	S	 18	R	 28	S	 0	 18	 0	 18	 ESBL	 CTX	 NEG	
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Winchester	
44	 E.coli	 Female	 92	 urine	
Dysuria,	
Frequency,	
Proteinuria	 GP	 None	 0	R	 34	S	 0	R	 20	S	 20	R	 14	R	 12	R	 0	R	 34	S	 24	I	 21	S	 24	R	 25	S	 0	 20	 0	 21	 ESBL	 CTX	 NEG	
Winchester	
45	
Klebsiella	
Pneumoniae	 Female	 88	 urine	
Nitrates,	Protein,	
Foul	smell,	Hae	
In	
patient	 None	 0	R	 26	S	 13	R	 22	S	 20	R	 14	R	 14	R	 0	R	 33	S	 9	R	 24	S	 24	R	 24	S	 0	 23	 0	 23	 ESBL	 SHV	 NEG	
Winchester	
46	 E.coli	 Female	 44	 urine	 UTI		 GP	
Pre	
Trimethoprim	 0	R	 28	S	 0	R	 21	S	 19	R	 18	R	 13	R	 0	R	 33	S	 28	S	 20	S	 23	R	 28	S	 0	 22	 0	 22	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
47	 E.coli	 Female	 9	 urine	
Dysuria	and	
frequency	 GP	 None	 26	S	 35	S	 0	R	 25	S	 9	R	 22	S	 16	S	 0	R	 36	S	 30	S	 24	S	 38	S	 27	S	 0	 13	 0	 15	 ESBL	 CTX	 NEG	
Winchester	
48	 E.coli	 Female	 68	 urine	
Dysuria,	
frequency,	protein	 GP	
Pre	
Trimethoprim	 0	R	 33	S	 0	R	 10	R	 0	R	 18	R	 12	R	 0	R	 31	S	 16	R	 20	S	 16	R	 28	S	 0	 15	 0	 16	 ESBL	 CTX	 NEG	
Winchester	
49	 E.coli	 Female	 55	 urine	
Dys,	Fre,	UTI,	
Nitrates,	
Leucocytes	 GP	 None	 0	R	 35	S	 0	R	 20	S	 10	R	 11	R	 10	R	 0	R	 36	S	 26	I	 19	S	 26	I	 26	S	 0	 19	 0	 17	 ESBL	 CTX	 NEG	
Winchester	5	
Klebsiella	
Oxytoca	 Female	 66	 Urine	 No	clinical	details	 GP	 None	 20	S	 26	I	 0	R	 15	R	 21	R	 0	R	 11	R	 0	R	 32	S	 28	S	 20	S	 22	R	 26	S	 12	 14	 13	 14	
Further	
work	
required	 CTX	 NEG	
Winchester	
50	 E.coli	 Female	 81	 urine	 Nitrates	 A	and	E	 None	 28	S	 35	S	 0	R	 0	R	 11	R	 23	S	 19	S	 0	R	 31	S	 10	R	 23	S	 14	R	 28	S	 0	 19	 0	 19	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
51	 E.coli	 Female	 90	 urine	
Keytones,	Nitrates,	
Protein	
In	
patient	 None	 14	R	 39	S	 14	R	 21	S	 27	I	 28	S	 22	S	 0	R	 33	S	 30	S	 16	I	 31	I	 28	S	 10	 28	 16	 28	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Winchester	
52	 E.coli	 Female	 88	 urine	 UTI	 GP	
Pre	
Nitrofurantoin	 0	R	 36	S	 0	R	 20	I	 20	S	 22	S	 20	S	 0	R	 35	S	 28	S	 27	S	 29	I	 26	S	 0	 21	 0	 22	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
53	
Klebsiella	
Pneumoniae	 Male	 90	 urine	
Nitrates,	
Haematuria,	
Protein	
In	
patient	 None	 12	R	 37	S	 11	R	 8	R	 16	R	 14	R	 14	R	 0	R	 21	I	 18	R	 21	S	 18	R	 24	S	 0	 17	 0	 16	 ESBL	
TEM	&	
SHV	 NEG	
Winchester	
54	 E.coli	 Female	 96	 urine	 Proteinuria	 GP	 None	 8	R	 40	S	 0	R	 24	S	 14	R	 28	S	 22	S	 0	R	 33	S	 19	R	 21	S	 18	R	 30	S	 0	 21	 0	 22	 ESBL	 CTX	 NEG	
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Winchester	
55	 E.coli	 Male	 94	 urine	
Nitrates,	
Leucoctyes	 A	and	E	 None	 0	R	 38	S	 11	R	 21	S	 20	S	 21	S	 14	R	 0	R	 31	S	 22	R	 14	R	 21	R	 27	S	 0	 24	 0	 25	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
56	 E.coli	 Female	 18	 urine	 Dysuria	 GP	
Pre	
Trimethoprim	 33	S	 39	S	 0	R	 23	S	 20	S	 27	S	 21	S	 0	R	 31	S	 26	I	 20	S	 21	R	 29	S	 0	 23	 11	 22	 ESBL	 CTX	 NEG	
Winchester	
57	 E.coli	 Female	 84	 urine	
Leucocytes,	
Protein,	
Haematuria	
In	
patient	 None	 0	R	 40	S	 0	R	 23	S	 23	S	 21	S	 0	R	 0	R	 20	I	 23	I	 19	S	 24	R	 25	S	 0	 25	 12	 28	
Further	
work	
required	
CTX	&	
TEM	 NEG	
Winchester	
58	 E.coli	 Female	 73	 urine	
Dysuria	and	
frequency	
In	
patient	 None	 0	R	 34	S	 0	R	 19	I	 18	R	 20	R	 18	S	 0	R	 34	S	 11	R	 21	S	 26	R	 24	S	 9	 24	 10	 25	 ESBL	
TEM	&	
SHV	 NEG	
Winchester	
59	 E.coli	 Female	 21	 urine	
Dysuria,	
frequency,	THR	 GP	 On	Amoxicillin	 9	R	 35	S	 12	R	 21	S	 13	R	 24	S	 24	S	 0	R	 35	S	 16	R	 20	S	 17	R	 28	S	 0	 21	 0	 20	 ESBL	 CTX	 NEG	
Winchester	6	
Klebsiella	
Oxytoca	 Female	 71	 urine	 Dysuria,	frequency	 GP	 None	 0	R	 30	S	 0	R	 22	S	 23	R	 0	R	 19	S	 0	R	 32	S	 31	S	 20	S	 24	R	 31	S	 13	 15	 12	 16	
Further	
work	
required	 CTX	 NEG	
Winchester	
60	 E.coli	 Female	 92	 urine	
Leucocytes,	
nitrates,	
haematuria	
In	
patient	 None	 26	S	 32	S	 0	R	 8	R	 9	R	 22	S	 24	S		 0	R	 32	S	 14	R	 19	S	 16	R	 27	S	 0	 18	 0	 19	 ESBL	 CTX	 NEG	
Winchester	
61	 E.coli	 Male	 20	
Urine	
(CSU)	 Dysuria	 GP	 None	 23	S	 32	S	 0	R	 0	R	 0	R	 16	R	 14	R	 0	R	 29	S	 10	R	 23	S	 12	R	 26	S	 0	 15	 0	 15	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
62	 E.coli	 Female	 77	 urine	 No	clinical	details	 GP	
On	
Trimethoprim	 8	R	 32	S	 0	R	 21	S	 15	R	 21	S	 15	S	 0	R	 34	S	 21	R	 21	S	 23	R	 28	S	 0	 22	 0	 23	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
63	 E.coli	 Female	 74	 Urine	
Nitrates,	
Leucoctyes	
In	
patient	 None	 37	S	 36	S	 15	R	 23	S	 13	R	 22	S	 16	S	 0	R	 31	S	 22	R	 21	S	 17	R	 28	S	 0	 14	 0	 14	 ESBL	 CTX	 NEG	
Winchester	
64	 E.coli	 Female	 18	 Urine	 No	clinical	details	 ANC	 None	 34	S	 33	S	 0	R	 9	R	 0	R	 14	R	 11	R	 0	R	 29	S	 0	R	 25	S	 10	R	 28	S	 0	 16	 0	 17	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
65	 E.coli	 Female	 18	 Urine	
Cystitis,	repeat	
sample	 GP	 None	 28	S	 35	S	 20	S	 9	R	 18	R	 10	R	 0	R	 0	R	 31	S	 22	R	 22	S	 16	R	 28	S	 0	 15	 0	 16	 ESBL	
CTX	&	
TEM	 NEG	
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Winchester	
66	
Klebsiella	
Pneumoniae	 Male	 90	 Urine	 Chest	Pain	 A	and	E	 None	 11	R	 31	S	 0	R	 9	R	 16	R	 16	R	 15	S	 0	R	 35	S	 25	I	 26	S	 25	R	 25	S	 0	 17	 0	 16	 ESBL	
TEM	&	
SHV	 NEG	
Winchester	
67	 E.coli	 Female	 34	 Urine	 No	clinical	details	 GP	 None	 35	S	 33	S	 0	R	 22	S	 11	R	 21	S	 12	R	 0	R	 30	S	 20	R	 25	S	 12	R	 28	S	 0	 11	 0	 12	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
68	 E.coli	 Female	 71	 Urine	 No	clinical	details	 GP	
On	
Ciprofloxacin	 0	R	 32	S	 0	R	 8	R	 0	R	 20	R	 12	R	 0	R	 26	I	 11	R	 23	S	 11	R	 27	S	 0	 13	 0	 14	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	
69	 E.coli	 Female	 86	 Urine	 UTI	 GP	
Post	
Trimethrprim	 0	R	 36	S	 0	R	 23	S	 0	R	 16	R	 12	R	 0	R	 29	S	 0	R	 24	S	 11	R	 30	S	 0	 18	 0	 19	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	7	 E.coli	 Female	 15	 urine	
Leucocytes,	
nitrites	+++	 GP	 None	 39	S	 31	S	 24	S	 16	R	 23	R	 28	S	 17	S	 0	R	 22	I	 28	S	 24	S	 38	S	 28	S	 23	 21	 26	 26	
Further	
work	
required	 TEM	 NEG	
Winchester	
70	 E.coli	 Female	 84	 Urine	
Leucocytes,	
nitrates,	haem,	
protein	
In	
patient	 None	 0	R	 38	S	 21	S	 21	S	 22	R	 19	R	 13	R	 0	R	 35	S	 24	I	 18	I	 24	R	 28	S	 0	 24	 9	 26	 ESBL	
CTX	&	
TEM	 NEG	
Winchester	8	 E.coli	 Female	 41	 urine	
Dys,	Fre,	Hae,	Leu,	
urodynamic	
studies	 GP	 None	 37	S	 24	I	 29	S	 11	R	 0	R	 23	S	 26	S	 0	R	 31	S	 16	R	 22	S	 18	R	 26	S	 0	 28	 0	 30	 ESBL	 CTX	 NEG	
Winchester	9	 E.coli	 Female	 28	 urine	
Dysuria,	
frequency,	
haematuria	 GP	
Pre	
Trimethoprim	 32	S	 36	S	 19	I	 10	R	 0	R	 24	S	 19	S	 0	R	 31	S	 14	R	 24	S	 16	R	 29	S	 0	 26	 0	 27	 ESBL	
CTX	&	
TEM	 NEG	
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Isolate	 Identity	
Se
x	 Age	
Isolate	
Obtained	
From	
Clinical	
Details	
Locatio
n	 Antibiotic	History	
CIP	
(R<1
6	-	
S>20
)	
ME
M	
(R<1
9	-	
S>27
)	
CXM	
(R<1
9	-	
S>20
)	
CN	
(R<1
6	-	
S>20
)	
CTX	
(R<2
3	-	
S>30
)	
PTZ	
(R<2
0	-	
S>21
)	
AMC	
(R<1
4	-	
S>15
)	
AML	
(R<1
4	-	
S>15
)	
ETP	
(R<1
5	-	
S>28
)	
CAZ	
(R<2
2	-	
S>27
)	
AK	
(R<1
5	-	
S>19
)	
FEP	
(R<2
6	-	
S>32
)	
TIG	
(R<1
9	-	
S>24
)	 A	 B	 C	 D	
ESBL/AMP
C	
Multiple
x	PCR	
Result	
Multiple
x	PCR	
Result2	
Basingstoke	
1	 E.Coli	 F	 68	 Urine	 ?	Infection	
In	
Patient	 Penicillin	 44	S	 32	S	 0	R	 24	S	 0	R	 22	S	 0	R	 0	R	 30	S	 22	I	 0	R	 0	R	 27	S	 		 		 		 		
ESBL	and	
AMPC	
CTX	&	
TEM	 Neg	
Basingstoke	
2	 E.Coli	 F	 68	 Urine	
UTI	
Symptomatic	
In	
Patient	 Pipericillin/Nitrofurantoin	 35	S	 30	S	 0	R	 24	S	 0	R	 0	R	 0	R	 0	R	 35	S	 29	S	 26	S	 18	R	 26	S	 		 		 		 		
Further	
work	
required	
CTX	&	
TEM	 Neg	
Basingstoke	
3	
Klebsiella	
pneumoniae	 F	 74	
Catheter	
Urine	
Dip	_ve,	
nitrites,	
leucocytes,	
protein,	
haem	
In	
Patient	
Doxycycline/Nitrofurantoi
n	 27	S	 30	S	 0	R	 25	S	 23	R	 20	R	 0	R	 0	R	 26	I	 19	R	 21	S	 21	R	 17	R	 		 		 		 		
Further	
work	
required	 TEM	 Neg	
Basingstoke	
4	 E.Coli	 F	 98	 Urine	
Urine	+ve	
nitrates	 GP	 Nitrofurantoin	 27	S	 38	S	 0	R	 28	S	 26	I	 10	R	 0	R	 0	R	 28	S	 22	R	 24	S	 24	R	 27	S	 		 		 		 		
Further	
work	
required	 TEM	 Neg	
Basingstoke	
5	 E.Coli	 F	 47	 Urine	
UTI	Not	
responding	 GP	 Trimethoprim/Augmentin	 9	R	 36	S	 0	R	 9	R	 0	R	 20	R	 0	R	 0	R	 39	S	 30	S	 28	S	 22	R	 30	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
6	 E.Coli	 F	 92	 Urine	 ?	UTI	 GP	 None	 29	S	 38	S	 0	R	 23	S	 0	R	 14	R	 0	R	 0	R	 38	S	 21	R	 27	S	 23	R	 27	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
7	 E.Coli	 F	 33	 Urine	
UTI,	Red,	
?beetroot	
related	 GP	 Nitrofurantoin	 9	R	 37	S	 0	R	 23	S	 0	R	 25	S	 0	R	 0	R	 32	S	 19	R	 24	S	 0	R	 31	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
8	 E.Coli	 M	 80	
Catheter	
Urine	
Pre	Op-	
Previous	UTI	
In	
Patient	 None	 0	R	 40	S	 0	R	 0	R	 0	R	 18	R	 0	R	 0	R	 30	S	 22	R	 22	S	 19	R	 29	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
9	 E.Coli	 F	 19	 Urine	 Cystitis	 GP	 Nitrofurantoin	 40	S	 35	S	 0	R	 25	S	 0	R	 24	S	 0	R	 0	R	 32	S	 25	I	 29	S	 16	R	 28	S	 		 		 		 		
ESBL	and	
AMPC	
CTX	&	
TEM	 Neg	
Basingstoke	
10	 E.Coli	 F		 75	 Urine	 Dysuria	 GP	 None	 42	S	 36	S	 10	R	 22	S	 18	R	 0	R	 0	R	 0	R	 37	S	 27	S	 25	S	 28	I	 28	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
11	 E.Coli	 F	 75	 Urine	
Dysuria,	
frequency,	
leucocytes,	
nitrites	 GP	 None	 0	R	 36	S	 0	R	 23	S	 0	R	 0	R	 14	R	 0	R	 28	S	 18	R	 20	S	 12	R	 26	S	 		 		 		 		 ESBL	 Neg	 Neg	
Basingstoke	
12	 E.Coli	 F	 81	
Catheter	
Urine	
?	Urinary	
Sepsis	
In	
Patient	 Gentamicin	 0	R	 36	S	 0	R	 21	S	 0	R	 19	R	 11	R	 0	R	 36	S	 21	R	 22	S	 22	R	 23	I	 		 		 		 		 ESBL	 CTX		 Neg	
Basingstoke	
13	 E.Coli	 M	 80	 Urine	 None	stated	 GP	 None	 0	R	 35	S	 0	R	 10	R	 0	R	 18	R	 16	S	 0	R	 25	I	 21	R	 18	I	 18	R	 27	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
14	 E.Coli	 F	 69	 Urine	
Urinary	
symptoms	
since	xmas	 GP	 Nitrofurantoin	 8	R	 35	S	 0	R	 21	S	 0	R	 27	S	 17	S	 0	R	 34	S	 10	R	 24	S	 0	R	 26	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
15	 E.Coli	 F	 9	 Urine	 Nitrates	++	 GP	 Trimethoprim	 41	S	 37	S	 14	R	 23	S	 21	R	 28	S	 10	R	 0	R	 37	S	 24	I	 25	S	 39	S	 28	S	 		 		 		 		 AMPC	 TEM	 Neg	
Basingstoke	
16	 E.Coli	 F	 87	 Urine	
?	UTI,	haem,	
protein,	
nitrates,	
leucocytes	 GP	 None	 38	S	 38	S	 26	S	 22	S	 32	S	 26	S	 11	R	 0	R	 48	S	 30	S	 26	S	 50	S	 26	S	 		 		 		 		 AMPC	 TEM	 Neg	
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Basingstoke	
17	 E.Coli	 F	 52	 Urine	
UTI	with	loin	
pain	 GP	 Ciprofloxacin	 10	R	 36	S	 0	R	 10	R	 14	R	 31	S	 18	S	 0	R	 41	S	 28	S	 27	S	 23	R	 28	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
18	 E.Coli	 F	 58	 Urine	
Positive	
dipstick	
In	
Patient	 None	 0	R	 39	S	 0	R	 21	S	 0	R	 21	S	 12	R	 0	R	 46	S	 43	S	 28	S	 49	S	 27	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
19	 E.Coli	 F		 61	 Urine	
Post	vaginal	
hysterectomy
,	dysuria	 GP	 None	 24	S	 38	S	 0	R	 11	R	 0	R	 26	S	 0	R	 0	R	 35	S	 11	R	 27	S	 15	R	 29	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
20	 E.Coli	 M	 80	
Catheter	
Urine	
?	UTI,	
previous	
ESBL	 GP	 Nitrofurantoin	 28	S	 35	S	 0	R	 12	R	 0	R	 19	R	 0	R	 0	R	 36	S	 12	R	 24	S	 16	R	 27	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
21	 E.Coli	 F		 90	 Urine	
Recurrent	
UTI	 GP	 Nitrofurantoin	 40	S	 36	S	 0	R	 22	S	 16	R	 18	R	 0	R	 0	R	 36	S	 21		R	 24	S	 39	S	 28	S	 		 		 		 		 AMPC	 Neg	 Neg	
Basingstoke	
22	 E.Coli	 M	 55	
Drain	
Fluid	
Robertson	
drain	right	
flank	
In	
Patient	 None	 44	S	 38	S	 12	R	 21	S	 16	R	 20	R	 0	R	 0	R	 42	S	 9	R	 25	S	 32	S	 30	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
23	 E.Coli	 F		 83	 Urine	
Confusion,	
foul	smelling	
urine	 GP	 None	 21	S	 38	S	 16	R	 23	S	 16	R	 25	S	 17	S	 0	R	 47	S	 13	R	 30	S	 36	S	 29	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
24	 E.Coli	 F	 84	 Urine	 UTI	 GP	 Nitrofurantoin	 30	S	 34	S	 16	R	 22	S	 27	I	 26	S	 12	R	 0	R	 45	S	 38	S	 28	S	 46	S	 26	S	 		 		 		 		
ESBL	and	
AMPC	 Neg	 Neg	
Basingstoke	
25	 E.Coli	 M	 54	 Urine	 Prostatitis	 GP	 Norfloxacilin	 32	S	 37	S	 23	S	 21	S	 28	I	 24	S	 12	R	 0	R	 37	S	 29	S	 25	S	 42	S	 29	S	 		 		 		 		 AMPC	 Neg	 Neg	
Basingstoke	
26	
Enterobacter	
cloacae	 F	 78	
Catheter	
Urine	
Indwelling	
Catheter,	?	
UTI	 A	and	E	 None	 14	R	 32	S	 0	R	 22	S	 23	R	 22	S	 0	R	 0	R	 35	S	 27	S	 24	S	 30	I	 17	R	 		 		 		 		
Further	
work	
required	 Neg	 Neg	
Basingstoke	
27	 E.Coli	 F	 32	 Urine	 UTI	 GP	 None	 33	S	 33	S	 19	R	 21	S	 28	I	 25	S	 10	R	 0	R	 38	S	 31	S	 24	S	 42	S	 27	S	 		 		 		 		 AMPC	 Neg	 Neg	
Basingstoke	
28	 E.Coli	 F	 32	 Urine	
UTI	and	loin	
pain	 GP	
Trimethoprim/Ciprofloxac
in	 0	R	 38	S	 0	R	 13	R	 8	R	 16	R	 13	R	 0	R	 33	S	 17	R	 22	S	 18	R	 26	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
29	 E.Coli	 M	 79	 Urine	
Recurrent	
UTI	&	Loose	
stools,	?	
Cause	 GP	 None	 0	R	 35	S	 0	R	 18	I	 0	R	 16	R	 12	R	 0	R	 36	S	 17	R	 21	S	 20	R	 29	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
30	 E.Coli	 F	 29	 Urine	
Antenatal	
MSU,	Severe	
UTI	in	last	 GP	 None	 31	S	 36	S	 0	R	 24	S	 7	R	 27	S	 15	S	 0	R	 38	S	 25	I	 27	S	 19	R	 28	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
31	 E.Coli	 F	 76	 Urine	
?	
Pylenophritis	 GP	 Ciprofloxacin	 33	S	 37	S	 0	R	 21	S	 7	R	 25	S	 16	S	 0	R	 35	S	 25	I	 24	S	 17	R	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
32	 E.Coli	 F	 68	 Urine	
Suspected	
UTI,	Still	
Haem	 GP	 Nitrofurantoin	 0	R	 36	S	 0	R	 22	S	 16	R	 22	S	 25	S	 0	R	 35	S	 23	I	 22	S	 22	R	 28	S	 		 		 		 		
Further	
work	
required	 CTX	 Neg	
Basingstoke	
33	
Citrobacter	
braakii	 F	 82	 Urine	
Positive	urine	
dip	
In	
Patient	 None	 35	S	 35	S	 0	R	 25	S	 0	R	 13	R	 9	R	 0	R	 35	S	 0	R	 28	S	 39	S	 27	S	 		 		 		 		 AMPC	 Neg	 Neg	
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Basingstoke	
34	 E.Coli	 F	 60	 Urine	
Recurrent	
UTI	 GP	 None	 0	R	 34	S	 0	R	 0	R	 0	R	 14	R	 11	R	 0	R	 39	S	 0	R	 21	S	 16	R	 27	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
35	
Citrobacter	
freundii	 F	 82	 Urine	
Positive	urine	
dip	
In	
Patient	 None	 12	R	 36	S	 0	R	 26	S	 0	R	 16	R	 0	R	 0	R	 35	S	 0	R	 30	S	 41	S	 28	S	 		 		 		 		 AMPC	 Neg	 Neg	
Basingstoke	
36	
Enterobacter	
cloacae	 F	 77	
Ankle	
swab	
Infected	
ankle,	open	
fracture	
In	
Patient	 None	 31	S	 32	S	 16	R	 21	S	 28	I	 27	S	 0	R	 0	R	 44	S	 36	S	 26	S	 41	S	 23	I	 		 		 		 		
Further	
work	
required	 Neg	 Neg	
Basingstoke	
37	 E.Coli	 M	 80	
Catheter	
Urine	
Previous	
ESBL	
In	
Patient	 None	 0	R	 39	S	 0	R	 13	R	 0	R	 20	R	 20	S	 0	R	 28	S	 14	R	 18	I	 0	R	 31	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
38	
Citrobacter	
freundii	 M	 89	 Urine	
Dip	+ve,	
leucocytes,	
nitrites	and	
protein	 GP	 None	 26	S	 37	S	 24	S	 14	R	 11	R	 21	S	 9	R	 0	R	 38	S	 12	R	 18	I	 30	I	 26	S	 		 		 		 		 ESBL	 Neg	 Neg	
Basingstoke	
39	 E.Coli	 F	 9	 Urine	
?	Recurrent	
UTI	 GP	 None	 41	S	 36	S	 20	I	 24	S	 24	I	 30	S	 10	R	 0	R	 34	S	 15	R	 26	S	 37	S	 29	S	 		 		 		 		 AMPC	 TEM	 Neg	
Basingstoke	
40	 E.Coli	 M	 2	 Urine	 Suspect	UTI	 GP	 None	 44	S	 38	S	 21	S	 25	S	 29	I	 26	S	 10	R	 0	R	 31	S	 26	I	 22	S	 35	S	 30	S	 		 		 		 		 AMPC	 Neg	 Neg	
Basingstoke	
41	 E.Coli	 F	 79	 Urine	
Urine	
frequency	 GP	 None	 0	R	 35	S	 0	R	 0	R	 0	R	 18	R	 16	S	 0	R	 34	S	 15	R	 29	S	 12	R	 27	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
42	 E.Coli	 F	 44	 Urine	
Dysuria,	
frequency,	
urinalysis	 GP	 Nitrofurantoin	 40	S	 32	S	 0	R	 10	R	 12	R	 32	S	 20	S	 0	R	 32	S	 20	R	 21	S	 21	R	 29	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
43	 E.Coli	 F	 71	 Urine	
Recurrent	
UTI,	
frequency,	
protein,	
WBC,	nitrites	 GP	 Trimethoprim	 0	R	 36	S	 0	R	 11	R	 0	R	 15	R	 12	R	 0	R	 34	S	 16	R	 23	S	 17	R	 30	S	 		 		 		 		 ESBL	 Neg	 Neg	
Basingstoke	
44	 E.Coli	 M	 87	 Urine	
Known	to	be	
ESBL	+ve	
In	
Patient	 Meropenem	 0	R	 39	S	 21	S	 23	S	 19	R	 27	S	 15	S	 0	R	 33	S	 11	R	 21	S	 25	R	 28	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
45	 E.Coli	 F	 8	 Urine	 None	stated	 GP	 None	 0	R	 35	S	 0	R	 11	R	 10	R	 28	S	 17	S	 0	R	 33	S	 23	I	 25	S	 15	R	 27	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
46	 E.Coli	 F	 68	
Catheter	
Urine	 ?	Infection	
In	
Patient	 None	 0	R	 32	S	 0	R	 0	R	 0	R	 16	R	 10	R	 0	R	 30	S	 10	R	 17	I	 12	R	 23	I	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
47	 E.Coli	 F	 34	 Urine	 None	stated	 GP	 None	 0	R	 36	S	 0	R	 13	R	 8	R	 25	S	 11	R	 0	R	 30	S	 10	R	 24	S	 14	R	 26	S	 		 		 		 		
ESBL	and	
AMPC	 CTX	 Neg	
Basingstoke	
48	 Proteus	mirabilis	 F	 80	 Urine	
Post	op	
Pyuria	 GP	 None	 12	R	 38	S	 22	S	 17	I	 25	I	 34	S	 6	R	 0	R	 32	S	 26	I	 20	S	 32	I	 23	I	 		 		 		 		
ESBL	and	
AMPC	 Neg	 Neg	
Basingstoke	
49	 E.Coli	 F	 64	 Urine	
Leucocytes,	
Nitrate	in	
Dipstick	 GP	 None	 15	R	 40	S	 0	R	 28	S	 0	R	 26	S	 19	S	 0	R	 21	I	 8	R	 24	S	 10	R	 27	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
50	
Enterobacter	
aerogenes	 F	 62	 Urine	
Recurrent	
UTI	 GP	 None	 0	R	 36	S	 0	R	 9	R	 10	R	 23	S	 10	R	 0	R	 25	I	 23	I	 20	S	 16	R	 14	R	 		 		 		 		 ESBL	 TEM	 Neg	
231	
	
Basingstoke	
51	 E.Coli	 F	 85	 Urine	
Dementia,	
green	urine,	
?	Infection	 GP	 None	 0	R	 37	S	 20	S	 12	R	 19	R	 25	S	 14	R	 0	R	 34	S	 34	S	 17	I	 36	S	 25	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
52	
Stenotrophomon
as	maltophilia	 M	 87	
Catheter	
Urine	
Swinging	
temperature	
and	malase,	
?UTI	 GP	 Cefalexine	 0	R	 18	R	 0	R	 19	I	 17	R	 12	R	 14	R	 0	R	 0	R	 32	S	 27	S	 25	R	 24	S	 		 		 		 		 ESBL	 Neg	 Neg	
Basingstoke	
53	 E.Coli	 F	 42	 Urine	
Urine	+ve,	
nitrites,	
protein,	
offensive,	
?UTI	 GP	 None	 42	S	 37	S	 12	R	 22	S	 15	R	 34	S	 21	S	 0	R	 28	S	 13	R	 21	S	 20	R	 28	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
54	 E.Coli	 F	 68	 Urine	
Dysuria	and	
frequency	 GP	 Nitrofurantoin	 15	R	 36	S	 22	S	 24	S	 16	R	 28	S	 19	S	 0	R	 26	I	 25	I	 23	S	 29	I	 27	S	 		 		 		 		 ESBL	 SHV	 Neg	
Basingstoke	
55	
Klebsiella	
pneumoniae	 F	 32	 Urine	
Leucocytes	
on	Dipstick	 GP	 None	 0	R	 31	S	 20	S	 21	S	 23	I	 24	S	 20	S	 0	R	 0	R	 31	S	 28	S	 26	I	 29	S	 		 		 		 		
ESBL	and	
AMPC	 Neg	 Neg	
Basingstoke	
56	
Klebsiella	
oxytoca	 F	 49	 Urine	
Dipstick	
positive	
In	
Patient	 None	 0	R	 43	S	 0	R	 11	R	 0	R	 18	R	 12	R	 0	R	 22	I	 12	R	 19	S	 12	R	 26	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
57	
Enterobacter	
cloacae	 F	 23	 Urine	 PV	Bleed	
In	
Patient	 None	 38	S	 30	S	 0	R	 21	S	 0	R	 22	S	 0	R	 0	R	 15	R	 0	R	 22	S	 23	R	 29	S	 		 		 		 		 ESBL	 Neg	 Neg	
Basingstoke	
58	 E.Coli	 F	 91	 Urine	
Increased	
confusion	 GP	 None	 0	R	 33	S	 0	R	 23	S	 0	R	 24	S	 11	R	 0	R	 25	I	 8	R	 21	S	 10	R	 26	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
59	 E.Coli	 F	 53	 Urine	
Right	sided	
pain	post	op	
In	
Patient	 None	 0	R	 36	S	 0	R	 9	R	 0	R	 25	S	 11	R	 0	R	 26	I	 10	R	 21	S	 9	R	 24	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
60	 E.Coli	 F	 80	 Urine	
High	nitrites	
and	ketones	 GP	 None	 0	R	 38	S	 0	R	 24	S	 19	R	 20	R	 10	R	 0	R	 32	S	 30	S	 23	S	 35	S	 27	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
61	 E.Coli	 F	 76	 Urine	
Leucocytes++
+,	nitrites+++,	
blood	++	 GP	 None	 33	S	 34	S	 0	R	 23	S	 9	R	 30	S	 12	R	 0	R	 26	I	 20	R	 22	S	 12	R	 28	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
62	 E.Coli	 F	 90	 Urine	 ?	UTI	 GP	 None	 0	R	 36	S	 0	R	 0	R	 0	R	 22	S	 9	R	 0	R	 28	I	 28	S	 19	S	 21	R	 29	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
63	
Enterobacter	
aerogenes	 F	 62	 Urine	
Leucocytes,	
nitrates,	
protein	and	
blood	 GP	 None	 0	R	 32	S	 0	R	 8	R	 14	R	 26	S	 7	R	 0	R	 29	S	 25	I	 23	S	 16	R	 16	R	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
64	 E.Coli	 M	 78	 Urine	
Dysuria,	
haem,	
protein,	
nitratesm	
leucocytes	 GP	 None	 0	R	 38	S	 0	R	 20	S	 0	R	 24	S	 13	R	 0	R	 24	I	 11	R	 16	I	 10	R	 27	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
65	 E.Coli	 F	 38	 Urine	 UTI	 GP	 Trimethoprim	 31	S	 37	S	 0	R	 25	S	 0	R	 30	S	 18	S	 0	R	 22	I	 0	R	 21	S	 0	R	 27	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
66	 E.Coli	 F	 17	 Urine	
UTI	with	
flank	pain	 GP	 Ciprofloxacin	 32	S	 36	S	 0	R	 24	S	 0	R	 21	S	 11	R	 0	R	 25	I	 8	R	 24	S	 10	R	 29	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
67	 E.Coli	 F	 34	 Urine	
Post	ERPOC,	
urgency,	
painful	
micturition	
In	
Patient	 None	 32	S	 34	S	 0	R	 23	S	 0	R	 28	S	 15	S	 0	R	 21	I	 0	R	 21	S	 0	R	 24	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
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Basingstoke	
68	 E.Coli	 F	 23	 Urine	
Recurrent	
infection	 GP	 None	 0	R	 35	S	 0	R	 10	R	 0	R	 20	R	 13	R	 0	R	 20	I	 0	R	 22	S	 0	R	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
69	 E.Coli	 F	 32	 Urine	
Suspected	
UTI	 GP	 Nitrofurantoin	 34	S	 33	S	 0	R	 21	S	 0	R	 24	S	 14	R	 0	R	 24	I	 8	R	 20	S	 13	R	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
70	 E.Coli	 M	 86	
Catheter	
Urine	
Urinalysis,	
smell	
indicates	UTI	 A	and	E	 None	 33	S	 36	S	 0	R	 24	S	 0	R	 32	S	 19	S	 0	R	 24	I	 10	R	 21	S	 11	R	 29	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
71	 E.Coli	 F	 89	 Urine	
Increased	
frequency,	
Leucocytes++
+	Blood+++	 GP	 None	 0	R	 42	S	 0	R	 11	R	 0	R	 26	S	 12	R	 0	R	 28	S	 12	R	 23	S	 15	R	 31	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
72	 E.Coli	 M	 78	 Urine	 ?	UTI	 GP	 Nitrofurantoin	 0	R	 39	S	 0	R	 22	S	 11	R	 22	S	 13	R	 0	R	 28	S	 14	R	 18	I	 15	R	 28	S	 		 		 		 		 ESBL	 CTX	 Neg	
Basingstoke	
73	 E.Coli	 F	 89	 Urine	 Leucocytes	+	
In	
Patient	 None	 0	R	 36	S	 0	R	 8	R	 0	R	 25	S	 14	R	 0	R	 25	I	 11	R	 19	S	 13	R	 27	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
74	 E.Coli	 M	 87	 Urine	
UTI,	shown	
on	ward	test	
In	
Patient	 None	 27	S	 33	S	 0	R	 25	S	 7	R	 23	S	 13	R	 0	R	 25	I	 11	R	 22	S	 12	R	 28	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
75	
No	Growth	from	
slope	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
Basingstoke	
76	 E.Coli	 F	 30	 Urine	
?	
Pylenophritis	 GP	 Ciprofloxacin	 0	R	 37	S	 16	R	 22	S	 20	R	 20	R	 11	R	 0	R	 31	S	 25	I	 20	S	 25	R	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
77	 E.Coli	 F	 66	 Urine	
Recurrent	
UTI	 GP	
Trimethoprim/Nitrofurant
oin	 0	R	 40	S	 0	R	 26	S	 16	R	 26	S	 12	R	 0	R	 35	S	 29	S	 26	S	 25	R	 27	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
78	 E.Coli	 F	 16	 Urine	
?	
Pylenophritis	 GP	 None	 34	S	 41	S	 0	R	 6	R	 8	R	 30	S	 17	S	 0	R	 33	S	 16	R	 27	S	 20	R	 28	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
79	 E.Coli	 F	 89	 Urine	 Dipstick	+ve	
In	
Patient	 None	 0	R	 40	S	 16	R	 21	S	 23	R	 30	S	 15	S	 0	R	 32	S	 10	R	 23	S	 26	R	 23	I	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
80	 E.Coli	 F	 85	 Urine	
Blood	+++,	
Protein	++,	
leucocytes	
+++,	nitrates	
+	 GP	 None	 0	R	 37	S	 0	R	 8	R	 0	R	 25	S	 12	R	 0	R	 31	S	 14	R	 25	S	 17	R	 29	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
81	 E.Coli	 F	 85	 Urine	 ?	UTI	 GP	 None	 0	R	 34	S	 0	R	 23	S	 8	R	 22	S	 13	R	 0	R	 20	I	 16	R	 26	S	 15	R	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
82	 E.Coli	 F	 32	 Urine	
TATT,	WBC	in	
urine	 GP	 Nitrofurantoin	 21	S	 26	I	 0	R	 12	R	 16	R	 14	R	 7	R	 0	R	 15	R	 23	I	 23	S	 19	R	 29	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
83	 E.Coli	 F	 46	 Urine	
Dysuria,	
frequency	
and	haem	 GP	 Nitrofurantoin	 0	R	 38	S	 0	R	 21	S	 13	R	 23	S	 13	R	 0	R	 39	S	 21	R	 20	S	 27	I	 26	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
84	 E.Coli	 F	 89	
Catheter	
Urine	 None	stated	
In	
Patient	 None	 0	R	 30	S	 16	R	 22	S	 19	R	 24	S	 13	R	 0	R	 30	S	 13	R	 22	S	 22	R	 27	S	 		 		 		 		 ESBL	 TEM	 Neg	
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Basingstoke	
85	 E.Coli	 F	 89	 Urine	
Leucocytes	
+++,	blood	++	
on	dipstick	 GP	 None	 16	R	 39	S	 17	R	 26	S	 17	R	 22	S	 16	S	 0	R	 30	S	 15	R	 21	S	 25	R	 30	S	 		 		 		 		 ESBL	 TEM	 Neg	
Basingstoke	
86	 Proteus	mirabilis	 F	 23	 Urine	 ?	Infection	 A	and	E	 None	 36	S	 25	I	 31	S	 28	S	 40	S	 25	S	 28	S	 24	S	 31	S	 34	S	 22	S	 35	S	 23	I	 		 		 		 		 Neg	
SHV,	
CTX	&	
TEM	 Neg	
Basingstoke	
87	
Klebsiella	
pneumoniae	 F	 84	 Urine	
Recurrent	
UTI	 GP	 None	 0	R	 38	S	 0	R	 24	S	 13	R	 34	S	 13	R	 0	R	 28	S	 0	R	 23	S	 14	R	 28	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Basingstoke	
88	 E.Coli	 M	 69	 Pus	
Maxillary	
sinus	debis	
In	
Patient	 None	 0	R	 32	S	 0	R	 7	R	 0	R	 17	R	 0	R	 0	R	 30	S	 29	S	 25	S	 29	I	 24	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
1	 E.Coli	 F		 93	 Urine	
Dysuria	and	
fever	 GP	 None	 0	R	 34	S	 0	R	 7	R	 0	R	 18	R	 0	R	 0	R	 31	S	 14	R	 21	S	 16	R	 26	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
2	
Citrobacter	
freundii	 F	 73	 Urine	 None	stated	 GP	 None	 26	S	 34	S	 0	R	 24	S	 14	R	 22	S	 0	R	 0	R	 31	S	 14	R	 27	S	 37	S	 29	S	 		 		 		 		 AMPC	 Neg	 Neg	
Winchester	
3	 E.Coli	 F	 87	 Urine	 Incontinence	 GP	 None	 0	R	 38	S	 0	R	 22	S	 0	R	 30	S	 8	R	 0	R	 35	S	 15	R	 27	S	 17	R	 27	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
4	 E.Coli	 F	 78	 Urine	 None	stated	 GP	 None	 40	S	 44	S	 0	R	 30	S	 27	I	 26	S	 0	R	 0	R	 25	I	 20	R	 31	S	 30	I	 28	S	 		 		 		 		
ESBL	and	
AMPC	 Neg	 Neg	
Winchester	
5	 E.Coli	 F	 64	 Urine	
Dip	+ve,	
leucocytes,	
nitrites	and	
blood	
In	
Patient	 None	 30	S	 34	S	 0	R	 24	S	 19	R	 14	R	 0	R	 0	R	 31	S	 17	R	 24	S	 23	R	 28	S	 		 		 		 		
Further	
work	
required	 Neg	 Neg	
Winchester	
6	 E.Coli	 F	 68	 Urine	
Urinary	
symptoms	
for	1/52	 GP	 None	 0	R	 39	S	 0	R	 26	S	 7	R	 28	S	 9	R	 0	R	 32	S	 16	R	 23	S	 19	R	 25	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
7	 E.Coli	 F		 77	 Urine	 E.Coli	 GP	 None	 28	S	 40	S	 0	R	 27	S	 13	R	 30	S	 0	R	 0	R	 32	S	 29	S	 25	S	 19	R	 30	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
8	 E.Coli	 F	 43	 Urine	
Dysuria,	
protein,	
frequency	
and	+	
leucocytes	 GP	 None	 0	R	 42	S	 0	R	 22	S	 0	R	 28	S	 0	R	 0	R	 32	S	 14	R	 25	S	 14	R	 30	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
9	 E.Coli	 F	 87	 Urine	
Frequency	
and	protein	 GP	 None	 0	R	 41	S	 0	R	 24	S	 15	R	 18	R	 0	R	 0	R	 36	S	 26	I	 24	S	 26	R	 29	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
10	
Morganella	
morganii	 F	 62	 Urine	
Due	
operation	
tomorrow	 GP	 None	 36	S	 49	S	 0	R	 33	S	 36	S	 35	S	 0	R	 0	R	 31	S	 30	S	 30	S	 39	S	 30	S	 		 		 		 		 AMPC	 Neg	 Neg	
Winchester	
11	 E.Coli	 F	 32	 Urine	
Blood,	
Leucocytes	 GP	 None	 24	S	 38	S	 14	R	 23	S	 20	R	 26	S	 12	R	 0	R	 34	S	 16	R	 25	S	 33	S	 29	S	 		 		 		 		 ESBL	
SHV	&	
TEM	 Neg	
Winchester	
12	 E.Coli	 F	 80	 Urine	 Dysuria	 GP	 Post	Nitrofurantoin	 0	R	 41	S	 0	R	 11	R	 9	R	 26	S	 0	R	 0	R	 33	S	 17	R	 21	S	 19	R	 31	S	 		 		 		 		
Further	
work	
required	 CTX	 Neg	
Winchester	
13	
Citrobacter	
freundii	 F	 84	 Urine	 Dysuria	 GP	 None	 18	R	 43	S	 0	R	 28	S	 30	S	 34	S	 0	R	 0	R	 37	S	 12	R	 17	I	 23	R	 20	I	 		 		 		 		
Further	
work	
required	 Neg	 Neg	
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Winchester	
14	 E.Coli	 F	 54	 Urine	
Abnormal	
urinalysis	 GP	 Post	?	 0	R	 35	S	 0	R	 0	R	 0	R	 17	R	 0	R	 0	R	 33	S	 10	R	 17	I	 14	R	 27	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
15	 Proteus	mirabilis	 F	 62	 Urine	
Dysuria	and	
frequency	 GP	 Pre	Nitrofurantoin	 0	R	 42	S	 16	R	 18	I	 20	R	 46	S	 18	S	 0	R	 37	S	 11	R	 17	I	 21	R	 25	S	 		 		 		 		
Further	
work	
required	 Neg	 Neg	
Winchester	
16	 E.Coli	 F	 88	 Urine	
Signs	of	UTI,	
+++	Nitrites	
and	
leucocytes	 GP	 None	 34	S	 40	S	 0	R	 26	S	 14	R	 32	S	 8	R	 0	R	 36	S	 11	R	 15	R	 22	R	 38	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
17	 E.Coli	 F	 63	 Urine	
UTI,	allergic	
to	Tri,	nitro	
and	
cephalexin	 GP	 None	 34	S	 35	S	 0	R	 23	S	 11	R	 26	S	 0	R	 0	R	 35	S	 23	I	 25	S	 15	R	 34	S	 		 		 		 		
ESBL	and	
AMPC	
CTX	&	
TEM	 Neg	
Winchester	
18	 E.Coli	 F	 75	 Urine	
Dysuria	and	
frequency	 GP	 Pre	Nitrofurantoin	 21	S	 38	S	 0	R	 12	R	 13	R	 32	S	 22	S	 0	R	 37	S	 31	S	 25	S	 29	I	 27	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
19	 E.Coli	 F	 77	 Urine	 Dysuria	 GP	
Pre	augmentin/Post	
Nitrofurantoin	 0	R	 36	S	 0	R	 21	S	 19	R	 33	S	 23	S	 0	R	 38	S	 24	I	 24	S	 25	R	 28	S	 		 		 		 		
Further	
work	
required	 CTX		 Neg	
Winchester	
20	 E.Coli	 F	 64	 Urine	
Dysuria,	
frequency,	
protein,	
recurrent	UTI	 GP	 Pre	augmentin	 0	R	 36	S	 0	R	 20	S	 9	R	 22	S	 17	S	 0	R	 40	S	 35	S	 26	S	 41	S	 25	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
21	 E.Coli	 F	 65	 Urine	 None	stated	 GP	 None	 0	R	 40	S	 0	R	 22	S	 15	R	 24	S	 9	R	 0	R	 31	S	 27	S	 22	S	 31	I	 27	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
22	 E.Coli	 M	 72	 Urine	
Recurrent	
UTI	 GP	 Post	fosfomycin	 0	R	 42	S	 10	R	 0	R	 11	R	 28	S	 19	S	 0	R	 30	S	 19	R	 23	S	 15	R	 34	S	 		 		 		 		 ESBL	 CTX		 Neg	
Winchester	
23	 E.Coli	 M	 74	 Urine	 Frequency		 GP	 None	 32	S	 39	S	 0	R	 21	S	 17	R	 32	S	 20	S	 0	R	 27	I	 26	I	 25	S	 21	R	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
24	 E.Coli	 F	 17	 Urine	 Protein	 GP	 None	 26	S	 40	S	 20	S	 21	S	 25	I	 32	S	 26	S	 0	R	 32	S	 26	I	 25	S	 32	S	 26	S	 		 		 		 		 ESBL	 TEM	 Neg	
Winchester	
25	
Enterobacter	
cloacae	 F	 64	
Catheter	
Urine	 ?	UTI	 GP	 None	 30	S	 31	S	 0	R	 21	S	 0	R	 19	R	 9	R	 0	R	 27	I	 30	S	 25	S	 26	I	 23	I	 		 		 		 		 AMPC	 Neg	 Neg	
Winchester	
26	 E.Coli	 F	 84	 Urine	 None	stated	 GP	 None	 13	R	 39	S	 0	R	 29	S	 0	R	 26	S	 18	S	 0	R	 30	S	 23	I	 21	S	 13	R	 27	S	 		 		 		 		 AMPC	 CTX	 Neg	
Winchester	
27	
Enterobacter	
cloacae	 M		 60	
Blood	
Culture	
Neutropenic	
sepsis	and	
temperature	 ICU	 Meropenem	 0	R	 19	R	 0	R	 0	R	 13	R	 26	S	 17	S	 0	R	 15	R	 14	R	 0	R	 0	R	 23	I	 0	 0	 0	 0	
Further	
work	
required	 CTX	 Neg	
Winchester	
28	 E.Coli	 F	 20	 Urine	
Dysuria,	
frequency,	
protein,	UTI	 GP	 Pre	Nitrofurantoin	 0	R	 36	S	 0	R	 21	S	 15	R	 32	S	 22	S	 0	R	 38	S	 28	S	 27	S	 29	I	 26	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
29	 E.Coli	 M		 60	
Intra	
Abdomin
al	Swab	 None	stated	 ICU	 None	 0	R	 34	S	 0	R	 0	R	 13	R	 28	S	 16	S	 0	R	 31	S	 29	S	 26	S	 25	R	 25	S	 		 		 		 		
Further	
work	
required	
CTX	&	
TEM	 Neg	
Winchester	
30	 E.Coli	 F	 45	 Urine	 None	stated	 GP	 None	 29	S	 33	S	 0	R	 16	R	 0	R	 20	R	 14	R	 0	R	 30	S	 19	R	 26	S	 17	R	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
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Winchester	
31	 E.Coli	 F	 55	 Urine	
Dysuria,	
frequencym	
protein,	abdo	
pain	 GP	 None	 0	R	 30	S	 0	R	 11	R	 0	R		 16	R	 10	R	 0	R	 30	S	 11	R	 24	S	 16	R	 24	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
32	 E.Coli	 F		 97	 Urine	
Recurrent	
hallucination
s,	recurrent	
UTI	 GP	 None	 0	R	 40	S	 0	R	 24	S	 15	R	 16	R	 11	R	 0	R	 34	S	 27	S	 28	S	 29	I	 28	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
33	 E.Coli	 M		 39	 Urine	 Dysuria	 GP	 None	 0	R	 32	S	 0	R	 18	I	 0	R	 27	S	 23	S	 0	R	 30	S	 20	R	 25	S	 16	R	 24	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
34	 E.Coli	 F		 50	 Urine	
Recurrent	
UTI	 GP	 None	 29	S	 32	S	 0	R	 20	S	 0	R	 34	S	 18	S	 0	R	 18	I	 12	R	 0	R	 15	R	 25	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
35	 E.Coli	 F	 81	 Urine	
Dysuria,	
frequency,	
persistant	
symptoms	 GP	
Pre	
Nitrofurantoin/amoxicillin	 19	I	 34	S	 0	R	 20	S	 18	R	 28	S	 19	S	 0	R	 30	S	 16	R	 23	S	 17	R	 25	S	 		 		 		 		 ESBL	
SHV	&	
CTX	 Neg	
Winchester	
36	 E.Coli	 F	 85	 Urine	
Dysuria	and	
frequency	 GP	 None	 21	S	 32	S	 0	R	 20	S	 0	R	 24	S	 12	R	 0	R	 30	S	 10	R	 20	S	 10	R	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
37	 E.Coli	 F	 48	 Urine	
Recurrent	
UTI,	nitrites	
and	++	
leucocytes	 GP	 Pre	Nitrofurantoin	 0	R	 34	S	 0	R	 23	S	 13	R	 28	S	 16	S	 0	R	 34	S	 25	I	 27	S	 16	R	 24	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
38	 E.Coli	 F	 88	 Urine	 Confusion	 GP	 None	 23	S	 35	S	 0	R	 22	S	 11	R	 15	R	 10	R	 0	R	 35	S	 27	S	 26	S	 18	R	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
39	 E.Coli	 F	 22	 Urine	
Leucocytes+,	
nitrites	++,	
blood	+	 GP	 None	 0	R	 37	S	 0	R	 21	S	 14	R	 28	S	 17	S	 0	R	 31	S	 23	I	 22	S	 19	R	 25	S	 		 		 		 		 ESBL	 CTX		 Neg	
Winchester	
40	
Morganella	
morganii	 F	 40	
Catheter	
Urine	 Catheterised	 GP	 None	 0	R	 36	S	 0	R	 8	R	 27	I	 34	S	 0	R	 0	R	 30	S	 29	S	 25	S	 34	S	 26	S	 		 		 		 		 AMPC	 Neg	 Neg	
Winchester	
41	 E.Coli	 F	 83	 Urine	
Leucocytes	+,	
blood	+++,	
protein	+	 GP	 None	 0	R	 41	S	 0	R	 23	S	 23	R	 23	S	 13	R	 0	R	 39	S	 30	S	 22	S	 30	I	 27	S	 		 		 		 		
Further	
work	
required	
CTX	&	
TEM	 Neg	
Winchester	
42	 E.Coli	 F	 97	 Urine	 Protein	 GP	 None	 0	R	 35	S	 0	R	 21	S	 18	R	 21	S	 12	R	 0	R	 39	S	 29	S	 23	S	 29	I	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
43	 E.Coli	 M	 86	 Urine	
Dysuria,	
frequency	
and	protein	 GP	 Ciprofloxacin	 0	R	 35	S	 0	R	 20	S	 17	R	 21	S	 10	R	 0	R	 40	S	 31	S	 23	S	 31	I	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
44	 E.Coli	 F	 79	 Urine	
Frequency	
and	dysuria	 GP	 Pre	?	 0	R	 36	S	 0	R	 15	R	 19	R	 30	S	 23	S	 0	R	 38	S	 25	I	 24	S	 26	I	 27	S	 		 		 		 		
ESBL	and	
AMPC	 CTX	 Neg	
Winchester	
45	 E.Coli	 F	 31	 Urine	
Dysuria,	
frequency	
and	protein	 GP	 Pre	?	 30	S	 33	S	 0	R	 22	S	 12	R	 26	S	 16	S	 0	R	 34	S	 26	I	 25	S	 18	R	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
46	 E.Coli	 F	 75	 Urine	
Dysuria,	
frequency	
and	protein	 GP	 None	 34	S	 36	S	 0	R	 23	S	 12	R	 30	S	 16	S	 0	R	 36	S	 27	S	 24	S	 19	R	 28	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
47	 E.Coli	 F	 31	 Urine	
Frequency	
and	dysuria	 GP	 Post	trimethoprim	 30	S	 34	S	 0	R	 22	S	 0	R	 23	S	 13	R	 0	R	 35	S	 26	I	 25	S	 19	R	 25	S	 		 		 		 		 ESBL	 TEM	 Neg	
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Winchester	
48	
Enterobacter	
cloacae	 F	 55	 Urine	 Frequency	 GP	 None	 34	S	 36	S	 0	R	 24	S	 40	S	 29	S	 0	R	 0	R	 36	S	 37	S	 25	S	 42	S	 16	R	 		 		 		 		
Further	
work	
required	 Neg	 Neg	
Winchester	
49	 E.Coli	 F	 48	 Urine	 Dysuria	 GP	 Pre	Nitrofurantoin	 34	S	 35	S	 0	R	 23	S	 11	R	 20	R	 12	R	 0	R	 34	S	 25	I	 25	S	 16	R	 29	S	 		 		 		 		 ESBL	 TEM	 Neg	
Winchester	
50	 E.Coli	 M	 75	 Urine	 Left	loin	pain	 GP	 None	 28	S	 34	S	 17	R	 21	S	 21	R	 32	S	 23	S	 0	R	 38	S	 23	I	 26	S	 33	S	 27	S	 		 		 		 		
ESBL	and	
AMPC	 TEM	 Neg	
Winchester	
51	 E.Coli	 F	 90	 Urine	
Recurrent	
UTI	 GP	
Post	trimethoprim/pre	
Nitrofurantoin	 0	R	 34	S	 0	R	 19	I	 0	R	 24	S	 18	S	 0	R	 34	S	 16	R	 21	S	 17	R	 29	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
52	 E.Coli	 F	 4	 Urine	
Dysuria	and	
frequency	 GP	 None	 33	S	 34	S	 0	R	 24	S	 11	R	 28	S	 15	S	 0	R	 34	S	 25	I	 25	S	 18	R	 30	S	 		 		 		 		
Further	
work	
required	
CTX	&	
TEM	 Neg	
Winchester	
53	 E.Coli	 F	 97	 Urine	
Frequency	
and	protein	 GP	
Pre	Nitrofurantoin/post	
trimethoprim	 0	R	 42	S	 0	R	 22	S	 20	R	 22	S	 12	R	 0	R	 38	S	 28	S	 19	S	 30	I	 32	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
54	 E.Coli	 F	 20	 Urine	
27/40	
pregnant	
+vce	dip	stick	 GP	 None	 29	S	 36	S	 0	R	 21	S	 10	R	 30	S	 21	S	 0	R	 36	S	 12	R	 26	S	 17	R	 23	I	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
55	 E.Coli	 F	 88	 Urine	 Frequency	 GP	 Nitrofurantoin	 0	R	 40	S	 0	R	 23	S	 0	R	 32	S	 23	S	 0	R	 40	S	 25	I	 24	S	 25	R	 30	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
56	 E.Coli	 F	 87	 Urine	 UTI	 GP	 Nitrofurantoin	 28	S	 39	S	 0	R	 25	S	 21	R	 28	S	 19	S	 0	R	 40	S	 36	S	 28	S	 30	I	 26	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
57	 E.Coli	 F	 55	 Urine	
Leucocytes,	
protein,	
haematuria,	
nitrites	 GP	 None	 15	R	 38	S	 0	R	 23	S	 0	R	 26	S	 13	R	 0	R	 31	S	 13	R	 24	S	 17	R	 27	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
58	
Enterobacter	
cloacae	 M	 86	 Urine	
Leucocytes++
+,	nitrites	+	
In	
Patient	 None	 24	S	 33	S	 0	R	 24	S	 0	R	 22	S	 12	R	 0	R	 28	S	 0	R	 20	S	 0	R	 28	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
59	 E.Coli	 F	 31	 Urine	 Protein	 GP	 Pre	Trimethoprim	 0	R	 39	S	 0	R	 23	S	 11	R	 24	S	 18	S	 0	R	 30	S	 0	R	 18	I	 0	R	 28	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
60	 E.Coli	 F	 60	 Urine	
Diabetic,	
Recurrent	
UTI	 GP	 None	 0	R	 32	S	 0	R	 21	S	 0	R	 25	S	 20	S	 0	R	 32	S	 11	R	 18	I	 14	R	 25	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
61	 E.Coli	 F	 76	 Urine	
Frequency,	
UTI	 GP	 None	 32	S	 36	S	 0	R	 21	S	 0	R	 26	S	 16	S	 0	R	 36	S	 26	I	 26	S	 22	R	 32	S	 		 		 		 		 ESBL	
CTX	&	
TEM	 Neg	
Winchester	
62	 E.Coli	 F	 53	 Urine	 None	stated	
In	
Patient	 None	 0	R	 42	S	 0	R	 24	S	 21	R	 26	S	 16	S	 0	R	 32	S	 28	S	 21	S	 30	I	 29	S	 		 		 		 		
Further	
work	
required	 TEM	 Neg	
Winchester	
63	 E.Coli	 F	 30	 Urine	 None	stated	 GP	 None	 22	S	 36	S	 0	R	 0	R	 0	R	 0	R	 0	R	 0	R	 33	S	 21	R	 25	S	 19	R	 27	S	 		 		 		 		 ESBL	 TEM	 Neg	
Winchester	
64	 E.Coli	 F	 42	 Urine	
Dysuria	and	
frequency	 GP	 Pre	Trimethoprim	 24	S	 34	S	 15	R	 23	S	 0	R	 26	S	 17	S	 0	R	 37	S	 26	I	 24	S	 22	R	 27	S	 		 		 		 		 ESBL	 CTX	 Neg	
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Winchester	
65	 E.Coli	 F	 32	 Urine	
Dysuria,	
frequency	
and	protein	 GP	 Post	Trimethoprim	 0	R	 38	S	 0	R	 24	S	 12	R	 30	S	 18	S	 0	R	 30	s	 10	R	 19	S	 0	R	 30	S	 		 		 		 		 ESBL	 TEM	 Neg	
Winchester	
66	 E.Coli	 F	 78	 Urine	
Urine	for	
ESBL	
In	
Patient	 None	 33	S	 28	S	 12	R	 0	R	 16	R	 21	S	 16	S	 0	R	 35	S	 0	R	 24	S	 24	R	 25	S	 		 		 		 		 ESBL	 TEM	 Neg	
Winchester	
67	 E.Coli	 F	 84	 Urine	 Protein	 GP	 None	 0	R	 34	S	 0	R	 0	R	 0	R	 26	S	 17	S	 0	R	 28	S	 10	R	 21	S	 0	R	 28	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
68	 E.Coli	 F	 53	 Urine	 None	stated	
In	
Patient	 None	 0	R	 33	S	 0	R	 8	R	 10	R	 24	S	 15	S	 0	R	 30	S	 23	I	 21	S	 0	R	 29	S	 		 		 		 		 ESBL	 TEM	 Neg	
Winchester	
69	 E.Coli	 F	 59	 Urine	
Leucocytes	
++,	nitrites	
+ve,	protein	
+	
In	
Patient	 Flucloxacillin	 0	R	 32	S	 0	R	 23	S	 0	R	 26	S	 24	S	 0	R	 32	S	 12	R	 24	S	 15	R	 26	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
70	 E.Coli	 F	 57	 Urine	 None	stated	 GP	 None	 28	S	 31	S	 0	R	 19	I	 0	R	 26	S	 22	S	 0	R	 30	S	 11	R	 18	I	 15	R	 25	S	 		 		 		 		 ESBL	 CTX	 Neg	
Winchester	
71	 E.Coli	 F	 75	 Urine	 UTI	 GP	 None	 27	S	 38	S	 21	S	 22	S	 22	R	 24	S	 20	S	 0	R	 33	S	 23	I	 23	S	 23	R	 22	I	 		 		 		 		 ESBL	 SHV	 Neg	
Winchester	
72	
Klebsiella	
pneumoniae	 F	 62	 Urine	
Over	7/7	UTI	
symptoms,	
blood	on	
dipstick	 GP	 None	 0	R	 36	S	 0	R	 11	R	 9	R	 20	R	 14	R	 0	R	 31	S	 15	R	 21	S	 18	R	 24	S	 		 		 		 		 ESBL	 CTX	 Neg	
Southampt
on	1	
Enterobacter	
cloacae	 F	 34	
Vaginal	
Swab	 ?	Sepsis	
In	
Patient	 None	 34	S	 27	I	 0	R	 25	S	 8	R	 20	R	 0	R	 0	R	 22	I	 11	R	 28	S	 35	S	 21	I	 0	 0	
1
8	
1
7	 AMPC	 Neg	 Neg	
Southampt
on	2	 E.Coli	 F	 69	 Urine	
Frequency,	
spiking	
temperatures	 GP	 Augmentin	 0	R	 31	S	 0	R	 23	S	 0	R	 24	S	 0	R	 0	R	 31	S	 19	R	 22	S	 18	R	 23	I	 0	
2
1	 0	
2
1	 ESBL	 CTX	 Neg	
Southampt
on	3	
Enterobacter	
cloacae	 M	 65	
Catheter	
Urine	 Pyrexia	
In	
Patient	 None	stated	 36	S	 31	S	 0	R	 12	R	 0	R	 28	S	 0	R	 0	R	 32	S	 18	R	 27	S	 21	R	 22	I	 0	
2
0	 0	
1
9	 ESBL	 Neg	 Neg	
Southampt
on	4	
Enterobacter	
cloacae	 M	 76	 Urine	 None	stated	 GP	 None	stated	 22	S	 30	S	 0	R	 13	R	 14	R	 29	S	 0	R	 0	R	 34	S	 26	I	 26	S	 29	I	 21	I	 0	
2
7	 0	
2
6	 ESBL	 TEM	 Neg	
Southampt
on	5	 E.Coli	 M	 68	 Urine	
Frequency	
and	pain	 GP	 Augmentin	 20	S	 33	S	 0	R	 8	R	 10	R	 18	R	 0	R	 0	R	 30	S	 0	R	 31	S	 36	S	 20	I	 0	
1
4	 0	
1
6	 ESBL	 TEM	 Neg	
Southampt
on	6	 E.Coli	 F	 68	 Urine	 Dysuria	 GP	 Trimethoprim	 0	R	 30	S	 0	R	 22	S	 0	R	 21	S	 0	R	 0	R	 29	S	 13	R	 22	S	 15	R	 25	S	 0	
1
6	 0	
1
6	 ESBL	 TEM	 Neg	
Southampt
on	7	
Klebsiella	
pneumoniae	 M	 28	
Blood	
Culture	 Pyrexia	
In	
Patient	 Gentamicin	 0	R	 30	S	 0	R	 10	R	 9	R	 12	R	 0	R	 0	R	 28	S	 18	R	 26	S	 20	R	 16	R	 0	
1
7	 0	
1
7	 ESBL	 SHV	 Neg	
Southampt
on	8	
Enterobacter	
cloacae	 M	 31	
Wound	
swab	
Laporotomy	
wound	 GP	 None	stated	 25	S	 25	I	 0	R	 25	S	 0	R	 18	R	 0	R	 0	R	 12	R	 0	R	 25	S	 25	R	 22	I	 0	
1
0	 0	
1
1	
ESBL	and	
AMPC	 Neg	 Neg	
Southampt
on	9	 E.Coli	 F	 74	 Urine	 Cystitis		 GP	 Post	Nitrofurantoin	 22	S	 30	S	 0	R	 9	R	 0	R	 26	S	 0	R	 0	R	 32	S	 12	R	 25	S	 32	S	 22	I	 0	
1
7	 0	
2
0	 ESBL	
CTX	and	
TEM	 Neg	
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Southampt
on	10	 E.Coli	 F	 71	 Urine	 ?	Uti	 GP	 None	stated	 0	R	 28	S	 0	R	 21	S	 0	R	 21	S	 0	R	 0	R	 29	S	 14	R	 23	S	 15	R	 25	S	 0	
1
6	 0	
1
6	 ESBL	 Neg	 Neg	
Southampt
on	11	 E.Coli	 F	 80	 Urine	
Dysuria	and	
frequency	
In	
Patient	 None	stated	 0	R	 31	S	 0	R	 24	S	 15	R	 32	S	 12	R	 0	R	 32	S	 27	S	 22	S	 27	I	 24	S	 0	
2
6	
1
0	
2
7	 ESBL	 CTX	 Neg	
Southampt
on	12	 E.Coli	 F	 68	 Urine	 Dysuria	 GP	 Ciprofloxacin	 31	S	 30	S	 0	R	 24	S	 8	R	 28	S	 8	R	 0	R	 32	S	 19	R	 25	S	 21	R	 23	I	 0	
1
9	 0	
1
9	 ESBL	 CTX	 Neg	
Southampt
on	13	 E.Coli	 M	 71	 Urine	 None	stated	 GP	 None	stated	 0	R	 31	S	 0	R	 24	S	 0	R	 29	S	 0	R	 0	R	 31	S	 16	R	 25	S	 20	R	 25	S	 0	
1
9	 0	
2
0	 ESBL	 Neg	 Neg	
Southampt
on	14	 E.Coli	 F	 73	 Urine	
Recurrent	
UTI	 GP	 Ciprofloxacin	 0	R	 33	S	 0	R	 14	R	 0	R	 32	S	 24	S	 0	R	 35	S	 19	R	 27	S	 22	R	 23	I	 0	
2
1	 0	
2
1	 ESBL	 Neg	 Neg	
Southampt
on	15	 E.Coli	 F	 7	 Urine	 Dysuria	 GP	 None	stated	 35	S	 32	S	 0	R	 24	S	 11	R	 30	S	 15	S	 0	R	 32	S	 26	I	 25	S	 18	R	 25	S	 0	
1
2	 0	
1
3	 ESBL	 TEM	 Neg	
Southampt
on	16	
Enterobacter	
cloacae	 F	 65	 Urine	 Pyrexia	 GP	 None	stated	 0	R	 31	S	 0	R	 10	R	 0	R	 20	R	 15	S	 0	R	 26	I	 9	R	 24	S	 12	R	 14	R	 0	
1
4	 0	
1
5	 ESBL	 CTX	 Neg	
Southampt
on	17	 E.Coli	 M	
8month
s	 Urine	
Non	
blanching	
rash	 A	and	E	 None	stated	 0	R	 35	S	 0	R	 23	S	 20	R	 32	S	 27	S	 0	R	 35	S	 26	I	 23	S	 30	I	 26	S	 0	
2
5	
1
0	
2
6	 ESBL	 CTX	 Neg	
Southampt
on	18	 E.Coli	 F	 60	 Urine	
Lower	back	
and	left	side	
pelvic	pain	 GP	 Amoxicillin	 0	R	 31	S	 0	R	 11	R	 11	R	 22	S	 15	S	 0	R	 31	S	 17	R	 23	S	 21	R	 22	I	 0	
2
3	 0	
2
2	 ESBL	 Neg	 Neg	
Southampt
on	19	 E.Coli	 F	 96	 Urine	 ?	UTI	
In	
Patient	 None	stated	 0	R	 34	S	 17	R	 23	S	 19	R	 20	R	 14	R	 0	R	 36	S	 26	I	 23	S	 29	I	 22	I	 0	
2
7	 0	
2
5	 ESBL	 CTX	 Neg	
Southampt
on	20	 E.Coli	 F	 29	 Urine	 Pregnant	 GP	 None	stated	 0	R	 33	S	 0	R	 24	S	 0	R	 34	S	 23	S	 0	R	 34	S	 18	R	 25	S	 22	R	 26	S	 0	
2
3	 0	
2
5	 ESBL	 Neg	 Neg	
Southampt
on	21	 E.Coli	 F	 46	 Urine	
Dysuria	and	
frequency	 GP	 None	stated	 18	I	 32	S	 0	R	 25	S	 0	R	 29	S	 21	S	 0	R	 31	S	 18	R	 25	S	 18	R	 27	S	 0	
1
8	 0	
1
9	 ESBL	 Neg	 Neg	
Southampt
on	22	 E.Coli	 F	 88	 Urine	 None	stated	 GP	 Ciprofloxacin	 0	R	 33	S	 0	R	 23	S	 0	R	 28	S	 20	S	 0	R	 34	S	 14	R	 26	S	 19	R	 25	S	 0	
2
0	 0	
2
2	 ESBL	 TEM	 Neg	
Southampt
on	23	 E.Coli	 F	 90	 Urine	 Dysuria	
In	
Patient	 Amoxicillin	 0	R	 34	S	 0	R	 27	S	 15	R	 35	S	 30	S	 0	R	 32	S	 24	I	 28	S	 27	I	 26	S	 0	
2
3	 0	
2
3	 ESBL	 CTX	 Neg	
Southampt
on	24	 E.Coli	 M	 87	 Urine	 None	stated	 GP	 None	stated	 0	R	 33	S	 0	R	 12	R	 0	R	 22	S	 14	R	 0	R	 32	S	 13	R	 24	S	 18	R	 22	I	 0	
1
8	 0	
1
9	 ESBL	 CTX	 Neg	
Southampt
on	25	
Klebsiella	
pneumoniae	 F	 88	
Catheter	
Urine	
Offensive	
urine	
In	
Patient	 None	stated	 0	R	 30	S	 0	R	 0	R	 0	R	 18	R	 12	R	 0	R	 30	S	 14	R	 26	S	 15	R	 19	I	 0	
1
6	 0	
1
6	 ESBL	
TEM	
and	SHV	 Neg	
Southampt
on	26	 E.Coli	 M	 68	 Ear	swab	 Cellulitis	 GP	 Chloramphenicol	 22	S	 34	S	 0	R	 0	R	 0	R	 26	S	 18	S	 0	R	 31	S	 10	R	 20	S	 16	R	 24	S	 0	
2
2	 0	
2
3	 ESBL	 Neg	 Neg	
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Southampt
on	27	
Enterobacter	
cloacae	 F	 89	
Blood	
Culture	
Ca	Gall	
bladder	
In	
Patient	 None	stated	 20	S	 31	S	 0	R	 15	R	 16	R	 28	S	 0	R	 0	R	 34	S	 23	I	 26	S	 28	I	 20	I	 0	
2
8	 0	
2
8	 ESBL	 TEM	 Neg	
Southampt
on	28	 E.Coli	 F	 74	 Urine	
Previous	UTI,	
still	
symptomatic	 GP	 None	stated	 0	R	 35	S	 0	R	 22	S	 16	R	 31	S	 23	S	 0	R	 35	S	 24	I	 24	S	 26	R	 22	I	 0	
2
8	 0	
2
6	 ESBL	 Neg	 Neg	
Southampt
on	29	 E.Coli	 F	 86	 Urine	
Recurrent	
UTI	 GP	 None	stated	 0	R	 38	S	 0	R	 10	R	 20	R	 22	S	 13	R	 0	R	 39	S	 32	S	 31	S	 30	I	 25	S	 0	
2
6	 0	
2
5	 ESBL	 Neg	 Neg	
Southampt
on	30	 E.Coli	 F	 66	 Urine	
UTI	
symptoms	 GP	 Amoxicillin	 0	R	 31	S	 0	R	 21	S	 0	R	 29	S	 23	S	 0	R	 30	S	 15	R	 21	S	 16	R	 20	I	 0	
2
3	 0	
2
1	 ESBL	 CTX	 Neg	
Southampt
on	31	 E.Coli	 F	 1	 Urine	 None	stated	 GP	 None	stated	 0	R	 32	S	 0	R	 22	S	 15	R	 26	S	 18	S	 0	R	 32	S	 22	R	 22	S	 19	R	 25	S	 0	
2
4	 0	
2
3	 ESBL	 Neg	 Neg	
Southampt
on	32	 E.Coli	 F	
3	
months	 Urine	
Cardiac	
failure	
In	
Patient	 None	stated	 20	S	 36	S	 18	R	 24	S	 25	I	 23	S	 15	S	 0	R	 38	S	 11	R	 27	S	 30	I	 23	I	
1
2	
3
0	
1
1	
2
8	 ESBL	
TEM	
and	SHV	 Neg	
Southampt
on	33	
Klebsiella	
pneumoniae	 F	 82	 Pus	 None	stated	
In	
Patient	 Metronidazole	 11	R	 30	S	 0	R	 0	R	 0	R	 15	R	 12	R	 0	R	 29	S	 13	R	 26	S	 16	R	 18	R	 0	
1
8	 0	
1
6	 ESBL	
TEM,	
CTX	and	
SHV	 Neg	
Southampt
on	34	 E.Coli	 M	 72	 Tissue	 Diabetic	
In	
Patient	
Vancomycin,	
Ciprofloxacin	and	
Metronidazole	 0	R	 39	S	 0	R	 13	R	 0	R	 22	S	 15	S	 0	R	 34	S	 16	R	 25	S	 19	R	 21	I	 0	
2
2	 0	
2
0	 ESBL	 CTX	 Neg	
Southampt
on	35	 E.Coli	 M	 60	 Urine	 Ca	Lung	 GP	 None	stated	 40	S	 44	S	 10	R	 28	S	 22	R	 40	S	 24	S	 0	R	 43	S	 34	S	 27	S	 28	I	 20	I	 0	
2
8	 0	
3
0	 ESBL	 CTX	 Neg	
Southampt
on	36	 E.Coli	 F	 74	 Urine	
Post	removal	
of	renal	
stone,	stent	
insitu	 GP	 None	stated	 0	R	 39	S	 0	R	 15	R	 10	R	 24	S	 15	S	 0	R	 35	S	 19	R	 24	S	 21	R	 23	I	 0	
2
4	 0	
2
3	 ESBL	 TEM	 Neg	
Southampt
on	37	 E.Coli	 F	 68	 Urine	 Cystitis		 GP	 Amoxicillin	 36	S	 32	S	 0	R	 25	S	 14	R	 27	S	 18	S	 0	R	 33	S	 24	I	 24	S	 19	R	 22	I	 0	
1
9	 0	
1
9	 ESBL	
CTX	and	
TEM	 Neg	
Southampt
on	38	 E.Coli	 M	 58	 Urine	
Dysuria	post	
hemicolecto
my	 GP	 Amoxicillin	 0	R	 31	S	 0	R	 9	R	 0	R	 20	R	 14	R	 0	R	 32	S	 14	R	 21	S	 15	R	 22	I	 0	
1
9	 0	
1
8	 ESBL	 TEM	 Neg	
Southampt
on	39	 E.Coli	 F	 73	 Urine	 UTI,	post	op	 GP	 None	stated	 0	R	 35	S	 16	R	 26	S	 25	I	 30	S	 11	R	 0	R	 35	S	 19	R	 26	S	 37	S	 19	R	 0	
2
1	 0	
2
1	 ESBL	 Neg	 Neg	
Southampt
on	40	
Klebsiella	
pneumoniae	 F	 93	 Urine	 UTI	
In	
Patient	 None	stated	 11	R	 32	S	 0	R	 8	R	 11	R	 24	S	 14	R	 0	R	 37	S	 21	R	 28	S	 23	R	 24	S	 0	
2
2	 0	
2
1	 ESBL	 TEM	 Neg	
Southampt
on	41	
Klebsiella	
pneumoniae	 M	 50	 Sputum	
Chest	
infection,	
pyrexia	 GP	 Clarthromycin	 0	R	 35	S	 15	R	 28	S	 33	S	 10	R	 15	S	 0	R	 34	S	 24	I	 30	S	 32	S	 17	R	
2
5	
2
5	
2
4	
2
4	 Neg	 SHV	 Neg	
Southampt
on	42	 E.Coli	 F	 9	 Urine	 Tummy	ache	 GP	 None	stated	 0	R	 40	S	 0	R	 11	R	 0	R	 24	S	 15	S	 0	R	 36	S	 16	R	 24	S	 20	R	 23	I	 0	
2
3	 0	
2
1	 ESBL	 Neg	 Neg	
Southampt
on	43	 E.Coli	 F	 3	 Urine	 ?	Kawasakis	 GP	 None	stated	 34	S	 40	S	 10	R	 24	S	 18	R	 26	S	 0	R	 0	R	 32	S	 17	R	 26	S	 36	S	 24	S	 0	
2
2	 0	
2
1	 ESBL	 Neg	 Neg	
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Southampt
on	44	 E.Coli	 F	 90	 Urine	 ?	UTI	
In	
Patient	 Amoxicillin	 0	R	 37	S	 0	R	 23	S	 0	R	 28	S	 21	S	 0	R	 36	S	 17	R	 25	S	 19	R	 23	I	 0	
2
1	 0	
2
1	 ESBL	 Neg	 Neg	
Southampt
on	45	
Enterobacter	
cloacae	 M	 81	 Urine	 ?	UTI	 GP	 None	stated	 10	R	 37	S	 0	R	 12	R	 0	R	 26	S	 0	R	 0	R	 35	S	 16	R	 26	S	 20	R	 21	I	 0	
2
2	 0	
2
2	 ESBL	 Neg	 Neg	
Southampt
on	46	 E.Coli	 F	 1	 Urine	 AML	
In	
Patient	 None	stated	 20	S	 36	S	 0	R	 11	R	 0	R	 14	R	 9	R	 0	R	 32	S	 17	R	 24	S	 17	R	 24	S	 0	
1
7	 0	
1
7	 ESBL	 TEM	 Neg	
Southampt
on	47	 E.Coli	 M	 83	 Urine	
Urinary	
incontinence	 GP	 None	stated	 0	R	 36	S	 0	R	 23	S	 10	R	 32	S	 24	S	 0	R	 36	S	 28	S	 24	S	 29	I	 25	S	 0	
2
8	
1
1	
2
8	
Further	
work	
required	 Neg	 Neg	
Southampt
on	48	 E.Coli	 F	 60	 Fluid	
Retained	
stone	in	
bileduct	
In	
Patient	 None	stated	 30	S	 42	S	 33	S	 25	S	 22	R	 27	S	 14	I	 0	R	 39	S	 33	S	 25	S	 42	S	 27	S	
1
9	
1
9	
3
0	
3
2	 AMPC	 CTX	 Neg	
Southampt
on	49	
Klebsiella	
pneumoniae	 F	 90	 Urine	 TKR	
In	
Patient	 None	stated	 0	R	 37	S	 0	R	 12	R	 0	R	 14	R	 13	R	 0	R	 30	S	 0	R	 29	S	 15	R	 13	R	 0	
1
7	 0	
1
7	 ESBL	
CTX	and	
SHV	 Neg	
Southampt
on	50	 E.Coli	 F	 7	 Urine	 Cystitis	 GP	 None	stated	 21	S	 36	S	 0	R	 22	S	 0	R	 21	S	 14	R	 0	R	 32	S	 16	R	 22	S	 16	R	 24	S	 0	
1
7	 0	
1
8	 ESBL	 CTX	 Neg	
Portsmouth	
1	 E.Coli	 F	 94	 Urine	
Previous	
multi-
resistant	uti	 GP	 No	recent	antibiotics	 29	S	 37	S	 0	R	 10	R	 13	R	 24	S	 0	R	 0	R	 35	S	 23	I	 22	S	 28	I	 23	I	 0	
2
4	 0	
2
4	 ESBL	 CTX	 Neg	
Portsmouth	
2	
No	Growth	from	
slope	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
Portsmouth	
3	 E.Coli	 F	 15	 Urine	 Loin	pain	
In	
Patient	 None	stated	 0	R	 38	S	 18	R	 24	S	 23	R	 36	S	 12	R	 0	R	 38	S	 22	R	 28	S	 31	I	 26	S	
1
1	
2
8	
1
3	
2
9	 ESBL	 TEM	 Neg	
Portsmouth	
4	 E.Coli	 F	 87	 Urine	 None	stated	
In	
Patient	 None	stated	 0	R	 36	S	 0	R	 26	S	 0	R	 28	S	 10	R	 0	R	 31	S	 9	R	 25	S	 13	R	 25	S	 0	
1
8	 0	
1
8	 ESBL	
CTX	and	
TEM	 Neg	
Portsmouth	
5	 E.Coli	 F	 38	 Urine	 ?	UTI	 GP	 None	stated	 0	R	 32	S	 0	R	 11	R	 9	R	 23	S	 0	R	 0	R	 35	S	 15	R	 23	S	 19	R	 27	S	
1
5	
2
3	
3
5	
1
9	
Further	
work	
required	
CTX	and	
TEM	 Neg	
Portsmouth	
6	 E.Coli	 M	 72	
Catheter	
Urine	 Pyrexia	
In	
Patient	 None	stated	 18	I	 34	S	 0	R	 25	S	 0	R	 30	S	 12	R	 0	R	 36	S	 15	R	 27	S	 18	R	 25	S	
1
5	
2
7	
3
6	
1
8	
Further	
work	
required	
CTX	and	
TEM	 Neg	
Portsmouth	
7	 E.Coli	 F	 38	 Urine	 None	stated	 GP	 None	stated	 23	S	 31	S	 0	R	 25	S	 11	R	 32	S	 8	R	 0	R	 32	S	 23	I	 25	S	 16	R	 24	S	
2
3	
2
5	
3
2	
1
6	
Further	
work	
required	
CTX	and	
TEM	 Neg	
Portsmouth	
8	 E.Coli	 F	 74	 Urine	 Cystitis	 GP	 None	stated	 24	S	 31	S	 0	R	 24	S	 0	R	 23	S	 0	R	 0	R	 32	S	 21	R	 27	S	 24	R	 24	S	 0	
2
0	 0	
2
1	 ESBL	 TEM	 Neg	
Portsmouth	
9	 E.Coli	 F	 81	 Urine	
Generally	
unwell	 GP	 None	stated	 0	R	 40	S	 9	R	 26	S	 19	R	 25	S	 0	R	 0	R	 36	S	 29	S	 22	S	 32	S	 28	S	
2
9	
2
2	
3
6	
3
2	
Further	
work	
required	 Neg	 Neg	
Portsmouth	
10	 E.Coli	 M	 85	
Catheter	
Urine	 ?	Sepsis	
In	
Patient	 None	stated	 36	S	 35	S	 0	R	 23	S	 0	R	 32	S	 0	R	 0	R	 32	S	 24	I	 23	S	 21	R	 25	S	
2
4	
2
3	
3
2	
2
1	
Further	
work	
required	 TEM	 Neg	
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Portsmouth	
11	 E.Coli	 M	 65	 Urine	 Frequency	 GP	 None	stated	 26	S	 29	S	 0	R	 19	I	 0	R	 30	S	 0	R	 0	R	 32	S	 28	S	 26	S	 20	R	 26	S	 0	
1
6	 0	
1
8	 ESBL	 TEM	 Neg	
Portsmouth	
12	 E.Coli	 F	 78	 Urine	 Cystitis	 GP	 None	stated	 0	R	 28	S	 0	R	 10	R	 0	R	 29	S	 10	R	 0	R	 33	S	 13	R	 27	S	 17	R	 27	S	 0	
2
1	 0	
2
1	 ESBL	 Neg	 Neg	
Portsmouth	
13	 E.Coli	 F	 24	 Urine	 ?	UTI	 GP	 None	stated	 0	R	 23	I	 0	R	 12	R	 0	R	 22	S	 0	R	 0	R	 23	I	 9	R	 22	S	 11	R	 28	S	 0	
1
5	 0	
1
5	 ESBL	 Neg	 Neg	
Portsmouth	
14	 E.Coli	 M	 2	 Urine	 Pyrexial	 GP	 None	stated	 26	S	 26	I	 0	R	 9	R	 0	R	 27	S	 0	R	 0	R	 34	S	 30	S	 26	S	 28	I	 30	S	 0	
2
3	
1
2	
2
2	
Further	
work	
required	 TEM	 Neg	
Portsmouth	
15	 E.Coli	 F	 61	 Urine	 Dysuria	 GP	 None	stated	 36	S	 31	S	 0	R	 24	S	 14	R	 27	S	 12	R	 0	R	 30	S	 9	R	 24	S	 26	R	 28	S	 0	
2
6	 0	
2
6	 ESBL	 CTX	 Neg	
Portsmouth	
16	 E.Coli	 F	 51	 Urine	 Cystitis	 GP	 None	stated	 24	S	 30	S	 16	R	 21	S	 20	R	 24	S	 13	R	 0	R	 34	S	 24	I	 24	S	 28	I	 29	S	
1
5	
2
6	
1
6	
2
8	 ESBL	 CTX	 Neg	
Portsmouth	
17	 E.Coli	 F	 93	 Urine	 None	stated	 GP	 None	stated	 0	R	 26	I	 0	R	 23	S	 0	R	 21	S	 0	R	 0	R	 28	S	 0	R	 23	S	 0	R	 28	S	 0	
1
3	 0	
1
5	 ESBL	 TEM	 Neg	
Portsmouth	
18	 E.Coli	 F	 16	 Urine	
Pyrexia	and	
loin	pain	 GP	 None	stated	 0	R	 31	S	 0	R	 10	R	 0	R	 18	R	 0	R	 0	R	 33	S	 17	R	 23	S	 19	R	 27	S	 0	
1
6	 0	
1
6	 ESBL	 TEM	 Neg	
Portsmouth	
19	 E.Coli	 M	 56	 Urine	
Pain	passing	
urine	 GP	 None	stated	 0	R	 32	S	 0	R	 11	R	 0	R	 27	S	 0	R	 0	R	 33	S	 19	R	 22	S	 20	R	 28	S	 0	
2
4	 0	
2
3	 ESBL	 Neg	 Neg	
Portsmouth	
20	 E.Coli	 F	 77	 Urine	
Frequency	
and	dysuria	
In	
Patient	 Trimethoprim	 22	S	 33	S	 0	R	 8	R	 10	R	 28	S	 8	R	 0	R	 31	S	 24	I	 25	S	 22	R	 28	S	 0	
2
1	 0	
2
1	 ESBL	 TEM	 Neg	
Portsmouth	
21	 E.Coli	 F	 79	 Urine	
Frequency	
and	pain	 GP	 None	stated	 32	S	 37	S	 0	R	 23	S	 12	R	 31	S	 9	R	 0	R	 30	S	 28	S	 22	S	 21	R	 28	S	 8	
2
1	
1
2	
2
1	 ESBL	 Neg	 Neg	
Portsmouth	
22	 E.Coli	 F	 84	 Urine	 Pyrexia	 GP	 None	stated	 36	S	 32	S	 0	R	 23	S	 0	R	 24	S	 0	R	 0	R	 31	S	 25	I	 23	S	 16	R	 27	S	 0	
1
5	 0	
1
6	 ESBL	 TEM	 Neg	
Portsmouth	
23	 E.Coli	 M	 43	 Urine	 Cystitis	 GP	 None	stated	 0	R	 34	S	 0	R	 22	S	 0	R	 32	S	 11	R	 0	R	 34	S	 17	R	 24	S	 16	R	 28	S	 0	
2
1	 0	
2
3	 ESBL	 Neg	 Neg	
Portsmouth	
24	 E.Coli	 F	 32	 Urine	 ?	UTI	 GP	 None	stated	 0	R	 33	S	 16	R	 23	S	 20	R	 28	S	 0	R	 0	R	 32	S	 15	R	 24	S	 30	I	 21	I	
1
2	
2
6	
1
1	
2
5	 ESBL	
CTX	and	
TEM	 Neg	
Portsmouth	
25	 E.Coli	 M	 61	 Urine	 Pyrexia	 GP	 Trimethoprim	 0	R	 35	S	 0	R	 25	S	 0	R	 27	S	 0	R	 0	R	 24	I	 10	R	 24	S	 9	R	 28	S	 0	
1
4	 0	
1
6	 ESBL	 Neg	 Neg	
Portsmouth	
26	 Proteus	mirabilis	 F	 82	 Urine	
Frequency,	
pyrexia	 GP	 None	stated	 31	S	 32	S	 0	R	 26	S	 18	R	 34	S	 0	R	 0	R	 28	S	 35	S	 28	S	 31	I	 26	S	 9	
2
2	 9	
2
1	 ESBL	 Neg	 Neg	
Portsmouth	
27	 E.Coli	 F	 3	 Urine	 Unwell,	?	UTI	 GP	 None	stated	 34	S	 35	S	 0	R	 23	S	 9	R	 28	S	 0	R	 0	R	 31	S	 14	R	 20	S	 21	R	 24	S	 0	
1
5	 0	
1
7	 ESBL	 TEM	 Neg	
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Portsmouth	
28	 E.Coli	 M	 71	 Urine	 Unwell	 GP	 None	stated	 23	S	 29	S	 0	R	 28	S	 18	R	 31	S	 0	R	 0	R	 31	S	 17	R	 28	S	 17	R	 26	S	 0	
2
4	 0	
2
5	 ESBL	
SHV,	
CTX	&	
TEM	 Neg	
Portsmouth	
29	 E.Coli	 F	 44	 Urine	 Dysuria	 GP	 None	stated	 40	S	 30	S	 0	R	 10	R	 16	R	 32	S	 0	R	 0	R	 32	S	 21	R	 27	S	 23	R	 26	S	 0	
2
6	 0	
2
7	 ESBL	 Neg	 Neg	
Portsmouth	
30	 E.Coli	 F	 31	 Urine	
Frequency	
and	dysuria	 GP	 None	stated	 25	S	 26	I	 0	R	 22	S	 10	R	 24	S	 0	R	 0	R	 31	S	 20	R	 26	S	 26	R	 26	S	 0	
2
1	 0	
2
1	 ESBL	 TEM	 Neg	
Portsmouth	
31	 E.Coli	 M	 44	 Urine	 None	stated	 GP	 None	stated	 28	S	 30	S	 25	S	 25	S	 29	I	 25	S	 8	R	 0	R	 35	S	 20	R	 27	S	 34	S	 27	S	
2
0	
3
1	
2
0	
3
3	 ESBL	 TEM	 Neg	
Portsmouth	
32	
Klebsiella	
pneumoniae	 F	 80	 Urine	 ?	Sepsis	
In	
Patient	 None	stated	 0	R	 29	S	 0	R	 14	R	 15	R	 24	S	 0	R	 0	R	 32	S	 20	R	 25	S	 22	R	 24	S	 0	
2
6	 0	
2
5	 ESBL	
TEM	
and	SHV	 Neg	
Portsmouth	
33	 E.Coli	 F	 92	 Urine	
UTI	
symptoms	 GP	 None	stated	 0	R	 26	I	 0	R	 10	R	 0	R	 27	S	 9	R	 0	R	 27	I	 0	R	 24	S	 10	R	 28	S	 0	
1
2	 0	
1
3	 ESBL	
CTX	and	
SHV	 Neg	
Portsmouth	
34	 E.Coli	 F	 44	 Urine	 ?	UTI	 GP	 None	stated	 28	S	 28	S	 0	R	 24	S	 9	R	 26	S	 14	R	 0	R	 31	S	 18	R	 27	S	 18	R	 29	S	 0	
2
5	 0	
2
5	 ESBL	 CTX	 Neg	
Portsmouth	
35	 E.Coli	 F	 68	 Urine	
Dysuria	and	
pyrexia	 GP	 Trimethoprim	 0	R	 28	S	 0	R	 12	R	 10	R	 23	S	 10	R	 0	R	 31	S	 18	R	 24	S	 18	R	 26	S	 0	
2
4	 0	
2
3	 ESBL	 TEM	 Neg	
Portsmouth	
36	 E.Coli	 F	 85	 Urine	 Frequency	 GP	 None	stated	 18	I	 27	S	 0	R	 24	S	 13	R	 25	S	 10	R	 0	R	 29	S	 23	I	 28	S	 18	R	 18	R	 0	
2
1	 0	
2
2	 ESBL	 CTX	 Neg	
Portsmouth	
37	 E.Coli	 F	 68	 Urine	 Cystitis	 GP	 None	stated	 0	R	 28	S	 0	R	 11	R	 9	R	 22	S	 8	R	 0	R	 31	S	 19	R	 24	S	 19	R	 26	S	 0	
2
6	 0	
2
5	 ESBL	 Neg	 Neg	
Portsmouth	
38	 E.Coli	 F	 84	 Urine	
Frequency	
and	dysuria	 GP	 None	stated	 27	S	 27	S	 0	R	 10	R	 12	R	 24	S	 18	S	 0	R	 31	S	 20	R	 28	S	 19	R	 26	S	 0	
2
8	 0	
2
8	 ESBL	
CTX	and	
TEM	 Neg	
Portsmouth	
39	 E.Coli	 F	 36	 Urine	 None	stated	 GP	 None	stated	 26	S	 27	S	 23	S	 23	S	 24	I	 24	S	 19	S	 0	R	 31	S	 18	R	 26	S	 33	S	 25	S	
1
8	
2
9	
1
9	
3
0	 ESBL	
SHV	and	
TEM	 Neg	
Portsmouth	
40	 E.Coli	 F	 65	 Urine	 Dysuria	 GP	 None	stated	 0	R	 26	I	 0	R	 23	S	 0	R	 25	S	 14	R	 0	R	 29	S	 13	R	 24	S	 19	R	 23	I	 0	
2
2	 0	
2
3	 ESBL	
SHV,	
CTX	&	
TEM	 Neg	
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Number	 Animal	 Colour	 A	 B	 C	 D	 ESBL/AMPC	 CN	 CTX	 TZP	 ETP	 CAZ	 FEP	 MEM	 CXM	 AMC	 AML	 TGC	 CIP	 AK	 Identification	
SHV	CTX	
CTM	
Multiplex	
PCR	
1	
Horse	
Brown	 27	 24	 33	 34	 AMPC		 27	 28	 32	 30	 30	 36	 34	 0	 0	 0	 20	 37	 27	
Acinetobacter	
sp	 NEGATIVE	
1	 Blue	 17	 30	 20	 32	 ESBL	 22	 26	 30	 36	 18	 30	 36	 20	 24	 0	 23	 18	 23	 E.coli	 SHV	
1	 White	 0	 0	 10	 22	 ESBL+AMPC	 23	 24	 30	 30	 19	 30	 31	 0	 0	 0	 21	 15	 26	
Pseudomonas	
sp	 NEGATIVE	
2	
Horse	
Blue	 7	 23	 9	 24	 ESBL	 22	 17	 26	 34	 24	 21	 34	 0	 16	 0	 19	 29	 24	 E.coli	 CTX	
2	
Purple	 31	 34	 30	 32	
FURTHER	
WORK	
REQUIRED	
30	 34	 40	 34	 32	 36	 36	 0	 20	 0	 22	 36	 28	 E.coli	 NEGATIVE	
2	 White	 8	 7	 21	 25	 AMPC	 32	 36	 38	 32	 32	 38	 44	 20	 14	 0	 20	 34	 28	
Pseudomonas	
sp	 NEGATIVE	
3	 Horse	
Blue		 0	 0	 12	 23	 ESBL+AMPC	 32	 30	 34	 27	 26	 38	 40	 14	 15	 0	 22	 36	 30	 E.coli	 NEGATIVE	
White	 0	 0	 8	 20	 ESBL+AMPC	 28	 29	 34	 30	 35	 38	 42	 10	 14	 0	 19	 16	 29	
Pseudomonas	
sp	 NEGATIVE	
4	 Horse	
Blue	 32	 36	 29	 32	 ESBL	+AMPC	 24	 38	 36	 31	 36	 34	 32	 0	 18	 0	 21	 35	 28	 E.coli	 NEGATIVE	
White	 0	 0	 19	 26	 ESBL+AMPC	 25	 38	 34	 34	 36	 36	 32	 0	 18	 0	 21	 38	 28	
Pseudomonas	
sp	 NEGATIVE	
5	 Horse	 D.Blue	 11	 28	 13	 29	 ESBL	
23	 23	 27	 18	 17	 14	 36	 10	 22	 0	 22	 18	 22	 E.coli	 SHV	
White	 15	 28	 14	 30	 ESBL	 22	 24	 29	 34	 17	 28	 36	 20	 13	 0	 22	 18	 24	 E.coli	 SHV	
6	 Horse	
Purple	 15	 30	 16	 31	 ESBL	 23	 24	 28	 36	 17	 29	 40	 16	 26	 0	 23	 18	 30	 E.coli	 SHV	
White	 0	 0	 10	 18	 ESBL+AMPC	 22	 7	 8	 32	 7	 13	 34	 0	 8	 0	 16	 15	 27	
Pseudomonas	
sp	 NEGATIVE	
Blue	 0	 0	 8	 22	 ESBL+AMPC	 23	 25	 22	 36	 18	 0	 37	 8	 28	 0	 22	 19	 26	 E.coli	 NEGATIVE	
7	 Horse	 Blue	 21	 24	 21	 28	 ESBL+AMPC	 29	 40	 42	 40	 40	 32	 44	 22	 39	 27	 30	 22	 30	 E.coli	 NEGATIVE	
8	 Horse	 White	 15	 30	 18	 31	 ESBL	
20	 22	 27	 33	 16	 27	 36	 19	 22	 0	 21	 17	 22	 Escherichia	vulneris	 NEGATIVE	
D.Blue	 14	 31	 16	 31	 ESBL	 22	 23	 27	 34	 17	 29	 40	 18	 23	 0	 23	 18	 23	 E.coli	 SHV	
9	 Horse	
Green	
Maj	 31	 32	 29	 30	
FURTHER	
WORK	
REQUIRED	
25	 36	 36	 36	 32	 36	 34	 0	 19	 0	 24	 24	 27	 Pseudomonas	sp	 NEGATIVE	
Green	
Min	 21	 22	 23	 30	 ESBL+AMPC	 		 	 	 	 	 	 	 	 	 	 	 	 		
Pseudomonas	
sp	 NEGATIVE	
White	 26	 23	 41	 41	 AMPC	 32	 40	 38	 42	 34	 50	 40	 0	 9	 0	 32	 20	 31	
Morganella	
Morganii	 NEGATIVE	
Blue	 30	 33	 29	 33	 FURTHER	 24	 32	 34	 32	 32	 32	 32	 0	 20	 0	 22	 26	 27	 E.coli	 NEGATIVE	
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WORK	
REQUIRED	
10	 Horse	 Brown	 0	 22	 9	 24	 ESBL	
8	 16	 26	 32	 26	 23	 36	 0	 17	 0	 21	 30	 24	 E.coli	 CTX	
Blue	 7	 22	 9	 22	 ESBL	 24	 16	 28	 33	 26	 23	 37	 0	 19	 0	 22	 29	 24	 E.coli	 CTX	
11	 Horse	
Blue	 30	 28	 32	 31	
FURTHER	
WORK	
REQUIRED	
24	 38	 32	 38	 36	 38	 36	 24	 18	 9	 28	 30	 26	 E.coli	 NEGATIVE	
12	 Horse	 Purple	 0	 0	 12	 24	 ESBL+AMPC	 28	 29	 40	 44	 30	 22	 44	 10	 30	 17	 28	 15	 30	 E.coli	 CTM	
13	 Horse	
Blue	 21	 0	 35	 36	
FURTHER	
WORK	
REQUIRED	
28	 38	 30	 34	 26	 40	 34	 0	 0	 0	 22	 36	 28	 E.coli	 NEGATIVE	
P.Brown	 11	 22	 11	 24	 ESBL	 10	 19	 26	 34	 8	 26	 36	 0	 19	 0	 21	 28	 24	 E.coli	 CTX	+	TEM	
White	 19	 0	 33	 32	
FURTHER	
WORK	
REQUIRED	
27	 36	 28	 32	 26	 38	 36	 8	 0	 0	 22	 36	 30	 Ochrobacterium	anthrope	 NEGATIVE	
14	 Horse	
Green	 18	 0	 32	 32	
FURTHER	
WORK	
REQUIRED	
28	 35	 28	 32	 24	 40	 34	 0	 8	 0	 21	 38	 27	 Ochrobacterium	anthrope	 NEGATIVE	
15	 Horse	
Green	 20	 21	 33	 34	 AMPC	 29	 38	 30	 32	 24	 44	 36	 0	 0	 0	 23	 37	 31	
Morganella	
Morganii	 NEGATIVE	
White	 18	 0	 32	 34	
FURTHER	
WORK	
REQUIRED	
28	 38	 30	 32	 32	 42	 34	 0	 0	 0	 21	 39	 28	 Ochrobacterium	anthrope	 SHV	
16	 Horse	
Blue	Maj	 17	 31	 18	 33	 ESBL	 23	 24	 30	 36	 17	 28	 40	 10	 24	 0	 22	 19	 24	 E.coli	 SHV	
Blue	Min	 0	 0	 14	 23	 ESBL+AMPC	 		 	 	 	 	 	 	 	 	 	 	 	 		 E.coli	 NEGATIVE	
White	 30	 27	 38	 41	 AMPC	 30	 40	 36	 38	 42	 40	 36	 0	 0	 0	 27	 50	 33	
Ochrobacteriu
m	anthrope	 NEGATIVE	
17	 Sheep	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
18	 Sheep	
White	 15	 16	 18	 26	 ESBL+AMPC	 27	 29	 28	 40	 28	 22	 42	 12	 32	 0	 18	 20	 28	
Pseudomonas	
sp	 NEGATIVE	
L.Blue	 15	 15	 16	 24	 ESBL+AMPC	 23	 26	 40	 38	 33	 22	 38	 10	 30	 0	 22	 13	 27	 E.coli	 NEGATIVE	
Brown	 0	 0	 0	 0	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 CTX	
D.Blue	 0	 24	 8	 23	 ESBL	 23	 17	 28	 36	 26	 22	 36	 0	 18	 0	 22	 10	 27	 E.coli	 CTX	
19	 Chicken	 Green	 0	 20	 7	 21	 ESBL	
22	 16	 34	 40	 27	 16	 38	 0	 21	 8	 27	 40	 28	 Hafnia	alvei	 CTX	
Purple	 0	 14	 7	 15	 ESBL	 20	 0	 21	 28	 21	 7	 29	 0	 0	 0	 19	 24	 		 E.coli	 NEGATIVE	
20	 Cow	 Green	 0	 0	 15	 26	 ESBL+AMPC	 25	 16	 40	 38	 32	 24	 40	 0	 24	 8	 23	 14	 28	
Pseudomonas	
sp	 NEGATIVE	
246	
	
Pink	 22	 23	 22	 27	 ESBL+AMPC	 28	 30	 42	 42	 32	 31	 44	 20	 36	 28	 25	 16	 28	 E.coli	 NEGATIVE	
21	 Cow	 D.Blue	 26	 26	 24	 26	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 E.coli	 NEGATIVE	
22	 Dog	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
23	 Dog	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
24	 Dog	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
25	 Dog	
No	
Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
D.Blue	 0	 0	 21	 24	 AMPC	 21	 14	 23	 27	 13	 30	 32	 8	 0	 0	 23	 29	 23	 E.coli	 NEGATIVE	
26	 Dog	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
27	 Rat	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
28	 Cat	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
29	 Dog	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
30	 Dog	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
31	 Dog	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
32	 Guinea	Pig	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
33	 Cat	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
34	 Cat	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
35	 Cat	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
36	 Cat	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
37	 Cat	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
38	 Cow	 White	 0	 0	 0	 8	 NEGATIVE	
		 		 		 		 		 		 		 		 		 		 		 		 		 		 NEGATIVE	
Blue	 0	 0	 0	 8	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 E.coli	 NEGATIVE	
39	 Cow	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
40	 Horse	 White	 7	 7	 7	 8	 NEGATIVE	
		 		 		 		 		 		 		 		 		 		 		 		 		 		 NEGATIVE	
Blue	 0	 0	 16	 29	 ESBL+AMPC	 18	 16	 21	 0	 0	 10	 0	 0	 25	 8	 27	 17	 10	 E.coli	 NEGATIVE	
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41	 Horse	 White	 0	 0	 0	 7	 NEGATIVE	
		 		 		 		 		 		 		 		 		 		 		 		 		 Pseudomonas	sp	 NEGATIVE	
Green	 0	 0	 7	 14	 ESBL+AMPC	 24	 21	 29	 17	 30	 32	 36	 0	 0	 0	 12	 28	 28	 		 NEGATIVE	
42	 Horse	
No	
Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
L.Blue	 24	 22	 34	 35	 AMPC	 15	 10	 30	 23	 0	 0	 21	 0	 34	 26	 28	 23	 11	 E.coli	 NEGATIVE	
43	 Horse	
Blue	 32	 33	 34	 35	
FURTHER	
WORK	
REQUIRED	
22	 34	 30	 34	 34	 36	 34	 24	 25	 13	 25	 29	 24	 E.coli	 NEGATIVE	
44	 Horse	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
45	 Horse	 White	 24	 23	 33	 35	 AMPC	
26	 36	 30	 30	 28	 36	 30	 0	 0	 0	 24	 36	 26	 Ochrobacterium	anthrope	 NEGATIVE	
Green	 0	 0	 8	 15	 ESBL+AMPC	 28	 24	 30	 20	 28	 30	 26	 0	 16	 0	 23	 30	 35	
Pseudomonas	
sp	 NEGATIVE	
46	 Horse	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
47	 Horse	
White	 0	 0	 0	 0	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 NEGATIVE	
Pink	 		
	 	 	
NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 E.coli	 NEGATIVE	
Green	 0	 0	 0	 7	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 NEGATIVE	
48	 Horse	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
49	 Horse	
White	 0	 0	 17	 31	 ESBL+AMPC	 20	 16	 44	 42	 34	 30	 44	 0	 29	 12	 28	 14	 30	 Pseudomonas	sp	 NEGATIVE	
D.Blue	 0	 0	 18	 30	 ESBL+AMPC	 22	 18	 48	 46	 36	 26	 48	 0	 30	 16	 31	 15	 32	 E.coli	 NEGATIVE	
50	 Horse	
Blue	 29	 31	 30	 32	
FURTHER	
WORK	
REQUIRED	
21	 34	 28	 32	 30	 36	 32	 22	 22	 11	 21	 28	 22	 E.coli	 NEGATIVE	
D.Blue	 29	 28	 28	 29	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 E.coli	 NEGATIVE	
51	 Horse	 D.Blue	 28	 30	 30	 30	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 E.coli	 NEGATIVE	
52	 Horse	 Blue	 29	 28	 28	 29	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 E.coli	 NEGATIVE	
53	 Cat	 White	 0	 0	 0	 0	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 NEGATIVE	
54	 Cat	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
55	 Dog	
Blue	 27	 28	 30	 32	
FURTHER	
WORK	
REQUIRED	
20	 32	 30	 15	 30	 36	 34	 26	 24	 0	 25	 0	 21	 E.coli	 NEGATIVE	
D.Blue	 27	 28	 30	 31	
FURTHER	
WORK	
REQUIRED	
21	 36	 30	 36	 32	 16	 36	 27	 25	 0	 25	 28	 20	 E.coli	 NEGATIVE	
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56	 Dog	 Blue		 35	 34	 35	 37	
FURTHER	
WORK	
REQUIRED	
22	 1	 34	 24	 32	 38	 30	 25	 24	 0	 20	 0	 20	 E.coli	 NEGATIVE	
57	 Dog	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
58	 Dog	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
59	 Dog	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
60	 Horse	Field	3	 White	 0	 0	 0	 23	 ESBL+AMPC	 30	 22	 42	 44	 24	 16	 46	 0	 27	 11	 40	 18	 30	
Pseudomonas	
sp	 NEGATIVE	
61	 Horse	Field	2	
White	 0	 0	 14	 22	 ESBL+AMPC	 36	 38	 44	 46	 46	 46	 48	 16	 27	 0	 30	 36	 38	 Pseudomonas	sp	 NEGATIVE	
Blue	 0	 0	 14	 24	 ESBL+AMPC	 32	 38	 44	 48	 50	 50	 52	 14	 24	 10	 34	 44	 33	 E.coli	 NEGATIVE	
62	 Horse	Milo	
White	 0	 0	 15	 25	 ESBL+AMPC	 30	 36	 40	 30	 36	 38	 40	 12	 22	 8	 24	 38	 30	 Ochrobacterium	anthrope	 NEGATIVE	
Blue	 0	 0	 12	 26	 ESBL+AMPC	 30	 38	 40	 42	 36	 38	 40	 14	 20	 0	 25	 38	 32	 E.coli	 NEGATIVE	
63	 Chicken	 Blue	 0	 23	 9	 24	 ESBL	 21	 21	 28	 32	 26	 23	 32	 0	 20	 0	 23	 30	 22	 E.coli	 NEGATIVE	
64	 Horse	Lola	
Brown	 8	 0	 32	 35	 AMPC	 		 	 	 	 	 	 	 	 	 	 	 	 		
Ochrobacteriu
m	anthrope	 NEGATIVE	
Green	 20	 18	 34	 35	 AMPC	 26	 30	 34	 28	 36	 40	 34	 0	 0	 0	 29	 37	 25	 Proteus	penneri	 NEGATIVE	
65	 Horse	Weeny	 Brown	 20	 18	 32	 33	 AMPC	 26	 44	 36	 32	 32	 36	 36	 8	 0	 0	 27	 36	 25	
Ochrobacteriu
m	anthrope	 NEGATIVE	
66	 Horse	Field	1	
White	 0	 0	 11	 16	 ESBL+AMPC	 42	 39	 46	 45	 46	 50	 50	 28	 40	 0	 30	 42	 34	 Providencia	sp	 NEGATIVE	
Green	 0	 0	 10	 22	 ESBL+AMPC	 30	 36	 40	 38	 36	 44	 46	 16	 20	 0	 23	 36	 28	 Pseudomonas	sp	 NEGATIVE	
67	 Horse	Sisi	 White	 0	 0	 8	 16	 ESBL+AMPC	 0	 8	 46	 46	 44	 44	 48	 16	 21	 21	 23	 37	 30	 Pseudomonas	sp	 NEGATIVE	
68	 Horse	Noddy	 Brown	 0	 0	 12	 22	 ESBL+AMPC	 0	 0	 40	 42	 36	 30	 48	 0	 18	 0	 23	 40	 30	
Ochrobacteriu
m	anthrope	 NEGATIVE	
69	 Puppy	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
70	 Dog	Kiki	 No	Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
71	 Dog	Stable	Flopsy	
No	
Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
72	 Foal	
Pink	 0	 0	 11	 18	 ESBL+AMPC	 30	 32	 42	 48	 32	 44	 42	 10	 12	 0	 30	 28	 30	 E.coli	 NEGATIVE	
White	 0	 0	 13	 28	 ESBL+AMPC	 0	 18	 46	 56	 34	 32	 50	 0	 18	 0	 38	 44	 36	 Providencia	sp	 NEGATIVE	
73	 Chicken	
White	 15	 16	 18	 24	 ESBL+AMPC	 26	 34	 40	 44	 30	 32	 42	 16	 34	 0	 28	 20	 29	 Ochrobacterium	anthrope	 NEGATIVE	
Blue	 0	 18	 0	 20	 ESBL	 23	 16	 28	 34	 27	 22	 36	 0	 20	 0	 27	 34	 26	 E.coli	 NEGATIVE	
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74	 Horse	 White	 0	 0	 10	 21	 ESBL+AMPC	 28	 28	 38	 34	 30	 46	 44	 10	 18	 0	 23	 36	 30	 Acinetobacter	sp	 NEGATIVE	
75	
Horse	
Field	1	
(different)	
White	 0	 0	 11	 22	 ESBL+AMPC	 28	 36	 40	 38	 40	 44	 44	 12	 21	 0	 25	 36	 31	 Ochrobacterium	anthrope	 NEGATIVE	
Pink	 0	 0	 12	 22	 ESBL+AMPC	 30	 32	 40	 36	 26	 16	 42	 10	 20	 0	 24	 10	 30	 E.coli	 NEGATIVE	
76	
Foal	
(mares	
and	foals)	
White	 0	 0	 16	 21	 ESBL+AMPC	 30	 28	 36	 27	 30	 36	 34	 0	 20	 0	 24	 36	 30	 Pseudomonas	sp	 NEGATIVE	
Pink	 0	 0	 17	 21	 AMPC	 30	 28	 36	 28	 31	 36	 36	 0	 18	 0	 24	 38	 31	 E.coli	 NEGATIVE	
77	
Horse	
Field	3	
(different)	
White	 0	 0	 8	 14	
FURTHER	
WORK	
REQUIRED	
27	 24	 32	 28	 28	 16	 36	 0	 14	 0	 23	 30	 28	 Providencia	sp	 NEGATIVE	
78	 Horse	Dinky	 Pink	 0	 0	 0	 11	 ESBL+AMPC	 24	 20	 32	 22	 30	 30	 36	 0	 0	 0	 11	 25	 28	 E.coli	 NEGATIVE	
79	 Mares	and	Foals	 Pink	 20	 21	 20	 26	 ESBL+AMPC	 24	 16	 44	 44	 34	 30	 42	 0	 25	 10	 30	 12	 32	 E.coli	 NEGATIVE	
80	
Horse	
Field	2	
(different)	
White	 30	 30	 32	 34	
FURTHER	
WORK	
REQUIRED	
26	 36	 36	 34	 34	 36	 36	 0	 0	 0	 27	 37	 26	 Ochrobacterium	anthrope	 NEGATIVE	
81	 Foal	 White	 24	 24	 33	 34	 AMPC	 32	 40	 30	 34	 26	 22	 36	 8	 0	 0	 28	 41	 30	 Ochrobacterium	anthrope	 NEGATIVE	
82	 Dog	 D.Blue	 30	 30	 30	 30	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 NEGATIVE	
83	
Chicken	
White	
31	
32	 28	 32	
FURTHER	
WORK	
REQUIRED	
36	 32	 40	 22	 36	 38	 28	 0	 9	 0	 28	 31	 37	 Acinetobacter	sp	 NEGATIVE	
84	 Dog	 D.Blue	 30	 30	 30	 32	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 E.coli	 NEGATIVE	
85	
Turkey	
White	
20	
19	 21	 23	
FURTHER	
WORK	
REQUIRED	
24	 18	 29	 10	 26	 24	 16	 0	 0	 0	 21	 0	 28	 Acinetobacter	sp	 NEGATIVE	
86	 Dog	
No	
Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
87	 Parrot	
D.Blue	 0	 0	 13	 16	 AMPC	 29	 21	 28	 13	 29	 30	 20	 0	 8	 0	 19	 28	 35	 E.coli	 NEGATIVE	
White	 0	 0	 10	 16	 ESBL+AMPC	 30	 22	 30	 11	 28	 28	 16	 0	 0	 0	 15	 23	 30	
Ochrobacteriu
m	anthrope	 NEGATIVE	
88	 Dog	 Green	 0	 24	 10	 24	 ESBL	 13	 0	 23	 32	 15	 18	 36	 0	 0	 0	 26	 0	 23	 E.coli	 CTX	
89	 Dog	
V.D.	
Blue	 0	 18	 0	 19	 ESBL	 12	 0	 24	 32	 16	 18	 36	 0	 15	 0	 26	 0	 23	 E.coli	 CTX	
90	 Dog	 D.Blue	 0	 0	 0	 0	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 E.coli	 CTX	+	TEM	
91	 Dog	
No	
Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
92	 Hamster	
No	
Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
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93	 Dog	
White	 0	 0	 22	 23	 AMPC	 21	 24	 50	 42	 36	 21	 40	 0	 26	 0	 23	 0	 27	
Ochrobacteriu
m	anthrope	 NEGATIVE	
D.Blue		 0	 0	 21	 22	 AMPC	 22	 16	 48	 46	 36	 30	 38	 0	 31	 0	 21	 0	 26	 E.coli	 NEGATIVE	
94	 Rabbit	 Green	 40	 40	 45	 48	 AMPC	 23	 30	 32	 35	 31	 32	 35	 0	 20	 0	 24	 22	 22	 Pantoea	sp	 NEGATIVE	
95	 Dog	
White	 0	 0	 0	 0	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 NEGATIVE	
D.	blue	 0	 0	 0	 0	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 NEGATIVE	
96	 Chicken	
Brown	 0	 21	 0	 20	 ESBL	 26	 23	 32	 36	 30	 28	 33	 0	 21	 0	 26	 24	 26	
Citrobacter	
freundii	 CTX	+	TEM	
D.	Blue	 0	 20	 0	 21	 ESBL	 23	 18	 28	 29	 25	 19	 29	 0	 19	 0	 23	 29	 23	 E.coli	 CTX	+	TEM	
97	 Dog	
No	
Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
98	 Dog	
No	
Growth	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
99	 Horse	 White	 0	 0	 0	 0	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 NEGATIVE	
99	 Horse	 Pink	 0	 0	 0	 0	 NEGATIVE	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 NEGATIVE	
100	 Chicken	 D.Blue	 0	 21	 10	 23	 ESBL	 26	 21	 30	 31	 27	 22	 31	 0	 18	 0	 22	 30	 22	 E.coli	 CTX	+	TEM	
100	 Chicken	 Purple	 0	 23	 10	 23	 ESBL	 25	 22	 32	 36	 29	 23	 34	 0	 19	 0	 23	 32	 24	 E.coli	 CTX	+	TEM	
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